doc_id,adu1_pos,adu2_pos,adu1_aty,adu2_aty,rel_label,adu1_text,adu2_text
11346336,1,2,Premise,Premise,none,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).","The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively."
11346336,1,3,Premise,Premise,none,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).",Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
11346336,1,4,Premise,Premise,none,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).",The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
11346336,1,5,Premise,Premise,none,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).","The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%])."
11346336,1,6,Premise,Premise,none,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).","No cases of drug-related neutropenic fever, sepsis, or death occurred."
11346336,1,7,Premise,Premise,none,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).","Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day."
11346336,1,8,Premise,Claim,support,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).",Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
11346336,1,9,Premise,Claim,none,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%).",Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
11346336,2,1,Premise,Premise,none,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.","Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%)."
11346336,2,3,Premise,Premise,none,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.",Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
11346336,2,4,Premise,Premise,none,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.",The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
11346336,2,5,Premise,Premise,none,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.","The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%])."
11346336,2,6,Premise,Premise,none,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.","No cases of drug-related neutropenic fever, sepsis, or death occurred."
11346336,2,7,Premise,Premise,none,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.","Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day."
11346336,2,8,Premise,Claim,support,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.",Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
11346336,2,9,Premise,Claim,none,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively.",Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
11346336,3,1,Premise,Premise,none,Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%)."
11346336,3,2,Premise,Premise,none,Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively."
11346336,3,4,Premise,Premise,none,Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.,The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
11346336,3,5,Premise,Premise,none,Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%])."
11346336,3,6,Premise,Premise,none,Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.,"No cases of drug-related neutropenic fever, sepsis, or death occurred."
11346336,3,7,Premise,Premise,none,Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day."
11346336,3,8,Premise,Claim,support,Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.,Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
11346336,3,9,Premise,Claim,none,Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.,Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
11346336,4,1,Premise,Premise,none,The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%)."
11346336,4,2,Premise,Premise,none,The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively."
11346336,4,3,Premise,Premise,none,The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.,Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
11346336,4,5,Premise,Premise,none,The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%])."
11346336,4,6,Premise,Premise,none,The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.,"No cases of drug-related neutropenic fever, sepsis, or death occurred."
11346336,4,7,Premise,Premise,none,The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day."
11346336,4,8,Premise,Claim,none,The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.,Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
11346336,4,9,Premise,Claim,none,The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.,Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
11346336,5,1,Premise,Premise,none,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).","Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%)."
11346336,5,2,Premise,Premise,none,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).","The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively."
11346336,5,3,Premise,Premise,none,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).",Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
11346336,5,4,Premise,Premise,none,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).",The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
11346336,5,6,Premise,Premise,none,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).","No cases of drug-related neutropenic fever, sepsis, or death occurred."
11346336,5,7,Premise,Premise,none,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).","Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day."
11346336,5,8,Premise,Claim,none,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).",Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
11346336,5,9,Premise,Claim,support,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%]).",Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
11346336,6,1,Premise,Premise,none,"No cases of drug-related neutropenic fever, sepsis, or death occurred.","Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%)."
11346336,6,2,Premise,Premise,none,"No cases of drug-related neutropenic fever, sepsis, or death occurred.","The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively."
11346336,6,3,Premise,Premise,none,"No cases of drug-related neutropenic fever, sepsis, or death occurred.",Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
11346336,6,4,Premise,Premise,none,"No cases of drug-related neutropenic fever, sepsis, or death occurred.",The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
11346336,6,5,Premise,Premise,none,"No cases of drug-related neutropenic fever, sepsis, or death occurred.","The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%])."
11346336,6,7,Premise,Premise,none,"No cases of drug-related neutropenic fever, sepsis, or death occurred.","Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day."
11346336,6,8,Premise,Claim,support,"No cases of drug-related neutropenic fever, sepsis, or death occurred.",Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
11346336,6,9,Premise,Claim,none,"No cases of drug-related neutropenic fever, sepsis, or death occurred.",Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
11346336,7,1,Premise,Premise,none,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.","Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%)."
11346336,7,2,Premise,Premise,none,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.","The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively."
11346336,7,3,Premise,Premise,none,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.",Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
11346336,7,4,Premise,Premise,none,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.",The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
11346336,7,5,Premise,Premise,none,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.","The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%])."
11346336,7,6,Premise,Premise,none,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.","No cases of drug-related neutropenic fever, sepsis, or death occurred."
11346336,7,8,Premise,Claim,none,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.",Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
11346336,7,9,Premise,Claim,support,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day.",Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
11346336,8,1,Claim,Premise,none,Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%)."
11346336,8,2,Claim,Premise,none,Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively."
11346336,8,3,Claim,Premise,none,Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.,Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
11346336,8,4,Claim,Premise,none,Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.,The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
11346336,8,5,Claim,Premise,none,Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%])."
11346336,8,6,Claim,Premise,none,Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.,"No cases of drug-related neutropenic fever, sepsis, or death occurred."
11346336,8,7,Claim,Premise,none,Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day."
11346336,8,9,Claim,Claim,none,Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.,Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.
11346336,9,1,Claim,Premise,none,Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.,"Responses (> or = 50% improvement) were seen in 3 (20%) of 15 patients with an initial dose at 6.5 mg/m(2) per day (95% confidence interval [CI], 0%-40%), 15 (54%) of 28 patients at 300 mg/m(2) per day (95% CI, 35%-72%), and 10 (67%) of 15 patients at above 300 mg/m(2) per day (95% CI, 43%-91%)."
11346336,9,2,Claim,Premise,none,Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.,"The rate of progressive disease was 47%, 21%, and 13% at the same dose levels, respectively."
11346336,9,3,Claim,Premise,none,Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.,Eight (73%) of 11 patients crossing over from 6.5 mg/m(2) per day to higher doses subsequently responded.
11346336,9,4,Claim,Premise,none,Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.,The median duration of response from start of therapy could not be estimated for the 15 patients at 300 mg/m(2) per day owing to low relapse rates in 2 patients (13%); at higher doses it was 516 days.
11346336,9,5,Claim,Premise,none,Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.,"The following drug-related adverse effects were reversible and treatable: hypertriglyceridemia (46 patients [79%]), hypercholesterolemia (28 patients [48%]), headache (27 patients [47%]), central hypothyroidism (23 patients [40%]), asthenia (21 patients [36%]), and leukopenia (16 patients [28%])."
11346336,9,6,Claim,Premise,none,Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.,"No cases of drug-related neutropenic fever, sepsis, or death occurred."
11346336,9,7,Claim,Premise,none,Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.,"Pancreatitis occurred in 3 patients with triglyceride levels higher than 14.69 mmol/L (1300 mg/dL), all of whom were taking 300 mg/m(2) or more of oral bexarotene per day."
11346336,9,8,Claim,Claim,none,Hypertriglyceridemia and hypothyroidism require monitoring but are reversible and manageable with concomitant medication.,Bexarotene (Targretin capsules) (the first retinoid X receptor-selective rexinoid) was well tolerated and effective as an oral treatment for 15 (54%) of 28 patients with refractory or persistent early-stage cutaneous T-cell lymphoma at doses of 300 mg/m(2) per day.
10210927,1,2,MajorClaim,Premise,none,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer.","The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score."
10210927,1,3,MajorClaim,Premise,none,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer.","Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,"
10210927,1,4,MajorClaim,Premise,none,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer.",whereas neoplasm grew according to an almost exponential trend in untreated patients
10210927,1,5,MajorClaim,Premise,none,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer.",survival was better in treated patients
10210927,1,6,MajorClaim,Premise,none,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer.",Karnofsky performance score was particularly high in both patients.
10210927,1,7,MajorClaim,Claim,none,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer.",octreotide is endowed with antiproliferative activity.
10210927,1,8,MajorClaim,Claim,none,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer.",octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.
10210927,2,1,Premise,MajorClaim,none,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score.","octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer."
10210927,2,3,Premise,Premise,none,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score.","Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,"
10210927,2,4,Premise,Premise,none,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score.",whereas neoplasm grew according to an almost exponential trend in untreated patients
10210927,2,5,Premise,Premise,none,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score.",survival was better in treated patients
10210927,2,6,Premise,Premise,none,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score.",Karnofsky performance score was particularly high in both patients.
10210927,2,7,Premise,Claim,none,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score.",octreotide is endowed with antiproliferative activity.
10210927,2,8,Premise,Claim,support,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score.",octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.
10210927,3,1,Premise,MajorClaim,none,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,","octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer."
10210927,3,2,Premise,Premise,none,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,","The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score."
10210927,3,4,Premise,Premise,none,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,",whereas neoplasm grew according to an almost exponential trend in untreated patients
10210927,3,5,Premise,Premise,none,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,",survival was better in treated patients
10210927,3,6,Premise,Premise,none,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,",Karnofsky performance score was particularly high in both patients.
10210927,3,7,Premise,Claim,none,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,",octreotide is endowed with antiproliferative activity.
10210927,3,8,Premise,Claim,none,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,",octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.
10210927,4,1,Premise,MajorClaim,none,whereas neoplasm grew according to an almost exponential trend in untreated patients,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer."
10210927,4,2,Premise,Premise,none,whereas neoplasm grew according to an almost exponential trend in untreated patients,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score."
10210927,4,3,Premise,Premise,none,whereas neoplasm grew according to an almost exponential trend in untreated patients,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,"
10210927,4,5,Premise,Premise,none,whereas neoplasm grew according to an almost exponential trend in untreated patients,survival was better in treated patients
10210927,4,6,Premise,Premise,none,whereas neoplasm grew according to an almost exponential trend in untreated patients,Karnofsky performance score was particularly high in both patients.
10210927,4,7,Premise,Claim,none,whereas neoplasm grew according to an almost exponential trend in untreated patients,octreotide is endowed with antiproliferative activity.
10210927,4,8,Premise,Claim,none,whereas neoplasm grew according to an almost exponential trend in untreated patients,octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.
10210927,5,1,Premise,MajorClaim,none,survival was better in treated patients,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer."
10210927,5,2,Premise,Premise,none,survival was better in treated patients,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score."
10210927,5,3,Premise,Premise,none,survival was better in treated patients,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,"
10210927,5,4,Premise,Premise,none,survival was better in treated patients,whereas neoplasm grew according to an almost exponential trend in untreated patients
10210927,5,6,Premise,Premise,none,survival was better in treated patients,Karnofsky performance score was particularly high in both patients.
10210927,5,7,Premise,Claim,none,survival was better in treated patients,octreotide is endowed with antiproliferative activity.
10210927,5,8,Premise,Claim,support,survival was better in treated patients,octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.
10210927,6,1,Premise,MajorClaim,none,Karnofsky performance score was particularly high in both patients.,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer."
10210927,6,2,Premise,Premise,none,Karnofsky performance score was particularly high in both patients.,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score."
10210927,6,3,Premise,Premise,none,Karnofsky performance score was particularly high in both patients.,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,"
10210927,6,4,Premise,Premise,none,Karnofsky performance score was particularly high in both patients.,whereas neoplasm grew according to an almost exponential trend in untreated patients
10210927,6,5,Premise,Premise,none,Karnofsky performance score was particularly high in both patients.,survival was better in treated patients
10210927,6,7,Premise,Claim,none,Karnofsky performance score was particularly high in both patients.,octreotide is endowed with antiproliferative activity.
10210927,6,8,Premise,Claim,none,Karnofsky performance score was particularly high in both patients.,octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.
10210927,7,1,Claim,MajorClaim,none,octreotide is endowed with antiproliferative activity.,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer."
10210927,7,2,Claim,Premise,none,octreotide is endowed with antiproliferative activity.,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score."
10210927,7,3,Claim,Premise,none,octreotide is endowed with antiproliferative activity.,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,"
10210927,7,4,Claim,Premise,none,octreotide is endowed with antiproliferative activity.,whereas neoplasm grew according to an almost exponential trend in untreated patients
10210927,7,5,Claim,Premise,none,octreotide is endowed with antiproliferative activity.,survival was better in treated patients
10210927,7,6,Claim,Premise,none,octreotide is endowed with antiproliferative activity.,Karnofsky performance score was particularly high in both patients.
10210927,7,8,Claim,Claim,none,octreotide is endowed with antiproliferative activity.,octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.
10210927,8,1,Claim,MajorClaim,support,octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.,"octreotide, the long acting somatostatin analogue, improves survival of animals with pancreatic cancer."
10210927,8,2,Claim,Premise,none,octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.,"The patients treated with octreotide showed a significant advantage in quality of life (restored appetite, improvement of digestion and intestine function, remission of abdominal pain and preservation of baseline body weight) with a mean > 80 of karnofsky performance score."
10210927,8,3,Claim,Premise,none,octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.,"Monitoring of tumour size changes (US-TC) over the 6 months study period, showed slackened neoplastic growth in all treated patients,"
10210927,8,4,Claim,Premise,none,octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.,whereas neoplasm grew according to an almost exponential trend in untreated patients
10210927,8,5,Claim,Premise,none,octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.,survival was better in treated patients
10210927,8,6,Claim,Premise,none,octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.,Karnofsky performance score was particularly high in both patients.
10210927,8,7,Claim,Claim,none,octreotide therapy seems to confer a survival benefit and a better quality of life in advanced pancreatic tumour.,octreotide is endowed with antiproliferative activity.
12748244,1,2,Premise,Premise,none,Efficacy was similar for the 250- and 500-mg/d groups.,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively."
12748244,1,3,Premise,Premise,none,Efficacy was similar for the 250- and 500-mg/d groups.,Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
12748244,1,4,Premise,Premise,none,Efficacy was similar for the 250- and 500-mg/d groups.,Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
12748244,1,5,Premise,Premise,none,Efficacy was similar for the 250- and 500-mg/d groups.,Drug-related toxicities were more frequent in the higher-dose group.
12748244,1,6,Premise,Premise,none,Efficacy was similar for the 250- and 500-mg/d groups.,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively."
12748244,1,7,Premise,Claim,none,Efficacy was similar for the 250- and 500-mg/d groups.,Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
12748244,1,8,Premise,Claim,none,Efficacy was similar for the 250- and 500-mg/d groups.,"At 250 mg/d, gefitinib had a favorable AE profile."
12748244,1,9,Premise,Claim,none,Efficacy was similar for the 250- and 500-mg/d groups.,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC."
12748244,2,1,Premise,Premise,none,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.",Efficacy was similar for the 250- and 500-mg/d groups.
12748244,2,3,Premise,Premise,none,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.",Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
12748244,2,4,Premise,Premise,none,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.",Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
12748244,2,5,Premise,Premise,none,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.",Drug-related toxicities were more frequent in the higher-dose group.
12748244,2,6,Premise,Premise,none,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.","Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively."
12748244,2,7,Premise,Claim,support,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.",Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
12748244,2,8,Premise,Claim,none,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.","At 250 mg/d, gefitinib had a favorable AE profile."
12748244,2,9,Premise,Claim,none,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.","Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC."
12748244,3,1,Premise,Premise,none,Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.,Efficacy was similar for the 250- and 500-mg/d groups.
12748244,3,2,Premise,Premise,none,Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively."
12748244,3,4,Premise,Premise,none,Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.,Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
12748244,3,5,Premise,Premise,none,Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.,Drug-related toxicities were more frequent in the higher-dose group.
12748244,3,6,Premise,Premise,none,Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively."
12748244,3,7,Premise,Claim,support,Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.,Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
12748244,3,8,Premise,Claim,none,Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.,"At 250 mg/d, gefitinib had a favorable AE profile."
12748244,3,9,Premise,Claim,none,Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC."
12748244,4,1,Premise,Premise,none,Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.,Efficacy was similar for the 250- and 500-mg/d groups.
12748244,4,2,Premise,Premise,none,Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively."
12748244,4,3,Premise,Premise,none,Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.,Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
12748244,4,5,Premise,Premise,none,Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.,Drug-related toxicities were more frequent in the higher-dose group.
12748244,4,6,Premise,Premise,none,Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively."
12748244,4,7,Premise,Claim,none,Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.,Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
12748244,4,8,Premise,Claim,support,Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.,"At 250 mg/d, gefitinib had a favorable AE profile."
12748244,4,9,Premise,Claim,none,Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC."
12748244,5,1,Premise,Premise,none,Drug-related toxicities were more frequent in the higher-dose group.,Efficacy was similar for the 250- and 500-mg/d groups.
12748244,5,2,Premise,Premise,none,Drug-related toxicities were more frequent in the higher-dose group.,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively."
12748244,5,3,Premise,Premise,none,Drug-related toxicities were more frequent in the higher-dose group.,Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
12748244,5,4,Premise,Premise,none,Drug-related toxicities were more frequent in the higher-dose group.,Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
12748244,5,6,Premise,Premise,none,Drug-related toxicities were more frequent in the higher-dose group.,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively."
12748244,5,7,Premise,Claim,none,Drug-related toxicities were more frequent in the higher-dose group.,Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
12748244,5,8,Premise,Claim,support,Drug-related toxicities were more frequent in the higher-dose group.,"At 250 mg/d, gefitinib had a favorable AE profile."
12748244,5,9,Premise,Claim,none,Drug-related toxicities were more frequent in the higher-dose group.,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC."
12748244,6,1,Premise,Premise,none,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.",Efficacy was similar for the 250- and 500-mg/d groups.
12748244,6,2,Premise,Premise,none,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.","Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively."
12748244,6,3,Premise,Premise,none,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.",Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
12748244,6,4,Premise,Premise,none,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.",Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
12748244,6,5,Premise,Premise,none,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.",Drug-related toxicities were more frequent in the higher-dose group.
12748244,6,7,Premise,Claim,none,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.",Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
12748244,6,8,Premise,Claim,support,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.","At 250 mg/d, gefitinib had a favorable AE profile."
12748244,6,9,Premise,Claim,none,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.","Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC."
12748244,7,1,Claim,Premise,none,Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.,Efficacy was similar for the 250- and 500-mg/d groups.
12748244,7,2,Claim,Premise,none,Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.,"Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively."
12748244,7,3,Claim,Premise,none,Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.,Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
12748244,7,4,Claim,Premise,none,Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.,Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
12748244,7,5,Claim,Premise,none,Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.,Drug-related toxicities were more frequent in the higher-dose group.
12748244,7,6,Claim,Premise,none,Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.,"Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively."
12748244,7,8,Claim,Claim,none,Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.,"At 250 mg/d, gefitinib had a favorable AE profile."
12748244,7,9,Claim,Claim,support,Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC."
12748244,8,1,Claim,Premise,none,"At 250 mg/d, gefitinib had a favorable AE profile.",Efficacy was similar for the 250- and 500-mg/d groups.
12748244,8,2,Claim,Premise,none,"At 250 mg/d, gefitinib had a favorable AE profile.","Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively."
12748244,8,3,Claim,Premise,none,"At 250 mg/d, gefitinib had a favorable AE profile.",Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
12748244,8,4,Claim,Premise,none,"At 250 mg/d, gefitinib had a favorable AE profile.",Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
12748244,8,5,Claim,Premise,none,"At 250 mg/d, gefitinib had a favorable AE profile.",Drug-related toxicities were more frequent in the higher-dose group.
12748244,8,6,Claim,Premise,none,"At 250 mg/d, gefitinib had a favorable AE profile.","Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively."
12748244,8,7,Claim,Claim,none,"At 250 mg/d, gefitinib had a favorable AE profile.",Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
12748244,8,9,Claim,Claim,support,"At 250 mg/d, gefitinib had a favorable AE profile.","Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC."
12748244,9,1,Claim,Premise,none,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.",Efficacy was similar for the 250- and 500-mg/d groups.
12748244,9,2,Claim,Premise,none,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.","Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively."
12748244,9,3,Claim,Premise,none,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.",Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
12748244,9,4,Claim,Premise,none,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.",Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
12748244,9,5,Claim,Premise,none,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.",Drug-related toxicities were more frequent in the higher-dose group.
12748244,9,6,Claim,Premise,none,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.","Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively."
12748244,9,7,Claim,Claim,none,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.",Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
12748244,9,8,Claim,Claim,none,"Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.","At 250 mg/d, gefitinib had a favorable AE profile."
24028441,1,2,MajorClaim,Premise,none,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy.",Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.
24028441,1,3,MajorClaim,Premise,none,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy.",All of the transoperative complications occurred in the LRH group.
24028441,1,4,MajorClaim,Premise,none,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy.",The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P = 0.694.
24028441,1,5,MajorClaim,Premise,none,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy.",LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04-2.80).
24028441,1,6,MajorClaim,Claim,none,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy.",LRH provided lower pain scores after 36 h of observation in this series.
24028441,1,7,MajorClaim,Claim,none,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy.",The perioperative and serious postoperative complications ratios were comparable between the groups.
24028441,2,1,Premise,MajorClaim,none,Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy."
24028441,2,3,Premise,Premise,none,Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.,All of the transoperative complications occurred in the LRH group.
24028441,2,4,Premise,Premise,none,Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.,The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P = 0.694.
24028441,2,5,Premise,Premise,none,Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04-2.80).
24028441,2,6,Premise,Claim,none,Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.,LRH provided lower pain scores after 36 h of observation in this series.
24028441,2,7,Premise,Claim,support,Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.,The perioperative and serious postoperative complications ratios were comparable between the groups.
24028441,3,1,Premise,MajorClaim,none,All of the transoperative complications occurred in the LRH group.,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy."
24028441,3,2,Premise,Premise,none,All of the transoperative complications occurred in the LRH group.,Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.
24028441,3,4,Premise,Premise,none,All of the transoperative complications occurred in the LRH group.,The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P = 0.694.
24028441,3,5,Premise,Premise,none,All of the transoperative complications occurred in the LRH group.,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04-2.80).
24028441,3,6,Premise,Claim,none,All of the transoperative complications occurred in the LRH group.,LRH provided lower pain scores after 36 h of observation in this series.
24028441,3,7,Premise,Claim,none,All of the transoperative complications occurred in the LRH group.,The perioperative and serious postoperative complications ratios were comparable between the groups.
24028441,4,1,Premise,MajorClaim,none,The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P = 0.694.,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy."
24028441,4,2,Premise,Premise,none,The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P = 0.694.,Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.
24028441,4,3,Premise,Premise,none,The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P = 0.694.,All of the transoperative complications occurred in the LRH group.
24028441,4,5,Premise,Premise,none,The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P = 0.694.,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04-2.80).
24028441,4,6,Premise,Claim,none,The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P = 0.694.,LRH provided lower pain scores after 36 h of observation in this series.
24028441,4,7,Premise,Claim,support,The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P = 0.694.,The perioperative and serious postoperative complications ratios were comparable between the groups.
24028441,5,1,Premise,MajorClaim,none,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04-2.80).,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy."
24028441,5,2,Premise,Premise,none,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04-2.80).,Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.
24028441,5,3,Premise,Premise,none,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04-2.80).,All of the transoperative complications occurred in the LRH group.
24028441,5,4,Premise,Premise,none,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04-2.80).,The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P = 0.694.
24028441,5,6,Premise,Claim,support,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04-2.80).,LRH provided lower pain scores after 36 h of observation in this series.
24028441,5,7,Premise,Claim,none,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04-2.80).,The perioperative and serious postoperative complications ratios were comparable between the groups.
24028441,6,1,Claim,MajorClaim,none,LRH provided lower pain scores after 36 h of observation in this series.,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy."
24028441,6,2,Claim,Premise,none,LRH provided lower pain scores after 36 h of observation in this series.,Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.
24028441,6,3,Claim,Premise,none,LRH provided lower pain scores after 36 h of observation in this series.,All of the transoperative complications occurred in the LRH group.
24028441,6,4,Claim,Premise,none,LRH provided lower pain scores after 36 h of observation in this series.,The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P = 0.694.
24028441,6,5,Claim,Premise,none,LRH provided lower pain scores after 36 h of observation in this series.,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04-2.80).
24028441,6,7,Claim,Claim,none,LRH provided lower pain scores after 36 h of observation in this series.,The perioperative and serious postoperative complications ratios were comparable between the groups.
24028441,7,1,Claim,MajorClaim,none,The perioperative and serious postoperative complications ratios were comparable between the groups.,"the postoperative complications of (Campos LS, Limberger LF, Stein AT, Kalil AN) laparoscopic radical hysterectomy are similar to those in abdominal radical hysterectomy."
24028441,7,2,Claim,Premise,none,The perioperative and serious postoperative complications ratios were comparable between the groups.,Four patients (25%) in the LRH group and 5 patients (36%) in the ARH group presented with transoperative or serious postoperative complications.
24028441,7,3,Claim,Premise,none,The perioperative and serious postoperative complications ratios were comparable between the groups.,All of the transoperative complications occurred in the LRH group.
24028441,7,4,Claim,Premise,none,The perioperative and serious postoperative complications ratios were comparable between the groups.,The relative risk of presenting with complications was 0.70; CI 95% (0.23-2.11); P = 0.694.
24028441,7,5,Claim,Premise,none,The perioperative and serious postoperative complications ratios were comparable between the groups.,LRH group mean pain score was significantly lower than ARH after 36 h of observation (P = 0.044; mean difference score: 1.42; 95% CI: 0.04-2.80).
24028441,7,6,Claim,Claim,none,The perioperative and serious postoperative complications ratios were comparable between the groups.,LRH provided lower pain scores after 36 h of observation in this series.
12004217,1,2,Claim,Premise,none,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life."
12004217,1,3,Claim,Premise,none,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
12004217,1,4,Claim,Premise,none,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
12004217,1,5,Claim,Premise,none,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume."
12004217,1,6,Claim,Premise,none,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
12004217,1,7,Claim,Claim,none,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
12004217,1,8,Claim,Claim,none,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
12004217,1,9,Claim,Premise,none,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.,"because neorectal capacity decreased equally in both groups,"
12004217,1,10,Claim,Claim,none,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
12004217,2,1,Premise,Claim,none,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.",Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
12004217,2,3,Premise,Premise,none,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.",problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
12004217,2,4,Premise,Premise,none,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.",The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
12004217,2,5,Premise,Premise,none,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.","in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume."
12004217,2,6,Premise,Premise,none,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.",the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
12004217,2,7,Premise,Claim,none,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.",The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
12004217,2,8,Premise,Claim,none,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.",stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
12004217,2,9,Premise,Premise,none,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.","because neorectal capacity decreased equally in both groups,"
12004217,2,10,Premise,Claim,none,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life.",we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
12004217,3,1,Premise,Claim,none,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
12004217,3,2,Premise,Premise,none,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life."
12004217,3,4,Premise,Premise,none,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
12004217,3,5,Premise,Premise,none,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume."
12004217,3,6,Premise,Premise,none,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
12004217,3,7,Premise,Claim,support,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
12004217,3,8,Premise,Claim,none,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
12004217,3,9,Premise,Premise,none,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.,"because neorectal capacity decreased equally in both groups,"
12004217,3,10,Premise,Claim,none,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
12004217,4,1,Premise,Claim,none,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
12004217,4,2,Premise,Premise,none,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life."
12004217,4,3,Premise,Premise,none,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
12004217,4,5,Premise,Premise,none,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume."
12004217,4,6,Premise,Premise,none,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
12004217,4,7,Premise,Claim,none,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
12004217,4,8,Premise,Claim,support,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
12004217,4,9,Premise,Premise,none,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).,"because neorectal capacity decreased equally in both groups,"
12004217,4,10,Premise,Claim,none,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
12004217,5,1,Premise,Claim,none,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.",Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
12004217,5,2,Premise,Premise,none,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.","However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life."
12004217,5,3,Premise,Premise,none,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.",problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
12004217,5,4,Premise,Premise,none,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.",The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
12004217,5,6,Premise,Premise,none,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.",the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
12004217,5,7,Premise,Claim,none,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.",The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
12004217,5,8,Premise,Claim,none,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.",stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
12004217,5,9,Premise,Premise,none,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.","because neorectal capacity decreased equally in both groups,"
12004217,5,10,Premise,Claim,support,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume.",we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
12004217,6,1,Premise,Claim,none,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
12004217,6,2,Premise,Premise,none,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life."
12004217,6,3,Premise,Premise,none,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
12004217,6,4,Premise,Premise,none,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
12004217,6,5,Premise,Premise,none,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume."
12004217,6,7,Premise,Claim,none,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
12004217,6,8,Premise,Claim,none,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
12004217,6,9,Premise,Premise,none,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.,"because neorectal capacity decreased equally in both groups,"
12004217,6,10,Premise,Claim,support,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
12004217,7,1,Claim,Claim,none,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
12004217,7,2,Claim,Premise,none,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life."
12004217,7,3,Claim,Premise,none,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
12004217,7,4,Claim,Premise,none,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
12004217,7,5,Claim,Premise,none,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume."
12004217,7,6,Claim,Premise,none,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
12004217,7,8,Claim,Claim,none,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
12004217,7,9,Claim,Premise,none,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.,"because neorectal capacity decreased equally in both groups,"
12004217,7,10,Claim,Claim,none,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
12004217,8,1,Claim,Claim,none,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
12004217,8,2,Claim,Premise,none,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life."
12004217,8,3,Claim,Premise,none,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
12004217,8,4,Claim,Premise,none,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
12004217,8,5,Claim,Premise,none,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume."
12004217,8,6,Claim,Premise,none,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
12004217,8,7,Claim,Claim,none,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
12004217,8,9,Claim,Premise,none,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.,"because neorectal capacity decreased equally in both groups,"
12004217,8,10,Claim,Claim,none,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
12004217,9,1,Premise,Claim,none,"because neorectal capacity decreased equally in both groups,",Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
12004217,9,2,Premise,Premise,none,"because neorectal capacity decreased equally in both groups,","However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life."
12004217,9,3,Premise,Premise,none,"because neorectal capacity decreased equally in both groups,",problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
12004217,9,4,Premise,Premise,none,"because neorectal capacity decreased equally in both groups,",The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
12004217,9,5,Premise,Premise,none,"because neorectal capacity decreased equally in both groups,","in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume."
12004217,9,6,Premise,Premise,none,"because neorectal capacity decreased equally in both groups,",the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
12004217,9,7,Premise,Claim,none,"because neorectal capacity decreased equally in both groups,",The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
12004217,9,8,Premise,Claim,none,"because neorectal capacity decreased equally in both groups,",stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
12004217,9,10,Premise,Claim,support,"because neorectal capacity decreased equally in both groups,",we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.
12004217,10,1,Claim,Claim,none,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.,Low anterior resection with coloanal anastomosis prevents a definitive stoma in patients with distal rectal cancer.
12004217,10,2,Claim,Premise,none,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.,"However, imperative stool urge, stool fragmentation, prolonged stooling sessions, and minor problems of incontinence are frequently observed in the postoperative situation and negatively affect quality of life."
12004217,10,3,Claim,Premise,none,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.,problems with continence for liquids or gas occurred less frequently in the colonic J-pouch group 6 months after surgery.
12004217,10,4,Claim,Premise,none,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.,The frequency of bowel movements was lower in the J-pouch group (2.5 per day) than in the coloanal group (4.7 per day).
12004217,10,5,Claim,Premise,none,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.,"in a manometric study at the same postoperative point, neorectal capacity was decreased to a similar degree in both groups compared with the preoperative rectal volume."
12004217,10,6,Claim,Premise,none,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.,the expected and postulated reservoir effect could not be achieved by forming a 5-cm colonic J-pouch.
12004217,10,7,Claim,Claim,none,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.,The colonic J-pouch was superior with regard to continence for gas and liquids compared with a straight coloanal anastomosis.
12004217,10,8,Claim,Claim,none,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.,stool frequency was significantly lower in the J-pouch group than in the coloanal reconstruction group.
12004217,10,9,Claim,Premise,none,we speculate that the advantage of the colonic J-pouch is not in the creation of a larger neorectal reservoir but rather may be related to decreased motility.,"because neorectal capacity decreased equally in both groups,"
10403690,1,2,Premise,Premise,none,Partial response rates were 40 and 41.7% in IEP and MVP arms.,"Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003)."
10403690,1,3,Premise,Premise,none,Partial response rates were 40 and 41.7% in IEP and MVP arms.,"One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively."
10403690,1,4,Premise,Premise,none,Partial response rates were 40 and 41.7% in IEP and MVP arms.,"Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively."
10403690,1,5,Premise,Premise,none,Partial response rates were 40 and 41.7% in IEP and MVP arms.,"Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm."
10403690,1,6,Premise,Claim,none,Partial response rates were 40 and 41.7% in IEP and MVP arms.,combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC.
10403690,2,1,Premise,Premise,none,"Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003).",Partial response rates were 40 and 41.7% in IEP and MVP arms.
10403690,2,3,Premise,Premise,none,"Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003).","One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively."
10403690,2,4,Premise,Premise,none,"Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003).","Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively."
10403690,2,5,Premise,Premise,none,"Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003).","Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm."
10403690,2,6,Premise,Claim,support,"Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003).",combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC.
10403690,3,1,Premise,Premise,none,"One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively.",Partial response rates were 40 and 41.7% in IEP and MVP arms.
10403690,3,2,Premise,Premise,none,"One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively.","Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003)."
10403690,3,4,Premise,Premise,none,"One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively.","Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively."
10403690,3,5,Premise,Premise,none,"One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively.","Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm."
10403690,3,6,Premise,Claim,support,"One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively.",combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC.
10403690,4,1,Premise,Premise,none,"Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively.",Partial response rates were 40 and 41.7% in IEP and MVP arms.
10403690,4,2,Premise,Premise,none,"Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively.","Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003)."
10403690,4,3,Premise,Premise,none,"Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively.","One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively."
10403690,4,5,Premise,Premise,none,"Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively.","Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm."
10403690,4,6,Premise,Claim,support,"Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively.",combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC.
10403690,5,1,Premise,Premise,none,"Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm.",Partial response rates were 40 and 41.7% in IEP and MVP arms.
10403690,5,2,Premise,Premise,none,"Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm.","Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003)."
10403690,5,3,Premise,Premise,none,"Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm.","One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively."
10403690,5,4,Premise,Premise,none,"Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm.","Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively."
10403690,5,6,Premise,Claim,support,"Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm.",combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC.
10403690,6,1,Claim,Premise,none,combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC.,Partial response rates were 40 and 41.7% in IEP and MVP arms.
10403690,6,2,Claim,Premise,none,combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC.,"Median survival durations were 5.9 and 8.1 months for the IEP and MVP chemotherapy arms, and 4.1 months for BSC (log-rank test: P = 0.0003)."
10403690,6,3,Claim,Premise,none,combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC.,"One year survival was 13, 29.8 and 39.3% for the BSC, IEP and MVP regimens, respectively."
10403690,6,4,Claim,Premise,none,combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC.,"Two years survival was 7.8, 6.4 and 13.1% for the BSC, IEP and MVP regimens, respectively."
10403690,6,5,Claim,Premise,none,combination chemotherapy improves the quality of life as well as prolonging the survival of patients with advanced NSCLC.,"Improvement in quality of life (QOL) scores at the first, second and third interview were seen in chemotherapy arms only, not in the BSC arm."
23788218,1,2,Premise,Premise,none,"Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).","The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04)."
23788218,1,3,Premise,Premise,none,"Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).","Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009)."
23788218,1,4,Premise,Premise,none,"Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).",Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.
23788218,1,5,Premise,Claim,support,"Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).","In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%."
23788218,1,6,Premise,Claim,none,"Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).","In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group."
23788218,1,7,Premise,Claim,none,"Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).",These findings have important implications for the treatment of patients with head and neck cancer.
23788218,2,1,Premise,Premise,none,"The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).","Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04)."
23788218,2,3,Premise,Premise,none,"The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).","Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009)."
23788218,2,4,Premise,Premise,none,"The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).",Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.
23788218,2,5,Premise,Claim,none,"The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).","In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%."
23788218,2,6,Premise,Claim,none,"The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).","In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group."
23788218,2,7,Premise,Claim,none,"The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).",These findings have important implications for the treatment of patients with head and neck cancer.
23788218,3,1,Premise,Premise,none,"Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).","Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04)."
23788218,3,2,Premise,Premise,none,"Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).","The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04)."
23788218,3,4,Premise,Premise,none,"Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).",Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.
23788218,3,5,Premise,Claim,support,"Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).","In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%."
23788218,3,6,Premise,Claim,none,"Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).","In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group."
23788218,3,7,Premise,Claim,none,"Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).",These findings have important implications for the treatment of patients with head and neck cancer.
23788218,4,1,Premise,Premise,none,Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.,"Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04)."
23788218,4,2,Premise,Premise,none,Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.,"The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04)."
23788218,4,3,Premise,Premise,none,Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.,"Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009)."
23788218,4,5,Premise,Claim,none,Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.,"In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%."
23788218,4,6,Premise,Claim,support,Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.,"In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group."
23788218,4,7,Premise,Claim,none,Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.,These findings have important implications for the treatment of patients with head and neck cancer.
23788218,5,1,Claim,Premise,none,"In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.","Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04)."
23788218,5,2,Claim,Premise,none,"In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.","The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04)."
23788218,5,3,Claim,Premise,none,"In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.","Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009)."
23788218,5,4,Claim,Premise,none,"In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.",Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.
23788218,5,6,Claim,Claim,none,"In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.","In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group."
23788218,5,7,Claim,Claim,support,"In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.",These findings have important implications for the treatment of patients with head and neck cancer.
23788218,6,1,Claim,Premise,none,"In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.","Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04)."
23788218,6,2,Claim,Premise,none,"In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.","The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04)."
23788218,6,3,Claim,Premise,none,"In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.","Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009)."
23788218,6,4,Claim,Premise,none,"In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.",Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.
23788218,6,5,Claim,Claim,none,"In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.","In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%."
23788218,6,7,Claim,Claim,support,"In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.",These findings have important implications for the treatment of patients with head and neck cancer.
23788218,7,1,Claim,Premise,none,These findings have important implications for the treatment of patients with head and neck cancer.,"Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04)."
23788218,7,2,Claim,Premise,none,These findings have important implications for the treatment of patients with head and neck cancer.,"The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04)."
23788218,7,3,Claim,Premise,none,These findings have important implications for the treatment of patients with head and neck cancer.,"Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009)."
23788218,7,4,Claim,Premise,none,These findings have important implications for the treatment of patients with head and neck cancer.,Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.
23788218,7,5,Claim,Claim,none,These findings have important implications for the treatment of patients with head and neck cancer.,"In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%."
23788218,7,6,Claim,Claim,none,These findings have important implications for the treatment of patients with head and neck cancer.,"In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group."
16446335,1,2,Premise,Premise,none,"Of the 103 participants, overall QOL at week 4 was maintained by the patients in the intervention (n = 49), whereas QOL at week 4 significantly decreased for patients in the control group (n = 54).",This change reflected a 3-point increase from baseline in the intervention group and a 9-point decrease from baseline in the control group (P = .009).
16446335,1,3,Premise,Premise,none,"Of the 103 participants, overall QOL at week 4 was maintained by the patients in the intervention (n = 49), whereas QOL at week 4 significantly decreased for patients in the control group (n = 54).","Intervention participants maintained their QOL, and controls gradually returned to baseline by the end of the 6-month follow-up period."
16446335,1,4,Premise,Claim,support,"Of the 103 participants, overall QOL at week 4 was maintained by the patients in the intervention (n = 49), whereas QOL at week 4 significantly decreased for patients in the control group (n = 54).","Although intervention participants maintained and actually improved their QOL during radiation therapy, control participants experienced a significant decrease in their QOL"
16446335,1,5,Premise,Claim,none,"Of the 103 participants, overall QOL at week 4 was maintained by the patients in the intervention (n = 49), whereas QOL at week 4 significantly decreased for patients in the control group (n = 54).","Thus, a structured multidisciplinary intervention can help maintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment."
16446335,2,1,Premise,Premise,none,This change reflected a 3-point increase from baseline in the intervention group and a 9-point decrease from baseline in the control group (P = .009).,"Of the 103 participants, overall QOL at week 4 was maintained by the patients in the intervention (n = 49), whereas QOL at week 4 significantly decreased for patients in the control group (n = 54)."
16446335,2,3,Premise,Premise,none,This change reflected a 3-point increase from baseline in the intervention group and a 9-point decrease from baseline in the control group (P = .009).,"Intervention participants maintained their QOL, and controls gradually returned to baseline by the end of the 6-month follow-up period."
16446335,2,4,Premise,Claim,support,This change reflected a 3-point increase from baseline in the intervention group and a 9-point decrease from baseline in the control group (P = .009).,"Although intervention participants maintained and actually improved their QOL during radiation therapy, control participants experienced a significant decrease in their QOL"
16446335,2,5,Premise,Claim,none,This change reflected a 3-point increase from baseline in the intervention group and a 9-point decrease from baseline in the control group (P = .009).,"Thus, a structured multidisciplinary intervention can help maintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment."
16446335,3,1,Premise,Premise,none,"Intervention participants maintained their QOL, and controls gradually returned to baseline by the end of the 6-month follow-up period.","Of the 103 participants, overall QOL at week 4 was maintained by the patients in the intervention (n = 49), whereas QOL at week 4 significantly decreased for patients in the control group (n = 54)."
16446335,3,2,Premise,Premise,none,"Intervention participants maintained their QOL, and controls gradually returned to baseline by the end of the 6-month follow-up period.",This change reflected a 3-point increase from baseline in the intervention group and a 9-point decrease from baseline in the control group (P = .009).
16446335,3,4,Premise,Claim,support,"Intervention participants maintained their QOL, and controls gradually returned to baseline by the end of the 6-month follow-up period.","Although intervention participants maintained and actually improved their QOL during radiation therapy, control participants experienced a significant decrease in their QOL"
16446335,3,5,Premise,Claim,none,"Intervention participants maintained their QOL, and controls gradually returned to baseline by the end of the 6-month follow-up period.","Thus, a structured multidisciplinary intervention can help maintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment."
16446335,4,1,Claim,Premise,none,"Although intervention participants maintained and actually improved their QOL during radiation therapy, control participants experienced a significant decrease in their QOL","Of the 103 participants, overall QOL at week 4 was maintained by the patients in the intervention (n = 49), whereas QOL at week 4 significantly decreased for patients in the control group (n = 54)."
16446335,4,2,Claim,Premise,none,"Although intervention participants maintained and actually improved their QOL during radiation therapy, control participants experienced a significant decrease in their QOL",This change reflected a 3-point increase from baseline in the intervention group and a 9-point decrease from baseline in the control group (P = .009).
16446335,4,3,Claim,Premise,none,"Although intervention participants maintained and actually improved their QOL during radiation therapy, control participants experienced a significant decrease in their QOL","Intervention participants maintained their QOL, and controls gradually returned to baseline by the end of the 6-month follow-up period."
16446335,4,5,Claim,Claim,support,"Although intervention participants maintained and actually improved their QOL during radiation therapy, control participants experienced a significant decrease in their QOL","Thus, a structured multidisciplinary intervention can help maintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment."
16446335,5,1,Claim,Premise,none,"Thus, a structured multidisciplinary intervention can help maintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment.","Of the 103 participants, overall QOL at week 4 was maintained by the patients in the intervention (n = 49), whereas QOL at week 4 significantly decreased for patients in the control group (n = 54)."
16446335,5,2,Claim,Premise,none,"Thus, a structured multidisciplinary intervention can help maintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment.",This change reflected a 3-point increase from baseline in the intervention group and a 9-point decrease from baseline in the control group (P = .009).
16446335,5,3,Claim,Premise,none,"Thus, a structured multidisciplinary intervention can help maintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment.","Intervention participants maintained their QOL, and controls gradually returned to baseline by the end of the 6-month follow-up period."
16446335,5,4,Claim,Claim,none,"Thus, a structured multidisciplinary intervention can help maintain or even improve QOL in patients with advanced cancer who are undergoing cancer treatment.","Although intervention participants maintained and actually improved their QOL during radiation therapy, control participants experienced a significant decrease in their QOL"
15226325,1,2,Premise,Premise,none,there were no statistically significant differences in HRQOL between the two treatment groups.,"In both groups, selected aspects of HRQOL were impaired over time, with increased fatigue,"
15226325,1,3,Premise,Premise,none,there were no statistically significant differences in HRQOL between the two treatment groups.,"although some clinically significant improvements in emotional functioning were seen, as well as a reduction in pain over time."
15226325,1,4,Premise,Claim,support,there were no statistically significant differences in HRQOL between the two treatment groups.,"Overall, global quality of life was maintained in both treatment groups."
15226325,1,5,Premise,Claim,none,there were no statistically significant differences in HRQOL between the two treatment groups.,This information is important when advising women patients of the expected HRQOL consequences of treatment regimens and should help clinicians and their patients make informed treatment decisions.
15226325,2,1,Premise,Premise,none,"In both groups, selected aspects of HRQOL were impaired over time, with increased fatigue,",there were no statistically significant differences in HRQOL between the two treatment groups.
15226325,2,3,Premise,Premise,none,"In both groups, selected aspects of HRQOL were impaired over time, with increased fatigue,","although some clinically significant improvements in emotional functioning were seen, as well as a reduction in pain over time."
15226325,2,4,Premise,Claim,attack,"In both groups, selected aspects of HRQOL were impaired over time, with increased fatigue,","Overall, global quality of life was maintained in both treatment groups."
15226325,2,5,Premise,Claim,none,"In both groups, selected aspects of HRQOL were impaired over time, with increased fatigue,",This information is important when advising women patients of the expected HRQOL consequences of treatment regimens and should help clinicians and their patients make informed treatment decisions.
15226325,3,1,Premise,Premise,none,"although some clinically significant improvements in emotional functioning were seen, as well as a reduction in pain over time.",there were no statistically significant differences in HRQOL between the two treatment groups.
15226325,3,2,Premise,Premise,attack,"although some clinically significant improvements in emotional functioning were seen, as well as a reduction in pain over time.","In both groups, selected aspects of HRQOL were impaired over time, with increased fatigue,"
15226325,3,4,Premise,Claim,none,"although some clinically significant improvements in emotional functioning were seen, as well as a reduction in pain over time.","Overall, global quality of life was maintained in both treatment groups."
15226325,3,5,Premise,Claim,none,"although some clinically significant improvements in emotional functioning were seen, as well as a reduction in pain over time.",This information is important when advising women patients of the expected HRQOL consequences of treatment regimens and should help clinicians and their patients make informed treatment decisions.
15226325,4,1,Claim,Premise,none,"Overall, global quality of life was maintained in both treatment groups.",there were no statistically significant differences in HRQOL between the two treatment groups.
15226325,4,2,Claim,Premise,none,"Overall, global quality of life was maintained in both treatment groups.","In both groups, selected aspects of HRQOL were impaired over time, with increased fatigue,"
15226325,4,3,Claim,Premise,none,"Overall, global quality of life was maintained in both treatment groups.","although some clinically significant improvements in emotional functioning were seen, as well as a reduction in pain over time."
15226325,4,5,Claim,Claim,none,"Overall, global quality of life was maintained in both treatment groups.",This information is important when advising women patients of the expected HRQOL consequences of treatment regimens and should help clinicians and their patients make informed treatment decisions.
15226325,5,1,Claim,Premise,none,This information is important when advising women patients of the expected HRQOL consequences of treatment regimens and should help clinicians and their patients make informed treatment decisions.,there were no statistically significant differences in HRQOL between the two treatment groups.
15226325,5,2,Claim,Premise,none,This information is important when advising women patients of the expected HRQOL consequences of treatment regimens and should help clinicians and their patients make informed treatment decisions.,"In both groups, selected aspects of HRQOL were impaired over time, with increased fatigue,"
15226325,5,3,Claim,Premise,none,This information is important when advising women patients of the expected HRQOL consequences of treatment regimens and should help clinicians and their patients make informed treatment decisions.,"although some clinically significant improvements in emotional functioning were seen, as well as a reduction in pain over time."
15226325,5,4,Claim,Claim,none,This information is important when advising women patients of the expected HRQOL consequences of treatment regimens and should help clinicians and their patients make informed treatment decisions.,"Overall, global quality of life was maintained in both treatment groups."
20651011,1,2,Premise,Premise,none,"Over time, levels of fatigue significantly decreased in all domains in all groups,",except in mental fatigue in the WLC group.
20651011,1,3,Premise,Premise,none,"Over time, levels of fatigue significantly decreased in all domains in all groups,","Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation."
20651011,1,4,Premise,Premise,none,"Over time, levels of fatigue significantly decreased in all domains in all groups,","Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only."
20651011,1,5,Premise,Premise,none,"Over time, levels of fatigue significantly decreased in all domains in all groups,",No significant differences in decline in fatigue were found between the PT+CBT and PT groups.
20651011,1,6,Premise,Premise,none,"Over time, levels of fatigue significantly decreased in all domains in all groups,",Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.
20651011,1,7,Premise,Claim,support,"Over time, levels of fatigue significantly decreased in all domains in all groups,","Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,"
20651011,1,8,Premise,Claim,none,"Over time, levels of fatigue significantly decreased in all domains in all groups,",cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.
20651011,2,1,Premise,Premise,attack,except in mental fatigue in the WLC group.,"Over time, levels of fatigue significantly decreased in all domains in all groups,"
20651011,2,3,Premise,Premise,none,except in mental fatigue in the WLC group.,"Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation."
20651011,2,4,Premise,Premise,none,except in mental fatigue in the WLC group.,"Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only."
20651011,2,5,Premise,Premise,none,except in mental fatigue in the WLC group.,No significant differences in decline in fatigue were found between the PT+CBT and PT groups.
20651011,2,6,Premise,Premise,none,except in mental fatigue in the WLC group.,Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.
20651011,2,7,Premise,Claim,none,except in mental fatigue in the WLC group.,"Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,"
20651011,2,8,Premise,Claim,none,except in mental fatigue in the WLC group.,cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.
20651011,3,1,Premise,Premise,none,"Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation.","Over time, levels of fatigue significantly decreased in all domains in all groups,"
20651011,3,2,Premise,Premise,none,"Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation.",except in mental fatigue in the WLC group.
20651011,3,4,Premise,Premise,none,"Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation.","Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only."
20651011,3,5,Premise,Premise,none,"Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation.",No significant differences in decline in fatigue were found between the PT+CBT and PT groups.
20651011,3,6,Premise,Premise,none,"Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation.",Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.
20651011,3,7,Premise,Claim,support,"Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation.","Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,"
20651011,3,8,Premise,Claim,none,"Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation.",cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.
20651011,4,1,Premise,Premise,none,"Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only.","Over time, levels of fatigue significantly decreased in all domains in all groups,"
20651011,4,2,Premise,Premise,none,"Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only.",except in mental fatigue in the WLC group.
20651011,4,3,Premise,Premise,none,"Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only.","Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation."
20651011,4,5,Premise,Premise,none,"Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only.",No significant differences in decline in fatigue were found between the PT+CBT and PT groups.
20651011,4,6,Premise,Premise,none,"Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only.",Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.
20651011,4,7,Premise,Claim,support,"Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only.","Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,"
20651011,4,8,Premise,Claim,none,"Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only.",cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.
20651011,5,1,Premise,Premise,none,No significant differences in decline in fatigue were found between the PT+CBT and PT groups.,"Over time, levels of fatigue significantly decreased in all domains in all groups,"
20651011,5,2,Premise,Premise,none,No significant differences in decline in fatigue were found between the PT+CBT and PT groups.,except in mental fatigue in the WLC group.
20651011,5,3,Premise,Premise,none,No significant differences in decline in fatigue were found between the PT+CBT and PT groups.,"Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation."
20651011,5,4,Premise,Premise,none,No significant differences in decline in fatigue were found between the PT+CBT and PT groups.,"Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only."
20651011,5,6,Premise,Premise,none,No significant differences in decline in fatigue were found between the PT+CBT and PT groups.,Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.
20651011,5,7,Premise,Claim,support,No significant differences in decline in fatigue were found between the PT+CBT and PT groups.,"Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,"
20651011,5,8,Premise,Claim,none,No significant differences in decline in fatigue were found between the PT+CBT and PT groups.,cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.
20651011,6,1,Premise,Premise,none,Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.,"Over time, levels of fatigue significantly decreased in all domains in all groups,"
20651011,6,2,Premise,Premise,none,Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.,except in mental fatigue in the WLC group.
20651011,6,3,Premise,Premise,none,Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.,"Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation."
20651011,6,4,Premise,Premise,none,Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.,"Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only."
20651011,6,5,Premise,Premise,none,Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.,No significant differences in decline in fatigue were found between the PT+CBT and PT groups.
20651011,6,7,Premise,Claim,support,Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.,"Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,"
20651011,6,8,Premise,Claim,none,Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.,cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.
20651011,7,1,Claim,Premise,none,"Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,","Over time, levels of fatigue significantly decreased in all domains in all groups,"
20651011,7,2,Claim,Premise,none,"Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,",except in mental fatigue in the WLC group.
20651011,7,3,Claim,Premise,none,"Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,","Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation."
20651011,7,4,Claim,Premise,none,"Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,","Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only."
20651011,7,5,Claim,Premise,none,"Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,",No significant differences in decline in fatigue were found between the PT+CBT and PT groups.
20651011,7,6,Claim,Premise,none,"Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,",Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.
20651011,7,8,Claim,Claim,support,"Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,",cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.
20651011,8,1,Claim,Premise,none,cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.,"Over time, levels of fatigue significantly decreased in all domains in all groups,"
20651011,8,2,Claim,Premise,none,cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.,except in mental fatigue in the WLC group.
20651011,8,3,Claim,Premise,none,cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.,"Analyses of variance of postintervention fatigue showed statistically significant group effects on general fatigue, on physical and mental fatigue, and on reduced activation but not on reduced motivation."
20651011,8,4,Claim,Premise,none,cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.,"Compared with the WLC group, the PT group reported significantly greater decline in 4 domains of fatigue, whereas the PT+CBT group reported significantly greater decline in physical fatigue only."
20651011,8,5,Claim,Premise,none,cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.,No significant differences in decline in fatigue were found between the PT+CBT and PT groups.
20651011,8,6,Claim,Premise,none,cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.,Physical training combined with cognitive-behavioral therapy and physical training alone had significant and beneficial effects on fatigue compared with no intervention.
20651011,8,7,Claim,Claim,none,cognitive-behavioral therapy did not have additional beneficial effects beyond the benefits of physical training.,"Physical training was equally effective as or more effective than physical training combined with cognitive-behavioral therapy in reducing cancer-related fatigue,"
12925071,1,2,Claim,Premise,none,Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).,"Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity"
12925071,1,3,Claim,Premise,none,Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).,"The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea."
12925071,1,4,Claim,Premise,none,Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea."
12925071,1,5,Claim,Premise,none,Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).,"Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing."
12925071,1,6,Claim,Claim,none,Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).,The patient accrual to the trial is satisfactory
12925071,1,7,Claim,Claim,none,Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).,Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
12925071,2,1,Premise,Claim,none,"Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity",Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
12925071,2,3,Premise,Premise,none,"Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity","The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea."
12925071,2,4,Premise,Premise,none,"Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity","Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea."
12925071,2,5,Premise,Premise,none,"Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity","Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing."
12925071,2,6,Premise,Claim,none,"Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity",The patient accrual to the trial is satisfactory
12925071,2,7,Premise,Claim,support,"Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity",Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
12925071,3,1,Premise,Claim,none,"The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.",Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
12925071,3,2,Premise,Premise,none,"The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.","Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity"
12925071,3,4,Premise,Premise,none,"The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.","Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea."
12925071,3,5,Premise,Premise,none,"The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.","Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing."
12925071,3,6,Premise,Claim,none,"The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.",The patient accrual to the trial is satisfactory
12925071,3,7,Premise,Claim,support,"The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.",Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
12925071,4,1,Premise,Claim,none,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.",Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
12925071,4,2,Premise,Premise,none,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.","Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity"
12925071,4,3,Premise,Premise,none,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.","The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea."
12925071,4,5,Premise,Premise,none,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.","Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing."
12925071,4,6,Premise,Claim,none,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.",The patient accrual to the trial is satisfactory
12925071,4,7,Premise,Claim,support,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.",Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
12925071,5,1,Premise,Claim,none,"Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.",Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
12925071,5,2,Premise,Premise,none,"Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.","Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity"
12925071,5,3,Premise,Premise,none,"Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.","The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea."
12925071,5,4,Premise,Premise,none,"Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.","Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea."
12925071,5,6,Premise,Claim,none,"Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.",The patient accrual to the trial is satisfactory
12925071,5,7,Premise,Claim,support,"Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.",Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
12925071,6,1,Claim,Claim,none,The patient accrual to the trial is satisfactory,Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
12925071,6,2,Claim,Premise,none,The patient accrual to the trial is satisfactory,"Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity"
12925071,6,3,Claim,Premise,none,The patient accrual to the trial is satisfactory,"The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea."
12925071,6,4,Claim,Premise,none,The patient accrual to the trial is satisfactory,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea."
12925071,6,5,Claim,Premise,none,The patient accrual to the trial is satisfactory,"Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing."
12925071,6,7,Claim,Claim,none,The patient accrual to the trial is satisfactory,Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
12925071,7,1,Claim,Claim,none,Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.,Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
12925071,7,2,Claim,Premise,none,Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.,"Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity"
12925071,7,3,Claim,Premise,none,Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.,"The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea."
12925071,7,4,Claim,Premise,none,Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea."
12925071,7,5,Claim,Premise,none,Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.,"Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing."
12925071,7,6,Claim,Claim,none,Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.,The patient accrual to the trial is satisfactory
16446330,1,2,Premise,Premise,none,"Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm.","Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < .001), less appetite loss (P < .001), and less fatigue (P = .033) after completion of treatment compared with patients undergoing PT."
16446330,1,3,Premise,Claim,support,"Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm.",The TC regimen achieved better QoL outcomes compared with the PT regimen.
16446330,1,4,Premise,Claim,none,"Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm.","Thus, clinicians may consider replacing cisplatin with carboplatin when treating ovarian cancer patients with chemotherapy."
16446330,2,1,Premise,Premise,none,"Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < .001), less appetite loss (P < .001), and less fatigue (P = .033) after completion of treatment compared with patients undergoing PT.","Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm."
16446330,2,3,Premise,Claim,support,"Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < .001), less appetite loss (P < .001), and less fatigue (P = .033) after completion of treatment compared with patients undergoing PT.",The TC regimen achieved better QoL outcomes compared with the PT regimen.
16446330,2,4,Premise,Claim,none,"Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < .001), less appetite loss (P < .001), and less fatigue (P = .033) after completion of treatment compared with patients undergoing PT.","Thus, clinicians may consider replacing cisplatin with carboplatin when treating ovarian cancer patients with chemotherapy."
16446330,3,1,Claim,Premise,none,The TC regimen achieved better QoL outcomes compared with the PT regimen.,"Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm."
16446330,3,2,Claim,Premise,none,The TC regimen achieved better QoL outcomes compared with the PT regimen.,"Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < .001), less appetite loss (P < .001), and less fatigue (P = .033) after completion of treatment compared with patients undergoing PT."
16446330,3,4,Claim,Claim,support,The TC regimen achieved better QoL outcomes compared with the PT regimen.,"Thus, clinicians may consider replacing cisplatin with carboplatin when treating ovarian cancer patients with chemotherapy."
16446330,4,1,Claim,Premise,none,"Thus, clinicians may consider replacing cisplatin with carboplatin when treating ovarian cancer patients with chemotherapy.","Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm."
16446330,4,2,Claim,Premise,none,"Thus, clinicians may consider replacing cisplatin with carboplatin when treating ovarian cancer patients with chemotherapy.","Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < .001), less appetite loss (P < .001), and less fatigue (P = .033) after completion of treatment compared with patients undergoing PT."
16446330,4,3,Claim,Claim,none,"Thus, clinicians may consider replacing cisplatin with carboplatin when treating ovarian cancer patients with chemotherapy.",The TC regimen achieved better QoL outcomes compared with the PT regimen.
12711121,1,2,Premise,Premise,none,Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.,"Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."
12711121,1,3,Premise,Premise,none,Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.,"Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."
12711121,1,4,Premise,Premise,none,Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.,"Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%."
12711121,1,5,Premise,Premise,none,Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.,"Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only."
12711121,1,6,Premise,Claim,support,Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.,Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
12711121,1,7,Premise,Claim,none,Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.,"GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."
12711121,1,8,Premise,Premise,none,Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.,"Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only."
12711121,2,1,Premise,Premise,none,"Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.",Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
12711121,2,3,Premise,Premise,none,"Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.","Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."
12711121,2,4,Premise,Premise,none,"Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.","Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%."
12711121,2,5,Premise,Premise,none,"Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.","Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only."
12711121,2,6,Premise,Claim,support,"Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.",Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
12711121,2,7,Premise,Claim,none,"Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.","GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."
12711121,2,8,Premise,Premise,none,"Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis.","Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only."
12711121,3,1,Premise,Premise,none,"Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).",Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
12711121,3,2,Premise,Premise,none,"Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).","Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."
12711121,3,4,Premise,Premise,none,"Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).","Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%."
12711121,3,5,Premise,Premise,none,"Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).","Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only."
12711121,3,6,Premise,Claim,none,"Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).",Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
12711121,3,7,Premise,Claim,support,"Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).","GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."
12711121,3,8,Premise,Premise,none,"Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008).","Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only."
12711121,4,1,Premise,Premise,none,"Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.",Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
12711121,4,2,Premise,Premise,none,"Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.","Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."
12711121,4,3,Premise,Premise,none,"Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.","Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."
12711121,4,5,Premise,Premise,none,"Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.","Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only."
12711121,4,6,Premise,Claim,none,"Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.",Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
12711121,4,7,Premise,Claim,none,"Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.","GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."
12711121,4,8,Premise,Premise,none,"Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%.","Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only."
12711121,5,1,Premise,Premise,none,"Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.",Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
12711121,5,2,Premise,Premise,none,"Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.","Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."
12711121,5,3,Premise,Premise,none,"Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.","Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."
12711121,5,4,Premise,Premise,none,"Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.","Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%."
12711121,5,6,Premise,Claim,none,"Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.",Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
12711121,5,7,Premise,Claim,none,"Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.","GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."
12711121,5,8,Premise,Premise,none,"Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only.","Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only."
12711121,6,1,Claim,Premise,none,Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.,Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
12711121,6,2,Claim,Premise,none,Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.,"Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."
12711121,6,3,Claim,Premise,none,Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.,"Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."
12711121,6,4,Claim,Premise,none,Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.,"Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%."
12711121,6,5,Claim,Premise,none,Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.,"Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only."
12711121,6,7,Claim,Claim,none,Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.,"GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."
12711121,6,8,Claim,Premise,none,Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.,"Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only."
12711121,7,1,Claim,Premise,none,"GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.",Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
12711121,7,2,Claim,Premise,none,"GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.","Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."
12711121,7,3,Claim,Premise,none,"GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.","Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."
12711121,7,4,Claim,Premise,none,"GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.","Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%."
12711121,7,5,Claim,Premise,none,"GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.","Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only."
12711121,7,6,Claim,Claim,none,"GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.",Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
12711121,7,8,Claim,Premise,none,"GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms.","Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only."
12711121,8,1,Premise,Premise,none,"Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.",Both patients with objective response and disease stabilisation had clearly better symptom control than those with disease progression.
12711121,8,2,Premise,Premise,none,"Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.","Symptom control in both arms was similar for 'disease-specific' symptoms such as cough, dyspnea, pain or haemoptysis."
12711121,8,3,Premise,Premise,none,"Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.","Compared to PV, a significantly larger number of GEM-patients had better scores for 'constitutional' items such as anorexia (P=0.007), ability to carry on with daily activities (P=0.04) and overall impression of quality-of-life (P=0.008)."
12711121,8,4,Premise,Premise,none,"Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.","Symptom control was very similar in younger (<65 years) versus older (>/=65 years) patients, and only slightly better in those with a Karnofsky PS >/=80% compared to those <80%."
12711121,8,5,Premise,Premise,none,"Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.","Most of the symptom improvement occurred in the first 3 cycles, with some further symptom improvement in the following cycles in the GEM-arm only."
12711121,8,6,Premise,Claim,none,"Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.",Both GEM and PV yield a symptom control rate much higher than expected by the objective tumour RR.
12711121,8,7,Premise,Claim,none,"Most of the symptom control was achieved during the first 3 cycles of treatment, with some further improvement thereafter in the GEM-arm only.","GEM is equally effective in controlling 'disease-specific' symptoms, but superior in controlling 'constitutional' symptoms."
23840308,1,2,MajorClaim,Premise,none,Delirium is a serious and common postoperative complication,"Delirium occurred in 31 patients (11.9%), and there was no significant difference between the incidence of delirium in the intervention group and the usual-care group (9.4% vs. 14.3%, OR: 0.63, 95% CI: 0.29-1.35)."
23840308,1,3,MajorClaim,Claim,none,Delirium is a serious and common postoperative complication,"Within this study, a geriatric liaison intervention based on frailty for the prevention of postoperative delirium in frail elderly cancer patients undergoing elective surgery for a solid tumour has not proven to be effective."
23840308,2,1,Premise,MajorClaim,none,"Delirium occurred in 31 patients (11.9%), and there was no significant difference between the incidence of delirium in the intervention group and the usual-care group (9.4% vs. 14.3%, OR: 0.63, 95% CI: 0.29-1.35).",Delirium is a serious and common postoperative complication
23840308,2,3,Premise,Claim,support,"Delirium occurred in 31 patients (11.9%), and there was no significant difference between the incidence of delirium in the intervention group and the usual-care group (9.4% vs. 14.3%, OR: 0.63, 95% CI: 0.29-1.35).","Within this study, a geriatric liaison intervention based on frailty for the prevention of postoperative delirium in frail elderly cancer patients undergoing elective surgery for a solid tumour has not proven to be effective."
23840308,3,1,Claim,MajorClaim,none,"Within this study, a geriatric liaison intervention based on frailty for the prevention of postoperative delirium in frail elderly cancer patients undergoing elective surgery for a solid tumour has not proven to be effective.",Delirium is a serious and common postoperative complication
23840308,3,2,Claim,Premise,none,"Within this study, a geriatric liaison intervention based on frailty for the prevention of postoperative delirium in frail elderly cancer patients undergoing elective surgery for a solid tumour has not proven to be effective.","Delirium occurred in 31 patients (11.9%), and there was no significant difference between the incidence of delirium in the intervention group and the usual-care group (9.4% vs. 14.3%, OR: 0.63, 95% CI: 0.29-1.35)."
17876009,1,2,Premise,Premise,none,"Overall, patients assigned to receive stress management training did not report significantly less psychological distress on the Medical Outcomes Study 36-Item Short Form (SF-36) Mental Component Summary Scale than did those assigned to usual care.",patients with above-average levels of psychological distress (scores < or = 50) who were randomly assigned to the intervention condition reported significant improvement in their distress compared with those assigned to usual care only on the SF-36 Mental Health Subscale and the Center for Epidemiologic Studies Depression Scale.
17876009,1,3,Premise,Claim,support,"Overall, patients assigned to receive stress management training did not report significantly less psychological distress on the Medical Outcomes Study 36-Item Short Form (SF-36) Mental Component Summary Scale than did those assigned to usual care.",This study found that self-administered stress management training is effective only in those radiotherapy patients with initially higher levels of psychological distress.
17876009,1,4,Premise,Claim,none,"Overall, patients assigned to receive stress management training did not report significantly less psychological distress on the Medical Outcomes Study 36-Item Short Form (SF-36) Mental Component Summary Scale than did those assigned to usual care.",Additional research should examine the benefits of stress management training targeted specifically to patients experiencing heightened distress.
17876009,2,1,Premise,Premise,none,patients with above-average levels of psychological distress (scores < or = 50) who were randomly assigned to the intervention condition reported significant improvement in their distress compared with those assigned to usual care only on the SF-36 Mental Health Subscale and the Center for Epidemiologic Studies Depression Scale.,"Overall, patients assigned to receive stress management training did not report significantly less psychological distress on the Medical Outcomes Study 36-Item Short Form (SF-36) Mental Component Summary Scale than did those assigned to usual care."
17876009,2,3,Premise,Claim,support,patients with above-average levels of psychological distress (scores < or = 50) who were randomly assigned to the intervention condition reported significant improvement in their distress compared with those assigned to usual care only on the SF-36 Mental Health Subscale and the Center for Epidemiologic Studies Depression Scale.,This study found that self-administered stress management training is effective only in those radiotherapy patients with initially higher levels of psychological distress.
17876009,2,4,Premise,Claim,none,patients with above-average levels of psychological distress (scores < or = 50) who were randomly assigned to the intervention condition reported significant improvement in their distress compared with those assigned to usual care only on the SF-36 Mental Health Subscale and the Center for Epidemiologic Studies Depression Scale.,Additional research should examine the benefits of stress management training targeted specifically to patients experiencing heightened distress.
17876009,3,1,Claim,Premise,none,This study found that self-administered stress management training is effective only in those radiotherapy patients with initially higher levels of psychological distress.,"Overall, patients assigned to receive stress management training did not report significantly less psychological distress on the Medical Outcomes Study 36-Item Short Form (SF-36) Mental Component Summary Scale than did those assigned to usual care."
17876009,3,2,Claim,Premise,none,This study found that self-administered stress management training is effective only in those radiotherapy patients with initially higher levels of psychological distress.,patients with above-average levels of psychological distress (scores < or = 50) who were randomly assigned to the intervention condition reported significant improvement in their distress compared with those assigned to usual care only on the SF-36 Mental Health Subscale and the Center for Epidemiologic Studies Depression Scale.
17876009,3,4,Claim,Claim,none,This study found that self-administered stress management training is effective only in those radiotherapy patients with initially higher levels of psychological distress.,Additional research should examine the benefits of stress management training targeted specifically to patients experiencing heightened distress.
17876009,4,1,Claim,Premise,none,Additional research should examine the benefits of stress management training targeted specifically to patients experiencing heightened distress.,"Overall, patients assigned to receive stress management training did not report significantly less psychological distress on the Medical Outcomes Study 36-Item Short Form (SF-36) Mental Component Summary Scale than did those assigned to usual care."
17876009,4,2,Claim,Premise,none,Additional research should examine the benefits of stress management training targeted specifically to patients experiencing heightened distress.,patients with above-average levels of psychological distress (scores < or = 50) who were randomly assigned to the intervention condition reported significant improvement in their distress compared with those assigned to usual care only on the SF-36 Mental Health Subscale and the Center for Epidemiologic Studies Depression Scale.
17876009,4,3,Claim,Claim,attack,Additional research should examine the benefits of stress management training targeted specifically to patients experiencing heightened distress.,This study found that self-administered stress management training is effective only in those radiotherapy patients with initially higher levels of psychological distress.
21993852,1,2,Premise,Premise,none,"Only the dyspnea symptom scale showed superior results for R-Y than for B-I (B-I 13.6 ± 17.9, R-Y 8.6 ± 16.3, p = 0.02).","With respect to DAUGS 20, the total score did not differ significantly between the R-Y and B-I groups (24.8 vs. 23.6, p = 0.41)."
21993852,1,3,Premise,Premise,none,"Only the dyspnea symptom scale showed superior results for R-Y than for B-I (B-I 13.6 ± 17.9, R-Y 8.6 ± 16.3, p = 0.02).","Only reflux symptoms were significantly worse for B-I than for R-Y (0.7 ± 0.6 vs. 0.5 ± 0.6, p = 0.01)."
21993852,1,4,Premise,Claim,support,"Only the dyspnea symptom scale showed superior results for R-Y than for B-I (B-I 13.6 ± 17.9, R-Y 8.6 ± 16.3, p = 0.02).",The B-I and R-Y techniques were generally equivalent in terms of postoperative QOL and dysfunction.
21993852,1,5,Premise,MajorClaim,none,"Only the dyspnea symptom scale showed superior results for R-Y than for B-I (B-I 13.6 ± 17.9, R-Y 8.6 ± 16.3, p = 0.02).",Both procedures seem acceptable as standard reconstructions after distal gastrectomy with regard to postoperative QOL and dysfunction.
21993852,2,1,Premise,Premise,none,"With respect to DAUGS 20, the total score did not differ significantly between the R-Y and B-I groups (24.8 vs. 23.6, p = 0.41).","Only the dyspnea symptom scale showed superior results for R-Y than for B-I (B-I 13.6 ± 17.9, R-Y 8.6 ± 16.3, p = 0.02)."
21993852,2,3,Premise,Premise,none,"With respect to DAUGS 20, the total score did not differ significantly between the R-Y and B-I groups (24.8 vs. 23.6, p = 0.41).","Only reflux symptoms were significantly worse for B-I than for R-Y (0.7 ± 0.6 vs. 0.5 ± 0.6, p = 0.01)."
21993852,2,4,Premise,Claim,support,"With respect to DAUGS 20, the total score did not differ significantly between the R-Y and B-I groups (24.8 vs. 23.6, p = 0.41).",The B-I and R-Y techniques were generally equivalent in terms of postoperative QOL and dysfunction.
21993852,2,5,Premise,MajorClaim,none,"With respect to DAUGS 20, the total score did not differ significantly between the R-Y and B-I groups (24.8 vs. 23.6, p = 0.41).",Both procedures seem acceptable as standard reconstructions after distal gastrectomy with regard to postoperative QOL and dysfunction.
21993852,3,1,Premise,Premise,none,"Only reflux symptoms were significantly worse for B-I than for R-Y (0.7 ± 0.6 vs. 0.5 ± 0.6, p = 0.01).","Only the dyspnea symptom scale showed superior results for R-Y than for B-I (B-I 13.6 ± 17.9, R-Y 8.6 ± 16.3, p = 0.02)."
21993852,3,2,Premise,Premise,none,"Only reflux symptoms were significantly worse for B-I than for R-Y (0.7 ± 0.6 vs. 0.5 ± 0.6, p = 0.01).","With respect to DAUGS 20, the total score did not differ significantly between the R-Y and B-I groups (24.8 vs. 23.6, p = 0.41)."
21993852,3,4,Premise,Claim,support,"Only reflux symptoms were significantly worse for B-I than for R-Y (0.7 ± 0.6 vs. 0.5 ± 0.6, p = 0.01).",The B-I and R-Y techniques were generally equivalent in terms of postoperative QOL and dysfunction.
21993852,3,5,Premise,MajorClaim,none,"Only reflux symptoms were significantly worse for B-I than for R-Y (0.7 ± 0.6 vs. 0.5 ± 0.6, p = 0.01).",Both procedures seem acceptable as standard reconstructions after distal gastrectomy with regard to postoperative QOL and dysfunction.
21993852,4,1,Claim,Premise,none,The B-I and R-Y techniques were generally equivalent in terms of postoperative QOL and dysfunction.,"Only the dyspnea symptom scale showed superior results for R-Y than for B-I (B-I 13.6 ± 17.9, R-Y 8.6 ± 16.3, p = 0.02)."
21993852,4,2,Claim,Premise,none,The B-I and R-Y techniques were generally equivalent in terms of postoperative QOL and dysfunction.,"With respect to DAUGS 20, the total score did not differ significantly between the R-Y and B-I groups (24.8 vs. 23.6, p = 0.41)."
21993852,4,3,Claim,Premise,none,The B-I and R-Y techniques were generally equivalent in terms of postoperative QOL and dysfunction.,"Only reflux symptoms were significantly worse for B-I than for R-Y (0.7 ± 0.6 vs. 0.5 ± 0.6, p = 0.01)."
21993852,4,5,Claim,MajorClaim,support,The B-I and R-Y techniques were generally equivalent in terms of postoperative QOL and dysfunction.,Both procedures seem acceptable as standard reconstructions after distal gastrectomy with regard to postoperative QOL and dysfunction.
21993852,5,1,MajorClaim,Premise,none,Both procedures seem acceptable as standard reconstructions after distal gastrectomy with regard to postoperative QOL and dysfunction.,"Only the dyspnea symptom scale showed superior results for R-Y than for B-I (B-I 13.6 ± 17.9, R-Y 8.6 ± 16.3, p = 0.02)."
21993852,5,2,MajorClaim,Premise,none,Both procedures seem acceptable as standard reconstructions after distal gastrectomy with regard to postoperative QOL and dysfunction.,"With respect to DAUGS 20, the total score did not differ significantly between the R-Y and B-I groups (24.8 vs. 23.6, p = 0.41)."
21993852,5,3,MajorClaim,Premise,none,Both procedures seem acceptable as standard reconstructions after distal gastrectomy with regard to postoperative QOL and dysfunction.,"Only reflux symptoms were significantly worse for B-I than for R-Y (0.7 ± 0.6 vs. 0.5 ± 0.6, p = 0.01)."
21993852,5,4,MajorClaim,Claim,none,Both procedures seem acceptable as standard reconstructions after distal gastrectomy with regard to postoperative QOL and dysfunction.,The B-I and R-Y techniques were generally equivalent in terms of postoperative QOL and dysfunction.
24127364,1,2,Premise,Premise,none,The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo.,"Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales."
24127364,1,3,Premise,Premise,none,The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo.,A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%).
24127364,1,4,Premise,Premise,none,The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo.,"Clinical adverse events of ≥ grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia."
24127364,1,5,Premise,Claim,support,The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo.,"Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30."
24127364,1,6,Premise,Claim,none,The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo.,This result may be due to higher rates of fatigue and gastrointestinal adverse events.
24127364,2,1,Premise,Premise,none,"Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales.",The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo.
24127364,2,3,Premise,Premise,none,"Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales.",A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%).
24127364,2,4,Premise,Premise,none,"Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales.","Clinical adverse events of ≥ grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia."
24127364,2,5,Premise,Claim,support,"Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales.","Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30."
24127364,2,6,Premise,Claim,none,"Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales.",This result may be due to higher rates of fatigue and gastrointestinal adverse events.
24127364,3,1,Premise,Premise,none,A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%).,The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo.
24127364,3,2,Premise,Premise,none,A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%).,"Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales."
24127364,3,4,Premise,Premise,none,A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%).,"Clinical adverse events of ≥ grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia."
24127364,3,5,Premise,Claim,none,A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%).,"Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30."
24127364,3,6,Premise,Claim,none,A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%).,This result may be due to higher rates of fatigue and gastrointestinal adverse events.
24127364,4,1,Premise,Premise,none,"Clinical adverse events of ≥ grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia.",The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo.
24127364,4,2,Premise,Premise,none,"Clinical adverse events of ≥ grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia.","Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales."
24127364,4,3,Premise,Premise,none,"Clinical adverse events of ≥ grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia.",A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%).
24127364,4,5,Premise,Claim,none,"Clinical adverse events of ≥ grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia.","Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30."
24127364,4,6,Premise,Claim,support,"Clinical adverse events of ≥ grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia.",This result may be due to higher rates of fatigue and gastrointestinal adverse events.
24127364,5,1,Claim,Premise,none,"Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30.",The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo.
24127364,5,2,Claim,Premise,none,"Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30.","Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales."
24127364,5,3,Claim,Premise,none,"Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30.",A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%).
24127364,5,4,Claim,Premise,none,"Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30.","Clinical adverse events of ≥ grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia."
24127364,5,6,Claim,Claim,none,"Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30.",This result may be due to higher rates of fatigue and gastrointestinal adverse events.
24127364,6,1,Claim,Premise,none,This result may be due to higher rates of fatigue and gastrointestinal adverse events.,The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo.
24127364,6,2,Claim,Premise,none,This result may be due to higher rates of fatigue and gastrointestinal adverse events.,"Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales."
24127364,6,3,Claim,Premise,none,This result may be due to higher rates of fatigue and gastrointestinal adverse events.,A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%).
24127364,6,4,Claim,Premise,none,This result may be due to higher rates of fatigue and gastrointestinal adverse events.,"Clinical adverse events of ≥ grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia."
24127364,6,5,Claim,Claim,attack,This result may be due to higher rates of fatigue and gastrointestinal adverse events.,"Compared with CET/placebo, the combination of CET/BRIV worsened time to QoL deterioration for patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer on the PF and GHS scales of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30."
20733132,1,2,Premise,Claim,support,Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.,quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.
20733132,1,3,Premise,Premise,none,Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.,"Although objective response was slightly higher in the TCG arm,"
20733132,1,4,Premise,Premise,none,Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.,this did not translate into improved progression-free survival (PFS) or overall survival (OS).
20733132,1,5,Premise,Premise,none,Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.,"Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044)."
20733132,1,6,Premise,Premise,none,Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.,"Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106)."
20733132,1,7,Premise,Claim,none,Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.,"The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer."
20733132,1,8,Premise,MajorClaim,none,Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.,"Therefore, we recommend no additional clinical use of TCG in this population."
20733132,2,1,Claim,Premise,none,quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.,Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.
20733132,2,3,Claim,Premise,none,quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.,"Although objective response was slightly higher in the TCG arm,"
20733132,2,4,Claim,Premise,none,quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.,this did not translate into improved progression-free survival (PFS) or overall survival (OS).
20733132,2,5,Claim,Premise,none,quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.,"Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044)."
20733132,2,6,Claim,Premise,none,quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.,"Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106)."
20733132,2,7,Claim,Claim,none,quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.,"The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer."
20733132,2,8,Claim,MajorClaim,support,quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.,"Therefore, we recommend no additional clinical use of TCG in this population."
20733132,3,1,Premise,Premise,none,"Although objective response was slightly higher in the TCG arm,",Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.
20733132,3,2,Premise,Claim,none,"Although objective response was slightly higher in the TCG arm,",quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.
20733132,3,4,Premise,Premise,none,"Although objective response was slightly higher in the TCG arm,",this did not translate into improved progression-free survival (PFS) or overall survival (OS).
20733132,3,5,Premise,Premise,none,"Although objective response was slightly higher in the TCG arm,","Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044)."
20733132,3,6,Premise,Premise,none,"Although objective response was slightly higher in the TCG arm,","Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106)."
20733132,3,7,Premise,Claim,none,"Although objective response was slightly higher in the TCG arm,","The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer."
20733132,3,8,Premise,MajorClaim,none,"Although objective response was slightly higher in the TCG arm,","Therefore, we recommend no additional clinical use of TCG in this population."
20733132,4,1,Premise,Premise,none,this did not translate into improved progression-free survival (PFS) or overall survival (OS).,Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.
20733132,4,2,Premise,Claim,none,this did not translate into improved progression-free survival (PFS) or overall survival (OS).,quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.
20733132,4,3,Premise,Premise,attack,this did not translate into improved progression-free survival (PFS) or overall survival (OS).,"Although objective response was slightly higher in the TCG arm,"
20733132,4,5,Premise,Premise,none,this did not translate into improved progression-free survival (PFS) or overall survival (OS).,"Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044)."
20733132,4,6,Premise,Premise,none,this did not translate into improved progression-free survival (PFS) or overall survival (OS).,"Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106)."
20733132,4,7,Premise,Claim,none,this did not translate into improved progression-free survival (PFS) or overall survival (OS).,"The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer."
20733132,4,8,Premise,MajorClaim,none,this did not translate into improved progression-free survival (PFS) or overall survival (OS).,"Therefore, we recommend no additional clinical use of TCG in this population."
20733132,5,1,Premise,Premise,none,"Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044).",Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.
20733132,5,2,Premise,Claim,none,"Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044).",quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.
20733132,5,3,Premise,Premise,none,"Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044).","Although objective response was slightly higher in the TCG arm,"
20733132,5,4,Premise,Premise,none,"Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044).",this did not translate into improved progression-free survival (PFS) or overall survival (OS).
20733132,5,6,Premise,Premise,none,"Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044).","Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106)."
20733132,5,7,Premise,Claim,support,"Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044).","The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer."
20733132,5,8,Premise,MajorClaim,none,"Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044).","Therefore, we recommend no additional clinical use of TCG in this population."
20733132,6,1,Premise,Premise,none,"Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106).",Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.
20733132,6,2,Premise,Claim,none,"Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106).",quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.
20733132,6,3,Premise,Premise,none,"Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106).","Although objective response was slightly higher in the TCG arm,"
20733132,6,4,Premise,Premise,none,"Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106).",this did not translate into improved progression-free survival (PFS) or overall survival (OS).
20733132,6,5,Premise,Premise,none,"Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106).","Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044)."
20733132,6,7,Premise,Claim,support,"Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106).","The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer."
20733132,6,8,Premise,MajorClaim,none,"Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106).","Therefore, we recommend no additional clinical use of TCG in this population."
20733132,7,1,Claim,Premise,none,"The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer.",Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.
20733132,7,2,Claim,Claim,none,"The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer.",quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.
20733132,7,3,Claim,Premise,none,"The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer.","Although objective response was slightly higher in the TCG arm,"
20733132,7,4,Claim,Premise,none,"The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer.",this did not translate into improved progression-free survival (PFS) or overall survival (OS).
20733132,7,5,Claim,Premise,none,"The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer.","Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044)."
20733132,7,6,Claim,Premise,none,"The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer.","Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106)."
20733132,7,8,Claim,MajorClaim,support,"The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer.","Therefore, we recommend no additional clinical use of TCG in this population."
20733132,8,1,MajorClaim,Premise,none,"Therefore, we recommend no additional clinical use of TCG in this population.",Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm.
20733132,8,2,MajorClaim,Claim,none,"Therefore, we recommend no additional clinical use of TCG in this population.",quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm.
20733132,8,3,MajorClaim,Premise,none,"Therefore, we recommend no additional clinical use of TCG in this population.","Although objective response was slightly higher in the TCG arm,"
20733132,8,4,MajorClaim,Premise,none,"Therefore, we recommend no additional clinical use of TCG in this population.",this did not translate into improved progression-free survival (PFS) or overall survival (OS).
20733132,8,5,MajorClaim,Premise,none,"Therefore, we recommend no additional clinical use of TCG in this population.","Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044)."
20733132,8,6,MajorClaim,Premise,none,"Therefore, we recommend no additional clinical use of TCG in this population.","Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106)."
20733132,8,7,MajorClaim,Claim,none,"Therefore, we recommend no additional clinical use of TCG in this population.","The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer."
18485819,1,2,MajorClaim,MajorClaim,none,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications.","Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks."
18485819,1,3,MajorClaim,Premise,none,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications.",The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).
18485819,1,4,MajorClaim,Premise,none,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications.","The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001)."
18485819,1,5,MajorClaim,Premise,none,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications.",The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).
18485819,1,6,MajorClaim,Premise,none,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications.",Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).
18485819,1,7,MajorClaim,Premise,none,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications.",The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).
18485819,1,8,MajorClaim,Claim,none,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications.",The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.
18485819,1,9,MajorClaim,MajorClaim,none,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications.",Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.
18485819,2,1,MajorClaim,MajorClaim,none,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks.","Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications."
18485819,2,3,MajorClaim,Premise,none,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks.",The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).
18485819,2,4,MajorClaim,Premise,none,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks.","The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001)."
18485819,2,5,MajorClaim,Premise,none,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks.",The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).
18485819,2,6,MajorClaim,Premise,none,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks.",Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).
18485819,2,7,MajorClaim,Premise,none,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks.",The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).
18485819,2,8,MajorClaim,Claim,none,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks.",The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.
18485819,2,9,MajorClaim,MajorClaim,none,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks.",Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.
18485819,3,1,Premise,MajorClaim,none,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications."
18485819,3,2,Premise,MajorClaim,none,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks."
18485819,3,4,Premise,Premise,none,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001)."
18485819,3,5,Premise,Premise,none,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).
18485819,3,6,Premise,Premise,none,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).
18485819,3,7,Premise,Premise,none,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).
18485819,3,8,Premise,Claim,support,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.
18485819,3,9,Premise,MajorClaim,none,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.
18485819,4,1,Premise,MajorClaim,none,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001).","Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications."
18485819,4,2,Premise,MajorClaim,none,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001).","Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks."
18485819,4,3,Premise,Premise,none,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001).",The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).
18485819,4,5,Premise,Premise,none,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001).",The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).
18485819,4,6,Premise,Premise,none,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001).",Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).
18485819,4,7,Premise,Premise,none,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001).",The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).
18485819,4,8,Premise,Claim,support,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001).",The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.
18485819,4,9,Premise,MajorClaim,none,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001).",Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.
18485819,5,1,Premise,MajorClaim,none,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications."
18485819,5,2,Premise,MajorClaim,none,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks."
18485819,5,3,Premise,Premise,none,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).
18485819,5,4,Premise,Premise,none,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001)."
18485819,5,6,Premise,Premise,none,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).
18485819,5,7,Premise,Premise,none,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).
18485819,5,8,Premise,Claim,support,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.
18485819,5,9,Premise,MajorClaim,none,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.
18485819,6,1,Premise,MajorClaim,none,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications."
18485819,6,2,Premise,MajorClaim,none,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks."
18485819,6,3,Premise,Premise,none,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).
18485819,6,4,Premise,Premise,none,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001)."
18485819,6,5,Premise,Premise,none,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).
18485819,6,7,Premise,Premise,none,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).
18485819,6,8,Premise,Claim,support,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.
18485819,6,9,Premise,MajorClaim,none,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.
18485819,7,1,Premise,MajorClaim,none,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications."
18485819,7,2,Premise,MajorClaim,none,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks."
18485819,7,3,Premise,Premise,none,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).
18485819,7,4,Premise,Premise,none,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001)."
18485819,7,5,Premise,Premise,none,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).
18485819,7,6,Premise,Premise,none,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).
18485819,7,8,Premise,Claim,support,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.
18485819,7,9,Premise,MajorClaim,none,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.
18485819,8,1,Claim,MajorClaim,none,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications."
18485819,8,2,Claim,MajorClaim,none,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks."
18485819,8,3,Claim,Premise,none,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).
18485819,8,4,Claim,Premise,none,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001)."
18485819,8,5,Claim,Premise,none,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).
18485819,8,6,Claim,Premise,none,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).
18485819,8,7,Claim,Premise,none,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).
18485819,8,9,Claim,MajorClaim,support,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.
18485819,9,1,MajorClaim,MajorClaim,none,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.,"Debilitating hot flushes and sleep dysfunction often affect survivors of breast cancer, most notably in those taking anti-oestrogen medications."
18485819,9,2,MajorClaim,MajorClaim,none,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.,"Conventional treatments have been only partially effective in diminishing these issues, and some have serious risks."
18485819,9,3,MajorClaim,Premise,none,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.,The total number of hot flushes decreased from a mean of 79.4 (SD 37.4) per week before the procedure to a mean of 49.9 (SD 39.9) per week during the first 2 weeks after the procedure (p=0.0002).
18485819,9,4,MajorClaim,Premise,none,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.,"The total number of hot flushes continued to decrease over the remaining follow-up period (weeks 3-12), and stabilised at a mean of 8.1 (SD 5.6) per week (p<0.0001)."
18485819,9,5,MajorClaim,Premise,none,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.,The number of very severe hot flushes was decreased to near zero by the end of the follow-up period (week 12; p<0.0001).
18485819,9,6,MajorClaim,Premise,none,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.,Night awakenings decreased from a mean of 19.5 (SD 14.8) per week before the procedure to a mean of 7.3 (SD 7.1) per week during the first 2 weeks after the procedure (p<0.0001).
18485819,9,7,MajorClaim,Premise,none,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.,The total number of night awakenings continued to decrease over the remaining follow-up period (weeks 3-12) and stabilised at a mean of 1.4 (SD 1.2) per week (p<0.0001).
18485819,9,8,MajorClaim,Claim,none,Long-term relief of symptoms has the potential to improve overall quality of life and increase compliance with anti-oestrogen medications for breast cancer.,The findings of this study suggest that stellate-ganglion block can provide survivors of breast cancer with relief from hot flushes and sleep dysfunction with few or no side-effects.
24038913,1,2,Premise,Premise,none,"Patients <3 years (n = 49, 19.5% of all enrolled patients) at diagnosis had a 10-year EFS and OS of 29 ± 6.5% and 37.5 ± 7%, respectively, while for patients 3-6 years (n = 34, 13.5% of all enrolled patients) 10-year EFS and OS were 35 ± 8% and 36 ± 8%, respectively.",Molecular marker analysis showed that a smaller proportion of patients <3 years harbored TP53 mutations (P = 0.05).
24038913,1,3,Premise,Premise,none,"Patients <3 years (n = 49, 19.5% of all enrolled patients) at diagnosis had a 10-year EFS and OS of 29 ± 6.5% and 37.5 ± 7%, respectively, while for patients 3-6 years (n = 34, 13.5% of all enrolled patients) 10-year EFS and OS were 35 ± 8% and 36 ± 8%, respectively.",Analysis of QOL outcomes with a median length of follow-up of 15.1 years (9.5-19.2) showed comparable results.
24038913,1,4,Premise,Claim,none,"Patients <3 years (n = 49, 19.5% of all enrolled patients) at diagnosis had a 10-year EFS and OS of 29 ± 6.5% and 37.5 ± 7%, respectively, while for patients 3-6 years (n = 34, 13.5% of all enrolled patients) 10-year EFS and OS were 35 ± 8% and 36 ± 8%, respectively.",QOL and survival data were similar for the two groups.
24038913,1,5,Premise,Claim,none,"Patients <3 years (n = 49, 19.5% of all enrolled patients) at diagnosis had a 10-year EFS and OS of 29 ± 6.5% and 37.5 ± 7%, respectively, while for patients 3-6 years (n = 34, 13.5% of all enrolled patients) 10-year EFS and OS were 35 ± 8% and 36 ± 8%, respectively.",A larger prospective study is justified to study the efficacy of chemotherapy only regimens in younger children.
24038913,2,1,Premise,Premise,none,Molecular marker analysis showed that a smaller proportion of patients <3 years harbored TP53 mutations (P = 0.05).,"Patients <3 years (n = 49, 19.5% of all enrolled patients) at diagnosis had a 10-year EFS and OS of 29 ± 6.5% and 37.5 ± 7%, respectively, while for patients 3-6 years (n = 34, 13.5% of all enrolled patients) 10-year EFS and OS were 35 ± 8% and 36 ± 8%, respectively."
24038913,2,3,Premise,Premise,none,Molecular marker analysis showed that a smaller proportion of patients <3 years harbored TP53 mutations (P = 0.05).,Analysis of QOL outcomes with a median length of follow-up of 15.1 years (9.5-19.2) showed comparable results.
24038913,2,4,Premise,Claim,none,Molecular marker analysis showed that a smaller proportion of patients <3 years harbored TP53 mutations (P = 0.05).,QOL and survival data were similar for the two groups.
24038913,2,5,Premise,Claim,none,Molecular marker analysis showed that a smaller proportion of patients <3 years harbored TP53 mutations (P = 0.05).,A larger prospective study is justified to study the efficacy of chemotherapy only regimens in younger children.
24038913,3,1,Premise,Premise,none,Analysis of QOL outcomes with a median length of follow-up of 15.1 years (9.5-19.2) showed comparable results.,"Patients <3 years (n = 49, 19.5% of all enrolled patients) at diagnosis had a 10-year EFS and OS of 29 ± 6.5% and 37.5 ± 7%, respectively, while for patients 3-6 years (n = 34, 13.5% of all enrolled patients) 10-year EFS and OS were 35 ± 8% and 36 ± 8%, respectively."
24038913,3,2,Premise,Premise,none,Analysis of QOL outcomes with a median length of follow-up of 15.1 years (9.5-19.2) showed comparable results.,Molecular marker analysis showed that a smaller proportion of patients <3 years harbored TP53 mutations (P = 0.05).
24038913,3,4,Premise,Claim,support,Analysis of QOL outcomes with a median length of follow-up of 15.1 years (9.5-19.2) showed comparable results.,QOL and survival data were similar for the two groups.
24038913,3,5,Premise,Claim,none,Analysis of QOL outcomes with a median length of follow-up of 15.1 years (9.5-19.2) showed comparable results.,A larger prospective study is justified to study the efficacy of chemotherapy only regimens in younger children.
24038913,4,1,Claim,Premise,none,QOL and survival data were similar for the two groups.,"Patients <3 years (n = 49, 19.5% of all enrolled patients) at diagnosis had a 10-year EFS and OS of 29 ± 6.5% and 37.5 ± 7%, respectively, while for patients 3-6 years (n = 34, 13.5% of all enrolled patients) 10-year EFS and OS were 35 ± 8% and 36 ± 8%, respectively."
24038913,4,2,Claim,Premise,none,QOL and survival data were similar for the two groups.,Molecular marker analysis showed that a smaller proportion of patients <3 years harbored TP53 mutations (P = 0.05).
24038913,4,3,Claim,Premise,none,QOL and survival data were similar for the two groups.,Analysis of QOL outcomes with a median length of follow-up of 15.1 years (9.5-19.2) showed comparable results.
24038913,4,5,Claim,Claim,none,QOL and survival data were similar for the two groups.,A larger prospective study is justified to study the efficacy of chemotherapy only regimens in younger children.
24038913,5,1,Claim,Premise,none,A larger prospective study is justified to study the efficacy of chemotherapy only regimens in younger children.,"Patients <3 years (n = 49, 19.5% of all enrolled patients) at diagnosis had a 10-year EFS and OS of 29 ± 6.5% and 37.5 ± 7%, respectively, while for patients 3-6 years (n = 34, 13.5% of all enrolled patients) 10-year EFS and OS were 35 ± 8% and 36 ± 8%, respectively."
24038913,5,2,Claim,Premise,none,A larger prospective study is justified to study the efficacy of chemotherapy only regimens in younger children.,Molecular marker analysis showed that a smaller proportion of patients <3 years harbored TP53 mutations (P = 0.05).
24038913,5,3,Claim,Premise,none,A larger prospective study is justified to study the efficacy of chemotherapy only regimens in younger children.,Analysis of QOL outcomes with a median length of follow-up of 15.1 years (9.5-19.2) showed comparable results.
24038913,5,4,Claim,Claim,none,A larger prospective study is justified to study the efficacy of chemotherapy only regimens in younger children.,QOL and survival data were similar for the two groups.
24246508,1,2,Premise,Premise,none,"We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).","At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures."
24246508,1,3,Premise,Claim,none,"We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).",We found no effect of the intervention on 6MWT or lung volumes at any time-point.
24246508,1,4,Premise,Claim,none,"We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).","Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,"
24246508,1,5,Premise,Claim,none,"We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).","except for the bodily pain domain, four months after lung cancer surgery."
24246508,1,6,Premise,Claim,attack,"We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).",No effects of the intervention were found for any outcome after one year.
24246508,2,1,Premise,Premise,attack,"At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.","We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06)."
24246508,2,3,Premise,Claim,none,"At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.",We found no effect of the intervention on 6MWT or lung volumes at any time-point.
24246508,2,4,Premise,Claim,none,"At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.","Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,"
24246508,2,5,Premise,Claim,none,"At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.","except for the bodily pain domain, four months after lung cancer surgery."
24246508,2,6,Premise,Claim,none,"At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.",No effects of the intervention were found for any outcome after one year.
24246508,3,1,Claim,Premise,none,We found no effect of the intervention on 6MWT or lung volumes at any time-point.,"We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06)."
24246508,3,2,Claim,Premise,none,We found no effect of the intervention on 6MWT or lung volumes at any time-point.,"At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures."
24246508,3,4,Claim,Claim,none,We found no effect of the intervention on 6MWT or lung volumes at any time-point.,"Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,"
24246508,3,5,Claim,Claim,none,We found no effect of the intervention on 6MWT or lung volumes at any time-point.,"except for the bodily pain domain, four months after lung cancer surgery."
24246508,3,6,Claim,Claim,support,We found no effect of the intervention on 6MWT or lung volumes at any time-point.,No effects of the intervention were found for any outcome after one year.
24246508,4,1,Claim,Premise,none,"Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,","We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06)."
24246508,4,2,Claim,Premise,none,"Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,","At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures."
24246508,4,3,Claim,Claim,none,"Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,",We found no effect of the intervention on 6MWT or lung volumes at any time-point.
24246508,4,5,Claim,Claim,none,"Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,","except for the bodily pain domain, four months after lung cancer surgery."
24246508,4,6,Claim,Claim,support,"Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,",No effects of the intervention were found for any outcome after one year.
24246508,5,1,Claim,Premise,none,"except for the bodily pain domain, four months after lung cancer surgery.","We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06)."
24246508,5,2,Claim,Premise,none,"except for the bodily pain domain, four months after lung cancer surgery.","At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures."
24246508,5,3,Claim,Claim,none,"except for the bodily pain domain, four months after lung cancer surgery.",We found no effect of the intervention on 6MWT or lung volumes at any time-point.
24246508,5,4,Claim,Claim,attack,"except for the bodily pain domain, four months after lung cancer surgery.","Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,"
24246508,5,6,Claim,Claim,none,"except for the bodily pain domain, four months after lung cancer surgery.",No effects of the intervention were found for any outcome after one year.
24246508,6,1,Claim,Premise,none,No effects of the intervention were found for any outcome after one year.,"We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06)."
24246508,6,2,Claim,Premise,none,No effects of the intervention were found for any outcome after one year.,"At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures."
24246508,6,3,Claim,Claim,none,No effects of the intervention were found for any outcome after one year.,We found no effect of the intervention on 6MWT or lung volumes at any time-point.
24246508,6,4,Claim,Claim,none,No effects of the intervention were found for any outcome after one year.,"Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,"
24246508,6,5,Claim,Claim,none,No effects of the intervention were found for any outcome after one year.,"except for the bodily pain domain, four months after lung cancer surgery."
23609927,1,2,Premise,Premise,none,"At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05).",Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02).
23609927,1,3,Premise,Premise,none,"At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05).","At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009)."
23609927,1,4,Premise,Premise,none,"At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05).","By week 52, there were no statistically significant gender differences in any of the QOL measures."
23609927,1,5,Premise,Claim,support,"At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05).","Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer,"
23609927,1,6,Premise,Claim,none,"At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05).",early interventions can be tailored for each gender.
23609927,2,1,Premise,Premise,none,Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02).,"At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05)."
23609927,2,3,Premise,Premise,none,Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02).,"At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009)."
23609927,2,4,Premise,Premise,none,Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02).,"By week 52, there were no statistically significant gender differences in any of the QOL measures."
23609927,2,5,Premise,Claim,support,Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02).,"Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer,"
23609927,2,6,Premise,Claim,none,Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02).,early interventions can be tailored for each gender.
23609927,3,1,Premise,Premise,none,"At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009).","At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05)."
23609927,3,2,Premise,Premise,none,"At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009).",Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02).
23609927,3,4,Premise,Premise,none,"At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009).","By week 52, there were no statistically significant gender differences in any of the QOL measures."
23609927,3,5,Premise,Claim,support,"At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009).","Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer,"
23609927,3,6,Premise,Claim,none,"At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009).",early interventions can be tailored for each gender.
23609927,4,1,Premise,Premise,none,"By week 52, there were no statistically significant gender differences in any of the QOL measures.","At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05)."
23609927,4,2,Premise,Premise,none,"By week 52, there were no statistically significant gender differences in any of the QOL measures.",Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02).
23609927,4,3,Premise,Premise,none,"By week 52, there were no statistically significant gender differences in any of the QOL measures.","At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009)."
23609927,4,5,Premise,Claim,support,"By week 52, there were no statistically significant gender differences in any of the QOL measures.","Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer,"
23609927,4,6,Premise,Claim,none,"By week 52, there were no statistically significant gender differences in any of the QOL measures.",early interventions can be tailored for each gender.
23609927,5,1,Claim,Premise,none,"Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer,","At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05)."
23609927,5,2,Claim,Premise,none,"Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer,",Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02).
23609927,5,3,Claim,Premise,none,"Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer,","At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009)."
23609927,5,4,Claim,Premise,none,"Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer,","By week 52, there were no statistically significant gender differences in any of the QOL measures."
23609927,5,6,Claim,Claim,support,"Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer,",early interventions can be tailored for each gender.
23609927,6,1,Claim,Premise,none,early interventions can be tailored for each gender.,"At week 4 postintervention, women in the intervention group had statistically significant improvement in their FACT-G score, FACT-G physical well-being subscale, LASA fatigue, POMS total score, POMS fatigue-inertia subscale, and POMS confusion-bewilderment subscale (p < 0.05)."
23609927,6,2,Claim,Premise,none,early interventions can be tailored for each gender.,Men receiving the intervention had a smaller decrease in FACT-G score compared to controls (p = 0.048) and also worsened on the LASA financial (p = 0.02).
23609927,6,3,Claim,Premise,none,early interventions can be tailored for each gender.,"At week 27, the only gender difference was that intervention group men had more POMS anger-hostility (p = 0.009)."
23609927,6,4,Claim,Premise,none,early interventions can be tailored for each gender.,"By week 52, there were no statistically significant gender differences in any of the QOL measures."
23609927,6,5,Claim,Claim,none,early interventions can be tailored for each gender.,"Gender-based differences appear to play a role in the early, but not late, response to a multidisciplinary intervention to improve QOL for patients with advanced cancer,"
21905158,1,2,Premise,Premise,none,"The PA group reported significant increases in minutes of PA at 3 months (7-day PAR) and caloric expenditure (CHAMPS) compared with the control group,",but the group differences were attenuated over time.
21905158,1,3,Premise,Premise,none,"The PA group reported significant increases in minutes of PA at 3 months (7-day PAR) and caloric expenditure (CHAMPS) compared with the control group,","The PA group showed significant improvements in fitness at 3, 6, and 12 months versus the control group."
21905158,1,4,Premise,Premise,none,"The PA group reported significant increases in minutes of PA at 3 months (7-day PAR) and caloric expenditure (CHAMPS) compared with the control group,",Improvements in motivational readiness for PA were reported in the PA group only at 3 months.
21905158,1,5,Premise,Premise,none,"The PA group reported significant increases in minutes of PA at 3 months (7-day PAR) and caloric expenditure (CHAMPS) compared with the control group,","No significant group differences were found for fatigue, self-reported physical functioning, and quality of life at 3, 6, and 12 months."
21905158,1,6,Premise,Claim,support,"The PA group reported significant increases in minutes of PA at 3 months (7-day PAR) and caloric expenditure (CHAMPS) compared with the control group,","A home-based intervention improved survivors' PA and motivational readiness at 3 months and increased submaximal aerobic fitness at 3, 6, and 12 months."
21905158,2,1,Premise,Premise,attack,but the group differences were attenuated over time.,"The PA group reported significant increases in minutes of PA at 3 months (7-day PAR) and caloric expenditure (CHAMPS) compared with the control group,"
21905158,2,3,Premise,Premise,none,but the group differences were attenuated over time.,"The PA group showed significant improvements in fitness at 3, 6, and 12 months versus the control group."
21905158,2,4,Premise,Premise,none,but the group differences were attenuated over time.,Improvements in motivational readiness for PA were reported in the PA group only at 3 months.
21905158,2,5,Premise,Premise,none,but the group differences were attenuated over time.,"No significant group differences were found for fatigue, self-reported physical functioning, and quality of life at 3, 6, and 12 months."
21905158,2,6,Premise,Claim,none,but the group differences were attenuated over time.,"A home-based intervention improved survivors' PA and motivational readiness at 3 months and increased submaximal aerobic fitness at 3, 6, and 12 months."
21905158,3,1,Premise,Premise,none,"The PA group showed significant improvements in fitness at 3, 6, and 12 months versus the control group.","The PA group reported significant increases in minutes of PA at 3 months (7-day PAR) and caloric expenditure (CHAMPS) compared with the control group,"
21905158,3,2,Premise,Premise,none,"The PA group showed significant improvements in fitness at 3, 6, and 12 months versus the control group.",but the group differences were attenuated over time.
21905158,3,4,Premise,Premise,none,"The PA group showed significant improvements in fitness at 3, 6, and 12 months versus the control group.",Improvements in motivational readiness for PA were reported in the PA group only at 3 months.
21905158,3,5,Premise,Premise,none,"The PA group showed significant improvements in fitness at 3, 6, and 12 months versus the control group.","No significant group differences were found for fatigue, self-reported physical functioning, and quality of life at 3, 6, and 12 months."
21905158,3,6,Premise,Claim,support,"The PA group showed significant improvements in fitness at 3, 6, and 12 months versus the control group.","A home-based intervention improved survivors' PA and motivational readiness at 3 months and increased submaximal aerobic fitness at 3, 6, and 12 months."
21905158,4,1,Premise,Premise,none,Improvements in motivational readiness for PA were reported in the PA group only at 3 months.,"The PA group reported significant increases in minutes of PA at 3 months (7-day PAR) and caloric expenditure (CHAMPS) compared with the control group,"
21905158,4,2,Premise,Premise,none,Improvements in motivational readiness for PA were reported in the PA group only at 3 months.,but the group differences were attenuated over time.
21905158,4,3,Premise,Premise,none,Improvements in motivational readiness for PA were reported in the PA group only at 3 months.,"The PA group showed significant improvements in fitness at 3, 6, and 12 months versus the control group."
21905158,4,5,Premise,Premise,none,Improvements in motivational readiness for PA were reported in the PA group only at 3 months.,"No significant group differences were found for fatigue, self-reported physical functioning, and quality of life at 3, 6, and 12 months."
21905158,4,6,Premise,Claim,support,Improvements in motivational readiness for PA were reported in the PA group only at 3 months.,"A home-based intervention improved survivors' PA and motivational readiness at 3 months and increased submaximal aerobic fitness at 3, 6, and 12 months."
21905158,5,1,Premise,Premise,none,"No significant group differences were found for fatigue, self-reported physical functioning, and quality of life at 3, 6, and 12 months.","The PA group reported significant increases in minutes of PA at 3 months (7-day PAR) and caloric expenditure (CHAMPS) compared with the control group,"
21905158,5,2,Premise,Premise,none,"No significant group differences were found for fatigue, self-reported physical functioning, and quality of life at 3, 6, and 12 months.",but the group differences were attenuated over time.
21905158,5,3,Premise,Premise,none,"No significant group differences were found for fatigue, self-reported physical functioning, and quality of life at 3, 6, and 12 months.","The PA group showed significant improvements in fitness at 3, 6, and 12 months versus the control group."
21905158,5,4,Premise,Premise,none,"No significant group differences were found for fatigue, self-reported physical functioning, and quality of life at 3, 6, and 12 months.",Improvements in motivational readiness for PA were reported in the PA group only at 3 months.
21905158,5,6,Premise,Claim,none,"No significant group differences were found for fatigue, self-reported physical functioning, and quality of life at 3, 6, and 12 months.","A home-based intervention improved survivors' PA and motivational readiness at 3 months and increased submaximal aerobic fitness at 3, 6, and 12 months."
21905158,6,1,Claim,Premise,none,"A home-based intervention improved survivors' PA and motivational readiness at 3 months and increased submaximal aerobic fitness at 3, 6, and 12 months.","The PA group reported significant increases in minutes of PA at 3 months (7-day PAR) and caloric expenditure (CHAMPS) compared with the control group,"
21905158,6,2,Claim,Premise,none,"A home-based intervention improved survivors' PA and motivational readiness at 3 months and increased submaximal aerobic fitness at 3, 6, and 12 months.",but the group differences were attenuated over time.
21905158,6,3,Claim,Premise,none,"A home-based intervention improved survivors' PA and motivational readiness at 3 months and increased submaximal aerobic fitness at 3, 6, and 12 months.","The PA group showed significant improvements in fitness at 3, 6, and 12 months versus the control group."
21905158,6,4,Claim,Premise,none,"A home-based intervention improved survivors' PA and motivational readiness at 3 months and increased submaximal aerobic fitness at 3, 6, and 12 months.",Improvements in motivational readiness for PA were reported in the PA group only at 3 months.
21905158,6,5,Claim,Premise,none,"A home-based intervention improved survivors' PA and motivational readiness at 3 months and increased submaximal aerobic fitness at 3, 6, and 12 months.","No significant group differences were found for fatigue, self-reported physical functioning, and quality of life at 3, 6, and 12 months."
24040301,1,2,MajorClaim,Premise,none,"Postcancer fatigue is a frequently occurring problem, impairing quality of life.",Change scores of volumetric and metabolic parameters from baseline to follow-up were not significantly different between patients in the therapy and the waiting list group.
24040301,1,3,MajorClaim,Premise,none,"Postcancer fatigue is a frequently occurring problem, impairing quality of life.",Patients in the therapy group reported a significant larger decrease in fatigue scores than patients in the waiting list group.
24040301,1,4,MajorClaim,Premise,none,"Postcancer fatigue is a frequently occurring problem, impairing quality of life.",No relation was found between postcancer fatigue and the studied volumetric and metabolic markers.
24040301,1,5,MajorClaim,Claim,none,"Postcancer fatigue is a frequently occurring problem, impairing quality of life.","This may suggest that, although postcancer fatigue and chronic fatigue syndrome show strong resemblances as a clinical syndrome, the underlying physiology is different."
24040301,2,1,Premise,MajorClaim,none,Change scores of volumetric and metabolic parameters from baseline to follow-up were not significantly different between patients in the therapy and the waiting list group.,"Postcancer fatigue is a frequently occurring problem, impairing quality of life."
24040301,2,3,Premise,Premise,none,Change scores of volumetric and metabolic parameters from baseline to follow-up were not significantly different between patients in the therapy and the waiting list group.,Patients in the therapy group reported a significant larger decrease in fatigue scores than patients in the waiting list group.
24040301,2,4,Premise,Premise,none,Change scores of volumetric and metabolic parameters from baseline to follow-up were not significantly different between patients in the therapy and the waiting list group.,No relation was found between postcancer fatigue and the studied volumetric and metabolic markers.
24040301,2,5,Premise,Claim,support,Change scores of volumetric and metabolic parameters from baseline to follow-up were not significantly different between patients in the therapy and the waiting list group.,"This may suggest that, although postcancer fatigue and chronic fatigue syndrome show strong resemblances as a clinical syndrome, the underlying physiology is different."
24040301,3,1,Premise,MajorClaim,none,Patients in the therapy group reported a significant larger decrease in fatigue scores than patients in the waiting list group.,"Postcancer fatigue is a frequently occurring problem, impairing quality of life."
24040301,3,2,Premise,Premise,none,Patients in the therapy group reported a significant larger decrease in fatigue scores than patients in the waiting list group.,Change scores of volumetric and metabolic parameters from baseline to follow-up were not significantly different between patients in the therapy and the waiting list group.
24040301,3,4,Premise,Premise,none,Patients in the therapy group reported a significant larger decrease in fatigue scores than patients in the waiting list group.,No relation was found between postcancer fatigue and the studied volumetric and metabolic markers.
24040301,3,5,Premise,Claim,support,Patients in the therapy group reported a significant larger decrease in fatigue scores than patients in the waiting list group.,"This may suggest that, although postcancer fatigue and chronic fatigue syndrome show strong resemblances as a clinical syndrome, the underlying physiology is different."
24040301,4,1,Premise,MajorClaim,none,No relation was found between postcancer fatigue and the studied volumetric and metabolic markers.,"Postcancer fatigue is a frequently occurring problem, impairing quality of life."
24040301,4,2,Premise,Premise,none,No relation was found between postcancer fatigue and the studied volumetric and metabolic markers.,Change scores of volumetric and metabolic parameters from baseline to follow-up were not significantly different between patients in the therapy and the waiting list group.
24040301,4,3,Premise,Premise,none,No relation was found between postcancer fatigue and the studied volumetric and metabolic markers.,Patients in the therapy group reported a significant larger decrease in fatigue scores than patients in the waiting list group.
24040301,4,5,Premise,Claim,support,No relation was found between postcancer fatigue and the studied volumetric and metabolic markers.,"This may suggest that, although postcancer fatigue and chronic fatigue syndrome show strong resemblances as a clinical syndrome, the underlying physiology is different."
24040301,5,1,Claim,MajorClaim,none,"This may suggest that, although postcancer fatigue and chronic fatigue syndrome show strong resemblances as a clinical syndrome, the underlying physiology is different.","Postcancer fatigue is a frequently occurring problem, impairing quality of life."
24040301,5,2,Claim,Premise,none,"This may suggest that, although postcancer fatigue and chronic fatigue syndrome show strong resemblances as a clinical syndrome, the underlying physiology is different.",Change scores of volumetric and metabolic parameters from baseline to follow-up were not significantly different between patients in the therapy and the waiting list group.
24040301,5,3,Claim,Premise,none,"This may suggest that, although postcancer fatigue and chronic fatigue syndrome show strong resemblances as a clinical syndrome, the underlying physiology is different.",Patients in the therapy group reported a significant larger decrease in fatigue scores than patients in the waiting list group.
24040301,5,4,Claim,Premise,none,"This may suggest that, although postcancer fatigue and chronic fatigue syndrome show strong resemblances as a clinical syndrome, the underlying physiology is different.",No relation was found between postcancer fatigue and the studied volumetric and metabolic markers.
20679600,1,2,Premise,Premise,none,"Arm symptoms were significantly more bothersome for SNAD compared with SNR patients at 6 months (mean, 4.8 v 3.0; P < .001) and at 12 months (3.6 v 2.5; P = .006).","Longitudinally, SNAD patients were more likely to experience ipsilateral arm and breast symptoms, restricted work and social activity, and impaired QOL (P < or = .002 all items)."
20679600,1,3,Premise,Premise,none,"Arm symptoms were significantly more bothersome for SNAD compared with SNR patients at 6 months (mean, 4.8 v 3.0; P < .001) and at 12 months (3.6 v 2.5; P = .006).","From 12 to 36 months, fewer than 15% of either SNAD or SNR patients reported moderate or greater severity of any given symptom or activity limitation."
20679600,1,4,Premise,Claim,support,"Arm symptoms were significantly more bothersome for SNAD compared with SNR patients at 6 months (mean, 4.8 v 3.0; P < .001) and at 12 months (3.6 v 2.5; P = .006).",Arm morbidity was greater with SNAD than with SNR.
20679600,1,5,Premise,Claim,none,"Arm symptoms were significantly more bothersome for SNAD compared with SNR patients at 6 months (mean, 4.8 v 3.0; P < .001) and at 12 months (3.6 v 2.5; P = .006).",this study demonstrates that initial problems with either surgery resolve over time.
20679600,2,1,Premise,Premise,none,"Longitudinally, SNAD patients were more likely to experience ipsilateral arm and breast symptoms, restricted work and social activity, and impaired QOL (P < or = .002 all items).","Arm symptoms were significantly more bothersome for SNAD compared with SNR patients at 6 months (mean, 4.8 v 3.0; P < .001) and at 12 months (3.6 v 2.5; P = .006)."
20679600,2,3,Premise,Premise,none,"Longitudinally, SNAD patients were more likely to experience ipsilateral arm and breast symptoms, restricted work and social activity, and impaired QOL (P < or = .002 all items).","From 12 to 36 months, fewer than 15% of either SNAD or SNR patients reported moderate or greater severity of any given symptom or activity limitation."
20679600,2,4,Premise,Claim,none,"Longitudinally, SNAD patients were more likely to experience ipsilateral arm and breast symptoms, restricted work and social activity, and impaired QOL (P < or = .002 all items).",Arm morbidity was greater with SNAD than with SNR.
20679600,2,5,Premise,Claim,none,"Longitudinally, SNAD patients were more likely to experience ipsilateral arm and breast symptoms, restricted work and social activity, and impaired QOL (P < or = .002 all items).",this study demonstrates that initial problems with either surgery resolve over time.
20679600,3,1,Premise,Premise,none,"From 12 to 36 months, fewer than 15% of either SNAD or SNR patients reported moderate or greater severity of any given symptom or activity limitation.","Arm symptoms were significantly more bothersome for SNAD compared with SNR patients at 6 months (mean, 4.8 v 3.0; P < .001) and at 12 months (3.6 v 2.5; P = .006)."
20679600,3,2,Premise,Premise,none,"From 12 to 36 months, fewer than 15% of either SNAD or SNR patients reported moderate or greater severity of any given symptom or activity limitation.","Longitudinally, SNAD patients were more likely to experience ipsilateral arm and breast symptoms, restricted work and social activity, and impaired QOL (P < or = .002 all items)."
20679600,3,4,Premise,Claim,none,"From 12 to 36 months, fewer than 15% of either SNAD or SNR patients reported moderate or greater severity of any given symptom or activity limitation.",Arm morbidity was greater with SNAD than with SNR.
20679600,3,5,Premise,Claim,support,"From 12 to 36 months, fewer than 15% of either SNAD or SNR patients reported moderate or greater severity of any given symptom or activity limitation.",this study demonstrates that initial problems with either surgery resolve over time.
20679600,4,1,Claim,Premise,none,Arm morbidity was greater with SNAD than with SNR.,"Arm symptoms were significantly more bothersome for SNAD compared with SNR patients at 6 months (mean, 4.8 v 3.0; P < .001) and at 12 months (3.6 v 2.5; P = .006)."
20679600,4,2,Claim,Premise,none,Arm morbidity was greater with SNAD than with SNR.,"Longitudinally, SNAD patients were more likely to experience ipsilateral arm and breast symptoms, restricted work and social activity, and impaired QOL (P < or = .002 all items)."
20679600,4,3,Claim,Premise,none,Arm morbidity was greater with SNAD than with SNR.,"From 12 to 36 months, fewer than 15% of either SNAD or SNR patients reported moderate or greater severity of any given symptom or activity limitation."
20679600,4,5,Claim,Claim,none,Arm morbidity was greater with SNAD than with SNR.,this study demonstrates that initial problems with either surgery resolve over time.
20679600,5,1,Claim,Premise,none,this study demonstrates that initial problems with either surgery resolve over time.,"Arm symptoms were significantly more bothersome for SNAD compared with SNR patients at 6 months (mean, 4.8 v 3.0; P < .001) and at 12 months (3.6 v 2.5; P = .006)."
20679600,5,2,Claim,Premise,none,this study demonstrates that initial problems with either surgery resolve over time.,"Longitudinally, SNAD patients were more likely to experience ipsilateral arm and breast symptoms, restricted work and social activity, and impaired QOL (P < or = .002 all items)."
20679600,5,3,Claim,Premise,none,this study demonstrates that initial problems with either surgery resolve over time.,"From 12 to 36 months, fewer than 15% of either SNAD or SNR patients reported moderate or greater severity of any given symptom or activity limitation."
20679600,5,4,Claim,Claim,none,this study demonstrates that initial problems with either surgery resolve over time.,Arm morbidity was greater with SNAD than with SNR.
8839553,1,2,Claim,Premise,none,Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;,No difference in survival was detected between the groups;
8839553,1,3,Claim,Premise,none,Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24)."
8839553,1,4,Claim,Premise,none,Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;,Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).
8839553,1,5,Claim,Premise,none,Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;,"There were no significant differences in the 30-day mortality, morbidity, or causes of death."
8839553,1,6,Claim,Premise,none,Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3)."
8839553,1,7,Claim,Premise,none,Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;,The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.
8839553,1,8,Claim,Claim,none,Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;,This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.
8839553,1,9,Claim,Claim,none,Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis."
8839553,2,1,Premise,Claim,none,No difference in survival was detected between the groups;,Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;
8839553,2,3,Premise,Premise,none,No difference in survival was detected between the groups;,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24)."
8839553,2,4,Premise,Premise,none,No difference in survival was detected between the groups;,Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).
8839553,2,5,Premise,Premise,none,No difference in survival was detected between the groups;,"There were no significant differences in the 30-day mortality, morbidity, or causes of death."
8839553,2,6,Premise,Premise,none,No difference in survival was detected between the groups;,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3)."
8839553,2,7,Premise,Premise,none,No difference in survival was detected between the groups;,The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.
8839553,2,8,Premise,Claim,support,No difference in survival was detected between the groups;,This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.
8839553,2,9,Premise,Claim,none,No difference in survival was detected between the groups;,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis."
8839553,3,1,Premise,Claim,none,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24).",Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;
8839553,3,2,Premise,Premise,support,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24).",No difference in survival was detected between the groups;
8839553,3,4,Premise,Premise,none,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24).",Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).
8839553,3,5,Premise,Premise,none,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24).","There were no significant differences in the 30-day mortality, morbidity, or causes of death."
8839553,3,6,Premise,Premise,none,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24).","Extracranial metastases was an important predictor of mortality (relative risk, 2.3)."
8839553,3,7,Premise,Premise,none,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24).",The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.
8839553,3,8,Premise,Claim,none,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24).",This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.
8839553,3,9,Premise,Claim,none,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24).","Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis."
8839553,4,1,Premise,Claim,none,Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).,Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;
8839553,4,2,Premise,Premise,none,Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).,No difference in survival was detected between the groups;
8839553,4,3,Premise,Premise,none,Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24)."
8839553,4,5,Premise,Premise,none,Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).,"There were no significant differences in the 30-day mortality, morbidity, or causes of death."
8839553,4,6,Premise,Premise,none,Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3)."
8839553,4,7,Premise,Premise,none,Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).,The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.
8839553,4,8,Premise,Claim,support,Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).,This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.
8839553,4,9,Premise,Claim,none,Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis."
8839553,5,1,Premise,Claim,none,"There were no significant differences in the 30-day mortality, morbidity, or causes of death.",Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;
8839553,5,2,Premise,Premise,none,"There were no significant differences in the 30-day mortality, morbidity, or causes of death.",No difference in survival was detected between the groups;
8839553,5,3,Premise,Premise,none,"There were no significant differences in the 30-day mortality, morbidity, or causes of death.","the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24)."
8839553,5,4,Premise,Premise,none,"There were no significant differences in the 30-day mortality, morbidity, or causes of death.",Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).
8839553,5,6,Premise,Premise,none,"There were no significant differences in the 30-day mortality, morbidity, or causes of death.","Extracranial metastases was an important predictor of mortality (relative risk, 2.3)."
8839553,5,7,Premise,Premise,none,"There were no significant differences in the 30-day mortality, morbidity, or causes of death.",The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.
8839553,5,8,Premise,Claim,support,"There were no significant differences in the 30-day mortality, morbidity, or causes of death.",This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.
8839553,5,9,Premise,Claim,none,"There were no significant differences in the 30-day mortality, morbidity, or causes of death.","Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis."
8839553,6,1,Premise,Claim,none,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3).",Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;
8839553,6,2,Premise,Premise,none,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3).",No difference in survival was detected between the groups;
8839553,6,3,Premise,Premise,none,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3).","the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24)."
8839553,6,4,Premise,Premise,none,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3).",Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).
8839553,6,5,Premise,Premise,none,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3).","There were no significant differences in the 30-day mortality, morbidity, or causes of death."
8839553,6,7,Premise,Premise,none,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3).",The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.
8839553,6,8,Premise,Claim,none,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3).",This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.
8839553,6,9,Premise,Claim,none,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3).","Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis."
8839553,7,1,Premise,Claim,none,The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.,Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;
8839553,7,2,Premise,Premise,none,The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.,No difference in survival was detected between the groups;
8839553,7,3,Premise,Premise,none,The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24)."
8839553,7,4,Premise,Premise,none,The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.,Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).
8839553,7,5,Premise,Premise,none,The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.,"There were no significant differences in the 30-day mortality, morbidity, or causes of death."
8839553,7,6,Premise,Premise,none,The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3)."
8839553,7,8,Premise,Claim,support,The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.,This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.
8839553,7,9,Premise,Claim,none,The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis."
8839553,8,1,Claim,Claim,none,This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.,Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;
8839553,8,2,Claim,Premise,none,This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.,No difference in survival was detected between the groups;
8839553,8,3,Claim,Premise,none,This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.,"the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24)."
8839553,8,4,Claim,Premise,none,This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.,Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).
8839553,8,5,Claim,Premise,none,This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.,"There were no significant differences in the 30-day mortality, morbidity, or causes of death."
8839553,8,6,Claim,Premise,none,This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.,"Extracranial metastases was an important predictor of mortality (relative risk, 2.3)."
8839553,8,7,Claim,Premise,none,This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.,The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.
8839553,8,9,Claim,Claim,support,This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis."
8839553,9,1,Claim,Claim,none,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis.",Cerebral metastasis is a common oncologic problem that occurs in 15-30% of cancer patients;
8839553,9,2,Claim,Premise,none,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis.",No difference in survival was detected between the groups;
8839553,9,3,Claim,Premise,none,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis.","the median survival for the radiation group was 6.3 months (95% confidence interval, 3-11.4) compared with 5.6 months for the surgery plus radiation group (95% confidence interval, 3.9-7.2) (P = 0.24)."
8839553,9,4,Claim,Premise,none,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis.",Most patients died within the first year (69.8% in the radiation arm vs. 87.8% in the surgery plus radiation arm).
8839553,9,5,Claim,Premise,none,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis.","There were no significant differences in the 30-day mortality, morbidity, or causes of death."
8839553,9,6,Claim,Premise,none,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis.","Extracranial metastases was an important predictor of mortality (relative risk, 2.3)."
8839553,9,7,Claim,Premise,none,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis.",The mean proportion of days that the Karnofsky performance status was > or = 70% did not differ between the 2 groups.
8839553,9,8,Claim,Claim,none,"Thus, the efficacy of surgery plus radiation compared with radiation alone needs to be addressed by further clinical trials and/or a meta-analysis.",This trial failed to demonstrate that the addition of surgery to radiation therapy improved outcome of patients with a single brain metastasis.
18589314,1,2,Premise,Premise,none,"The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281).","The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586)."
18589314,1,3,Premise,Premise,none,"The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281).","Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy)."
18589314,1,4,Premise,Premise,none,"The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281).","The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107)."
18589314,1,5,Premise,Premise,none,"The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281).",The 24-month cumulative cost of UAE is lower than that of hysterectomy.
18589314,1,6,Premise,Claim,support,"The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281).","From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids."
18589314,2,1,Premise,Premise,none,"The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586).","The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281)."
18589314,2,3,Premise,Premise,none,"The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586).","Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy)."
18589314,2,4,Premise,Premise,none,"The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586).","The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107)."
18589314,2,5,Premise,Premise,none,"The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586).",The 24-month cumulative cost of UAE is lower than that of hysterectomy.
18589314,2,6,Premise,Claim,support,"The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586).","From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids."
18589314,3,1,Premise,Premise,none,"Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy).","The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281)."
18589314,3,2,Premise,Premise,none,"Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy).","The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586)."
18589314,3,4,Premise,Premise,none,"Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy).","The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107)."
18589314,3,5,Premise,Premise,none,"Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy).",The 24-month cumulative cost of UAE is lower than that of hysterectomy.
18589314,3,6,Premise,Claim,support,"Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy).","From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids."
18589314,4,1,Premise,Premise,none,"The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107).","The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281)."
18589314,4,2,Premise,Premise,none,"The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107).","The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586)."
18589314,4,3,Premise,Premise,none,"The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107).","Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy)."
18589314,4,5,Premise,Premise,none,"The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107).",The 24-month cumulative cost of UAE is lower than that of hysterectomy.
18589314,4,6,Premise,Claim,support,"The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107).","From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids."
18589314,5,1,Premise,Premise,none,The 24-month cumulative cost of UAE is lower than that of hysterectomy.,"The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281)."
18589314,5,2,Premise,Premise,none,The 24-month cumulative cost of UAE is lower than that of hysterectomy.,"The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586)."
18589314,5,3,Premise,Premise,none,The 24-month cumulative cost of UAE is lower than that of hysterectomy.,"Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy)."
18589314,5,4,Premise,Premise,none,The 24-month cumulative cost of UAE is lower than that of hysterectomy.,"The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107)."
18589314,5,6,Premise,Claim,support,The 24-month cumulative cost of UAE is lower than that of hysterectomy.,"From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids."
18589314,6,1,Claim,Premise,none,"From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids.","The mean total costs per patient in the UAE group were significantly lower than those in the hysterectomy group ($11,626 vs $18,563; mean difference, -$6,936 [-37%], 95% CI: -$9,548, $4,281)."
18589314,6,2,Claim,Premise,none,"From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids.","The direct medical in-hospital costs were significantly lower in the UAE group: $6,688 vs $8,313 (mean difference, -$1,624 [-20%], 95% CI: -$2,605, -$586)."
18589314,6,3,Claim,Premise,none,"From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids.","Direct medical out-of-hospital and direct nonmedical costs were low in both groups (mean cost difference, $156 in favor of hysterectomy)."
18589314,6,4,Claim,Premise,none,"From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids.","The costs related to absence from work differed significantly between the treatment strategies in favor of UAE (mean difference, -$5,453; 95% CI: -$7,718, -$3,107)."
18589314,6,5,Claim,Premise,none,"From a societal economic perspective, UAE is the superior treatment strategy in women with symptomatic uterine fibroids.",The 24-month cumulative cost of UAE is lower than that of hysterectomy.
8648360,1,2,Premise,Premise,none,A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.,"After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group."
8648360,1,3,Premise,Premise,none,A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.,This difference of 2.0 kg was statistically significant (P = .04).
8648360,1,4,Premise,Premise,none,A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.,"During the study, several areas of QL deteriorated in the total group of patients."
8648360,1,5,Premise,Claim,none,A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.,"With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated."
8648360,1,6,Premise,Premise,none,A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.,The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.
8648360,1,7,Premise,Claim,support,A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.,"In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss."
8648360,1,8,Premise,Claim,none,A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.,"However, general QL in the present study was not measurably influenced by MPA treatment."
8648360,2,1,Premise,Premise,none,"After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group.",A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.
8648360,2,3,Premise,Premise,none,"After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group.",This difference of 2.0 kg was statistically significant (P = .04).
8648360,2,4,Premise,Premise,none,"After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group.","During the study, several areas of QL deteriorated in the total group of patients."
8648360,2,5,Premise,Claim,none,"After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group.","With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated."
8648360,2,6,Premise,Premise,none,"After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group.",The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.
8648360,2,7,Premise,Claim,support,"After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group.","In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss."
8648360,2,8,Premise,Claim,none,"After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group.","However, general QL in the present study was not measurably influenced by MPA treatment."
8648360,3,1,Premise,Premise,none,This difference of 2.0 kg was statistically significant (P = .04).,A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.
8648360,3,2,Premise,Premise,support,This difference of 2.0 kg was statistically significant (P = .04).,"After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group."
8648360,3,4,Premise,Premise,none,This difference of 2.0 kg was statistically significant (P = .04).,"During the study, several areas of QL deteriorated in the total group of patients."
8648360,3,5,Premise,Claim,none,This difference of 2.0 kg was statistically significant (P = .04).,"With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated."
8648360,3,6,Premise,Premise,none,This difference of 2.0 kg was statistically significant (P = .04).,The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.
8648360,3,7,Premise,Claim,none,This difference of 2.0 kg was statistically significant (P = .04).,"In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss."
8648360,3,8,Premise,Claim,none,This difference of 2.0 kg was statistically significant (P = .04).,"However, general QL in the present study was not measurably influenced by MPA treatment."
8648360,4,1,Premise,Premise,none,"During the study, several areas of QL deteriorated in the total group of patients.",A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.
8648360,4,2,Premise,Premise,none,"During the study, several areas of QL deteriorated in the total group of patients.","After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group."
8648360,4,3,Premise,Premise,none,"During the study, several areas of QL deteriorated in the total group of patients.",This difference of 2.0 kg was statistically significant (P = .04).
8648360,4,5,Premise,Claim,support,"During the study, several areas of QL deteriorated in the total group of patients.","With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated."
8648360,4,6,Premise,Premise,none,"During the study, several areas of QL deteriorated in the total group of patients.",The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.
8648360,4,7,Premise,Claim,none,"During the study, several areas of QL deteriorated in the total group of patients.","In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss."
8648360,4,8,Premise,Claim,none,"During the study, several areas of QL deteriorated in the total group of patients.","However, general QL in the present study was not measurably influenced by MPA treatment."
8648360,5,1,Claim,Premise,none,"With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated.",A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.
8648360,5,2,Claim,Premise,none,"With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated.","After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group."
8648360,5,3,Claim,Premise,none,"With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated.",This difference of 2.0 kg was statistically significant (P = .04).
8648360,5,4,Claim,Premise,none,"With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated.","During the study, several areas of QL deteriorated in the total group of patients."
8648360,5,6,Claim,Premise,none,"With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated.",The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.
8648360,5,7,Claim,Claim,none,"With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated.","In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss."
8648360,5,8,Claim,Claim,support,"With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated.","However, general QL in the present study was not measurably influenced by MPA treatment."
8648360,6,1,Premise,Premise,none,The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.,A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.
8648360,6,2,Premise,Premise,none,The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.,"After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group."
8648360,6,3,Premise,Premise,none,The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.,This difference of 2.0 kg was statistically significant (P = .04).
8648360,6,4,Premise,Premise,none,The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.,"During the study, several areas of QL deteriorated in the total group of patients."
8648360,6,5,Premise,Claim,none,The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.,"With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated."
8648360,6,7,Premise,Claim,support,The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.,"In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss."
8648360,6,8,Premise,Claim,none,The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.,"However, general QL in the present study was not measurably influenced by MPA treatment."
8648360,7,1,Claim,Premise,none,"In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss.",A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.
8648360,7,2,Claim,Premise,none,"In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss.","After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group."
8648360,7,3,Claim,Premise,none,"In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss.",This difference of 2.0 kg was statistically significant (P = .04).
8648360,7,4,Claim,Premise,none,"In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss.","During the study, several areas of QL deteriorated in the total group of patients."
8648360,7,5,Claim,Claim,none,"In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss.","With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated."
8648360,7,6,Claim,Premise,none,"In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss.",The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.
8648360,7,8,Claim,Claim,none,"In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss.","However, general QL in the present study was not measurably influenced by MPA treatment."
8648360,8,1,Claim,Premise,none,"However, general QL in the present study was not measurably influenced by MPA treatment.",A beneficial effect of MPA on appetite was observed after both 6 weeks (P = .008) and 12 weeks (P = .01) of treatment.
8648360,8,2,Claim,Premise,none,"However, general QL in the present study was not measurably influenced by MPA treatment.","After 12 weeks, a mean weight gain of 0.6 +/- 4.4 kg was seen in the MPA, versus an ongoing mean weight loss of 1.4 +/- 4.6 kg in the placebo group."
8648360,8,3,Claim,Premise,none,"However, general QL in the present study was not measurably influenced by MPA treatment.",This difference of 2.0 kg was statistically significant (P = .04).
8648360,8,4,Claim,Premise,none,"However, general QL in the present study was not measurably influenced by MPA treatment.","During the study, several areas of QL deteriorated in the total group of patients."
8648360,8,5,Claim,Claim,none,"However, general QL in the present study was not measurably influenced by MPA treatment.","With the exception of an improvement in appetite and possible also a reduction in nausea and vomiting, no measurable beneficial effects of MPA on QL could be demonstrated."
8648360,8,6,Claim,Premise,none,"However, general QL in the present study was not measurably influenced by MPA treatment.",The side effects profile of MPA was favorable: only a trend toward an increase in (usually mild) peripheral edema was observed.
8648360,8,7,Claim,Claim,attack,"However, general QL in the present study was not measurably influenced by MPA treatment.","In weight-losing, advanced-stage non-hormone-sensitive cancer patients, MPA exhibits a mild side effects profile, has a beneficial effect on appetite, and may prevent further weight loss."
10526263,1,2,Claim,Premise,none,"For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.","After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free."
10526263,1,3,Claim,Premise,none,"For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.",A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
10526263,1,4,Claim,Premise,none,"For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.",Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
10526263,1,5,Claim,Claim,none,"For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.",the survival rates were by-and-large the same for the two groups.
10526263,1,6,Claim,Claim,none,"For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.","Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture."
10526263,1,7,Claim,Claim,none,"For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.",The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
10526263,1,8,Claim,Claim,none,"For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck.","Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation."
10526263,2,1,Premise,Claim,none,"After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.","For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck."
10526263,2,3,Premise,Premise,none,"After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.",A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
10526263,2,4,Premise,Premise,none,"After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.",Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
10526263,2,5,Premise,Claim,support,"After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.",the survival rates were by-and-large the same for the two groups.
10526263,2,6,Premise,Claim,none,"After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.","Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture."
10526263,2,7,Premise,Claim,none,"After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.",The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
10526263,2,8,Premise,Claim,none,"After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free.","Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation."
10526263,3,1,Premise,Claim,none,A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).,"For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck."
10526263,3,2,Premise,Premise,none,A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).,"After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free."
10526263,3,4,Premise,Premise,none,A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).,Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
10526263,3,5,Premise,Claim,support,A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).,the survival rates were by-and-large the same for the two groups.
10526263,3,6,Premise,Claim,none,A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).,"Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture."
10526263,3,7,Premise,Claim,none,A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).,The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
10526263,3,8,Premise,Claim,none,A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).,"Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation."
10526263,4,1,Premise,Claim,none,Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).,"For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck."
10526263,4,2,Premise,Premise,none,Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).,"After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free."
10526263,4,3,Premise,Premise,none,Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).,A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
10526263,4,5,Premise,Claim,none,Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).,the survival rates were by-and-large the same for the two groups.
10526263,4,6,Premise,Claim,none,Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).,"Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture."
10526263,4,7,Premise,Claim,none,Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).,The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
10526263,4,8,Premise,Claim,none,Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).,"Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation."
10526263,5,1,Claim,Claim,none,the survival rates were by-and-large the same for the two groups.,"For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck."
10526263,5,2,Claim,Premise,none,the survival rates were by-and-large the same for the two groups.,"After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free."
10526263,5,3,Claim,Premise,none,the survival rates were by-and-large the same for the two groups.,A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
10526263,5,4,Claim,Premise,none,the survival rates were by-and-large the same for the two groups.,Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
10526263,5,6,Claim,Claim,none,the survival rates were by-and-large the same for the two groups.,"Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture."
10526263,5,7,Claim,Claim,support,the survival rates were by-and-large the same for the two groups.,The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
10526263,5,8,Claim,Claim,none,the survival rates were by-and-large the same for the two groups.,"Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation."
10526263,6,1,Claim,Claim,none,"Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.","For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck."
10526263,6,2,Claim,Premise,none,"Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.","After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free."
10526263,6,3,Claim,Premise,none,"Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.",A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
10526263,6,4,Claim,Premise,none,"Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.",Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
10526263,6,5,Claim,Claim,none,"Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.",the survival rates were by-and-large the same for the two groups.
10526263,6,7,Claim,Claim,none,"Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.",The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
10526263,6,8,Claim,Claim,support,"Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture.","Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation."
10526263,7,1,Claim,Claim,none,The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.,"For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck."
10526263,7,2,Claim,Premise,none,The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.,"After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free."
10526263,7,3,Claim,Premise,none,The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.,A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
10526263,7,4,Claim,Premise,none,The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.,Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
10526263,7,5,Claim,Claim,none,The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.,the survival rates were by-and-large the same for the two groups.
10526263,7,6,Claim,Claim,none,The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.,"Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture."
10526263,7,8,Claim,Claim,none,The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.,"Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation."
10526263,8,1,Claim,Claim,none,"Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.","For several decades, both preoperative intra-arterial chemotherapy and preoperative irradiation have been accepted treatments for patients with tumors of the head and neck."
10526263,8,2,Claim,Premise,none,"Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.","After 5 years, 18 of the 47 patients who received chemotherapy and 15 of the 48 patients who received irradiation were still alive and tumor free."
10526263,8,3,Claim,Premise,none,"Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.",A few more patients had died of recurrence or regional metastasis in the chemotherapy group (23 patients) than in the irradiation group (20 patients).
10526263,8,4,Claim,Premise,none,"Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.",Occurrence of a second carcinoma was 3 times as frequent in the irradiation group (9 patients) as in the chemotherapy group (3 patients).
10526263,8,5,Claim,Claim,none,"Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.",the survival rates were by-and-large the same for the two groups.
10526263,8,6,Claim,Claim,none,"Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.","Regarding postoperative quality of life, the chemotherapy group presented a more favorable picture."
10526263,8,7,Claim,Claim,none,"Regarding postoperative quality of life, patients who underwent intra-arterial chemotherapy appeared to be in a slightly more favorable situation.",The long term survival results subsequent to preoperative intra-arterial chemotherapy or preoperative radiotherapy were practically the same.
23598172,1,2,Premise,Premise,none,"Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).","Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001)."
23598172,1,3,Premise,Premise,none,"Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).","Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,"
23598172,1,4,Premise,Premise,none,"Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).",but decreased at end-of-treatment.
23598172,1,5,Premise,Premise,none,"Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).","Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients."
23598172,1,6,Premise,Premise,none,"Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).","In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020)."
23598172,1,7,Premise,Claim,support,"Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).","overall survival, a secondary endpoint for the study, did not differ between the two groups,"
23598172,1,8,Premise,Claim,none,"Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).",investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
23598172,1,9,Premise,Claim,none,"Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).",These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
23598172,2,1,Premise,Premise,none,"Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).","Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744)."
23598172,2,3,Premise,Premise,none,"Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).","Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,"
23598172,2,4,Premise,Premise,none,"Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).",but decreased at end-of-treatment.
23598172,2,5,Premise,Premise,none,"Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).","Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients."
23598172,2,6,Premise,Premise,none,"Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).","In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020)."
23598172,2,7,Premise,Claim,none,"Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).","overall survival, a secondary endpoint for the study, did not differ between the two groups,"
23598172,2,8,Premise,Claim,support,"Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).",investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
23598172,2,9,Premise,Claim,none,"Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).",These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
23598172,3,1,Premise,Premise,none,"Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,","Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744)."
23598172,3,2,Premise,Premise,none,"Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,","Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001)."
23598172,3,4,Premise,Premise,none,"Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,",but decreased at end-of-treatment.
23598172,3,5,Premise,Premise,none,"Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,","Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients."
23598172,3,6,Premise,Premise,none,"Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,","In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020)."
23598172,3,7,Premise,Claim,none,"Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,","overall survival, a secondary endpoint for the study, did not differ between the two groups,"
23598172,3,8,Premise,Claim,none,"Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,",investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
23598172,3,9,Premise,Claim,support,"Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,",These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
23598172,4,1,Premise,Premise,none,but decreased at end-of-treatment.,"Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744)."
23598172,4,2,Premise,Premise,none,but decreased at end-of-treatment.,"Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001)."
23598172,4,3,Premise,Premise,attack,but decreased at end-of-treatment.,"Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,"
23598172,4,5,Premise,Premise,none,but decreased at end-of-treatment.,"Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients."
23598172,4,6,Premise,Premise,none,but decreased at end-of-treatment.,"In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020)."
23598172,4,7,Premise,Claim,none,but decreased at end-of-treatment.,"overall survival, a secondary endpoint for the study, did not differ between the two groups,"
23598172,4,8,Premise,Claim,none,but decreased at end-of-treatment.,investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
23598172,4,9,Premise,Claim,none,but decreased at end-of-treatment.,These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
23598172,5,1,Premise,Premise,none,"Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.","Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744)."
23598172,5,2,Premise,Premise,none,"Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.","Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001)."
23598172,5,3,Premise,Premise,none,"Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.","Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,"
23598172,5,4,Premise,Premise,none,"Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.",but decreased at end-of-treatment.
23598172,5,6,Premise,Premise,none,"Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.","In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020)."
23598172,5,7,Premise,Claim,none,"Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.","overall survival, a secondary endpoint for the study, did not differ between the two groups,"
23598172,5,8,Premise,Claim,none,"Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.",investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
23598172,5,9,Premise,Claim,support,"Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.",These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
23598172,6,1,Premise,Premise,none,"In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).","Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744)."
23598172,6,2,Premise,Premise,none,"In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).","Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001)."
23598172,6,3,Premise,Premise,none,"In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).","Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,"
23598172,6,4,Premise,Premise,none,"In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).",but decreased at end-of-treatment.
23598172,6,5,Premise,Premise,none,"In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).","Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients."
23598172,6,7,Premise,Claim,support,"In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).","overall survival, a secondary endpoint for the study, did not differ between the two groups,"
23598172,6,8,Premise,Claim,none,"In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).",investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
23598172,6,9,Premise,Claim,none,"In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).",These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
23598172,7,1,Claim,Premise,none,"overall survival, a secondary endpoint for the study, did not differ between the two groups,","Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744)."
23598172,7,2,Claim,Premise,none,"overall survival, a secondary endpoint for the study, did not differ between the two groups,","Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001)."
23598172,7,3,Claim,Premise,none,"overall survival, a secondary endpoint for the study, did not differ between the two groups,","Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,"
23598172,7,4,Claim,Premise,none,"overall survival, a secondary endpoint for the study, did not differ between the two groups,",but decreased at end-of-treatment.
23598172,7,5,Claim,Premise,none,"overall survival, a secondary endpoint for the study, did not differ between the two groups,","Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients."
23598172,7,6,Claim,Premise,none,"overall survival, a secondary endpoint for the study, did not differ between the two groups,","In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020)."
23598172,7,8,Claim,Claim,none,"overall survival, a secondary endpoint for the study, did not differ between the two groups,",investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
23598172,7,9,Claim,Claim,attack,"overall survival, a secondary endpoint for the study, did not differ between the two groups,",These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
23598172,8,1,Claim,Premise,none,investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.,"Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744)."
23598172,8,2,Claim,Premise,none,investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.,"Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001)."
23598172,8,3,Claim,Premise,none,investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.,"Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,"
23598172,8,4,Claim,Premise,none,investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.,but decreased at end-of-treatment.
23598172,8,5,Claim,Premise,none,investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.,"Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients."
23598172,8,6,Claim,Premise,none,investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.,"In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020)."
23598172,8,7,Claim,Claim,none,investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.,"overall survival, a secondary endpoint for the study, did not differ between the two groups,"
23598172,8,9,Claim,Claim,support,investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.,These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
23598172,9,1,Claim,Premise,none,These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.,"Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744)."
23598172,9,2,Claim,Premise,none,These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.,"Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001)."
23598172,9,3,Claim,Premise,none,These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.,"Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,"
23598172,9,4,Claim,Premise,none,These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.,but decreased at end-of-treatment.
23598172,9,5,Claim,Premise,none,These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.,"Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients."
23598172,9,6,Claim,Premise,none,These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.,"In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020)."
23598172,9,7,Claim,Claim,none,These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.,"overall survival, a secondary endpoint for the study, did not differ between the two groups,"
23598172,9,8,Claim,Claim,none,These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.,investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
11370551,1,2,Claim,Claim,none,Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).,"In recent years, encouraging results of preoperative radiotherapy have been reported."
11370551,1,3,Claim,Premise,none,Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).,"Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity"
11370551,1,4,Claim,Premise,none,Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).,"The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea."
11370551,1,5,Claim,Premise,none,Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea."
11370551,1,6,Claim,Premise,none,Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).,"Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing."
11370551,1,7,Claim,Claim,none,Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).,"The patient accrual of our trial is satisfactory,"
11370551,1,8,Claim,Claim,none,Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).,neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
11370551,2,1,Claim,Claim,none,"In recent years, encouraging results of preoperative radiotherapy have been reported.",Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
11370551,2,3,Claim,Premise,none,"In recent years, encouraging results of preoperative radiotherapy have been reported.","Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity"
11370551,2,4,Claim,Premise,none,"In recent years, encouraging results of preoperative radiotherapy have been reported.","The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea."
11370551,2,5,Claim,Premise,none,"In recent years, encouraging results of preoperative radiotherapy have been reported.","Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea."
11370551,2,6,Claim,Premise,none,"In recent years, encouraging results of preoperative radiotherapy have been reported.","Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing."
11370551,2,7,Claim,Claim,none,"In recent years, encouraging results of preoperative radiotherapy have been reported.","The patient accrual of our trial is satisfactory,"
11370551,2,8,Claim,Claim,none,"In recent years, encouraging results of preoperative radiotherapy have been reported.",neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
11370551,3,1,Premise,Claim,none,"Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity",Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
11370551,3,2,Premise,Claim,none,"Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity","In recent years, encouraging results of preoperative radiotherapy have been reported."
11370551,3,4,Premise,Premise,none,"Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity","The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea."
11370551,3,5,Premise,Premise,none,"Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity","Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea."
11370551,3,6,Premise,Premise,none,"Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity","Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing."
11370551,3,7,Premise,Claim,none,"Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity","The patient accrual of our trial is satisfactory,"
11370551,3,8,Premise,Claim,support,"Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity",neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
11370551,4,1,Premise,Claim,none,"The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.",Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
11370551,4,2,Premise,Claim,none,"The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.","In recent years, encouraging results of preoperative radiotherapy have been reported."
11370551,4,3,Premise,Premise,none,"The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.","Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity"
11370551,4,5,Premise,Premise,none,"The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.","Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea."
11370551,4,6,Premise,Premise,none,"The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.","Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing."
11370551,4,7,Premise,Claim,none,"The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.","The patient accrual of our trial is satisfactory,"
11370551,4,8,Premise,Claim,support,"The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea.",neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
11370551,5,1,Premise,Claim,none,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.",Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
11370551,5,2,Premise,Claim,none,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.","In recent years, encouraging results of preoperative radiotherapy have been reported."
11370551,5,3,Premise,Premise,none,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.","Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity"
11370551,5,4,Premise,Premise,none,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.","The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea."
11370551,5,6,Premise,Premise,none,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.","Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing."
11370551,5,7,Premise,Claim,none,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.","The patient accrual of our trial is satisfactory,"
11370551,5,8,Premise,Claim,support,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea.",neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
11370551,6,1,Premise,Claim,none,"Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.",Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
11370551,6,2,Premise,Claim,none,"Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.","In recent years, encouraging results of preoperative radiotherapy have been reported."
11370551,6,3,Premise,Premise,none,"Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.","Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity"
11370551,6,4,Premise,Premise,none,"Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.","The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea."
11370551,6,5,Premise,Premise,none,"Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.","Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea."
11370551,6,7,Premise,Claim,none,"Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.","The patient accrual of our trial is satisfactory,"
11370551,6,8,Premise,Claim,support,"Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing.",neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
11370551,7,1,Claim,Claim,none,"The patient accrual of our trial is satisfactory,",Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
11370551,7,2,Claim,Claim,none,"The patient accrual of our trial is satisfactory,","In recent years, encouraging results of preoperative radiotherapy have been reported."
11370551,7,3,Claim,Premise,none,"The patient accrual of our trial is satisfactory,","Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity"
11370551,7,4,Claim,Premise,none,"The patient accrual of our trial is satisfactory,","The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea."
11370551,7,5,Claim,Premise,none,"The patient accrual of our trial is satisfactory,","Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea."
11370551,7,6,Claim,Premise,none,"The patient accrual of our trial is satisfactory,","Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing."
11370551,7,8,Claim,Claim,none,"The patient accrual of our trial is satisfactory,",neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.
11370551,8,1,Claim,Claim,none,neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.,Postoperative radiochemotherapy is recommended for patients with advanced disease (pT3/4 or pN+).
11370551,8,2,Claim,Claim,none,neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.,"In recent years, encouraging results of preoperative radiotherapy have been reported."
11370551,8,3,Claim,Premise,none,neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.,"Acute toxicity (WHO) of radiochemotherapy was low, with less than 15% of patients experiencing Grade 3 or higher toxicity"
11370551,8,4,Claim,Premise,none,neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.,"The principal toxicity was diarrhea, with 12% in the postoperative radiochemotherapy arm and 10% in the preoperative radiochemotherapy arm having Grade-3, and 1% in either arm having Grade-4 diarrhea."
11370551,8,5,Claim,Premise,none,neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.,"Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering Grade 3 or greater leukopenia or nausea."
11370551,8,6,Claim,Premise,none,neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.,"Postoperative complication rates were similar in both arms, with 12% (postoperative radiochemotherapy) and 13% (preoperative radiochemotherapy) of patients, respectively, suffering from anastomotic leakage, 4% (postoperative radiochemotherapy) and 3% (preoperative radiochemotherapy) from postoperative bleeding, and 6% (postoperative radiochemotherapy) and 5% (preoperative radiochemotherapy) from delayed wound healing."
11370551,8,7,Claim,Claim,none,neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity.,"The patient accrual of our trial is satisfactory,"
17848814,1,2,Claim,Premise,none,Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.,The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.
17848814,1,3,Claim,Premise,none,Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.,There was an improvement of muscle strength at the end of rehabilitation for both groups.
17848814,1,4,Claim,Premise,none,Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.,The increase from t1 to t2 was significantly higher for the training group.
17848814,1,5,Claim,Premise,none,Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,"
17848814,1,6,Claim,Premise,none,Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.,but further improvement in the follow-up (t3) was only observed in the training group.
17848814,1,7,Claim,Premise,none,Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group."
17848814,1,8,Claim,Claim,none,Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.,Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.
17848814,2,1,Premise,Claim,none,The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.,Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.
17848814,2,3,Premise,Premise,none,The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.,There was an improvement of muscle strength at the end of rehabilitation for both groups.
17848814,2,4,Premise,Premise,none,The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.,The increase from t1 to t2 was significantly higher for the training group.
17848814,2,5,Premise,Premise,none,The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,"
17848814,2,6,Premise,Premise,none,The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.,but further improvement in the follow-up (t3) was only observed in the training group.
17848814,2,7,Premise,Premise,none,The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group."
17848814,2,8,Premise,Claim,support,The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.,Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.
17848814,3,1,Premise,Claim,none,There was an improvement of muscle strength at the end of rehabilitation for both groups.,Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.
17848814,3,2,Premise,Premise,none,There was an improvement of muscle strength at the end of rehabilitation for both groups.,The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.
17848814,3,4,Premise,Premise,none,There was an improvement of muscle strength at the end of rehabilitation for both groups.,The increase from t1 to t2 was significantly higher for the training group.
17848814,3,5,Premise,Premise,none,There was an improvement of muscle strength at the end of rehabilitation for both groups.,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,"
17848814,3,6,Premise,Premise,none,There was an improvement of muscle strength at the end of rehabilitation for both groups.,but further improvement in the follow-up (t3) was only observed in the training group.
17848814,3,7,Premise,Premise,none,There was an improvement of muscle strength at the end of rehabilitation for both groups.,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group."
17848814,3,8,Premise,Claim,support,There was an improvement of muscle strength at the end of rehabilitation for both groups.,Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.
17848814,4,1,Premise,Claim,none,The increase from t1 to t2 was significantly higher for the training group.,Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.
17848814,4,2,Premise,Premise,none,The increase from t1 to t2 was significantly higher for the training group.,The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.
17848814,4,3,Premise,Premise,none,The increase from t1 to t2 was significantly higher for the training group.,There was an improvement of muscle strength at the end of rehabilitation for both groups.
17848814,4,5,Premise,Premise,none,The increase from t1 to t2 was significantly higher for the training group.,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,"
17848814,4,6,Premise,Premise,none,The increase from t1 to t2 was significantly higher for the training group.,but further improvement in the follow-up (t3) was only observed in the training group.
17848814,4,7,Premise,Premise,none,The increase from t1 to t2 was significantly higher for the training group.,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group."
17848814,4,8,Premise,Claim,support,The increase from t1 to t2 was significantly higher for the training group.,Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.
17848814,5,1,Premise,Claim,none,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,",Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.
17848814,5,2,Premise,Premise,none,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,",The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.
17848814,5,3,Premise,Premise,none,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,",There was an improvement of muscle strength at the end of rehabilitation for both groups.
17848814,5,4,Premise,Premise,none,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,",The increase from t1 to t2 was significantly higher for the training group.
17848814,5,6,Premise,Premise,none,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,",but further improvement in the follow-up (t3) was only observed in the training group.
17848814,5,7,Premise,Premise,none,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,","The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group."
17848814,5,8,Premise,Claim,support,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,",Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.
17848814,6,1,Premise,Claim,none,but further improvement in the follow-up (t3) was only observed in the training group.,Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.
17848814,6,2,Premise,Premise,none,but further improvement in the follow-up (t3) was only observed in the training group.,The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.
17848814,6,3,Premise,Premise,none,but further improvement in the follow-up (t3) was only observed in the training group.,There was an improvement of muscle strength at the end of rehabilitation for both groups.
17848814,6,4,Premise,Premise,none,but further improvement in the follow-up (t3) was only observed in the training group.,The increase from t1 to t2 was significantly higher for the training group.
17848814,6,5,Premise,Premise,attack,but further improvement in the follow-up (t3) was only observed in the training group.,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,"
17848814,6,7,Premise,Premise,none,but further improvement in the follow-up (t3) was only observed in the training group.,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group."
17848814,6,8,Premise,Claim,none,but further improvement in the follow-up (t3) was only observed in the training group.,Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.
17848814,7,1,Premise,Claim,none,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group.",Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.
17848814,7,2,Premise,Premise,none,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group.",The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.
17848814,7,3,Premise,Premise,none,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group.",There was an improvement of muscle strength at the end of rehabilitation for both groups.
17848814,7,4,Premise,Premise,none,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group.",The increase from t1 to t2 was significantly higher for the training group.
17848814,7,5,Premise,Premise,none,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group.","The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,"
17848814,7,6,Premise,Premise,none,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group.",but further improvement in the follow-up (t3) was only observed in the training group.
17848814,7,8,Premise,Claim,support,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group.",Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.
17848814,8,1,Claim,Claim,none,Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.,Cancer-related fatigue is the most disabling symptom experienced by breast cancer patients following the cancer treatment.
17848814,8,2,Claim,Premise,none,Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.,The positive effects of physical activity in the rehabilitation of breast cancer patients are documented in several studies.
17848814,8,3,Claim,Premise,none,Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.,There was an improvement of muscle strength at the end of rehabilitation for both groups.
17848814,8,4,Claim,Premise,none,Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.,The increase from t1 to t2 was significantly higher for the training group.
17848814,8,5,Claim,Premise,none,Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.,"The scores for global quality of life, physical well-being, and functionality increased from t1 to t2,"
17848814,8,6,Claim,Premise,none,Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.,but further improvement in the follow-up (t3) was only observed in the training group.
17848814,8,7,Claim,Premise,none,Structured physical training programs initiated during inpatient rehabilitation and continuously practiced in the time thereafter can improve symptoms of chronic fatigue and quality of life in breast cancer patients.,"The cancer-related fatigue was significantly reduced in the training group from t1 to t3, however, not in the control group."
24007947,1,2,MajorClaim,Premise,none,Analgesia and early quality of recovery may be improved by epidural analgesia.,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).
24007947,1,3,MajorClaim,Premise,none,Analgesia and early quality of recovery may be improved by epidural analgesia.,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01)
24007947,1,4,MajorClaim,Premise,none,Analgesia and early quality of recovery may be improved by epidural analgesia.,there was no difference in serious adverse events (p=0.19).
24007947,1,5,MajorClaim,Premise,none,Analgesia and early quality of recovery may be improved by epidural analgesia.,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).
24007947,1,6,MajorClaim,Claim,none,Analgesia and early quality of recovery may be improved by epidural analgesia.,There was no difference in postoperative quality of life up to six months after surgery.
24007947,1,7,MajorClaim,Claim,none,Analgesia and early quality of recovery may be improved by epidural analgesia.,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy."
24007947,1,8,MajorClaim,MajorClaim,none,Analgesia and early quality of recovery may be improved by epidural analgesia.,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,"
24007947,1,9,MajorClaim,Claim,none,Analgesia and early quality of recovery may be improved by epidural analgesia.,the present data do not support a quality of life benefit with epidural analgesia.
24007947,2,1,Premise,MajorClaim,none,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).,Analgesia and early quality of recovery may be improved by epidural analgesia.
24007947,2,3,Premise,Premise,none,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01)
24007947,2,4,Premise,Premise,none,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).,there was no difference in serious adverse events (p=0.19).
24007947,2,5,Premise,Premise,none,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).
24007947,2,6,Premise,Claim,none,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).,There was no difference in postoperative quality of life up to six months after surgery.
24007947,2,7,Premise,Claim,none,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy."
24007947,2,8,Premise,MajorClaim,none,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,"
24007947,2,9,Premise,Claim,none,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).,the present data do not support a quality of life benefit with epidural analgesia.
24007947,3,1,Premise,MajorClaim,none,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01),Analgesia and early quality of recovery may be improved by epidural analgesia.
24007947,3,2,Premise,Premise,none,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01),More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).
24007947,3,4,Premise,Premise,none,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01),there was no difference in serious adverse events (p=0.19).
24007947,3,5,Premise,Premise,none,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01),Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).
24007947,3,6,Premise,Claim,none,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01),There was no difference in postoperative quality of life up to six months after surgery.
24007947,3,7,Premise,Claim,support,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01),"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy."
24007947,3,8,Premise,MajorClaim,none,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01),"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,"
24007947,3,9,Premise,Claim,none,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01),the present data do not support a quality of life benefit with epidural analgesia.
24007947,4,1,Premise,MajorClaim,none,there was no difference in serious adverse events (p=0.19).,Analgesia and early quality of recovery may be improved by epidural analgesia.
24007947,4,2,Premise,Premise,none,there was no difference in serious adverse events (p=0.19).,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).
24007947,4,3,Premise,Premise,none,there was no difference in serious adverse events (p=0.19).,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01)
24007947,4,5,Premise,Premise,none,there was no difference in serious adverse events (p=0.19).,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).
24007947,4,6,Premise,Claim,none,there was no difference in serious adverse events (p=0.19).,There was no difference in postoperative quality of life up to six months after surgery.
24007947,4,7,Premise,Claim,support,there was no difference in serious adverse events (p=0.19).,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy."
24007947,4,8,Premise,MajorClaim,none,there was no difference in serious adverse events (p=0.19).,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,"
24007947,4,9,Premise,Claim,none,there was no difference in serious adverse events (p=0.19).,the present data do not support a quality of life benefit with epidural analgesia.
24007947,5,1,Premise,MajorClaim,none,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).,Analgesia and early quality of recovery may be improved by epidural analgesia.
24007947,5,2,Premise,Premise,none,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).
24007947,5,3,Premise,Premise,none,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01)
24007947,5,4,Premise,Premise,none,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).,there was no difference in serious adverse events (p=0.19).
24007947,5,6,Premise,Claim,none,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).,There was no difference in postoperative quality of life up to six months after surgery.
24007947,5,7,Premise,Claim,support,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy."
24007947,5,8,Premise,MajorClaim,none,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,"
24007947,5,9,Premise,Claim,none,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).,the present data do not support a quality of life benefit with epidural analgesia.
24007947,6,1,Claim,MajorClaim,none,There was no difference in postoperative quality of life up to six months after surgery.,Analgesia and early quality of recovery may be improved by epidural analgesia.
24007947,6,2,Claim,Premise,none,There was no difference in postoperative quality of life up to six months after surgery.,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).
24007947,6,3,Claim,Premise,none,There was no difference in postoperative quality of life up to six months after surgery.,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01)
24007947,6,4,Claim,Premise,none,There was no difference in postoperative quality of life up to six months after surgery.,there was no difference in serious adverse events (p=0.19).
24007947,6,5,Claim,Premise,none,There was no difference in postoperative quality of life up to six months after surgery.,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).
24007947,6,7,Claim,Claim,none,There was no difference in postoperative quality of life up to six months after surgery.,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy."
24007947,6,8,Claim,MajorClaim,none,There was no difference in postoperative quality of life up to six months after surgery.,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,"
24007947,6,9,Claim,Claim,none,There was no difference in postoperative quality of life up to six months after surgery.,the present data do not support a quality of life benefit with epidural analgesia.
24007947,7,1,Claim,MajorClaim,none,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy.",Analgesia and early quality of recovery may be improved by epidural analgesia.
24007947,7,2,Claim,Premise,none,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy.",More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).
24007947,7,3,Claim,Premise,none,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy.",Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01)
24007947,7,4,Claim,Premise,none,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy.",there was no difference in serious adverse events (p=0.19).
24007947,7,5,Claim,Premise,none,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy.",Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).
24007947,7,6,Claim,Claim,none,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy.",There was no difference in postoperative quality of life up to six months after surgery.
24007947,7,8,Claim,MajorClaim,none,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy.","Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,"
24007947,7,9,Claim,Claim,none,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy.",the present data do not support a quality of life benefit with epidural analgesia.
24007947,8,1,MajorClaim,MajorClaim,none,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,",Analgesia and early quality of recovery may be improved by epidural analgesia.
24007947,8,2,MajorClaim,Premise,none,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,",More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).
24007947,8,3,MajorClaim,Premise,none,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,",Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01)
24007947,8,4,MajorClaim,Premise,none,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,",there was no difference in serious adverse events (p=0.19).
24007947,8,5,MajorClaim,Premise,none,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,",Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).
24007947,8,6,MajorClaim,Claim,none,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,",There was no difference in postoperative quality of life up to six months after surgery.
24007947,8,7,MajorClaim,Claim,none,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,","Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy."
24007947,8,9,MajorClaim,Claim,none,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,",the present data do not support a quality of life benefit with epidural analgesia.
24007947,9,1,Claim,MajorClaim,attack,the present data do not support a quality of life benefit with epidural analgesia.,Analgesia and early quality of recovery may be improved by epidural analgesia.
24007947,9,2,Claim,Premise,none,the present data do not support a quality of life benefit with epidural analgesia.,More patients without epidural (34%) ceased opioid analgesia 3-5 days after surgery compared to patients who had an epidural (7%; p<0.01).
24007947,9,3,Claim,Premise,none,the present data do not support a quality of life benefit with epidural analgesia.,Postoperative complications (any grade) occurred in 86% of patients with and in 66% of patients without an epidural (p<0.01)
24007947,9,4,Claim,Premise,none,the present data do not support a quality of life benefit with epidural analgesia.,there was no difference in serious adverse events (p=0.19).
24007947,9,5,Claim,Premise,none,the present data do not support a quality of life benefit with epidural analgesia.,Epidural analgesia was associated with increased length of stay (up to 48 days compared to up to 34 days in the non-epidural group).
24007947,9,6,Claim,Claim,none,the present data do not support a quality of life benefit with epidural analgesia.,There was no difference in postoperative quality of life up to six months after surgery.
24007947,9,7,Claim,Claim,none,the present data do not support a quality of life benefit with epidural analgesia.,"Epidural analgesia was associated with an increase in any, but not serious, postoperative complications and length of stay after abdominal hysterectomy."
24007947,9,8,Claim,MajorClaim,none,the present data do not support a quality of life benefit with epidural analgesia.,"Randomised controlled trials are needed to examine the effect of epidural analgesia on surgical adverse events,"
20809177,1,2,Premise,Premise,none,"The dysfunction score was 58.9 ± 15.0 after distal gastrectomy, 66.8 ± 14.1 after total gastrectomy, and 62.4 ± 21.6 after pylorus-preserving gastrectomy.",These values differed significantly among the groups (P = .007).
20809177,1,3,Premise,Premise,none,"The dysfunction score was 58.9 ± 15.0 after distal gastrectomy, 66.8 ± 14.1 after total gastrectomy, and 62.4 ± 21.6 after pylorus-preserving gastrectomy.","Dysfunction scores according to postoperative activity status were 49.1 ± 15.6 in 71 patients who resumed their activities, 56.9 ± 15.7 in 39 patients with reduced activities, 57.3 ± 8.8 in 15 patients with minimal activities, and 63.3 ± 11.8 (P < .05) in 16 patients who did not resume activities because of poor physical condition."
20809177,1,4,Premise,Claim,support,"The dysfunction score was 58.9 ± 15.0 after distal gastrectomy, 66.8 ± 14.1 after total gastrectomy, and 62.4 ± 21.6 after pylorus-preserving gastrectomy.",This scoring system for postoperative gastrointestinal dysfunction provides an objective measure of dysfunction related to specific surgical procedures and correlates with activities of daily living in the postoperative period.
20809177,2,1,Premise,Premise,attack,These values differed significantly among the groups (P = .007).,"The dysfunction score was 58.9 ± 15.0 after distal gastrectomy, 66.8 ± 14.1 after total gastrectomy, and 62.4 ± 21.6 after pylorus-preserving gastrectomy."
20809177,2,3,Premise,Premise,none,These values differed significantly among the groups (P = .007).,"Dysfunction scores according to postoperative activity status were 49.1 ± 15.6 in 71 patients who resumed their activities, 56.9 ± 15.7 in 39 patients with reduced activities, 57.3 ± 8.8 in 15 patients with minimal activities, and 63.3 ± 11.8 (P < .05) in 16 patients who did not resume activities because of poor physical condition."
20809177,2,4,Premise,Claim,none,These values differed significantly among the groups (P = .007).,This scoring system for postoperative gastrointestinal dysfunction provides an objective measure of dysfunction related to specific surgical procedures and correlates with activities of daily living in the postoperative period.
20809177,3,1,Premise,Premise,none,"Dysfunction scores according to postoperative activity status were 49.1 ± 15.6 in 71 patients who resumed their activities, 56.9 ± 15.7 in 39 patients with reduced activities, 57.3 ± 8.8 in 15 patients with minimal activities, and 63.3 ± 11.8 (P < .05) in 16 patients who did not resume activities because of poor physical condition.","The dysfunction score was 58.9 ± 15.0 after distal gastrectomy, 66.8 ± 14.1 after total gastrectomy, and 62.4 ± 21.6 after pylorus-preserving gastrectomy."
20809177,3,2,Premise,Premise,none,"Dysfunction scores according to postoperative activity status were 49.1 ± 15.6 in 71 patients who resumed their activities, 56.9 ± 15.7 in 39 patients with reduced activities, 57.3 ± 8.8 in 15 patients with minimal activities, and 63.3 ± 11.8 (P < .05) in 16 patients who did not resume activities because of poor physical condition.",These values differed significantly among the groups (P = .007).
20809177,3,4,Premise,Claim,support,"Dysfunction scores according to postoperative activity status were 49.1 ± 15.6 in 71 patients who resumed their activities, 56.9 ± 15.7 in 39 patients with reduced activities, 57.3 ± 8.8 in 15 patients with minimal activities, and 63.3 ± 11.8 (P < .05) in 16 patients who did not resume activities because of poor physical condition.",This scoring system for postoperative gastrointestinal dysfunction provides an objective measure of dysfunction related to specific surgical procedures and correlates with activities of daily living in the postoperative period.
20809177,4,1,Claim,Premise,none,This scoring system for postoperative gastrointestinal dysfunction provides an objective measure of dysfunction related to specific surgical procedures and correlates with activities of daily living in the postoperative period.,"The dysfunction score was 58.9 ± 15.0 after distal gastrectomy, 66.8 ± 14.1 after total gastrectomy, and 62.4 ± 21.6 after pylorus-preserving gastrectomy."
20809177,4,2,Claim,Premise,none,This scoring system for postoperative gastrointestinal dysfunction provides an objective measure of dysfunction related to specific surgical procedures and correlates with activities of daily living in the postoperative period.,These values differed significantly among the groups (P = .007).
20809177,4,3,Claim,Premise,none,This scoring system for postoperative gastrointestinal dysfunction provides an objective measure of dysfunction related to specific surgical procedures and correlates with activities of daily living in the postoperative period.,"Dysfunction scores according to postoperative activity status were 49.1 ± 15.6 in 71 patients who resumed their activities, 56.9 ± 15.7 in 39 patients with reduced activities, 57.3 ± 8.8 in 15 patients with minimal activities, and 63.3 ± 11.8 (P < .05) in 16 patients who did not resume activities because of poor physical condition."
17852440,1,2,Claim,Claim,none,"Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).",Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
17852440,1,3,Claim,Premise,none,"Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).","Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001)."
17852440,1,4,Claim,Premise,none,"Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).","An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days."
17852440,1,5,Claim,Premise,none,"Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).",The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
17852440,1,6,Claim,Premise,none,"Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).","In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation."
17852440,1,7,Claim,Premise,none,"Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).",QW epoetin-alpha was found to be well tolerated.
17852440,1,8,Claim,Claim,none,"Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).","Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy."
17852440,1,9,Claim,Claim,none,"Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).","The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic."
17852440,2,1,Claim,Claim,none,Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).,"Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL)."
17852440,2,3,Claim,Premise,none,Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).,"Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001)."
17852440,2,4,Claim,Premise,none,Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).,"An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days."
17852440,2,5,Claim,Premise,none,Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).,The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
17852440,2,6,Claim,Premise,none,Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).,"In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation."
17852440,2,7,Claim,Premise,none,Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).,QW epoetin-alpha was found to be well tolerated.
17852440,2,8,Claim,Claim,none,Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).,"Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy."
17852440,2,9,Claim,Claim,none,Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).,"The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic."
17852440,3,1,Premise,Claim,none,"Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).","Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL)."
17852440,3,2,Premise,Claim,none,"Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).",Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
17852440,3,4,Premise,Premise,none,"Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).","An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days."
17852440,3,5,Premise,Premise,none,"Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).",The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
17852440,3,6,Premise,Premise,none,"Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).","In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation."
17852440,3,7,Premise,Premise,none,"Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).",QW epoetin-alpha was found to be well tolerated.
17852440,3,8,Premise,Claim,support,"Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).","Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy."
17852440,3,9,Premise,Claim,none,"Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).","The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic."
17852440,4,1,Premise,Claim,none,"An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.","Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL)."
17852440,4,2,Premise,Claim,none,"An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.",Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
17852440,4,3,Premise,Premise,none,"An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.","Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001)."
17852440,4,5,Premise,Premise,none,"An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.",The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
17852440,4,6,Premise,Premise,none,"An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.","In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation."
17852440,4,7,Premise,Premise,none,"An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.",QW epoetin-alpha was found to be well tolerated.
17852440,4,8,Premise,Claim,support,"An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.","Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy."
17852440,4,9,Premise,Claim,none,"An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.","The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic."
17852440,5,1,Premise,Claim,none,The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).,"Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL)."
17852440,5,2,Premise,Claim,none,The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).,Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
17852440,5,3,Premise,Premise,none,The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).,"Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001)."
17852440,5,4,Premise,Premise,none,The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).,"An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days."
17852440,5,6,Premise,Premise,none,The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).,"In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation."
17852440,5,7,Premise,Premise,none,The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).,QW epoetin-alpha was found to be well tolerated.
17852440,5,8,Premise,Claim,support,The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).,"Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy."
17852440,5,9,Premise,Claim,none,The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).,"The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic."
17852440,6,1,Premise,Claim,none,"In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.","Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL)."
17852440,6,2,Premise,Claim,none,"In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.",Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
17852440,6,3,Premise,Premise,none,"In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.","Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001)."
17852440,6,4,Premise,Premise,none,"In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.","An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days."
17852440,6,5,Premise,Premise,none,"In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.",The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
17852440,6,7,Premise,Premise,none,"In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.",QW epoetin-alpha was found to be well tolerated.
17852440,6,8,Premise,Claim,support,"In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.","Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy."
17852440,6,9,Premise,Claim,none,"In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.","The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic."
17852440,7,1,Premise,Claim,none,QW epoetin-alpha was found to be well tolerated.,"Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL)."
17852440,7,2,Premise,Claim,none,QW epoetin-alpha was found to be well tolerated.,Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
17852440,7,3,Premise,Premise,none,QW epoetin-alpha was found to be well tolerated.,"Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001)."
17852440,7,4,Premise,Premise,none,QW epoetin-alpha was found to be well tolerated.,"An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days."
17852440,7,5,Premise,Premise,none,QW epoetin-alpha was found to be well tolerated.,The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
17852440,7,6,Premise,Premise,none,QW epoetin-alpha was found to be well tolerated.,"In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation."
17852440,7,8,Premise,Claim,none,QW epoetin-alpha was found to be well tolerated.,"Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy."
17852440,7,9,Premise,Claim,support,QW epoetin-alpha was found to be well tolerated.,"The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic."
17852440,8,1,Claim,Claim,none,"Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.","Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL)."
17852440,8,2,Claim,Claim,none,"Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.",Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
17852440,8,3,Claim,Premise,none,"Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.","Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001)."
17852440,8,4,Claim,Premise,none,"Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.","An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days."
17852440,8,5,Claim,Premise,none,"Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.",The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
17852440,8,6,Claim,Premise,none,"Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.","In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation."
17852440,8,7,Claim,Premise,none,"Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.",QW epoetin-alpha was found to be well tolerated.
17852440,8,9,Claim,Claim,support,"Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.","The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic."
17852440,9,1,Claim,Claim,none,"The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.","Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL)."
17852440,9,2,Claim,Claim,none,"The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.",Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
17852440,9,3,Claim,Premise,none,"The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.","Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001)."
17852440,9,4,Claim,Premise,none,"The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.","An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days."
17852440,9,5,Claim,Premise,none,"The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.",The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
17852440,9,6,Claim,Premise,none,"The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.","In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation."
17852440,9,7,Claim,Premise,none,"The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.",QW epoetin-alpha was found to be well tolerated.
17852440,9,8,Claim,Claim,none,"The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.","Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy."
16571129,1,2,Claim,Claim,none,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema.","the treatments are not always well-accepted,"
16571129,1,3,Claim,Claim,none,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema.",patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.
16571129,1,4,Claim,Premise,none,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema.","Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage."
16571129,1,5,Claim,Premise,none,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema.","The patients' mean weight decreased significantly with Flexitouch use, but not with massage."
16571129,1,6,Claim,Premise,none,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema.",The Flexitouch device was apparently well-tolerated and accepted by patients.
16571129,1,7,Claim,Premise,none,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema.",Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;
16571129,1,8,Claim,Premise,none,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema.",there were no statistical differences in scores when the two treatment modalities were compared.
16571129,1,9,Claim,Claim,none,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema.",This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.
16571129,1,10,Claim,Claim,none,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema.",The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.
16571129,2,1,Claim,Claim,attack,"the treatments are not always well-accepted,","Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema."
16571129,2,3,Claim,Claim,none,"the treatments are not always well-accepted,",patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.
16571129,2,4,Claim,Premise,none,"the treatments are not always well-accepted,","Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage."
16571129,2,5,Claim,Premise,none,"the treatments are not always well-accepted,","The patients' mean weight decreased significantly with Flexitouch use, but not with massage."
16571129,2,6,Claim,Premise,none,"the treatments are not always well-accepted,",The Flexitouch device was apparently well-tolerated and accepted by patients.
16571129,2,7,Claim,Premise,none,"the treatments are not always well-accepted,",Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;
16571129,2,8,Claim,Premise,none,"the treatments are not always well-accepted,",there were no statistical differences in scores when the two treatment modalities were compared.
16571129,2,9,Claim,Claim,none,"the treatments are not always well-accepted,",This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.
16571129,2,10,Claim,Claim,none,"the treatments are not always well-accepted,",The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.
16571129,3,1,Claim,Claim,attack,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema."
16571129,3,2,Claim,Claim,none,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.,"the treatments are not always well-accepted,"
16571129,3,4,Claim,Premise,none,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage."
16571129,3,5,Claim,Premise,none,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage."
16571129,3,6,Claim,Premise,none,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.,The Flexitouch device was apparently well-tolerated and accepted by patients.
16571129,3,7,Claim,Premise,none,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;
16571129,3,8,Claim,Premise,none,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.,there were no statistical differences in scores when the two treatment modalities were compared.
16571129,3,9,Claim,Claim,none,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.
16571129,3,10,Claim,Claim,none,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.
16571129,4,1,Premise,Claim,none,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage.","Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema."
16571129,4,2,Premise,Claim,none,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage.","the treatments are not always well-accepted,"
16571129,4,3,Premise,Claim,none,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage.",patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.
16571129,4,5,Premise,Premise,none,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage.","The patients' mean weight decreased significantly with Flexitouch use, but not with massage."
16571129,4,6,Premise,Premise,none,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage.",The Flexitouch device was apparently well-tolerated and accepted by patients.
16571129,4,7,Premise,Premise,none,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage.",Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;
16571129,4,8,Premise,Premise,none,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage.",there were no statistical differences in scores when the two treatment modalities were compared.
16571129,4,9,Premise,Claim,support,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage.",This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.
16571129,4,10,Premise,Claim,none,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage.",The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.
16571129,5,1,Premise,Claim,none,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage.","Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema."
16571129,5,2,Premise,Claim,none,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage.","the treatments are not always well-accepted,"
16571129,5,3,Premise,Claim,none,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage.",patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.
16571129,5,4,Premise,Premise,none,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage.","Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage."
16571129,5,6,Premise,Premise,none,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage.",The Flexitouch device was apparently well-tolerated and accepted by patients.
16571129,5,7,Premise,Premise,none,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage.",Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;
16571129,5,8,Premise,Premise,none,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage.",there were no statistical differences in scores when the two treatment modalities were compared.
16571129,5,9,Premise,Claim,support,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage.",This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.
16571129,5,10,Premise,Claim,none,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage.",The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.
16571129,6,1,Premise,Claim,none,The Flexitouch device was apparently well-tolerated and accepted by patients.,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema."
16571129,6,2,Premise,Claim,none,The Flexitouch device was apparently well-tolerated and accepted by patients.,"the treatments are not always well-accepted,"
16571129,6,3,Premise,Claim,none,The Flexitouch device was apparently well-tolerated and accepted by patients.,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.
16571129,6,4,Premise,Premise,none,The Flexitouch device was apparently well-tolerated and accepted by patients.,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage."
16571129,6,5,Premise,Premise,none,The Flexitouch device was apparently well-tolerated and accepted by patients.,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage."
16571129,6,7,Premise,Premise,none,The Flexitouch device was apparently well-tolerated and accepted by patients.,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;
16571129,6,8,Premise,Premise,none,The Flexitouch device was apparently well-tolerated and accepted by patients.,there were no statistical differences in scores when the two treatment modalities were compared.
16571129,6,9,Premise,Claim,none,The Flexitouch device was apparently well-tolerated and accepted by patients.,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.
16571129,6,10,Premise,Claim,support,The Flexitouch device was apparently well-tolerated and accepted by patients.,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.
16571129,7,1,Premise,Claim,none,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema."
16571129,7,2,Premise,Claim,none,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;,"the treatments are not always well-accepted,"
16571129,7,3,Premise,Claim,none,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.
16571129,7,4,Premise,Premise,none,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage."
16571129,7,5,Premise,Premise,none,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage."
16571129,7,6,Premise,Premise,none,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;,The Flexitouch device was apparently well-tolerated and accepted by patients.
16571129,7,8,Premise,Premise,none,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;,there were no statistical differences in scores when the two treatment modalities were compared.
16571129,7,9,Premise,Claim,support,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.
16571129,7,10,Premise,Claim,none,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.
16571129,8,1,Premise,Claim,none,there were no statistical differences in scores when the two treatment modalities were compared.,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema."
16571129,8,2,Premise,Claim,none,there were no statistical differences in scores when the two treatment modalities were compared.,"the treatments are not always well-accepted,"
16571129,8,3,Premise,Claim,none,there were no statistical differences in scores when the two treatment modalities were compared.,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.
16571129,8,4,Premise,Premise,none,there were no statistical differences in scores when the two treatment modalities were compared.,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage."
16571129,8,5,Premise,Premise,none,there were no statistical differences in scores when the two treatment modalities were compared.,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage."
16571129,8,6,Premise,Premise,none,there were no statistical differences in scores when the two treatment modalities were compared.,The Flexitouch device was apparently well-tolerated and accepted by patients.
16571129,8,7,Premise,Premise,attack,there were no statistical differences in scores when the two treatment modalities were compared.,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;
16571129,8,9,Premise,Claim,none,there were no statistical differences in scores when the two treatment modalities were compared.,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.
16571129,8,10,Premise,Claim,none,there were no statistical differences in scores when the two treatment modalities were compared.,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.
16571129,9,1,Claim,Claim,none,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema."
16571129,9,2,Claim,Claim,none,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.,"the treatments are not always well-accepted,"
16571129,9,3,Claim,Claim,none,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.
16571129,9,4,Claim,Premise,none,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage."
16571129,9,5,Claim,Premise,none,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage."
16571129,9,6,Claim,Premise,none,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.,The Flexitouch device was apparently well-tolerated and accepted by patients.
16571129,9,7,Claim,Premise,none,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;
16571129,9,8,Claim,Premise,none,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.,there were no statistical differences in scores when the two treatment modalities were compared.
16571129,9,10,Claim,Claim,support,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.
16571129,10,1,Claim,Claim,none,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.,"Prospective investigations of complete decongestive lymphatic physiotherapy (CDPT), including manual lymphatic drainage (MLD), have validated the efficacy of these interventions for the initial reduction of edema and long-term maintenance of limb volume in lymphedema."
16571129,10,2,Claim,Claim,none,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.,"the treatments are not always well-accepted,"
16571129,10,3,Claim,Claim,none,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.,patients may suffer from a deterioration in quality-of-life or a time-dependent loss of initial treatment benefits.
16571129,10,4,Claim,Premise,none,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.,"Post-treatment arm volume reduced significantly after the Flexitouch, but not after self-administered massage."
16571129,10,5,Claim,Premise,none,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.,"The patients' mean weight decreased significantly with Flexitouch use, but not with massage."
16571129,10,6,Claim,Premise,none,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.,The Flexitouch device was apparently well-tolerated and accepted by patients.
16571129,10,7,Claim,Premise,none,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.,Serial SF-36 administration showed no deterioration in physical or psychosocial scores compared to baseline measurements;
16571129,10,8,Claim,Premise,none,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.,there were no statistical differences in scores when the two treatment modalities were compared.
16571129,10,9,Claim,Claim,none,The apparent ease of use and reliability of response to the device suggest that further broad-scale testing is warranted.,This short-term prospective evaluation of the Flexitouch suggests that the device may provide better maintenance edema control than self-adiminstered massage in breast cancer-associated lymphedema.
12011126,1,2,Premise,Premise,none,"Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.","The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001)."
12011126,1,3,Premise,Premise,none,"Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.","After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);"
12011126,1,4,Premise,Premise,none,"Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.",this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).
12011126,1,5,Premise,Claim,support,"Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively.","Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL."
12011126,2,1,Premise,Premise,none,"The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).","Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively."
12011126,2,3,Premise,Premise,none,"The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).","After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);"
12011126,2,4,Premise,Premise,none,"The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).",this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).
12011126,2,5,Premise,Claim,none,"The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001).","Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL."
12011126,3,1,Premise,Premise,none,"After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);","Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively."
12011126,3,2,Premise,Premise,none,"After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);","The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001)."
12011126,3,4,Premise,Premise,none,"After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);",this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).
12011126,3,5,Premise,Claim,support,"After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);","Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL."
12011126,4,1,Premise,Premise,none,this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).,"Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively."
12011126,4,2,Premise,Premise,none,this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).,"The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001)."
12011126,4,3,Premise,Premise,none,this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).,"After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);"
12011126,4,5,Premise,Claim,none,this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).,"Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL."
12011126,5,1,Claim,Premise,none,"Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.","Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival (P =.0001) were significantly greater in the epoetin beta group versus placebo (Wald chi(2) test), giving a relative risk reduction of 43% and 51%, respectively."
12011126,5,2,Claim,Premise,none,"Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.","The response rate was 67% and 27% in the epoetin beta versus the placebo group, respectively (P <.0001)."
12011126,5,3,Claim,Premise,none,"Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.","After 12 and 16 weeks of treatment, QOL significantly improved in the epoetin beta group compared with placebo (P <.05);"
12011126,5,4,Claim,Premise,none,"Many severely anemic and transfusion-dependent patients with advanced MM, NHL, and CLL and a low performance status benefited from epoetin therapy, with elimination of severe anemia and transfusion need, and improvement in QOL.",this improvement correlated with an increase in Hb concentration (> or = 2 g/dL).
20631341,1,2,Premise,Premise,none,"Overall survival remained better in those assigned to 3B(90)E(500)P than in those assigned to 4B(30)E(360)P (8-year survival: 92% vs 83%; hazard ratio of death = 0.38, 95% confidence interval = 0.15 to 0.97, P = .037).","Progression-free survival favored 3B(90)E(500)P but was not statistically significantly different between the treatment groups (8-year progression-free survival, 3B(90)E(500)P vs 4B(30)E(360)P: 86% vs 79%; hazard ratio of progression = 0.6, 95% confidence interval = 0.3 to 1.1, P = .15)."
20631341,1,3,Premise,Claim,none,"Overall survival remained better in those assigned to 3B(90)E(500)P than in those assigned to 4B(30)E(360)P (8-year survival: 92% vs 83%; hazard ratio of death = 0.38, 95% confidence interval = 0.15 to 0.97, P = .037).","At the end of treatment, average scores for most side effect scales favored 3B(90)E(500)P."
20631341,1,4,Premise,Premise,none,"Overall survival remained better in those assigned to 3B(90)E(500)P than in those assigned to 4B(30)E(360)P (8-year survival: 92% vs 83%; hazard ratio of death = 0.38, 95% confidence interval = 0.15 to 0.97, P = .037).","After the completion of treatment, average GLQ-8 scores for numbness (P = .003) and hair loss (P = .04) and the Spitzer Quality of Life Index (P = .05) favored 3B(90)E(500)P."
20631341,1,5,Premise,Claim,support,"Overall survival remained better in those assigned to 3B(90)E(500)P than in those assigned to 4B(30)E(360)P (8-year survival: 92% vs 83%; hazard ratio of death = 0.38, 95% confidence interval = 0.15 to 0.97, P = .037).",The survival benefit of 3B(90)E(500)P over 4B(30)E(360)P was maintained with long-term follow-up.
20631341,2,1,Premise,Premise,none,"Progression-free survival favored 3B(90)E(500)P but was not statistically significantly different between the treatment groups (8-year progression-free survival, 3B(90)E(500)P vs 4B(30)E(360)P: 86% vs 79%; hazard ratio of progression = 0.6, 95% confidence interval = 0.3 to 1.1, P = .15).","Overall survival remained better in those assigned to 3B(90)E(500)P than in those assigned to 4B(30)E(360)P (8-year survival: 92% vs 83%; hazard ratio of death = 0.38, 95% confidence interval = 0.15 to 0.97, P = .037)."
20631341,2,3,Premise,Claim,none,"Progression-free survival favored 3B(90)E(500)P but was not statistically significantly different between the treatment groups (8-year progression-free survival, 3B(90)E(500)P vs 4B(30)E(360)P: 86% vs 79%; hazard ratio of progression = 0.6, 95% confidence interval = 0.3 to 1.1, P = .15).","At the end of treatment, average scores for most side effect scales favored 3B(90)E(500)P."
20631341,2,4,Premise,Premise,none,"Progression-free survival favored 3B(90)E(500)P but was not statistically significantly different between the treatment groups (8-year progression-free survival, 3B(90)E(500)P vs 4B(30)E(360)P: 86% vs 79%; hazard ratio of progression = 0.6, 95% confidence interval = 0.3 to 1.1, P = .15).","After the completion of treatment, average GLQ-8 scores for numbness (P = .003) and hair loss (P = .04) and the Spitzer Quality of Life Index (P = .05) favored 3B(90)E(500)P."
20631341,2,5,Premise,Claim,support,"Progression-free survival favored 3B(90)E(500)P but was not statistically significantly different between the treatment groups (8-year progression-free survival, 3B(90)E(500)P vs 4B(30)E(360)P: 86% vs 79%; hazard ratio of progression = 0.6, 95% confidence interval = 0.3 to 1.1, P = .15).",The survival benefit of 3B(90)E(500)P over 4B(30)E(360)P was maintained with long-term follow-up.
20631341,3,1,Claim,Premise,none,"At the end of treatment, average scores for most side effect scales favored 3B(90)E(500)P.","Overall survival remained better in those assigned to 3B(90)E(500)P than in those assigned to 4B(30)E(360)P (8-year survival: 92% vs 83%; hazard ratio of death = 0.38, 95% confidence interval = 0.15 to 0.97, P = .037)."
20631341,3,2,Claim,Premise,none,"At the end of treatment, average scores for most side effect scales favored 3B(90)E(500)P.","Progression-free survival favored 3B(90)E(500)P but was not statistically significantly different between the treatment groups (8-year progression-free survival, 3B(90)E(500)P vs 4B(30)E(360)P: 86% vs 79%; hazard ratio of progression = 0.6, 95% confidence interval = 0.3 to 1.1, P = .15)."
20631341,3,4,Claim,Premise,none,"At the end of treatment, average scores for most side effect scales favored 3B(90)E(500)P.","After the completion of treatment, average GLQ-8 scores for numbness (P = .003) and hair loss (P = .04) and the Spitzer Quality of Life Index (P = .05) favored 3B(90)E(500)P."
20631341,3,5,Claim,Claim,none,"At the end of treatment, average scores for most side effect scales favored 3B(90)E(500)P.",The survival benefit of 3B(90)E(500)P over 4B(30)E(360)P was maintained with long-term follow-up.
20631341,4,1,Premise,Premise,none,"After the completion of treatment, average GLQ-8 scores for numbness (P = .003) and hair loss (P = .04) and the Spitzer Quality of Life Index (P = .05) favored 3B(90)E(500)P.","Overall survival remained better in those assigned to 3B(90)E(500)P than in those assigned to 4B(30)E(360)P (8-year survival: 92% vs 83%; hazard ratio of death = 0.38, 95% confidence interval = 0.15 to 0.97, P = .037)."
20631341,4,2,Premise,Premise,none,"After the completion of treatment, average GLQ-8 scores for numbness (P = .003) and hair loss (P = .04) and the Spitzer Quality of Life Index (P = .05) favored 3B(90)E(500)P.","Progression-free survival favored 3B(90)E(500)P but was not statistically significantly different between the treatment groups (8-year progression-free survival, 3B(90)E(500)P vs 4B(30)E(360)P: 86% vs 79%; hazard ratio of progression = 0.6, 95% confidence interval = 0.3 to 1.1, P = .15)."
20631341,4,3,Premise,Claim,support,"After the completion of treatment, average GLQ-8 scores for numbness (P = .003) and hair loss (P = .04) and the Spitzer Quality of Life Index (P = .05) favored 3B(90)E(500)P.","At the end of treatment, average scores for most side effect scales favored 3B(90)E(500)P."
20631341,4,5,Premise,Claim,none,"After the completion of treatment, average GLQ-8 scores for numbness (P = .003) and hair loss (P = .04) and the Spitzer Quality of Life Index (P = .05) favored 3B(90)E(500)P.",The survival benefit of 3B(90)E(500)P over 4B(30)E(360)P was maintained with long-term follow-up.
20631341,5,1,Claim,Premise,none,The survival benefit of 3B(90)E(500)P over 4B(30)E(360)P was maintained with long-term follow-up.,"Overall survival remained better in those assigned to 3B(90)E(500)P than in those assigned to 4B(30)E(360)P (8-year survival: 92% vs 83%; hazard ratio of death = 0.38, 95% confidence interval = 0.15 to 0.97, P = .037)."
20631341,5,2,Claim,Premise,none,The survival benefit of 3B(90)E(500)P over 4B(30)E(360)P was maintained with long-term follow-up.,"Progression-free survival favored 3B(90)E(500)P but was not statistically significantly different between the treatment groups (8-year progression-free survival, 3B(90)E(500)P vs 4B(30)E(360)P: 86% vs 79%; hazard ratio of progression = 0.6, 95% confidence interval = 0.3 to 1.1, P = .15)."
20631341,5,3,Claim,Claim,none,The survival benefit of 3B(90)E(500)P over 4B(30)E(360)P was maintained with long-term follow-up.,"At the end of treatment, average scores for most side effect scales favored 3B(90)E(500)P."
20631341,5,4,Claim,Premise,none,The survival benefit of 3B(90)E(500)P over 4B(30)E(360)P was maintained with long-term follow-up.,"After the completion of treatment, average GLQ-8 scores for numbness (P = .003) and hair loss (P = .04) and the Spitzer Quality of Life Index (P = .05) favored 3B(90)E(500)P."
18591549,1,2,Premise,Premise,none,CBT was associated with mean reductions in wakefulness of 55 minutes per night compared with no change in TAU.,"Standardized relative effect sizes were large for complaints of difficulty initiating sleep, waking from sleep during the night, and for sleep efficiency (percentage of time in bed spent asleep)."
18591549,1,3,Premise,Premise,none,CBT was associated with mean reductions in wakefulness of 55 minutes per night compared with no change in TAU.,"CBT was associated with moderate to large effect sizes for five of seven QOL outcomes, including significant reduction in daytime fatigue."
18591549,1,4,Premise,Premise,none,CBT was associated with mean reductions in wakefulness of 55 minutes per night compared with no change in TAU.,"There was no significant interaction effect between any of these outcomes and baseline demographic, clinical, or sleep characteristics."
18591549,1,5,Premise,Claim,support,CBT was associated with mean reductions in wakefulness of 55 minutes per night compared with no change in TAU.,CBT for insomnia may be both clinically effective and feasible to deliver in real world practice.
18591549,2,1,Premise,Premise,none,"Standardized relative effect sizes were large for complaints of difficulty initiating sleep, waking from sleep during the night, and for sleep efficiency (percentage of time in bed spent asleep).",CBT was associated with mean reductions in wakefulness of 55 minutes per night compared with no change in TAU.
18591549,2,3,Premise,Premise,none,"Standardized relative effect sizes were large for complaints of difficulty initiating sleep, waking from sleep during the night, and for sleep efficiency (percentage of time in bed spent asleep).","CBT was associated with moderate to large effect sizes for five of seven QOL outcomes, including significant reduction in daytime fatigue."
18591549,2,4,Premise,Premise,none,"Standardized relative effect sizes were large for complaints of difficulty initiating sleep, waking from sleep during the night, and for sleep efficiency (percentage of time in bed spent asleep).","There was no significant interaction effect between any of these outcomes and baseline demographic, clinical, or sleep characteristics."
18591549,2,5,Premise,Claim,none,"Standardized relative effect sizes were large for complaints of difficulty initiating sleep, waking from sleep during the night, and for sleep efficiency (percentage of time in bed spent asleep).",CBT for insomnia may be both clinically effective and feasible to deliver in real world practice.
18591549,3,1,Premise,Premise,none,"CBT was associated with moderate to large effect sizes for five of seven QOL outcomes, including significant reduction in daytime fatigue.",CBT was associated with mean reductions in wakefulness of 55 minutes per night compared with no change in TAU.
18591549,3,2,Premise,Premise,none,"CBT was associated with moderate to large effect sizes for five of seven QOL outcomes, including significant reduction in daytime fatigue.","Standardized relative effect sizes were large for complaints of difficulty initiating sleep, waking from sleep during the night, and for sleep efficiency (percentage of time in bed spent asleep)."
18591549,3,4,Premise,Premise,none,"CBT was associated with moderate to large effect sizes for five of seven QOL outcomes, including significant reduction in daytime fatigue.","There was no significant interaction effect between any of these outcomes and baseline demographic, clinical, or sleep characteristics."
18591549,3,5,Premise,Claim,support,"CBT was associated with moderate to large effect sizes for five of seven QOL outcomes, including significant reduction in daytime fatigue.",CBT for insomnia may be both clinically effective and feasible to deliver in real world practice.
18591549,4,1,Premise,Premise,none,"There was no significant interaction effect between any of these outcomes and baseline demographic, clinical, or sleep characteristics.",CBT was associated with mean reductions in wakefulness of 55 minutes per night compared with no change in TAU.
18591549,4,2,Premise,Premise,none,"There was no significant interaction effect between any of these outcomes and baseline demographic, clinical, or sleep characteristics.","Standardized relative effect sizes were large for complaints of difficulty initiating sleep, waking from sleep during the night, and for sleep efficiency (percentage of time in bed spent asleep)."
18591549,4,3,Premise,Premise,none,"There was no significant interaction effect between any of these outcomes and baseline demographic, clinical, or sleep characteristics.","CBT was associated with moderate to large effect sizes for five of seven QOL outcomes, including significant reduction in daytime fatigue."
18591549,4,5,Premise,Claim,support,"There was no significant interaction effect between any of these outcomes and baseline demographic, clinical, or sleep characteristics.",CBT for insomnia may be both clinically effective and feasible to deliver in real world practice.
18591549,5,1,Claim,Premise,none,CBT for insomnia may be both clinically effective and feasible to deliver in real world practice.,CBT was associated with mean reductions in wakefulness of 55 minutes per night compared with no change in TAU.
18591549,5,2,Claim,Premise,none,CBT for insomnia may be both clinically effective and feasible to deliver in real world practice.,"Standardized relative effect sizes were large for complaints of difficulty initiating sleep, waking from sleep during the night, and for sleep efficiency (percentage of time in bed spent asleep)."
18591549,5,3,Claim,Premise,none,CBT for insomnia may be both clinically effective and feasible to deliver in real world practice.,"CBT was associated with moderate to large effect sizes for five of seven QOL outcomes, including significant reduction in daytime fatigue."
18591549,5,4,Claim,Premise,none,CBT for insomnia may be both clinically effective and feasible to deliver in real world practice.,"There was no significant interaction effect between any of these outcomes and baseline demographic, clinical, or sleep characteristics."
18520802,1,2,Premise,Premise,none,"Alopecia, arthralgias/myalgias, and cardiac events were significantly less frequent with PPX/carboplatin, whereas grade > or =3 neutropenia and grade 3 neuropathy showed a trend of worsening.",There was no significant difference in the incidence of hypersensitivity reactions despite the absence of routine premedication in the PPX arm.
18520802,1,3,Premise,Premise,none,"Alopecia, arthralgias/myalgias, and cardiac events were significantly less frequent with PPX/carboplatin, whereas grade > or =3 neutropenia and grade 3 neuropathy showed a trend of worsening.","Overall survival was similar between treatment arms (hazard ratio, 0.97; log rank p = 0.769)."
18520802,1,4,Premise,Premise,none,"Alopecia, arthralgias/myalgias, and cardiac events were significantly less frequent with PPX/carboplatin, whereas grade > or =3 neutropenia and grade 3 neuropathy showed a trend of worsening.","Median and 1-year survival rates were 7.9 months and 31%, for PPX versus 8 months and 31% for paclitaxel."
18520802,1,5,Premise,Claim,support,"Alopecia, arthralgias/myalgias, and cardiac events were significantly less frequent with PPX/carboplatin, whereas grade > or =3 neutropenia and grade 3 neuropathy showed a trend of worsening.","PPX/carboplatin failed to provide superior survival compared with paclitaxel/carboplatin in the first-line treatment of PS 2 patients with NSCLC,"
18520802,1,6,Premise,Claim,none,"Alopecia, arthralgias/myalgias, and cardiac events were significantly less frequent with PPX/carboplatin, whereas grade > or =3 neutropenia and grade 3 neuropathy showed a trend of worsening.",but the results with respect to progression-free survival and overall survival were comparable and the PPX regimen was more convenient.
18520802,2,1,Premise,Premise,none,There was no significant difference in the incidence of hypersensitivity reactions despite the absence of routine premedication in the PPX arm.,"Alopecia, arthralgias/myalgias, and cardiac events were significantly less frequent with PPX/carboplatin, whereas grade > or =3 neutropenia and grade 3 neuropathy showed a trend of worsening."
18520802,2,3,Premise,Premise,none,There was no significant difference in the incidence of hypersensitivity reactions despite the absence of routine premedication in the PPX arm.,"Overall survival was similar between treatment arms (hazard ratio, 0.97; log rank p = 0.769)."
18520802,2,4,Premise,Premise,none,There was no significant difference in the incidence of hypersensitivity reactions despite the absence of routine premedication in the PPX arm.,"Median and 1-year survival rates were 7.9 months and 31%, for PPX versus 8 months and 31% for paclitaxel."
18520802,2,5,Premise,Claim,support,There was no significant difference in the incidence of hypersensitivity reactions despite the absence of routine premedication in the PPX arm.,"PPX/carboplatin failed to provide superior survival compared with paclitaxel/carboplatin in the first-line treatment of PS 2 patients with NSCLC,"
18520802,2,6,Premise,Claim,none,There was no significant difference in the incidence of hypersensitivity reactions despite the absence of routine premedication in the PPX arm.,but the results with respect to progression-free survival and overall survival were comparable and the PPX regimen was more convenient.
18520802,3,1,Premise,Premise,none,"Overall survival was similar between treatment arms (hazard ratio, 0.97; log rank p = 0.769).","Alopecia, arthralgias/myalgias, and cardiac events were significantly less frequent with PPX/carboplatin, whereas grade > or =3 neutropenia and grade 3 neuropathy showed a trend of worsening."
18520802,3,2,Premise,Premise,none,"Overall survival was similar between treatment arms (hazard ratio, 0.97; log rank p = 0.769).",There was no significant difference in the incidence of hypersensitivity reactions despite the absence of routine premedication in the PPX arm.
18520802,3,4,Premise,Premise,none,"Overall survival was similar between treatment arms (hazard ratio, 0.97; log rank p = 0.769).","Median and 1-year survival rates were 7.9 months and 31%, for PPX versus 8 months and 31% for paclitaxel."
18520802,3,5,Premise,Claim,support,"Overall survival was similar between treatment arms (hazard ratio, 0.97; log rank p = 0.769).","PPX/carboplatin failed to provide superior survival compared with paclitaxel/carboplatin in the first-line treatment of PS 2 patients with NSCLC,"
18520802,3,6,Premise,Claim,none,"Overall survival was similar between treatment arms (hazard ratio, 0.97; log rank p = 0.769).",but the results with respect to progression-free survival and overall survival were comparable and the PPX regimen was more convenient.
18520802,4,1,Premise,Premise,none,"Median and 1-year survival rates were 7.9 months and 31%, for PPX versus 8 months and 31% for paclitaxel.","Alopecia, arthralgias/myalgias, and cardiac events were significantly less frequent with PPX/carboplatin, whereas grade > or =3 neutropenia and grade 3 neuropathy showed a trend of worsening."
18520802,4,2,Premise,Premise,none,"Median and 1-year survival rates were 7.9 months and 31%, for PPX versus 8 months and 31% for paclitaxel.",There was no significant difference in the incidence of hypersensitivity reactions despite the absence of routine premedication in the PPX arm.
18520802,4,3,Premise,Premise,none,"Median and 1-year survival rates were 7.9 months and 31%, for PPX versus 8 months and 31% for paclitaxel.","Overall survival was similar between treatment arms (hazard ratio, 0.97; log rank p = 0.769)."
18520802,4,5,Premise,Claim,support,"Median and 1-year survival rates were 7.9 months and 31%, for PPX versus 8 months and 31% for paclitaxel.","PPX/carboplatin failed to provide superior survival compared with paclitaxel/carboplatin in the first-line treatment of PS 2 patients with NSCLC,"
18520802,4,6,Premise,Claim,none,"Median and 1-year survival rates were 7.9 months and 31%, for PPX versus 8 months and 31% for paclitaxel.",but the results with respect to progression-free survival and overall survival were comparable and the PPX regimen was more convenient.
18520802,5,1,Claim,Premise,none,"PPX/carboplatin failed to provide superior survival compared with paclitaxel/carboplatin in the first-line treatment of PS 2 patients with NSCLC,","Alopecia, arthralgias/myalgias, and cardiac events were significantly less frequent with PPX/carboplatin, whereas grade > or =3 neutropenia and grade 3 neuropathy showed a trend of worsening."
18520802,5,2,Claim,Premise,none,"PPX/carboplatin failed to provide superior survival compared with paclitaxel/carboplatin in the first-line treatment of PS 2 patients with NSCLC,",There was no significant difference in the incidence of hypersensitivity reactions despite the absence of routine premedication in the PPX arm.
18520802,5,3,Claim,Premise,none,"PPX/carboplatin failed to provide superior survival compared with paclitaxel/carboplatin in the first-line treatment of PS 2 patients with NSCLC,","Overall survival was similar between treatment arms (hazard ratio, 0.97; log rank p = 0.769)."
18520802,5,4,Claim,Premise,none,"PPX/carboplatin failed to provide superior survival compared with paclitaxel/carboplatin in the first-line treatment of PS 2 patients with NSCLC,","Median and 1-year survival rates were 7.9 months and 31%, for PPX versus 8 months and 31% for paclitaxel."
18520802,5,6,Claim,Claim,none,"PPX/carboplatin failed to provide superior survival compared with paclitaxel/carboplatin in the first-line treatment of PS 2 patients with NSCLC,",but the results with respect to progression-free survival and overall survival were comparable and the PPX regimen was more convenient.
18520802,6,1,Claim,Premise,none,but the results with respect to progression-free survival and overall survival were comparable and the PPX regimen was more convenient.,"Alopecia, arthralgias/myalgias, and cardiac events were significantly less frequent with PPX/carboplatin, whereas grade > or =3 neutropenia and grade 3 neuropathy showed a trend of worsening."
18520802,6,2,Claim,Premise,none,but the results with respect to progression-free survival and overall survival were comparable and the PPX regimen was more convenient.,There was no significant difference in the incidence of hypersensitivity reactions despite the absence of routine premedication in the PPX arm.
18520802,6,3,Claim,Premise,none,but the results with respect to progression-free survival and overall survival were comparable and the PPX regimen was more convenient.,"Overall survival was similar between treatment arms (hazard ratio, 0.97; log rank p = 0.769)."
18520802,6,4,Claim,Premise,none,but the results with respect to progression-free survival and overall survival were comparable and the PPX regimen was more convenient.,"Median and 1-year survival rates were 7.9 months and 31%, for PPX versus 8 months and 31% for paclitaxel."
18520802,6,5,Claim,Claim,attack,but the results with respect to progression-free survival and overall survival were comparable and the PPX regimen was more convenient.,"PPX/carboplatin failed to provide superior survival compared with paclitaxel/carboplatin in the first-line treatment of PS 2 patients with NSCLC,"
20585099,1,2,Premise,Premise,none,"Male sexual dysfunction was significantly increased following surgery (P < .001),",although there was no difference between treatment arms.
20585099,1,3,Premise,Premise,none,"Male sexual dysfunction was significantly increased following surgery (P < .001),","Both treatment groups reported similar levels of decreased physical function at 3 months,"
20585099,1,4,Premise,Premise,none,"Male sexual dysfunction was significantly increased following surgery (P < .001),",but thereafter it returned to baseline levels.
20585099,1,5,Premise,Premise,none,"Male sexual dysfunction was significantly increased following surgery (P < .001),","There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,"
20585099,1,6,Premise,Premise,none,"Male sexual dysfunction was significantly increased following surgery (P < .001),",but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
20585099,1,7,Premise,Claim,support,"Male sexual dysfunction was significantly increased following surgery (P < .001),","These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,"
20585099,1,8,Premise,Claim,none,"Male sexual dysfunction was significantly increased following surgery (P < .001),",PRE also affected sexual and some aspects of bowel functioning.
20585099,2,1,Premise,Premise,attack,although there was no difference between treatment arms.,"Male sexual dysfunction was significantly increased following surgery (P < .001),"
20585099,2,3,Premise,Premise,none,although there was no difference between treatment arms.,"Both treatment groups reported similar levels of decreased physical function at 3 months,"
20585099,2,4,Premise,Premise,none,although there was no difference between treatment arms.,but thereafter it returned to baseline levels.
20585099,2,5,Premise,Premise,none,although there was no difference between treatment arms.,"There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,"
20585099,2,6,Premise,Premise,none,although there was no difference between treatment arms.,but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
20585099,2,7,Premise,Claim,none,although there was no difference between treatment arms.,"These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,"
20585099,2,8,Premise,Claim,none,although there was no difference between treatment arms.,PRE also affected sexual and some aspects of bowel functioning.
20585099,3,1,Premise,Premise,none,"Both treatment groups reported similar levels of decreased physical function at 3 months,","Male sexual dysfunction was significantly increased following surgery (P < .001),"
20585099,3,2,Premise,Premise,none,"Both treatment groups reported similar levels of decreased physical function at 3 months,",although there was no difference between treatment arms.
20585099,3,4,Premise,Premise,none,"Both treatment groups reported similar levels of decreased physical function at 3 months,",but thereafter it returned to baseline levels.
20585099,3,5,Premise,Premise,none,"Both treatment groups reported similar levels of decreased physical function at 3 months,","There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,"
20585099,3,6,Premise,Premise,none,"Both treatment groups reported similar levels of decreased physical function at 3 months,",but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
20585099,3,7,Premise,Claim,support,"Both treatment groups reported similar levels of decreased physical function at 3 months,","These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,"
20585099,3,8,Premise,Claim,none,"Both treatment groups reported similar levels of decreased physical function at 3 months,",PRE also affected sexual and some aspects of bowel functioning.
20585099,4,1,Premise,Premise,none,but thereafter it returned to baseline levels.,"Male sexual dysfunction was significantly increased following surgery (P < .001),"
20585099,4,2,Premise,Premise,none,but thereafter it returned to baseline levels.,although there was no difference between treatment arms.
20585099,4,3,Premise,Premise,attack,but thereafter it returned to baseline levels.,"Both treatment groups reported similar levels of decreased physical function at 3 months,"
20585099,4,5,Premise,Premise,none,but thereafter it returned to baseline levels.,"There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,"
20585099,4,6,Premise,Premise,none,but thereafter it returned to baseline levels.,but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
20585099,4,7,Premise,Claim,none,but thereafter it returned to baseline levels.,"These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,"
20585099,4,8,Premise,Claim,none,but thereafter it returned to baseline levels.,PRE also affected sexual and some aspects of bowel functioning.
20585099,5,1,Premise,Premise,none,"There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,","Male sexual dysfunction was significantly increased following surgery (P < .001),"
20585099,5,2,Premise,Premise,none,"There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,",although there was no difference between treatment arms.
20585099,5,3,Premise,Premise,none,"There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,","Both treatment groups reported similar levels of decreased physical function at 3 months,"
20585099,5,4,Premise,Premise,none,"There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,",but thereafter it returned to baseline levels.
20585099,5,6,Premise,Premise,none,"There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,",but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
20585099,5,7,Premise,Claim,none,"There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,","These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,"
20585099,5,8,Premise,Claim,attack,"There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,",PRE also affected sexual and some aspects of bowel functioning.
20585099,6,1,Premise,Premise,none,but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.,"Male sexual dysfunction was significantly increased following surgery (P < .001),"
20585099,6,2,Premise,Premise,none,but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.,although there was no difference between treatment arms.
20585099,6,3,Premise,Premise,none,but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.,"Both treatment groups reported similar levels of decreased physical function at 3 months,"
20585099,6,4,Premise,Premise,none,but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.,but thereafter it returned to baseline levels.
20585099,6,5,Premise,Premise,attack,but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.,"There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,"
20585099,6,7,Premise,Claim,none,but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.,"These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,"
20585099,6,8,Premise,Claim,none,but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.,PRE also affected sexual and some aspects of bowel functioning.
20585099,7,1,Claim,Premise,none,"These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,","Male sexual dysfunction was significantly increased following surgery (P < .001),"
20585099,7,2,Claim,Premise,none,"These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,",although there was no difference between treatment arms.
20585099,7,3,Claim,Premise,none,"These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,","Both treatment groups reported similar levels of decreased physical function at 3 months,"
20585099,7,4,Claim,Premise,none,"These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,",but thereafter it returned to baseline levels.
20585099,7,5,Claim,Premise,none,"These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,","There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,"
20585099,7,6,Claim,Premise,none,"These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,",but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
20585099,7,8,Claim,Claim,none,"These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,",PRE also affected sexual and some aspects of bowel functioning.
20585099,8,1,Claim,Premise,none,PRE also affected sexual and some aspects of bowel functioning.,"Male sexual dysfunction was significantly increased following surgery (P < .001),"
20585099,8,2,Claim,Premise,none,PRE also affected sexual and some aspects of bowel functioning.,although there was no difference between treatment arms.
20585099,8,3,Claim,Premise,none,PRE also affected sexual and some aspects of bowel functioning.,"Both treatment groups reported similar levels of decreased physical function at 3 months,"
20585099,8,4,Claim,Premise,none,PRE also affected sexual and some aspects of bowel functioning.,but thereafter it returned to baseline levels.
20585099,8,5,Claim,Premise,none,PRE also affected sexual and some aspects of bowel functioning.,"There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,"
20585099,8,6,Claim,Premise,none,PRE also affected sexual and some aspects of bowel functioning.,but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
20585099,8,7,Claim,Claim,none,PRE also affected sexual and some aspects of bowel functioning.,"These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,"
18669464,1,2,Premise,Premise,none,"Patients receiving sunitinib reported higher FKSI-15 and FKSI-DRS scores at each cycle than those receiving IFN-alpha, with a significant difference in the overall least squares means (3.27 and 1.98, respectively; P < .0001).","differences in least squares means for FACT-G (and all subscales), EQ-5D Index, and EQ-VAS were all significantly favorable for sunitinib (P < .01)."
18669464,1,3,Premise,Claim,support,"Patients receiving sunitinib reported higher FKSI-15 and FKSI-DRS scores at each cycle than those receiving IFN-alpha, with a significant difference in the overall least squares means (3.27 and 1.98, respectively; P < .0001).",Sunitinib provides superior QOL compared with IFN-alpha in mRCC patients.
18669464,2,1,Premise,Premise,none,"differences in least squares means for FACT-G (and all subscales), EQ-5D Index, and EQ-VAS were all significantly favorable for sunitinib (P < .01).","Patients receiving sunitinib reported higher FKSI-15 and FKSI-DRS scores at each cycle than those receiving IFN-alpha, with a significant difference in the overall least squares means (3.27 and 1.98, respectively; P < .0001)."
18669464,2,3,Premise,Claim,support,"differences in least squares means for FACT-G (and all subscales), EQ-5D Index, and EQ-VAS were all significantly favorable for sunitinib (P < .01).",Sunitinib provides superior QOL compared with IFN-alpha in mRCC patients.
18669464,3,1,Claim,Premise,none,Sunitinib provides superior QOL compared with IFN-alpha in mRCC patients.,"Patients receiving sunitinib reported higher FKSI-15 and FKSI-DRS scores at each cycle than those receiving IFN-alpha, with a significant difference in the overall least squares means (3.27 and 1.98, respectively; P < .0001)."
18669464,3,2,Claim,Premise,none,Sunitinib provides superior QOL compared with IFN-alpha in mRCC patients.,"differences in least squares means for FACT-G (and all subscales), EQ-5D Index, and EQ-VAS were all significantly favorable for sunitinib (P < .01)."
21901389,1,2,Premise,Premise,none,"Secondary outcome improvements resulting in significant between-group contrasts favoring the MBSR group at 4 months included meaningfulness, depression, paranoid ideation, hostility, anxiety, unhappiness, and emotional control.","Results tended to decline at 12 months and even more at 24 months, though at all times, they were as robust in women with lower expectation of effect as in those with higher expectation."
21901389,1,3,Premise,Claim,support,"Secondary outcome improvements resulting in significant between-group contrasts favoring the MBSR group at 4 months included meaningfulness, depression, paranoid ideation, hostility, anxiety, unhappiness, and emotional control.","The MBSR intervention appears to benefit psychosocial adjustment in cancer patients, over and above the effects of usual care or a credible control condition."
21901389,1,4,Premise,MajorClaim,none,"Secondary outcome improvements resulting in significant between-group contrasts favoring the MBSR group at 4 months included meaningfulness, depression, paranoid ideation, hostility, anxiety, unhappiness, and emotional control.",The universality of effects across levels of expectation indicates a potential to utilize this stress reduction approach as complementary therapy in oncologic practice.
21901389,2,1,Premise,Premise,none,"Results tended to decline at 12 months and even more at 24 months, though at all times, they were as robust in women with lower expectation of effect as in those with higher expectation.","Secondary outcome improvements resulting in significant between-group contrasts favoring the MBSR group at 4 months included meaningfulness, depression, paranoid ideation, hostility, anxiety, unhappiness, and emotional control."
21901389,2,3,Premise,Claim,attack,"Results tended to decline at 12 months and even more at 24 months, though at all times, they were as robust in women with lower expectation of effect as in those with higher expectation.","The MBSR intervention appears to benefit psychosocial adjustment in cancer patients, over and above the effects of usual care or a credible control condition."
21901389,2,4,Premise,MajorClaim,none,"Results tended to decline at 12 months and even more at 24 months, though at all times, they were as robust in women with lower expectation of effect as in those with higher expectation.",The universality of effects across levels of expectation indicates a potential to utilize this stress reduction approach as complementary therapy in oncologic practice.
21901389,3,1,Claim,Premise,none,"The MBSR intervention appears to benefit psychosocial adjustment in cancer patients, over and above the effects of usual care or a credible control condition.","Secondary outcome improvements resulting in significant between-group contrasts favoring the MBSR group at 4 months included meaningfulness, depression, paranoid ideation, hostility, anxiety, unhappiness, and emotional control."
21901389,3,2,Claim,Premise,none,"The MBSR intervention appears to benefit psychosocial adjustment in cancer patients, over and above the effects of usual care or a credible control condition.","Results tended to decline at 12 months and even more at 24 months, though at all times, they were as robust in women with lower expectation of effect as in those with higher expectation."
21901389,3,4,Claim,MajorClaim,support,"The MBSR intervention appears to benefit psychosocial adjustment in cancer patients, over and above the effects of usual care or a credible control condition.",The universality of effects across levels of expectation indicates a potential to utilize this stress reduction approach as complementary therapy in oncologic practice.
21901389,4,1,MajorClaim,Premise,none,The universality of effects across levels of expectation indicates a potential to utilize this stress reduction approach as complementary therapy in oncologic practice.,"Secondary outcome improvements resulting in significant between-group contrasts favoring the MBSR group at 4 months included meaningfulness, depression, paranoid ideation, hostility, anxiety, unhappiness, and emotional control."
21901389,4,2,MajorClaim,Premise,none,The universality of effects across levels of expectation indicates a potential to utilize this stress reduction approach as complementary therapy in oncologic practice.,"Results tended to decline at 12 months and even more at 24 months, though at all times, they were as robust in women with lower expectation of effect as in those with higher expectation."
21901389,4,3,MajorClaim,Claim,none,The universality of effects across levels of expectation indicates a potential to utilize this stress reduction approach as complementary therapy in oncologic practice.,"The MBSR intervention appears to benefit psychosocial adjustment in cancer patients, over and above the effects of usual care or a credible control condition."
16490846,1,2,Premise,Premise,none,"Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros).","For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros."
16490846,1,3,Premise,Premise,none,"Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros).","The acceptability curves showed that for these ratios, the probability of MMS being more cost-effective than surgical excision never reached 50%."
16490846,1,4,Premise,Claim,support,"Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros).","At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC."
16490846,1,5,Premise,Premise,none,"Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros).",because a 5-year period is normally required to determine definite recurrence rates
16490846,1,6,Premise,Claim,none,"Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros).",it is possible that MMS may become a cost-effective treatment for recurrent BCC.
16490846,2,1,Premise,Premise,none,"For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros.","Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros)."
16490846,2,3,Premise,Premise,none,"For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros.","The acceptability curves showed that for these ratios, the probability of MMS being more cost-effective than surgical excision never reached 50%."
16490846,2,4,Premise,Claim,support,"For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros.","At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC."
16490846,2,5,Premise,Premise,none,"For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros.",because a 5-year period is normally required to determine definite recurrence rates
16490846,2,6,Premise,Claim,none,"For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros.",it is possible that MMS may become a cost-effective treatment for recurrent BCC.
16490846,3,1,Premise,Premise,none,"The acceptability curves showed that for these ratios, the probability of MMS being more cost-effective than surgical excision never reached 50%.","Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros)."
16490846,3,2,Premise,Premise,none,"The acceptability curves showed that for these ratios, the probability of MMS being more cost-effective than surgical excision never reached 50%.","For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros."
16490846,3,4,Premise,Claim,support,"The acceptability curves showed that for these ratios, the probability of MMS being more cost-effective than surgical excision never reached 50%.","At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC."
16490846,3,5,Premise,Premise,none,"The acceptability curves showed that for these ratios, the probability of MMS being more cost-effective than surgical excision never reached 50%.",because a 5-year period is normally required to determine definite recurrence rates
16490846,3,6,Premise,Claim,none,"The acceptability curves showed that for these ratios, the probability of MMS being more cost-effective than surgical excision never reached 50%.",it is possible that MMS may become a cost-effective treatment for recurrent BCC.
16490846,4,1,Claim,Premise,none,"At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC.","Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros)."
16490846,4,2,Claim,Premise,none,"At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC.","For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros."
16490846,4,3,Claim,Premise,none,"At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC.","The acceptability curves showed that for these ratios, the probability of MMS being more cost-effective than surgical excision never reached 50%."
16490846,4,5,Claim,Premise,none,"At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC.",because a 5-year period is normally required to determine definite recurrence rates
16490846,4,6,Claim,Claim,none,"At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC.",it is possible that MMS may become a cost-effective treatment for recurrent BCC.
16490846,5,1,Premise,Premise,none,because a 5-year period is normally required to determine definite recurrence rates,"Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros)."
16490846,5,2,Premise,Premise,none,because a 5-year period is normally required to determine definite recurrence rates,"For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros."
16490846,5,3,Premise,Premise,none,because a 5-year period is normally required to determine definite recurrence rates,"The acceptability curves showed that for these ratios, the probability of MMS being more cost-effective than surgical excision never reached 50%."
16490846,5,4,Premise,Claim,none,because a 5-year period is normally required to determine definite recurrence rates,"At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC."
16490846,5,6,Premise,Claim,support,because a 5-year period is normally required to determine definite recurrence rates,it is possible that MMS may become a cost-effective treatment for recurrent BCC.
16490846,6,1,Claim,Premise,none,it is possible that MMS may become a cost-effective treatment for recurrent BCC.,"Compared with surgical excision, the total treatment costs of MMS are significantly higher (cost difference: primary BCC, 254 euros; 95% confidence interval, 181-324 euros; recurrent BCC, 249 euros; 95% confidence interval, 175-323 euros)."
16490846,6,2,Claim,Premise,none,it is possible that MMS may become a cost-effective treatment for recurrent BCC.,"For primary BCC, the incremental cost-effectiveness ratio was 29,231 euros, while the ratio for recurrent BCC amounted to 8094 euros."
16490846,6,3,Claim,Premise,none,it is possible that MMS may become a cost-effective treatment for recurrent BCC.,"The acceptability curves showed that for these ratios, the probability of MMS being more cost-effective than surgical excision never reached 50%."
16490846,6,4,Claim,Claim,attack,it is possible that MMS may become a cost-effective treatment for recurrent BCC.,"At present, it does not seem cost-effective to introduce MMS on a large scale for both primary and recurrent BCC."
16490846,6,5,Claim,Premise,none,it is possible that MMS may become a cost-effective treatment for recurrent BCC.,because a 5-year period is normally required to determine definite recurrence rates
20625123,1,2,Premise,Premise,none,"Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).","Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative."
20625123,1,3,Premise,Premise,none,"Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).","However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02)."
20625123,1,4,Premise,Premise,none,"Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).","There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm."
20625123,1,5,Premise,Claim,support,"Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).",This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.
20625123,2,1,Premise,Premise,none,"Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.","Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35)."
20625123,2,3,Premise,Premise,none,"Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.","However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02)."
20625123,2,4,Premise,Premise,none,"Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.","There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm."
20625123,2,5,Premise,Claim,support,"Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.",This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.
20625123,3,1,Premise,Premise,none,"However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).","Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35)."
20625123,3,2,Premise,Premise,none,"However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).","Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative."
20625123,3,4,Premise,Premise,none,"However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).","There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm."
20625123,3,5,Premise,Claim,support,"However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).",This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.
20625123,4,1,Premise,Premise,none,"There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.","Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35)."
20625123,4,2,Premise,Premise,none,"There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.","Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative."
20625123,4,3,Premise,Premise,none,"There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.","However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02)."
20625123,4,5,Premise,Claim,support,"There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.",This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.
20625123,5,1,Claim,Premise,none,This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.,"Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35)."
20625123,5,2,Claim,Premise,none,This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.,"Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative."
20625123,5,3,Claim,Premise,none,This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.,"However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02)."
20625123,5,4,Claim,Premise,none,This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.,"There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm."
9640214,1,2,Premise,Premise,none,"The Cronbach's alpha coefficients were 0.79 and 0.73 for the body image and fear of recurrence scales, respectively.",Significant benefit in body image and satisfaction with treatment was observed in the BCT patients.
9640214,1,3,Premise,Premise,none,"The Cronbach's alpha coefficients were 0.79 and 0.73 for the body image and fear of recurrence scales, respectively.",No significant difference was observed in fear of recurrence between the two groups.
9640214,1,4,Premise,Premise,none,"The Cronbach's alpha coefficients were 0.79 and 0.73 for the body image and fear of recurrence scales, respectively.","Ratings of cosmetic results decreased with time, in line with clinical observations of long-term side-effects of radiotherapy."
9640214,1,5,Premise,Claim,none,"The Cronbach's alpha coefficients were 0.79 and 0.73 for the body image and fear of recurrence scales, respectively.",Wide excision appeared to be the most important predictive factor for poor cosmetic result.
9640214,1,6,Premise,Claim,support,"The Cronbach's alpha coefficients were 0.79 and 0.73 for the body image and fear of recurrence scales, respectively.","In this multicentre randomised study, BCT helped to maintain the patients' body image, resulted in higher satisfaction with treatment and yielded no significant difference from MRM with respect to fear of recurrence."
9640214,2,1,Premise,Premise,none,Significant benefit in body image and satisfaction with treatment was observed in the BCT patients.,"The Cronbach's alpha coefficients were 0.79 and 0.73 for the body image and fear of recurrence scales, respectively."
9640214,2,3,Premise,Premise,none,Significant benefit in body image and satisfaction with treatment was observed in the BCT patients.,No significant difference was observed in fear of recurrence between the two groups.
9640214,2,4,Premise,Premise,none,Significant benefit in body image and satisfaction with treatment was observed in the BCT patients.,"Ratings of cosmetic results decreased with time, in line with clinical observations of long-term side-effects of radiotherapy."
9640214,2,5,Premise,Claim,none,Significant benefit in body image and satisfaction with treatment was observed in the BCT patients.,Wide excision appeared to be the most important predictive factor for poor cosmetic result.
9640214,2,6,Premise,Claim,support,Significant benefit in body image and satisfaction with treatment was observed in the BCT patients.,"In this multicentre randomised study, BCT helped to maintain the patients' body image, resulted in higher satisfaction with treatment and yielded no significant difference from MRM with respect to fear of recurrence."
9640214,3,1,Premise,Premise,none,No significant difference was observed in fear of recurrence between the two groups.,"The Cronbach's alpha coefficients were 0.79 and 0.73 for the body image and fear of recurrence scales, respectively."
9640214,3,2,Premise,Premise,none,No significant difference was observed in fear of recurrence between the two groups.,Significant benefit in body image and satisfaction with treatment was observed in the BCT patients.
9640214,3,4,Premise,Premise,none,No significant difference was observed in fear of recurrence between the two groups.,"Ratings of cosmetic results decreased with time, in line with clinical observations of long-term side-effects of radiotherapy."
9640214,3,5,Premise,Claim,none,No significant difference was observed in fear of recurrence between the two groups.,Wide excision appeared to be the most important predictive factor for poor cosmetic result.
9640214,3,6,Premise,Claim,support,No significant difference was observed in fear of recurrence between the two groups.,"In this multicentre randomised study, BCT helped to maintain the patients' body image, resulted in higher satisfaction with treatment and yielded no significant difference from MRM with respect to fear of recurrence."
9640214,4,1,Premise,Premise,none,"Ratings of cosmetic results decreased with time, in line with clinical observations of long-term side-effects of radiotherapy.","The Cronbach's alpha coefficients were 0.79 and 0.73 for the body image and fear of recurrence scales, respectively."
9640214,4,2,Premise,Premise,none,"Ratings of cosmetic results decreased with time, in line with clinical observations of long-term side-effects of radiotherapy.",Significant benefit in body image and satisfaction with treatment was observed in the BCT patients.
9640214,4,3,Premise,Premise,none,"Ratings of cosmetic results decreased with time, in line with clinical observations of long-term side-effects of radiotherapy.",No significant difference was observed in fear of recurrence between the two groups.
9640214,4,5,Premise,Claim,none,"Ratings of cosmetic results decreased with time, in line with clinical observations of long-term side-effects of radiotherapy.",Wide excision appeared to be the most important predictive factor for poor cosmetic result.
9640214,4,6,Premise,Claim,attack,"Ratings of cosmetic results decreased with time, in line with clinical observations of long-term side-effects of radiotherapy.","In this multicentre randomised study, BCT helped to maintain the patients' body image, resulted in higher satisfaction with treatment and yielded no significant difference from MRM with respect to fear of recurrence."
9640214,5,1,Claim,Premise,none,Wide excision appeared to be the most important predictive factor for poor cosmetic result.,"The Cronbach's alpha coefficients were 0.79 and 0.73 for the body image and fear of recurrence scales, respectively."
9640214,5,2,Claim,Premise,none,Wide excision appeared to be the most important predictive factor for poor cosmetic result.,Significant benefit in body image and satisfaction with treatment was observed in the BCT patients.
9640214,5,3,Claim,Premise,none,Wide excision appeared to be the most important predictive factor for poor cosmetic result.,No significant difference was observed in fear of recurrence between the two groups.
9640214,5,4,Claim,Premise,none,Wide excision appeared to be the most important predictive factor for poor cosmetic result.,"Ratings of cosmetic results decreased with time, in line with clinical observations of long-term side-effects of radiotherapy."
9640214,5,6,Claim,Claim,none,Wide excision appeared to be the most important predictive factor for poor cosmetic result.,"In this multicentre randomised study, BCT helped to maintain the patients' body image, resulted in higher satisfaction with treatment and yielded no significant difference from MRM with respect to fear of recurrence."
9640214,6,1,Claim,Premise,none,"In this multicentre randomised study, BCT helped to maintain the patients' body image, resulted in higher satisfaction with treatment and yielded no significant difference from MRM with respect to fear of recurrence.","The Cronbach's alpha coefficients were 0.79 and 0.73 for the body image and fear of recurrence scales, respectively."
9640214,6,2,Claim,Premise,none,"In this multicentre randomised study, BCT helped to maintain the patients' body image, resulted in higher satisfaction with treatment and yielded no significant difference from MRM with respect to fear of recurrence.",Significant benefit in body image and satisfaction with treatment was observed in the BCT patients.
9640214,6,3,Claim,Premise,none,"In this multicentre randomised study, BCT helped to maintain the patients' body image, resulted in higher satisfaction with treatment and yielded no significant difference from MRM with respect to fear of recurrence.",No significant difference was observed in fear of recurrence between the two groups.
9640214,6,4,Claim,Premise,none,"In this multicentre randomised study, BCT helped to maintain the patients' body image, resulted in higher satisfaction with treatment and yielded no significant difference from MRM with respect to fear of recurrence.","Ratings of cosmetic results decreased with time, in line with clinical observations of long-term side-effects of radiotherapy."
9640214,6,5,Claim,Claim,none,"In this multicentre randomised study, BCT helped to maintain the patients' body image, resulted in higher satisfaction with treatment and yielded no significant difference from MRM with respect to fear of recurrence.",Wide excision appeared to be the most important predictive factor for poor cosmetic result.
24151326,1,2,Premise,Premise,none,Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome.,"In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02)."
24151326,1,3,Premise,Premise,none,Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome.,COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength.
24151326,1,4,Premise,Premise,none,Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome.,HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03).
24151326,1,5,Premise,Premise,none,Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome.,No differences emerged for body composition or chemotherapy completion.
24151326,1,6,Premise,Claim,none,Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome.,A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.
24151326,2,1,Premise,Premise,none,"In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02).",Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome.
24151326,2,3,Premise,Premise,none,"In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02).",COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength.
24151326,2,4,Premise,Premise,none,"In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02).",HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03).
24151326,2,5,Premise,Premise,none,"In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02).",No differences emerged for body composition or chemotherapy completion.
24151326,2,6,Premise,Claim,support,"In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02).",A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.
24151326,3,1,Premise,Premise,none,COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength.,Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome.
24151326,3,2,Premise,Premise,none,COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength.,"In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02)."
24151326,3,4,Premise,Premise,none,COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength.,HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03).
24151326,3,5,Premise,Premise,none,COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength.,No differences emerged for body composition or chemotherapy completion.
24151326,3,6,Premise,Claim,support,COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength.,A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.
24151326,4,1,Premise,Premise,none,HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03).,Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome.
24151326,4,2,Premise,Premise,none,HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03).,"In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02)."
24151326,4,3,Premise,Premise,none,HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03).,COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength.
24151326,4,5,Premise,Premise,none,HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03).,No differences emerged for body composition or chemotherapy completion.
24151326,4,6,Premise,Claim,support,HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03).,A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.
24151326,5,1,Premise,Premise,none,No differences emerged for body composition or chemotherapy completion.,Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome.
24151326,5,2,Premise,Premise,none,No differences emerged for body composition or chemotherapy completion.,"In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02)."
24151326,5,3,Premise,Premise,none,No differences emerged for body composition or chemotherapy completion.,COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength.
24151326,5,4,Premise,Premise,none,No differences emerged for body composition or chemotherapy completion.,HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03).
24151326,5,6,Premise,Claim,none,No differences emerged for body composition or chemotherapy completion.,A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.
24151326,6,1,Claim,Premise,none,A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.,Adjusted linear mixed-model analyses showed that neither HIGH (+0.8; 95% confidence interval [CI] = -0.8 to 2.4; P = .30) nor COMB (+0.5; 95% CI = -1.1 to 2.1; P = .52] were superior to STAN for the primary outcome.
24151326,6,2,Claim,Premise,none,A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.,"In secondary analyses not adjusted for multiple comparisons, HIGH was superior to STAN for the SF-36 physical component summary (P = .04), SF-36 bodily pain (P = .02), and endocrine symptoms (P = .02)."
24151326,6,3,Claim,Premise,none,A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.,COMB was superior to STAN for endocrine symptoms (P = .009) and superior to STAN (P < .001) and HIGH (P < .001) for muscular strength.
24151326,6,4,Claim,Premise,none,A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.,HIGH was superior to COMB for the SF-36 bodily pain (P = .04) and aerobic fitness (P = .03).
24151326,6,5,Claim,Premise,none,A higher volume of aerobic or combined exercise is achievable and safe during breast cancer chemotherapy and may manage declines in physical functioning and worsening symptoms better than standard volumes.,No differences emerged for body composition or chemotherapy completion.
20600809,1,2,Premise,Premise,none,HT patients had a minimal decrease in natural killer cell cytotoxicity (NKCC) over the course of treatment whereas NKCC of RT and UC patients declined sharply during chemoradiation (group by time interaction: p = 0.018).,HT patients showed greater decreases in two different indicators of depressed mood (CES-D depressed mood subscale and POMS depression scale) compared to RT and UC (group by time interactions: p<0.05).
20600809,1,3,Premise,Premise,none,HT patients had a minimal decrease in natural killer cell cytotoxicity (NKCC) over the course of treatment whereas NKCC of RT and UC patients declined sharply during chemoradiation (group by time interaction: p = 0.018).,"No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities."
20600809,1,4,Premise,Claim,support,HT patients had a minimal decrease in natural killer cell cytotoxicity (NKCC) over the course of treatment whereas NKCC of RT and UC patients declined sharply during chemoradiation (group by time interaction: p = 0.018).,HT may benefit cervical cancer patients by moderating effects of chemoradiation on depressed mood and cellular immunity.
20600809,1,5,Premise,Claim,none,HT patients had a minimal decrease in natural killer cell cytotoxicity (NKCC) over the course of treatment whereas NKCC of RT and UC patients declined sharply during chemoradiation (group by time interaction: p = 0.018).,"Effects of HT on toxicities, treatment delay, QOL, and fatigue were not observed."
20600809,2,1,Premise,Premise,none,HT patients showed greater decreases in two different indicators of depressed mood (CES-D depressed mood subscale and POMS depression scale) compared to RT and UC (group by time interactions: p<0.05).,HT patients had a minimal decrease in natural killer cell cytotoxicity (NKCC) over the course of treatment whereas NKCC of RT and UC patients declined sharply during chemoradiation (group by time interaction: p = 0.018).
20600809,2,3,Premise,Premise,none,HT patients showed greater decreases in two different indicators of depressed mood (CES-D depressed mood subscale and POMS depression scale) compared to RT and UC (group by time interactions: p<0.05).,"No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities."
20600809,2,4,Premise,Claim,support,HT patients showed greater decreases in two different indicators of depressed mood (CES-D depressed mood subscale and POMS depression scale) compared to RT and UC (group by time interactions: p<0.05).,HT may benefit cervical cancer patients by moderating effects of chemoradiation on depressed mood and cellular immunity.
20600809,2,5,Premise,Claim,none,HT patients showed greater decreases in two different indicators of depressed mood (CES-D depressed mood subscale and POMS depression scale) compared to RT and UC (group by time interactions: p<0.05).,"Effects of HT on toxicities, treatment delay, QOL, and fatigue were not observed."
20600809,3,1,Premise,Premise,none,"No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities.",HT patients had a minimal decrease in natural killer cell cytotoxicity (NKCC) over the course of treatment whereas NKCC of RT and UC patients declined sharply during chemoradiation (group by time interaction: p = 0.018).
20600809,3,2,Premise,Premise,none,"No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities.",HT patients showed greater decreases in two different indicators of depressed mood (CES-D depressed mood subscale and POMS depression scale) compared to RT and UC (group by time interactions: p<0.05).
20600809,3,4,Premise,Claim,none,"No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities.",HT may benefit cervical cancer patients by moderating effects of chemoradiation on depressed mood and cellular immunity.
20600809,3,5,Premise,Claim,support,"No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities.","Effects of HT on toxicities, treatment delay, QOL, and fatigue were not observed."
20600809,4,1,Claim,Premise,none,HT may benefit cervical cancer patients by moderating effects of chemoradiation on depressed mood and cellular immunity.,HT patients had a minimal decrease in natural killer cell cytotoxicity (NKCC) over the course of treatment whereas NKCC of RT and UC patients declined sharply during chemoradiation (group by time interaction: p = 0.018).
20600809,4,2,Claim,Premise,none,HT may benefit cervical cancer patients by moderating effects of chemoradiation on depressed mood and cellular immunity.,HT patients showed greater decreases in two different indicators of depressed mood (CES-D depressed mood subscale and POMS depression scale) compared to RT and UC (group by time interactions: p<0.05).
20600809,4,3,Claim,Premise,none,HT may benefit cervical cancer patients by moderating effects of chemoradiation on depressed mood and cellular immunity.,"No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities."
20600809,4,5,Claim,Claim,none,HT may benefit cervical cancer patients by moderating effects of chemoradiation on depressed mood and cellular immunity.,"Effects of HT on toxicities, treatment delay, QOL, and fatigue were not observed."
20600809,5,1,Claim,Premise,none,"Effects of HT on toxicities, treatment delay, QOL, and fatigue were not observed.",HT patients had a minimal decrease in natural killer cell cytotoxicity (NKCC) over the course of treatment whereas NKCC of RT and UC patients declined sharply during chemoradiation (group by time interaction: p = 0.018).
20600809,5,2,Claim,Premise,none,"Effects of HT on toxicities, treatment delay, QOL, and fatigue were not observed.",HT patients showed greater decreases in two different indicators of depressed mood (CES-D depressed mood subscale and POMS depression scale) compared to RT and UC (group by time interactions: p<0.05).
20600809,5,3,Claim,Premise,none,"Effects of HT on toxicities, treatment delay, QOL, and fatigue were not observed.","No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities."
20600809,5,4,Claim,Claim,none,"Effects of HT on toxicities, treatment delay, QOL, and fatigue were not observed.",HT may benefit cervical cancer patients by moderating effects of chemoradiation on depressed mood and cellular immunity.
10506606,1,2,Premise,Premise,none,The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).,All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.
10506606,1,3,Premise,Premise,none,The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).,"Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05)."
10506606,1,4,Premise,Premise,none,The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).,DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).
10506606,1,5,Premise,Premise,none,The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).,"The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease."
10506606,1,6,Premise,Claim,support,The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).,DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.
10506606,2,1,Premise,Premise,none,All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.,The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).
10506606,2,3,Premise,Premise,none,All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.,"Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05)."
10506606,2,4,Premise,Premise,none,All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.,DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).
10506606,2,5,Premise,Premise,none,All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.,"The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease."
10506606,2,6,Premise,Claim,none,All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.,DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.
10506606,3,1,Premise,Premise,none,"Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).",The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).
10506606,3,2,Premise,Premise,none,"Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).",All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.
10506606,3,4,Premise,Premise,none,"Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).",DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).
10506606,3,5,Premise,Premise,none,"Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).","The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease."
10506606,3,6,Premise,Claim,none,"Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05).",DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.
10506606,4,1,Premise,Premise,none,DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).,The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).
10506606,4,2,Premise,Premise,none,DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).,All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.
10506606,4,3,Premise,Premise,none,DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).,"Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05)."
10506606,4,5,Premise,Premise,none,DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).,"The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease."
10506606,4,6,Premise,Claim,support,DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).,DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.
10506606,5,1,Premise,Premise,none,"The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.",The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).
10506606,5,2,Premise,Premise,none,"The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.",All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.
10506606,5,3,Premise,Premise,none,"The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.","Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05)."
10506606,5,4,Premise,Premise,none,"The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.",DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).
10506606,5,6,Premise,Claim,none,"The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease.",DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.
10506606,6,1,Claim,Premise,none,DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.,The response rate was 71% for DepoCyt and 15% for ara-C on an intent-to-treat basis (P =.006).
10506606,6,2,Claim,Premise,none,DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.,All of the patients on the DepoCyt arm but only 53% of those on the ara-C arm were able to complete the planned 1-month induction therapy regimen.
10506606,6,3,Claim,Premise,none,DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.,"Time to neurologic progression and survival trend in favor of DepoCyt (median, 78.5 v 42 days and 99.5 v 63 days, respectively; P >.05)."
10506606,6,4,Claim,Premise,none,DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.,DepoCyt treatment was associated with an improved mean change in Karnofsky performance score at the end of induction (P =.041).
10506606,6,5,Claim,Premise,none,DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.,"The major adverse events on both arms were headache and arachnoiditis, which were often caused by the underlying disease."
23735703,1,2,Premise,Premise,none,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively.","Although quality of life did not differ significantly,"
23735703,1,3,Premise,Premise,none,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively.",chemotherapy compliance was significantly higher in the PRE group.
23735703,1,4,Premise,Premise,none,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively.","The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001)."
23735703,1,5,Premise,Premise,none,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively.","In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007)."
23735703,1,6,Premise,Premise,none,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively.","There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates."
23735703,1,7,Premise,Premise,none,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively.",the regimens' toxicity profiles differed.
23735703,1,8,Premise,Claim,none,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively.",This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.
23735703,1,9,Premise,Claim,support,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively.",The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.
23735703,2,1,Premise,Premise,none,"Although quality of life did not differ significantly,","Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively."
23735703,2,3,Premise,Premise,none,"Although quality of life did not differ significantly,",chemotherapy compliance was significantly higher in the PRE group.
23735703,2,4,Premise,Premise,none,"Although quality of life did not differ significantly,","The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001)."
23735703,2,5,Premise,Premise,none,"Although quality of life did not differ significantly,","In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007)."
23735703,2,6,Premise,Premise,none,"Although quality of life did not differ significantly,","There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates."
23735703,2,7,Premise,Premise,none,"Although quality of life did not differ significantly,",the regimens' toxicity profiles differed.
23735703,2,8,Premise,Claim,none,"Although quality of life did not differ significantly,",This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.
23735703,2,9,Premise,Claim,none,"Although quality of life did not differ significantly,",The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.
23735703,3,1,Premise,Premise,none,chemotherapy compliance was significantly higher in the PRE group.,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively."
23735703,3,2,Premise,Premise,none,chemotherapy compliance was significantly higher in the PRE group.,"Although quality of life did not differ significantly,"
23735703,3,4,Premise,Premise,none,chemotherapy compliance was significantly higher in the PRE group.,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001)."
23735703,3,5,Premise,Premise,none,chemotherapy compliance was significantly higher in the PRE group.,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007)."
23735703,3,6,Premise,Premise,none,chemotherapy compliance was significantly higher in the PRE group.,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates."
23735703,3,7,Premise,Premise,none,chemotherapy compliance was significantly higher in the PRE group.,the regimens' toxicity profiles differed.
23735703,3,8,Premise,Claim,none,chemotherapy compliance was significantly higher in the PRE group.,This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.
23735703,3,9,Premise,Claim,none,chemotherapy compliance was significantly higher in the PRE group.,The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.
23735703,4,1,Premise,Premise,none,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001).","Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively."
23735703,4,2,Premise,Premise,none,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001).","Although quality of life did not differ significantly,"
23735703,4,3,Premise,Premise,none,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001).",chemotherapy compliance was significantly higher in the PRE group.
23735703,4,5,Premise,Premise,none,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001).","In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007)."
23735703,4,6,Premise,Premise,none,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001).","There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates."
23735703,4,7,Premise,Premise,none,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001).",the regimens' toxicity profiles differed.
23735703,4,8,Premise,Claim,none,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001).",This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.
23735703,4,9,Premise,Claim,none,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001).",The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.
23735703,5,1,Premise,Premise,none,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007).","Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively."
23735703,5,2,Premise,Premise,none,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007).","Although quality of life did not differ significantly,"
23735703,5,3,Premise,Premise,none,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007).",chemotherapy compliance was significantly higher in the PRE group.
23735703,5,4,Premise,Premise,none,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007).","The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001)."
23735703,5,6,Premise,Premise,none,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007).","There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates."
23735703,5,7,Premise,Premise,none,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007).",the regimens' toxicity profiles differed.
23735703,5,8,Premise,Claim,none,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007).",This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.
23735703,5,9,Premise,Claim,none,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007).",The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.
23735703,6,1,Premise,Premise,none,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates.","Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively."
23735703,6,2,Premise,Premise,none,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates.","Although quality of life did not differ significantly,"
23735703,6,3,Premise,Premise,none,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates.",chemotherapy compliance was significantly higher in the PRE group.
23735703,6,4,Premise,Premise,none,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates.","The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001)."
23735703,6,5,Premise,Premise,none,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates.","In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007)."
23735703,6,7,Premise,Premise,none,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates.",the regimens' toxicity profiles differed.
23735703,6,8,Premise,Claim,support,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates.",This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.
23735703,6,9,Premise,Claim,none,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates.",The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.
23735703,7,1,Premise,Premise,none,the regimens' toxicity profiles differed.,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively."
23735703,7,2,Premise,Premise,none,the regimens' toxicity profiles differed.,"Although quality of life did not differ significantly,"
23735703,7,3,Premise,Premise,none,the regimens' toxicity profiles differed.,chemotherapy compliance was significantly higher in the PRE group.
23735703,7,4,Premise,Premise,none,the regimens' toxicity profiles differed.,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001)."
23735703,7,5,Premise,Premise,none,the regimens' toxicity profiles differed.,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007)."
23735703,7,6,Premise,Premise,none,the regimens' toxicity profiles differed.,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates."
23735703,7,8,Premise,Claim,none,the regimens' toxicity profiles differed.,This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.
23735703,7,9,Premise,Claim,none,the regimens' toxicity profiles differed.,The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.
23735703,8,1,Claim,Premise,none,This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively."
23735703,8,2,Claim,Premise,none,This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.,"Although quality of life did not differ significantly,"
23735703,8,3,Claim,Premise,none,This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.,chemotherapy compliance was significantly higher in the PRE group.
23735703,8,4,Claim,Premise,none,This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001)."
23735703,8,5,Claim,Premise,none,This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007)."
23735703,8,6,Claim,Premise,none,This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates."
23735703,8,7,Claim,Premise,none,This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.,the regimens' toxicity profiles differed.
23735703,8,9,Claim,Claim,none,This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.,The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.
23735703,9,1,Claim,Premise,none,The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.,"Pathological complete response was observed in 22 (8.2%) and 16 patients (6.1%), respectively."
23735703,9,2,Claim,Premise,none,The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.,"Although quality of life did not differ significantly,"
23735703,9,3,Claim,Premise,none,The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.,chemotherapy compliance was significantly higher in the PRE group.
23735703,9,4,Claim,Premise,none,The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.,"The proportion of responders who received Cycles 3 and 4 was significantly higher in the PRE group (90.4% versus 75.2%, p=0.001)."
23735703,9,5,Claim,Premise,none,The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.,"In responders, the dose intensity of Cycles 3 and 4 was higher in the PRE group than in the PERI group (mean relative dose intensity of 90.4% versus 82.6%, respectively; p=0.0007)."
23735703,9,6,Claim,Premise,none,The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.,"There was no difference between GP and TC in 3-year OS (HR=0.97 [95% confidence interval (CI): 0.76-1.25], p=0.80) or response rates."
23735703,9,7,Claim,Premise,none,The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.,the regimens' toxicity profiles differed.
23735703,9,8,Claim,Claim,none,The increase from two to four preoperative chemotherapy cycles did not increase the pathological response rate.,This study failed to demonstrate any difference in survival between patients receiving preoperative and perioperative chemotherapy in early-stage NSCLC.
11438417,1,2,Premise,Premise,none,"Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.","The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine."
11438417,1,3,Premise,Premise,none,"Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.","The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP."
11438417,1,4,Premise,Claim,none,"Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.","Fludarabine was consistently a better treatment than ChOP,"
11438417,1,5,Premise,Premise,none,"Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.",except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
11438417,1,6,Premise,Premise,none,"Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.","from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months)."
11438417,1,7,Premise,Claim,none,"Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.",patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
11438417,1,8,Premise,Claim,support,"Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP.",These two treatments are always superior to CAP.
11438417,2,1,Premise,Premise,none,"The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.","Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP."
11438417,2,3,Premise,Premise,none,"The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.","The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP."
11438417,2,4,Premise,Claim,none,"The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.","Fludarabine was consistently a better treatment than ChOP,"
11438417,2,5,Premise,Premise,none,"The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.",except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
11438417,2,6,Premise,Premise,none,"The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.","from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months)."
11438417,2,7,Premise,Claim,none,"The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.",patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
11438417,2,8,Premise,Claim,support,"The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine.",These two treatments are always superior to CAP.
11438417,3,1,Premise,Premise,none,"The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.","Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP."
11438417,3,2,Premise,Premise,none,"The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.","The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine."
11438417,3,4,Premise,Claim,none,"The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.","Fludarabine was consistently a better treatment than ChOP,"
11438417,3,5,Premise,Premise,none,"The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.",except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
11438417,3,6,Premise,Premise,none,"The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.","from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months)."
11438417,3,7,Premise,Claim,support,"The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.",patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
11438417,3,8,Premise,Claim,none,"The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP.",These two treatments are always superior to CAP.
11438417,4,1,Claim,Premise,none,"Fludarabine was consistently a better treatment than ChOP,","Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP."
11438417,4,2,Claim,Premise,none,"Fludarabine was consistently a better treatment than ChOP,","The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine."
11438417,4,3,Claim,Premise,none,"Fludarabine was consistently a better treatment than ChOP,","The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP."
11438417,4,5,Claim,Premise,none,"Fludarabine was consistently a better treatment than ChOP,",except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
11438417,4,6,Claim,Premise,none,"Fludarabine was consistently a better treatment than ChOP,","from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months)."
11438417,4,7,Claim,Claim,none,"Fludarabine was consistently a better treatment than ChOP,",patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
11438417,4,8,Claim,Claim,none,"Fludarabine was consistently a better treatment than ChOP,",These two treatments are always superior to CAP.
11438417,5,1,Premise,Premise,none,except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.,"Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP."
11438417,5,2,Premise,Premise,none,except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.,"The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine."
11438417,5,3,Premise,Premise,none,except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.,"The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP."
11438417,5,4,Premise,Claim,attack,except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.,"Fludarabine was consistently a better treatment than ChOP,"
11438417,5,6,Premise,Premise,none,except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.,"from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months)."
11438417,5,7,Premise,Claim,none,except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.,patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
11438417,5,8,Premise,Claim,none,except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.,These two treatments are always superior to CAP.
11438417,6,1,Premise,Premise,none,"from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).","Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP."
11438417,6,2,Premise,Premise,none,"from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).","The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine."
11438417,6,3,Premise,Premise,none,"from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).","The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP."
11438417,6,4,Premise,Claim,support,"from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).","Fludarabine was consistently a better treatment than ChOP,"
11438417,6,5,Premise,Premise,none,"from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).",except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
11438417,6,7,Premise,Claim,none,"from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).",patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
11438417,6,8,Premise,Claim,none,"from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months).",These two treatments are always superior to CAP.
11438417,7,1,Claim,Premise,none,patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.,"Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP."
11438417,7,2,Claim,Premise,none,patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.,"The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine."
11438417,7,3,Claim,Premise,none,patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.,"The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP."
11438417,7,4,Claim,Claim,none,patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.,"Fludarabine was consistently a better treatment than ChOP,"
11438417,7,5,Claim,Premise,none,patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.,except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
11438417,7,6,Claim,Premise,none,patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.,"from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months)."
11438417,7,8,Claim,Claim,none,patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.,These two treatments are always superior to CAP.
11438417,8,1,Claim,Premise,none,These two treatments are always superior to CAP.,"Over 73 months after randomization, the fludarabine group gained a mean of 45 days of toxicity-free survival at CAP, and 61 days over ChOP."
11438417,8,2,Claim,Premise,none,These two treatments are always superior to CAP.,"The mean TWIST was 27.05 months with CAP, 31.5 months with ChOP and 32.95 months with fludarabine."
11438417,8,3,Claim,Premise,none,These two treatments are always superior to CAP.,"The threshold analyses showed that, whatever the utility weights, the mean Q-TWIST was always greater with ChOP or fludarabine as compared to CAP."
11438417,8,4,Claim,Claim,none,These two treatments are always superior to CAP.,"Fludarabine was consistently a better treatment than ChOP,"
11438417,8,5,Claim,Premise,none,These two treatments are always superior to CAP.,except in the unlikely case of high utility weights attributed to toxicity and low utility weights attributed to treatment.
11438417,8,6,Claim,Premise,none,These two treatments are always superior to CAP.,"from a clinical point of view, differences between ChOP and fludarabine were moderate or event slight (mean difference in TWIST of 1.45 months)."
11438417,8,7,Claim,Claim,none,These two treatments are always superior to CAP.,patients with advanced CLL have a moderate benefit in terms of Q-TWIST when treated with fludarabine over ChOP.
17717452,1,2,Claim,Premise,none,More recently coloplasty has been advocated as an alternative to a colonic pouch.,Twenty-three (7.4%) died within 24 months of surgery.
17717452,1,3,Claim,Premise,none,More recently coloplasty has been advocated as an alternative to a colonic pouch.,No significant difference was observed in the complications among the 4 groups.
17717452,1,4,Claim,Premise,none,More recently coloplasty has been advocated as an alternative to a colonic pouch.,There was no difference in bowel function between the CP-1 and SA groups.
17717452,1,5,Claim,Premise,none,More recently coloplasty has been advocated as an alternative to a colonic pouch.,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group."
17717452,1,6,Claim,Premise,none,More recently coloplasty has been advocated as an alternative to a colonic pouch.,Other parameters were not statistically different.
17717452,1,7,Claim,Premise,none,More recently coloplasty has been advocated as an alternative to a colonic pouch.,QOL scores at 24 months were similar for each of the 4 groups.
17717452,1,8,Claim,Claim,none,More recently coloplasty has been advocated as an alternative to a colonic pouch.,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty."
17717452,1,9,Claim,Claim,none,More recently coloplasty has been advocated as an alternative to a colonic pouch.,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA."
17717452,2,1,Premise,Claim,none,Twenty-three (7.4%) died within 24 months of surgery.,More recently coloplasty has been advocated as an alternative to a colonic pouch.
17717452,2,3,Premise,Premise,none,Twenty-three (7.4%) died within 24 months of surgery.,No significant difference was observed in the complications among the 4 groups.
17717452,2,4,Premise,Premise,none,Twenty-three (7.4%) died within 24 months of surgery.,There was no difference in bowel function between the CP-1 and SA groups.
17717452,2,5,Premise,Premise,none,Twenty-three (7.4%) died within 24 months of surgery.,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group."
17717452,2,6,Premise,Premise,none,Twenty-three (7.4%) died within 24 months of surgery.,Other parameters were not statistically different.
17717452,2,7,Premise,Premise,none,Twenty-three (7.4%) died within 24 months of surgery.,QOL scores at 24 months were similar for each of the 4 groups.
17717452,2,8,Premise,Claim,none,Twenty-three (7.4%) died within 24 months of surgery.,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty."
17717452,2,9,Premise,Claim,none,Twenty-three (7.4%) died within 24 months of surgery.,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA."
17717452,3,1,Premise,Claim,none,No significant difference was observed in the complications among the 4 groups.,More recently coloplasty has been advocated as an alternative to a colonic pouch.
17717452,3,2,Premise,Premise,none,No significant difference was observed in the complications among the 4 groups.,Twenty-three (7.4%) died within 24 months of surgery.
17717452,3,4,Premise,Premise,none,No significant difference was observed in the complications among the 4 groups.,There was no difference in bowel function between the CP-1 and SA groups.
17717452,3,5,Premise,Premise,none,No significant difference was observed in the complications among the 4 groups.,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group."
17717452,3,6,Premise,Premise,none,No significant difference was observed in the complications among the 4 groups.,Other parameters were not statistically different.
17717452,3,7,Premise,Premise,none,No significant difference was observed in the complications among the 4 groups.,QOL scores at 24 months were similar for each of the 4 groups.
17717452,3,8,Premise,Claim,support,No significant difference was observed in the complications among the 4 groups.,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty."
17717452,3,9,Premise,Claim,none,No significant difference was observed in the complications among the 4 groups.,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA."
17717452,4,1,Premise,Claim,none,There was no difference in bowel function between the CP-1 and SA groups.,More recently coloplasty has been advocated as an alternative to a colonic pouch.
17717452,4,2,Premise,Premise,none,There was no difference in bowel function between the CP-1 and SA groups.,Twenty-three (7.4%) died within 24 months of surgery.
17717452,4,3,Premise,Premise,none,There was no difference in bowel function between the CP-1 and SA groups.,No significant difference was observed in the complications among the 4 groups.
17717452,4,5,Premise,Premise,none,There was no difference in bowel function between the CP-1 and SA groups.,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group."
17717452,4,6,Premise,Premise,none,There was no difference in bowel function between the CP-1 and SA groups.,Other parameters were not statistically different.
17717452,4,7,Premise,Premise,none,There was no difference in bowel function between the CP-1 and SA groups.,QOL scores at 24 months were similar for each of the 4 groups.
17717452,4,8,Premise,Claim,none,There was no difference in bowel function between the CP-1 and SA groups.,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty."
17717452,4,9,Premise,Claim,support,There was no difference in bowel function between the CP-1 and SA groups.,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA."
17717452,5,1,Premise,Claim,none,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group.",More recently coloplasty has been advocated as an alternative to a colonic pouch.
17717452,5,2,Premise,Premise,none,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group.",Twenty-three (7.4%) died within 24 months of surgery.
17717452,5,3,Premise,Premise,none,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group.",No significant difference was observed in the complications among the 4 groups.
17717452,5,4,Premise,Premise,none,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group.",There was no difference in bowel function between the CP-1 and SA groups.
17717452,5,6,Premise,Premise,none,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group.",Other parameters were not statistically different.
17717452,5,7,Premise,Premise,none,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group.",QOL scores at 24 months were similar for each of the 4 groups.
17717452,5,8,Premise,Claim,support,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group.","In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty."
17717452,5,9,Premise,Claim,none,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group.","In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA."
17717452,6,1,Premise,Claim,none,Other parameters were not statistically different.,More recently coloplasty has been advocated as an alternative to a colonic pouch.
17717452,6,2,Premise,Premise,none,Other parameters were not statistically different.,Twenty-three (7.4%) died within 24 months of surgery.
17717452,6,3,Premise,Premise,none,Other parameters were not statistically different.,No significant difference was observed in the complications among the 4 groups.
17717452,6,4,Premise,Premise,none,Other parameters were not statistically different.,There was no difference in bowel function between the CP-1 and SA groups.
17717452,6,5,Premise,Premise,none,Other parameters were not statistically different.,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group."
17717452,6,7,Premise,Premise,none,Other parameters were not statistically different.,QOL scores at 24 months were similar for each of the 4 groups.
17717452,6,8,Premise,Claim,support,Other parameters were not statistically different.,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty."
17717452,6,9,Premise,Claim,none,Other parameters were not statistically different.,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA."
17717452,7,1,Premise,Claim,none,QOL scores at 24 months were similar for each of the 4 groups.,More recently coloplasty has been advocated as an alternative to a colonic pouch.
17717452,7,2,Premise,Premise,none,QOL scores at 24 months were similar for each of the 4 groups.,Twenty-three (7.4%) died within 24 months of surgery.
17717452,7,3,Premise,Premise,none,QOL scores at 24 months were similar for each of the 4 groups.,No significant difference was observed in the complications among the 4 groups.
17717452,7,4,Premise,Premise,none,QOL scores at 24 months were similar for each of the 4 groups.,There was no difference in bowel function between the CP-1 and SA groups.
17717452,7,5,Premise,Premise,none,QOL scores at 24 months were similar for each of the 4 groups.,"JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group."
17717452,7,6,Premise,Premise,none,QOL scores at 24 months were similar for each of the 4 groups.,Other parameters were not statistically different.
17717452,7,8,Premise,Claim,support,QOL scores at 24 months were similar for each of the 4 groups.,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty."
17717452,7,9,Premise,Claim,none,QOL scores at 24 months were similar for each of the 4 groups.,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA."
17717452,8,1,Claim,Claim,none,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty.",More recently coloplasty has been advocated as an alternative to a colonic pouch.
17717452,8,2,Claim,Premise,none,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty.",Twenty-three (7.4%) died within 24 months of surgery.
17717452,8,3,Claim,Premise,none,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty.",No significant difference was observed in the complications among the 4 groups.
17717452,8,4,Claim,Premise,none,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty.",There was no difference in bowel function between the CP-1 and SA groups.
17717452,8,5,Claim,Premise,none,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty.","JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group."
17717452,8,6,Claim,Premise,none,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty.",Other parameters were not statistically different.
17717452,8,7,Claim,Premise,none,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty.",QOL scores at 24 months were similar for each of the 4 groups.
17717452,8,9,Claim,Claim,none,"In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty.","In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA."
17717452,9,1,Claim,Claim,none,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA.",More recently coloplasty has been advocated as an alternative to a colonic pouch.
17717452,9,2,Claim,Premise,none,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA.",Twenty-three (7.4%) died within 24 months of surgery.
17717452,9,3,Claim,Premise,none,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA.",No significant difference was observed in the complications among the 4 groups.
17717452,9,4,Claim,Premise,none,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA.",There was no difference in bowel function between the CP-1 and SA groups.
17717452,9,5,Claim,Premise,none,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA.","JP patients had fewer bowel movements, less clustering, used fewer pads and had a lower FISI than the CP-2 group."
17717452,9,6,Claim,Premise,none,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA.",Other parameters were not statistically different.
17717452,9,7,Claim,Premise,none,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA.",QOL scores at 24 months were similar for each of the 4 groups.
17717452,9,8,Claim,Claim,none,"In patients who cannot have a pouch, coloplasty seems not to improve the bowel function of patients over that with an SA.","In patients undergoing a restorative resection for low rectal cancer, a colonic JP offers significant advantages in function over an SA or a coloplasty."
23632471,1,2,Premise,Claim,support,"Participants in the PPDI intervention demonstrated significant (P < .05) reductions in adverse dietary symptoms and significant improvements (P < .05) in functional status, performance status, dietary intake, adherence to dietary guidelines, dietary knowledge, and satisfaction with the intervention as compared with the control group over time.",The PPDI was an effective dietary intervention for patients undergoing a gastrectomy for gastric cancer and deserves additional study in other populations of patients.
23632471,1,3,Premise,MajorClaim,none,"Participants in the PPDI intervention demonstrated significant (P < .05) reductions in adverse dietary symptoms and significant improvements (P < .05) in functional status, performance status, dietary intake, adherence to dietary guidelines, dietary knowledge, and satisfaction with the intervention as compared with the control group over time.",Incorporating patients' perspectives into a dietary intervention after gastrectomy for gastric cancer may contribute to improved patient outcomes and quality care.
23632471,2,1,Claim,Premise,none,The PPDI was an effective dietary intervention for patients undergoing a gastrectomy for gastric cancer and deserves additional study in other populations of patients.,"Participants in the PPDI intervention demonstrated significant (P < .05) reductions in adverse dietary symptoms and significant improvements (P < .05) in functional status, performance status, dietary intake, adherence to dietary guidelines, dietary knowledge, and satisfaction with the intervention as compared with the control group over time."
23632471,2,3,Claim,MajorClaim,support,The PPDI was an effective dietary intervention for patients undergoing a gastrectomy for gastric cancer and deserves additional study in other populations of patients.,Incorporating patients' perspectives into a dietary intervention after gastrectomy for gastric cancer may contribute to improved patient outcomes and quality care.
23632471,3,1,MajorClaim,Premise,none,Incorporating patients' perspectives into a dietary intervention after gastrectomy for gastric cancer may contribute to improved patient outcomes and quality care.,"Participants in the PPDI intervention demonstrated significant (P < .05) reductions in adverse dietary symptoms and significant improvements (P < .05) in functional status, performance status, dietary intake, adherence to dietary guidelines, dietary knowledge, and satisfaction with the intervention as compared with the control group over time."
23632471,3,2,MajorClaim,Claim,none,Incorporating patients' perspectives into a dietary intervention after gastrectomy for gastric cancer may contribute to improved patient outcomes and quality care.,The PPDI was an effective dietary intervention for patients undergoing a gastrectomy for gastric cancer and deserves additional study in other populations of patients.
23814044,1,2,Premise,Premise,none,Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12-month assessment.,"Systemic side effect (SE) change scores were significantly improved for TCH-treated patients compared with AC→TH and AC→T at EOC, suggesting improved tolerability."
23814044,1,3,Premise,Premise,none,Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12-month assessment.,"Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC→TH regimen, but was otherwise similar between arms."
23814044,1,4,Premise,Claim,none,Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12-month assessment.,"All treatment arms recovered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up."
23814044,1,5,Premise,Claim,none,Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12-month assessment.,HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option.
23814044,2,1,Premise,Premise,none,"Systemic side effect (SE) change scores were significantly improved for TCH-treated patients compared with AC→TH and AC→T at EOC, suggesting improved tolerability.",Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12-month assessment.
23814044,2,3,Premise,Premise,none,"Systemic side effect (SE) change scores were significantly improved for TCH-treated patients compared with AC→TH and AC→T at EOC, suggesting improved tolerability.","Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC→TH regimen, but was otherwise similar between arms."
23814044,2,4,Premise,Claim,support,"Systemic side effect (SE) change scores were significantly improved for TCH-treated patients compared with AC→TH and AC→T at EOC, suggesting improved tolerability.","All treatment arms recovered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up."
23814044,2,5,Premise,Claim,support,"Systemic side effect (SE) change scores were significantly improved for TCH-treated patients compared with AC→TH and AC→T at EOC, suggesting improved tolerability.",HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option.
23814044,3,1,Premise,Premise,none,"Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC→TH regimen, but was otherwise similar between arms.",Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12-month assessment.
23814044,3,2,Premise,Premise,none,"Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC→TH regimen, but was otherwise similar between arms.","Systemic side effect (SE) change scores were significantly improved for TCH-treated patients compared with AC→TH and AC→T at EOC, suggesting improved tolerability."
23814044,3,4,Premise,Claim,support,"Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC→TH regimen, but was otherwise similar between arms.","All treatment arms recovered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up."
23814044,3,5,Premise,Claim,support,"Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC→TH regimen, but was otherwise similar between arms.",HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option.
23814044,4,1,Claim,Premise,none,"All treatment arms recovered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up.",Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12-month assessment.
23814044,4,2,Claim,Premise,none,"All treatment arms recovered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up.","Systemic side effect (SE) change scores were significantly improved for TCH-treated patients compared with AC→TH and AC→T at EOC, suggesting improved tolerability."
23814044,4,3,Claim,Premise,none,"All treatment arms recovered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up.","Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC→TH regimen, but was otherwise similar between arms."
23814044,4,5,Claim,Claim,none,"All treatment arms recovered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up.",HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option.
23814044,5,1,Claim,Premise,none,HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option.,Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12-month assessment.
23814044,5,2,Claim,Premise,none,HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option.,"Systemic side effect (SE) change scores were significantly improved for TCH-treated patients compared with AC→TH and AC→T at EOC, suggesting improved tolerability."
23814044,5,3,Claim,Premise,none,HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option.,"Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC→TH regimen, but was otherwise similar between arms."
23814044,5,4,Claim,Claim,none,HRQL outcomes for adjuvant docetaxel and trastuzumab-based regimens are favorable and support TCH as a more tolerable treatment option.,"All treatment arms recovered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and follow-up."
12047964,1,2,Premise,Premise,none,"For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.","The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed."
12047964,1,3,Premise,Premise,none,"For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.","An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity."
12047964,1,4,Premise,Premise,none,"For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.","Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."
12047964,1,5,Premise,Claim,support,"For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.","The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates."
12047964,1,6,Premise,Claim,none,"For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.",The Lokich regimen was associated with more central line complications and hand-foot syndrome.
12047964,1,7,Premise,Claim,none,"For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.","Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,"
12047964,1,8,Premise,Claim,none,"For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days.",but resulted in greater toxicity and inferior quality of life.
12047964,2,1,Premise,Premise,none,"The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.","For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days."
12047964,2,3,Premise,Premise,none,"The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.","An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity."
12047964,2,4,Premise,Premise,none,"The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.","Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."
12047964,2,5,Premise,Claim,support,"The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.","The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates."
12047964,2,6,Premise,Claim,none,"The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.",The Lokich regimen was associated with more central line complications and hand-foot syndrome.
12047964,2,7,Premise,Claim,none,"The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.","Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,"
12047964,2,8,Premise,Claim,none,"The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed.",but resulted in greater toxicity and inferior quality of life.
12047964,3,1,Premise,Premise,none,"An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.","For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days."
12047964,3,2,Premise,Premise,none,"An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.","The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed."
12047964,3,4,Premise,Premise,none,"An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.","Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."
12047964,3,5,Premise,Claim,none,"An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.","The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates."
12047964,3,6,Premise,Claim,none,"An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.",The Lokich regimen was associated with more central line complications and hand-foot syndrome.
12047964,3,7,Premise,Claim,none,"An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.","Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,"
12047964,3,8,Premise,Claim,none,"An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity.",but resulted in greater toxicity and inferior quality of life.
12047964,4,1,Premise,Premise,none,"Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.","For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days."
12047964,4,2,Premise,Premise,none,"Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.","The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed."
12047964,4,3,Premise,Premise,none,"Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.","An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity."
12047964,4,5,Premise,Claim,none,"Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.","The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates."
12047964,4,6,Premise,Claim,none,"Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.",The Lokich regimen was associated with more central line complications and hand-foot syndrome.
12047964,4,7,Premise,Claim,none,"Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.","Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,"
12047964,4,8,Premise,Claim,support,"Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning.",but resulted in greater toxicity and inferior quality of life.
12047964,5,1,Claim,Premise,none,"The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.","For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days."
12047964,5,2,Claim,Premise,none,"The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.","The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed."
12047964,5,3,Claim,Premise,none,"The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.","An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity."
12047964,5,4,Claim,Premise,none,"The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.","Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."
12047964,5,6,Claim,Claim,none,"The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.",The Lokich regimen was associated with more central line complications and hand-foot syndrome.
12047964,5,7,Claim,Claim,none,"The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.","Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,"
12047964,5,8,Claim,Claim,none,"The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates.",but resulted in greater toxicity and inferior quality of life.
12047964,6,1,Claim,Premise,none,The Lokich regimen was associated with more central line complications and hand-foot syndrome.,"For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days."
12047964,6,2,Claim,Premise,none,The Lokich regimen was associated with more central line complications and hand-foot syndrome.,"The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed."
12047964,6,3,Claim,Premise,none,The Lokich regimen was associated with more central line complications and hand-foot syndrome.,"An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity."
12047964,6,4,Claim,Premise,none,The Lokich regimen was associated with more central line complications and hand-foot syndrome.,"Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."
12047964,6,5,Claim,Claim,none,The Lokich regimen was associated with more central line complications and hand-foot syndrome.,"The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates."
12047964,6,7,Claim,Claim,none,The Lokich regimen was associated with more central line complications and hand-foot syndrome.,"Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,"
12047964,6,8,Claim,Claim,none,The Lokich regimen was associated with more central line complications and hand-foot syndrome.,but resulted in greater toxicity and inferior quality of life.
12047964,7,1,Claim,Premise,none,"Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,","For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days."
12047964,7,2,Claim,Premise,none,"Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,","The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed."
12047964,7,3,Claim,Premise,none,"Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,","An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity."
12047964,7,4,Claim,Premise,none,"Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,","Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."
12047964,7,5,Claim,Claim,none,"Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,","The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates."
12047964,7,6,Claim,Claim,none,"Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,",The Lokich regimen was associated with more central line complications and hand-foot syndrome.
12047964,7,8,Claim,Claim,none,"Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,",but resulted in greater toxicity and inferior quality of life.
12047964,8,1,Claim,Premise,none,but resulted in greater toxicity and inferior quality of life.,"For the de Gramont, Lokich, and raltitrexed groups, respectively, median survival was 294, 302, and 266 days."
12047964,8,2,Claim,Premise,none,but resulted in greater toxicity and inferior quality of life.,"The hazard ratios for overall survival were 0.88 (95% CI 0.70-1.12, p=0.17) for de Gramont versus Lokich, and 0.99 (0.79-1.25, p=0.94) for de Gramont versus raltitrexed."
12047964,8,3,Claim,Premise,none,but resulted in greater toxicity and inferior quality of life.,"An increase in treatment-related deaths was seen on raltitrexed (de Gramont one, Lokich two, raltitrexed 18) due to combined gastrointestinal and haematological toxicity."
12047964,8,4,Claim,Premise,none,but resulted in greater toxicity and inferior quality of life.,"Patients' assessment of quality of life showed that raltitrexed was inferior to the fluorouracil-based regimens, especially in terms of palliation and functioning."
12047964,8,5,Claim,Claim,none,but resulted in greater toxicity and inferior quality of life.,"The deGramont and Lokich regimens were similar in terms of survival, quality of life, and response rates."
12047964,8,6,Claim,Claim,none,but resulted in greater toxicity and inferior quality of life.,The Lokich regimen was associated with more central line complications and hand-foot syndrome.
12047964,8,7,Claim,Claim,attack,but resulted in greater toxicity and inferior quality of life.,"Raltitrexed showed similar response rates and overall survival to the de Gramont regimen and was easier to administer,"
24178750,1,2,Premise,Premise,none,"The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001.","Longer neutropenia duration was observed in all patient subgroups,"
24178750,1,3,Premise,Premise,none,"The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001.",except for patients undergoing autologous HCT.
24178750,1,4,Premise,Premise,none,"The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001.","There was no significant difference between groups in the occurrence of infection or death,"
24178750,1,5,Premise,Premise,none,"The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001.","but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196."
24178750,1,6,Premise,Claim,none,"The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001.",Patients reported similar pain and satisfaction scores in both groups.
24178750,1,7,Premise,Claim,support,"The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001.","Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures."
24178750,2,1,Premise,Premise,none,"Longer neutropenia duration was observed in all patient subgroups,","The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001."
24178750,2,3,Premise,Premise,none,"Longer neutropenia duration was observed in all patient subgroups,",except for patients undergoing autologous HCT.
24178750,2,4,Premise,Premise,none,"Longer neutropenia duration was observed in all patient subgroups,","There was no significant difference between groups in the occurrence of infection or death,"
24178750,2,5,Premise,Premise,none,"Longer neutropenia duration was observed in all patient subgroups,","but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196."
24178750,2,6,Premise,Claim,none,"Longer neutropenia duration was observed in all patient subgroups,",Patients reported similar pain and satisfaction scores in both groups.
24178750,2,7,Premise,Claim,support,"Longer neutropenia duration was observed in all patient subgroups,","Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures."
24178750,3,1,Premise,Premise,none,except for patients undergoing autologous HCT.,"The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001."
24178750,3,2,Premise,Premise,attack,except for patients undergoing autologous HCT.,"Longer neutropenia duration was observed in all patient subgroups,"
24178750,3,4,Premise,Premise,none,except for patients undergoing autologous HCT.,"There was no significant difference between groups in the occurrence of infection or death,"
24178750,3,5,Premise,Premise,none,except for patients undergoing autologous HCT.,"but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196."
24178750,3,6,Premise,Claim,none,except for patients undergoing autologous HCT.,Patients reported similar pain and satisfaction scores in both groups.
24178750,3,7,Premise,Claim,none,except for patients undergoing autologous HCT.,"Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures."
24178750,4,1,Premise,Premise,none,"There was no significant difference between groups in the occurrence of infection or death,","The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001."
24178750,4,2,Premise,Premise,none,"There was no significant difference between groups in the occurrence of infection or death,","Longer neutropenia duration was observed in all patient subgroups,"
24178750,4,3,Premise,Premise,none,"There was no significant difference between groups in the occurrence of infection or death,",except for patients undergoing autologous HCT.
24178750,4,5,Premise,Premise,none,"There was no significant difference between groups in the occurrence of infection or death,","but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196."
24178750,4,6,Premise,Claim,none,"There was no significant difference between groups in the occurrence of infection or death,",Patients reported similar pain and satisfaction scores in both groups.
24178750,4,7,Premise,Claim,none,"There was no significant difference between groups in the occurrence of infection or death,","Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures."
24178750,5,1,Premise,Premise,none,"but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196.","The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001."
24178750,5,2,Premise,Premise,none,"but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196.","Longer neutropenia duration was observed in all patient subgroups,"
24178750,5,3,Premise,Premise,none,"but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196.",except for patients undergoing autologous HCT.
24178750,5,4,Premise,Premise,attack,"but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196.","There was no significant difference between groups in the occurrence of infection or death,"
24178750,5,6,Premise,Claim,none,"but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196.",Patients reported similar pain and satisfaction scores in both groups.
24178750,5,7,Premise,Claim,none,"but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196.","Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures."
24178750,6,1,Claim,Premise,none,Patients reported similar pain and satisfaction scores in both groups.,"The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001."
24178750,6,2,Claim,Premise,none,Patients reported similar pain and satisfaction scores in both groups.,"Longer neutropenia duration was observed in all patient subgroups,"
24178750,6,3,Claim,Premise,none,Patients reported similar pain and satisfaction scores in both groups.,except for patients undergoing autologous HCT.
24178750,6,4,Claim,Premise,none,Patients reported similar pain and satisfaction scores in both groups.,"There was no significant difference between groups in the occurrence of infection or death,"
24178750,6,5,Claim,Premise,none,Patients reported similar pain and satisfaction scores in both groups.,"but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196."
24178750,6,7,Claim,Claim,support,Patients reported similar pain and satisfaction scores in both groups.,"Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures."
24178750,7,1,Claim,Premise,none,"Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures.","The mean time to neutropenia resolution was longer with IV G-CSF [7.9 days, 95% confidence interval (CI) 6.6-9.1] compared with SC G-CSF (5.4 days, 95% CI 4.6-6.2), log-rank P = 0.001."
24178750,7,2,Claim,Premise,none,"Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures.","Longer neutropenia duration was observed in all patient subgroups,"
24178750,7,3,Claim,Premise,none,"Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures.",except for patients undergoing autologous HCT.
24178750,7,4,Claim,Premise,none,"Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures.","There was no significant difference between groups in the occurrence of infection or death,"
24178750,7,5,Claim,Premise,none,"Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures.","but more deaths were observed with IV (4/57, 7%) versus SC (1/61, 1.6%) G-CSF administration, P = 0.196."
24178750,7,6,Claim,Claim,none,"Bolus IV administration of G-CSF results in longer neutropenia duration than SC administration, with no difference in clinical or quality-of-life measures.",Patients reported similar pain and satisfaction scores in both groups.
23768153,1,2,Premise,Premise,none,"Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;","however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0)."
23768153,1,3,Premise,Premise,none,"Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;",No statistically significant differences were found for secondary outcomes.
23768153,1,4,Premise,Premise,none,"Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;","Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable."
23768153,1,5,Premise,Claim,support,"Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;","Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,"
23768153,1,6,Premise,Claim,none,"Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;",but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.
23768153,1,7,Premise,MajorClaim,none,"Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;",VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.
23768153,2,1,Premise,Premise,attack,"however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).","Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;"
23768153,2,3,Premise,Premise,none,"however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).",No statistically significant differences were found for secondary outcomes.
23768153,2,4,Premise,Premise,none,"however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).","Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable."
23768153,2,5,Premise,Claim,none,"however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).","Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,"
23768153,2,6,Premise,Claim,none,"however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).",but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.
23768153,2,7,Premise,MajorClaim,none,"however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).",VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.
23768153,3,1,Premise,Premise,none,No statistically significant differences were found for secondary outcomes.,"Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;"
23768153,3,2,Premise,Premise,none,No statistically significant differences were found for secondary outcomes.,"however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0)."
23768153,3,4,Premise,Premise,none,No statistically significant differences were found for secondary outcomes.,"Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable."
23768153,3,5,Premise,Claim,none,No statistically significant differences were found for secondary outcomes.,"Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,"
23768153,3,6,Premise,Claim,none,No statistically significant differences were found for secondary outcomes.,but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.
23768153,3,7,Premise,MajorClaim,none,No statistically significant differences were found for secondary outcomes.,VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.
23768153,4,1,Premise,Premise,none,"Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.","Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;"
23768153,4,2,Premise,Premise,none,"Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.","however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0)."
23768153,4,3,Premise,Premise,none,"Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.",No statistically significant differences were found for secondary outcomes.
23768153,4,5,Premise,Claim,support,"Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.","Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,"
23768153,4,6,Premise,Claim,none,"Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.",but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.
23768153,4,7,Premise,MajorClaim,none,"Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.",VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.
23768153,5,1,Claim,Premise,none,"Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,","Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;"
23768153,5,2,Claim,Premise,none,"Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,","however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0)."
23768153,5,3,Claim,Premise,none,"Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,",No statistically significant differences were found for secondary outcomes.
23768153,5,4,Claim,Premise,none,"Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,","Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable."
23768153,5,6,Claim,Claim,none,"Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,",but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.
23768153,5,7,Claim,MajorClaim,none,"Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,",VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.
23768153,6,1,Claim,Premise,none,but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.,"Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;"
23768153,6,2,Claim,Premise,none,but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.,"however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0)."
23768153,6,3,Claim,Premise,none,but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.,No statistically significant differences were found for secondary outcomes.
23768153,6,4,Claim,Premise,none,but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.,"Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable."
23768153,6,5,Claim,Claim,attack,but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.,"Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,"
23768153,6,7,Claim,MajorClaim,none,but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.,VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.
23768153,7,1,MajorClaim,Premise,none,VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.,"Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;"
23768153,7,2,MajorClaim,Premise,none,VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.,"however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0)."
23768153,7,3,MajorClaim,Premise,none,VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.,No statistically significant differences were found for secondary outcomes.
23768153,7,4,MajorClaim,Premise,none,VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.,"Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable."
23768153,7,5,MajorClaim,Claim,none,VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.,"Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,"
23768153,7,6,MajorClaim,Claim,none,VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.,but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.
15226773,1,2,Claim,Premise,none,Malnutrition occurs frequently in patients with cancer of the gastrointestinal (GI) or head and neck area and can lead to negative outcomes.,"The NI group had statistically smaller deteriorations in weight (P<0.001), nutritional status (P=0.020) and global QoL (P=0.009) compared with those receiving UC."
15226773,1,3,Claim,Premise,none,Malnutrition occurs frequently in patients with cancer of the gastrointestinal (GI) or head and neck area and can lead to negative outcomes.,"Clinically, but not statistically significant differences in fat-free mass were observed between the groups (P=0.195)."
15226773,1,4,Claim,Claim,none,Malnutrition occurs frequently in patients with cancer of the gastrointestinal (GI) or head and neck area and can lead to negative outcomes.,"Early and intensive NI appears beneficial in terms of minimising weight loss, deterioration in nutritional status, global QoL and physical function in oncology outpatients receiving radiotherapy to the GI or head and neck area."
15226773,1,5,Claim,Claim,none,Malnutrition occurs frequently in patients with cancer of the gastrointestinal (GI) or head and neck area and can lead to negative outcomes.,"Weight maintenance in this population leads to beneficial outcomes and suggests that this, rather than weight gain, may be a more appropriate aim of NI."
15226773,2,1,Premise,Claim,none,"The NI group had statistically smaller deteriorations in weight (P<0.001), nutritional status (P=0.020) and global QoL (P=0.009) compared with those receiving UC.",Malnutrition occurs frequently in patients with cancer of the gastrointestinal (GI) or head and neck area and can lead to negative outcomes.
15226773,2,3,Premise,Premise,none,"The NI group had statistically smaller deteriorations in weight (P<0.001), nutritional status (P=0.020) and global QoL (P=0.009) compared with those receiving UC.","Clinically, but not statistically significant differences in fat-free mass were observed between the groups (P=0.195)."
15226773,2,4,Premise,Claim,support,"The NI group had statistically smaller deteriorations in weight (P<0.001), nutritional status (P=0.020) and global QoL (P=0.009) compared with those receiving UC.","Early and intensive NI appears beneficial in terms of minimising weight loss, deterioration in nutritional status, global QoL and physical function in oncology outpatients receiving radiotherapy to the GI or head and neck area."
15226773,2,5,Premise,Claim,none,"The NI group had statistically smaller deteriorations in weight (P<0.001), nutritional status (P=0.020) and global QoL (P=0.009) compared with those receiving UC.","Weight maintenance in this population leads to beneficial outcomes and suggests that this, rather than weight gain, may be a more appropriate aim of NI."
15226773,3,1,Premise,Claim,none,"Clinically, but not statistically significant differences in fat-free mass were observed between the groups (P=0.195).",Malnutrition occurs frequently in patients with cancer of the gastrointestinal (GI) or head and neck area and can lead to negative outcomes.
15226773,3,2,Premise,Premise,none,"Clinically, but not statistically significant differences in fat-free mass were observed between the groups (P=0.195).","The NI group had statistically smaller deteriorations in weight (P<0.001), nutritional status (P=0.020) and global QoL (P=0.009) compared with those receiving UC."
15226773,3,4,Premise,Claim,support,"Clinically, but not statistically significant differences in fat-free mass were observed between the groups (P=0.195).","Early and intensive NI appears beneficial in terms of minimising weight loss, deterioration in nutritional status, global QoL and physical function in oncology outpatients receiving radiotherapy to the GI or head and neck area."
15226773,3,5,Premise,Claim,none,"Clinically, but not statistically significant differences in fat-free mass were observed between the groups (P=0.195).","Weight maintenance in this population leads to beneficial outcomes and suggests that this, rather than weight gain, may be a more appropriate aim of NI."
15226773,4,1,Claim,Claim,none,"Early and intensive NI appears beneficial in terms of minimising weight loss, deterioration in nutritional status, global QoL and physical function in oncology outpatients receiving radiotherapy to the GI or head and neck area.",Malnutrition occurs frequently in patients with cancer of the gastrointestinal (GI) or head and neck area and can lead to negative outcomes.
15226773,4,2,Claim,Premise,none,"Early and intensive NI appears beneficial in terms of minimising weight loss, deterioration in nutritional status, global QoL and physical function in oncology outpatients receiving radiotherapy to the GI or head and neck area.","The NI group had statistically smaller deteriorations in weight (P<0.001), nutritional status (P=0.020) and global QoL (P=0.009) compared with those receiving UC."
15226773,4,3,Claim,Premise,none,"Early and intensive NI appears beneficial in terms of minimising weight loss, deterioration in nutritional status, global QoL and physical function in oncology outpatients receiving radiotherapy to the GI or head and neck area.","Clinically, but not statistically significant differences in fat-free mass were observed between the groups (P=0.195)."
15226773,4,5,Claim,Claim,none,"Early and intensive NI appears beneficial in terms of minimising weight loss, deterioration in nutritional status, global QoL and physical function in oncology outpatients receiving radiotherapy to the GI or head and neck area.","Weight maintenance in this population leads to beneficial outcomes and suggests that this, rather than weight gain, may be a more appropriate aim of NI."
15226773,5,1,Claim,Claim,none,"Weight maintenance in this population leads to beneficial outcomes and suggests that this, rather than weight gain, may be a more appropriate aim of NI.",Malnutrition occurs frequently in patients with cancer of the gastrointestinal (GI) or head and neck area and can lead to negative outcomes.
15226773,5,2,Claim,Premise,none,"Weight maintenance in this population leads to beneficial outcomes and suggests that this, rather than weight gain, may be a more appropriate aim of NI.","The NI group had statistically smaller deteriorations in weight (P<0.001), nutritional status (P=0.020) and global QoL (P=0.009) compared with those receiving UC."
15226773,5,3,Claim,Premise,none,"Weight maintenance in this population leads to beneficial outcomes and suggests that this, rather than weight gain, may be a more appropriate aim of NI.","Clinically, but not statistically significant differences in fat-free mass were observed between the groups (P=0.195)."
15226773,5,4,Claim,Claim,none,"Weight maintenance in this population leads to beneficial outcomes and suggests that this, rather than weight gain, may be a more appropriate aim of NI.","Early and intensive NI appears beneficial in terms of minimising weight loss, deterioration in nutritional status, global QoL and physical function in oncology outpatients receiving radiotherapy to the GI or head and neck area."
8683634,1,2,MajorClaim,Claim,none,"Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer.","However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient."
8683634,1,3,MajorClaim,Premise,none,"Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer.","As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone."
8683634,1,4,MajorClaim,Premise,none,"Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer.","In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone."
8683634,1,5,MajorClaim,Claim,none,"Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer.","Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease."
8683634,1,6,MajorClaim,Claim,none,"Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer.","Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,"
8683634,1,7,MajorClaim,Premise,none,"Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer.",since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.
8683634,1,8,MajorClaim,Claim,none,"Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer.",The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.
8683634,2,1,Claim,MajorClaim,none,"However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient.","Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer."
8683634,2,3,Claim,Premise,none,"However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient.","As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone."
8683634,2,4,Claim,Premise,none,"However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient.","In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone."
8683634,2,5,Claim,Claim,none,"However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient.","Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease."
8683634,2,6,Claim,Claim,none,"However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient.","Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,"
8683634,2,7,Claim,Premise,none,"However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient.",since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.
8683634,2,8,Claim,Claim,none,"However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient.",The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.
8683634,3,1,Premise,MajorClaim,none,"As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone.","Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer."
8683634,3,2,Premise,Claim,none,"As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone.","However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient."
8683634,3,4,Premise,Premise,none,"As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone.","In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone."
8683634,3,5,Premise,Claim,none,"As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone.","Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease."
8683634,3,6,Premise,Claim,support,"As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone.","Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,"
8683634,3,7,Premise,Premise,none,"As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone.",since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.
8683634,3,8,Premise,Claim,none,"As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone.",The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.
8683634,4,1,Premise,MajorClaim,none,"In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone.","Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer."
8683634,4,2,Premise,Claim,none,"In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone.","However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient."
8683634,4,3,Premise,Premise,none,"In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone.","As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone."
8683634,4,5,Premise,Claim,support,"In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone.","Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease."
8683634,4,6,Premise,Claim,none,"In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone.","Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,"
8683634,4,7,Premise,Premise,none,"In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone.",since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.
8683634,4,8,Premise,Claim,none,"In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone.",The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.
8683634,5,1,Claim,MajorClaim,none,"Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease.","Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer."
8683634,5,2,Claim,Claim,none,"Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease.","However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient."
8683634,5,3,Claim,Premise,none,"Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease.","As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone."
8683634,5,4,Claim,Premise,none,"Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease.","In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone."
8683634,5,6,Claim,Claim,none,"Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease.","Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,"
8683634,5,7,Claim,Premise,none,"Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease.",since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.
8683634,5,8,Claim,Claim,none,"Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease.",The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.
8683634,6,1,Claim,MajorClaim,none,"Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,","Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer."
8683634,6,2,Claim,Claim,none,"Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,","However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient."
8683634,6,3,Claim,Premise,none,"Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,","As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone."
8683634,6,4,Claim,Premise,none,"Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,","In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone."
8683634,6,5,Claim,Claim,none,"Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,","Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease."
8683634,6,7,Claim,Premise,none,"Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,",since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.
8683634,6,8,Claim,Claim,none,"Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,",The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.
8683634,7,1,Premise,MajorClaim,none,since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.,"Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer."
8683634,7,2,Premise,Claim,none,since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.,"However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient."
8683634,7,3,Premise,Premise,none,since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.,"As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone."
8683634,7,4,Premise,Premise,none,since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.,"In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone."
8683634,7,5,Premise,Claim,none,since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.,"Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease."
8683634,7,6,Premise,Claim,support,since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.,"Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,"
8683634,7,8,Premise,Claim,none,since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.,The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.
8683634,8,1,Claim,MajorClaim,none,The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.,"Combined radiation therapy and chemotherapy after surgery, compared with postsurgical radiation therapy alone, has been shown to improve disease-free survival and overall survival significantly among patients with poor-prognosis (i.e., advanced stage disease or metastasis to regional lymph nodes) resectable rectal cancer."
8683634,8,2,Claim,Claim,none,The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.,"However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient."
8683634,8,3,Claim,Premise,none,The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.,"As reported previously, the combined therapy reduced the risk of relapse by 34% (95% confidence interval [CI] = 12%-50%; P = .0016) and reduced the overall death rate by 29% (95% CI = 7%-45%; P = .025) in comparison with adjuvant radiation therapy alone."
8683634,8,4,Claim,Premise,none,The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.,"In the 5 years following assignment to treatment, patients who received the combined therapy had more time with toxicity (3.1 months; 95% CI = 2.0-4.1 months), shorter survival after relapse (3.6 months less; 95% CI = 0.9-6.3 months less), and more TWiST (6.1 months; 95% CI = 0.2-12.0 months) than patients who received adjuvant radiation therapy alone."
8683634,8,5,Claim,Claim,none,The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.,"Despite an increase in the amount of time that individuals spent with early and late toxic effects, the Q-TWiST analysis indicated that the combined therapy conferred significantly greater benefit for a wide range of patient preferences about living with the toxicity of treatment or the symptoms of overt disease."
8683634,8,6,Claim,Claim,none,The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.,"Use of combined chemotherapy and radiation therapy as an adjuvant to surgery for patients with poor-prognosis resectable rectal cancer is justified,"
8683634,8,7,Claim,Premise,none,The Q-TWiST method is an excellent way to compare treatment outcomes that include quality-of-life considerations.,since the improved outcome in terms of delayed recurrence and increased survival balances the time spent with early and late toxic effects.
20697941,1,2,Premise,Premise,none,"The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),",but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).
20697941,1,3,Premise,Premise,none,"The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),","XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01)."
20697941,1,4,Premise,Premise,none,"The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),","Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01)."
20697941,1,5,Premise,Claim,attack,"The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),","Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions."
20697941,2,1,Premise,Premise,attack,but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).,"The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),"
20697941,2,3,Premise,Premise,none,but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).,"XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01)."
20697941,2,4,Premise,Premise,none,but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).,"Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01)."
20697941,2,5,Premise,Claim,none,but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).,"Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions."
20697941,3,1,Premise,Premise,none,"XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).","The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),"
20697941,3,2,Premise,Premise,none,"XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).",but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).
20697941,3,4,Premise,Premise,none,"XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).","Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01)."
20697941,3,5,Premise,Claim,support,"XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).","Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions."
20697941,4,1,Premise,Premise,none,"Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).","The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),"
20697941,4,2,Premise,Premise,none,"Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).",but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).
20697941,4,3,Premise,Premise,none,"Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).","XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01)."
20697941,4,5,Premise,Claim,support,"Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).","Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions."
20697941,5,1,Claim,Premise,none,"Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.","The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),"
20697941,5,2,Claim,Premise,none,"Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.",but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).
20697941,5,3,Claim,Premise,none,"Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.","XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01)."
20697941,5,4,Claim,Premise,none,"Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.","Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01)."
18448745,1,2,Premise,Premise,none,No serious adverse events were reported.,"Compared with PLC, CDB-2914 significantly reduced leiomyoma volume after three cycles, or 90-102 days."
18448745,1,3,Premise,Premise,none,No serious adverse events were reported.,CDB-2914 treatment resulted in improvements in the concern subscale of the Uterine Fibroid Symptom Quality of Life assessment.
18448745,1,4,Premise,Claim,support,No serious adverse events were reported.,"In this small study, CDB-2914 was well-tolerated without serious adverse events."
18448745,1,5,Premise,Claim,none,No serious adverse events were reported.,"Thus, there may be a role for CDB-2914 in the treatment of leiomyomata."
18448745,2,1,Premise,Premise,none,"Compared with PLC, CDB-2914 significantly reduced leiomyoma volume after three cycles, or 90-102 days.",No serious adverse events were reported.
18448745,2,3,Premise,Premise,none,"Compared with PLC, CDB-2914 significantly reduced leiomyoma volume after three cycles, or 90-102 days.",CDB-2914 treatment resulted in improvements in the concern subscale of the Uterine Fibroid Symptom Quality of Life assessment.
18448745,2,4,Premise,Claim,none,"Compared with PLC, CDB-2914 significantly reduced leiomyoma volume after three cycles, or 90-102 days.","In this small study, CDB-2914 was well-tolerated without serious adverse events."
18448745,2,5,Premise,Claim,support,"Compared with PLC, CDB-2914 significantly reduced leiomyoma volume after three cycles, or 90-102 days.","Thus, there may be a role for CDB-2914 in the treatment of leiomyomata."
18448745,3,1,Premise,Premise,none,CDB-2914 treatment resulted in improvements in the concern subscale of the Uterine Fibroid Symptom Quality of Life assessment.,No serious adverse events were reported.
18448745,3,2,Premise,Premise,none,CDB-2914 treatment resulted in improvements in the concern subscale of the Uterine Fibroid Symptom Quality of Life assessment.,"Compared with PLC, CDB-2914 significantly reduced leiomyoma volume after three cycles, or 90-102 days."
18448745,3,4,Premise,Claim,none,CDB-2914 treatment resulted in improvements in the concern subscale of the Uterine Fibroid Symptom Quality of Life assessment.,"In this small study, CDB-2914 was well-tolerated without serious adverse events."
18448745,3,5,Premise,Claim,support,CDB-2914 treatment resulted in improvements in the concern subscale of the Uterine Fibroid Symptom Quality of Life assessment.,"Thus, there may be a role for CDB-2914 in the treatment of leiomyomata."
18448745,4,1,Claim,Premise,none,"In this small study, CDB-2914 was well-tolerated without serious adverse events.",No serious adverse events were reported.
18448745,4,2,Claim,Premise,none,"In this small study, CDB-2914 was well-tolerated without serious adverse events.","Compared with PLC, CDB-2914 significantly reduced leiomyoma volume after three cycles, or 90-102 days."
18448745,4,3,Claim,Premise,none,"In this small study, CDB-2914 was well-tolerated without serious adverse events.",CDB-2914 treatment resulted in improvements in the concern subscale of the Uterine Fibroid Symptom Quality of Life assessment.
18448745,4,5,Claim,Claim,support,"In this small study, CDB-2914 was well-tolerated without serious adverse events.","Thus, there may be a role for CDB-2914 in the treatment of leiomyomata."
18448745,5,1,Claim,Premise,none,"Thus, there may be a role for CDB-2914 in the treatment of leiomyomata.",No serious adverse events were reported.
18448745,5,2,Claim,Premise,none,"Thus, there may be a role for CDB-2914 in the treatment of leiomyomata.","Compared with PLC, CDB-2914 significantly reduced leiomyoma volume after three cycles, or 90-102 days."
18448745,5,3,Claim,Premise,none,"Thus, there may be a role for CDB-2914 in the treatment of leiomyomata.",CDB-2914 treatment resulted in improvements in the concern subscale of the Uterine Fibroid Symptom Quality of Life assessment.
18448745,5,4,Claim,Claim,none,"Thus, there may be a role for CDB-2914 in the treatment of leiomyomata.","In this small study, CDB-2914 was well-tolerated without serious adverse events."
21892106,1,2,Premise,Premise,none,The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).,Grade 3/4 toxicity in both arms was acceptable.
21892106,1,3,Premise,Premise,none,The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).,"There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19)."
21892106,1,4,Premise,Premise,none,The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).,Patients in arm A had longer median survival
21892106,1,5,Premise,Premise,none,The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).,"but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25)."
21892106,1,6,Premise,Claim,none,The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).,No difference in quality of life was observed.
21892106,1,7,Premise,Claim,support,The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).,"radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B."
21892106,2,1,Premise,Premise,none,Grade 3/4 toxicity in both arms was acceptable.,The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).
21892106,2,3,Premise,Premise,none,Grade 3/4 toxicity in both arms was acceptable.,"There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19)."
21892106,2,4,Premise,Premise,none,Grade 3/4 toxicity in both arms was acceptable.,Patients in arm A had longer median survival
21892106,2,5,Premise,Premise,none,Grade 3/4 toxicity in both arms was acceptable.,"but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25)."
21892106,2,6,Premise,Claim,support,Grade 3/4 toxicity in both arms was acceptable.,No difference in quality of life was observed.
21892106,2,7,Premise,Claim,none,Grade 3/4 toxicity in both arms was acceptable.,"radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B."
21892106,3,1,Premise,Premise,none,"There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19).",The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).
21892106,3,2,Premise,Premise,none,"There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19).",Grade 3/4 toxicity in both arms was acceptable.
21892106,3,4,Premise,Premise,none,"There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19).",Patients in arm A had longer median survival
21892106,3,5,Premise,Premise,none,"There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19).","but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25)."
21892106,3,6,Premise,Claim,none,"There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19).",No difference in quality of life was observed.
21892106,3,7,Premise,Claim,attack,"There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19).","radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B."
21892106,4,1,Premise,Premise,none,Patients in arm A had longer median survival,The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).
21892106,4,2,Premise,Premise,none,Patients in arm A had longer median survival,Grade 3/4 toxicity in both arms was acceptable.
21892106,4,3,Premise,Premise,none,Patients in arm A had longer median survival,"There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19)."
21892106,4,5,Premise,Premise,none,Patients in arm A had longer median survival,"but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25)."
21892106,4,6,Premise,Claim,none,Patients in arm A had longer median survival,No difference in quality of life was observed.
21892106,4,7,Premise,Claim,support,Patients in arm A had longer median survival,"radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B."
21892106,5,1,Premise,Premise,none,"but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25).",The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).
21892106,5,2,Premise,Premise,none,"but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25).",Grade 3/4 toxicity in both arms was acceptable.
21892106,5,3,Premise,Premise,none,"but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25).","There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19)."
21892106,5,4,Premise,Premise,attack,"but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25).",Patients in arm A had longer median survival
21892106,5,6,Premise,Claim,none,"but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25).",No difference in quality of life was observed.
21892106,5,7,Premise,Claim,none,"but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25).","radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B."
21892106,6,1,Claim,Premise,none,No difference in quality of life was observed.,The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).
21892106,6,2,Claim,Premise,none,No difference in quality of life was observed.,Grade 3/4 toxicity in both arms was acceptable.
21892106,6,3,Claim,Premise,none,No difference in quality of life was observed.,"There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19)."
21892106,6,4,Claim,Premise,none,No difference in quality of life was observed.,Patients in arm A had longer median survival
21892106,6,5,Claim,Premise,none,No difference in quality of life was observed.,"but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25)."
21892106,6,7,Claim,Claim,none,No difference in quality of life was observed.,"radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B."
21892106,7,1,Claim,Premise,none,"radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B.",The overall response rate was 51% in arm A and 38% in arm B (p = 0.147).
21892106,7,2,Claim,Premise,none,"radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B.",Grade 3/4 toxicity in both arms was acceptable.
21892106,7,3,Claim,Premise,none,"radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B.","There was no difference in median progression-free survival between the two arms (5.5 versus 5.0 months, p = 0.19)."
21892106,7,4,Claim,Premise,none,"radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B.",Patients in arm A had longer median survival
21892106,7,5,Claim,Premise,none,"radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B.","but this did not reach statistical significance (13.1 versus 8.3 months, p = 0.25)."
21892106,7,6,Claim,Claim,none,"radiation therapy alone as it demonstrated a response rate greater than 50%, and data suggested that arm A had superior survival to arm B.",No difference in quality of life was observed.
18457329,1,2,Premise,Premise,none,"On the basis of intention-to-treat analyses, PRET was superior to TP for improving shoulder pain and disability (-9.6; 95% confidence interval [95% CI], -16.4 to -4.5; P = .001), upper extremity strength (+10.8 kg; 95% CI, 5.4-16.2 kg; P < .001), and upper extremity endurance (+194 repetitions x kg; 95% CI, 10-378 repetitions x kg; P = .039).","Changes in neck dissection impairment, fatigue, and quality of life favored the PRET group"
18457329,1,3,Premise,Premise,none,"On the basis of intention-to-treat analyses, PRET was superior to TP for improving shoulder pain and disability (-9.6; 95% confidence interval [95% CI], -16.4 to -4.5; P = .001), upper extremity strength (+10.8 kg; 95% CI, 5.4-16.2 kg; P < .001), and upper extremity endurance (+194 repetitions x kg; 95% CI, 10-378 repetitions x kg; P = .039).",but did not reach statistical significance.
18457329,1,4,Premise,Premise,none,"On the basis of intention-to-treat analyses, PRET was superior to TP for improving shoulder pain and disability (-9.6; 95% confidence interval [95% CI], -16.4 to -4.5; P = .001), upper extremity strength (+10.8 kg; 95% CI, 5.4-16.2 kg; P < .001), and upper extremity endurance (+194 repetitions x kg; 95% CI, 10-378 repetitions x kg; P = .039).",The PRET program significantly reduced shoulder pain and disability and improved upper extremity muscular strength and endurance in head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage.
18457329,1,5,Premise,Claim,support,"On the basis of intention-to-treat analyses, PRET was superior to TP for improving shoulder pain and disability (-9.6; 95% confidence interval [95% CI], -16.4 to -4.5; P = .001), upper extremity strength (+10.8 kg; 95% CI, 5.4-16.2 kg; P < .001), and upper extremity endurance (+194 repetitions x kg; 95% CI, 10-378 repetitions x kg; P = .039).",Clinicians should consider the addition of PRET in the rehabilitation of postsurgical head and neck cancer survivors.
18457329,2,1,Premise,Premise,none,"Changes in neck dissection impairment, fatigue, and quality of life favored the PRET group","On the basis of intention-to-treat analyses, PRET was superior to TP for improving shoulder pain and disability (-9.6; 95% confidence interval [95% CI], -16.4 to -4.5; P = .001), upper extremity strength (+10.8 kg; 95% CI, 5.4-16.2 kg; P < .001), and upper extremity endurance (+194 repetitions x kg; 95% CI, 10-378 repetitions x kg; P = .039)."
18457329,2,3,Premise,Premise,none,"Changes in neck dissection impairment, fatigue, and quality of life favored the PRET group",but did not reach statistical significance.
18457329,2,4,Premise,Premise,none,"Changes in neck dissection impairment, fatigue, and quality of life favored the PRET group",The PRET program significantly reduced shoulder pain and disability and improved upper extremity muscular strength and endurance in head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage.
18457329,2,5,Premise,Claim,support,"Changes in neck dissection impairment, fatigue, and quality of life favored the PRET group",Clinicians should consider the addition of PRET in the rehabilitation of postsurgical head and neck cancer survivors.
18457329,3,1,Premise,Premise,none,but did not reach statistical significance.,"On the basis of intention-to-treat analyses, PRET was superior to TP for improving shoulder pain and disability (-9.6; 95% confidence interval [95% CI], -16.4 to -4.5; P = .001), upper extremity strength (+10.8 kg; 95% CI, 5.4-16.2 kg; P < .001), and upper extremity endurance (+194 repetitions x kg; 95% CI, 10-378 repetitions x kg; P = .039)."
18457329,3,2,Premise,Premise,attack,but did not reach statistical significance.,"Changes in neck dissection impairment, fatigue, and quality of life favored the PRET group"
18457329,3,4,Premise,Premise,none,but did not reach statistical significance.,The PRET program significantly reduced shoulder pain and disability and improved upper extremity muscular strength and endurance in head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage.
18457329,3,5,Premise,Claim,none,but did not reach statistical significance.,Clinicians should consider the addition of PRET in the rehabilitation of postsurgical head and neck cancer survivors.
18457329,4,1,Premise,Premise,none,The PRET program significantly reduced shoulder pain and disability and improved upper extremity muscular strength and endurance in head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage.,"On the basis of intention-to-treat analyses, PRET was superior to TP for improving shoulder pain and disability (-9.6; 95% confidence interval [95% CI], -16.4 to -4.5; P = .001), upper extremity strength (+10.8 kg; 95% CI, 5.4-16.2 kg; P < .001), and upper extremity endurance (+194 repetitions x kg; 95% CI, 10-378 repetitions x kg; P = .039)."
18457329,4,2,Premise,Premise,none,The PRET program significantly reduced shoulder pain and disability and improved upper extremity muscular strength and endurance in head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage.,"Changes in neck dissection impairment, fatigue, and quality of life favored the PRET group"
18457329,4,3,Premise,Premise,none,The PRET program significantly reduced shoulder pain and disability and improved upper extremity muscular strength and endurance in head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage.,but did not reach statistical significance.
18457329,4,5,Premise,Claim,support,The PRET program significantly reduced shoulder pain and disability and improved upper extremity muscular strength and endurance in head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage.,Clinicians should consider the addition of PRET in the rehabilitation of postsurgical head and neck cancer survivors.
18457329,5,1,Claim,Premise,none,Clinicians should consider the addition of PRET in the rehabilitation of postsurgical head and neck cancer survivors.,"On the basis of intention-to-treat analyses, PRET was superior to TP for improving shoulder pain and disability (-9.6; 95% confidence interval [95% CI], -16.4 to -4.5; P = .001), upper extremity strength (+10.8 kg; 95% CI, 5.4-16.2 kg; P < .001), and upper extremity endurance (+194 repetitions x kg; 95% CI, 10-378 repetitions x kg; P = .039)."
18457329,5,2,Claim,Premise,none,Clinicians should consider the addition of PRET in the rehabilitation of postsurgical head and neck cancer survivors.,"Changes in neck dissection impairment, fatigue, and quality of life favored the PRET group"
18457329,5,3,Claim,Premise,none,Clinicians should consider the addition of PRET in the rehabilitation of postsurgical head and neck cancer survivors.,but did not reach statistical significance.
18457329,5,4,Claim,Premise,none,Clinicians should consider the addition of PRET in the rehabilitation of postsurgical head and neck cancer survivors.,The PRET program significantly reduced shoulder pain and disability and improved upper extremity muscular strength and endurance in head and neck cancer survivors who had shoulder dysfunction because of spinal accessory nerve damage.
23803270,1,2,Premise,Premise,none,No statistically significant between-group differences were found in volume reduction;,"however, all groups had clinically and statistically significant reduction in volume."
23803270,1,3,Premise,Premise,none,No statistically significant between-group differences were found in volume reduction;,No group differences were noted in psychological and physical symptoms or QOL;
23803270,1,4,Premise,Premise,none,No statistically significant between-group differences were found in volume reduction;,"however, treatment-related improvements were noted in symptom burden within all groups."
23803270,1,5,Premise,Premise,none,No statistically significant between-group differences were found in volume reduction;,Skin improvement was noted in each group that received LLLT.
23803270,1,6,Premise,Claim,none,No statistically significant between-group differences were found in volume reduction;,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.
23803270,1,7,Premise,Claim,support,No statistically significant between-group differences were found in volume reduction;,compression bandaging alone could account for the demonstrated volume reduction.
23803270,1,8,Premise,Claim,none,No statistically significant between-group differences were found in volume reduction;,APNs can effectively treat lymphedema.
23803270,1,9,Premise,Claim,none,No statistically significant between-group differences were found in volume reduction;,"Lasers may provide effective, less burdensome treatment for lymphedema."
23803270,1,10,Premise,Claim,none,No statistically significant between-group differences were found in volume reduction;,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.
23803270,1,11,Premise,Claim,none,No statistically significant between-group differences were found in volume reduction;,bioelectrical impedance and tape measurements can be used to assess lymphedema.
23803270,2,1,Premise,Premise,attack,"however, all groups had clinically and statistically significant reduction in volume.",No statistically significant between-group differences were found in volume reduction;
23803270,2,3,Premise,Premise,none,"however, all groups had clinically and statistically significant reduction in volume.",No group differences were noted in psychological and physical symptoms or QOL;
23803270,2,4,Premise,Premise,none,"however, all groups had clinically and statistically significant reduction in volume.","however, treatment-related improvements were noted in symptom burden within all groups."
23803270,2,5,Premise,Premise,none,"however, all groups had clinically and statistically significant reduction in volume.",Skin improvement was noted in each group that received LLLT.
23803270,2,6,Premise,Claim,none,"however, all groups had clinically and statistically significant reduction in volume.",LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.
23803270,2,7,Premise,Claim,none,"however, all groups had clinically and statistically significant reduction in volume.",compression bandaging alone could account for the demonstrated volume reduction.
23803270,2,8,Premise,Claim,none,"however, all groups had clinically and statistically significant reduction in volume.",APNs can effectively treat lymphedema.
23803270,2,9,Premise,Claim,none,"however, all groups had clinically and statistically significant reduction in volume.","Lasers may provide effective, less burdensome treatment for lymphedema."
23803270,2,10,Premise,Claim,none,"however, all groups had clinically and statistically significant reduction in volume.",APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.
23803270,2,11,Premise,Claim,none,"however, all groups had clinically and statistically significant reduction in volume.",bioelectrical impedance and tape measurements can be used to assess lymphedema.
23803270,3,1,Premise,Premise,none,No group differences were noted in psychological and physical symptoms or QOL;,No statistically significant between-group differences were found in volume reduction;
23803270,3,2,Premise,Premise,none,No group differences were noted in psychological and physical symptoms or QOL;,"however, all groups had clinically and statistically significant reduction in volume."
23803270,3,4,Premise,Premise,none,No group differences were noted in psychological and physical symptoms or QOL;,"however, treatment-related improvements were noted in symptom burden within all groups."
23803270,3,5,Premise,Premise,none,No group differences were noted in psychological and physical symptoms or QOL;,Skin improvement was noted in each group that received LLLT.
23803270,3,6,Premise,Claim,none,No group differences were noted in psychological and physical symptoms or QOL;,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.
23803270,3,7,Premise,Claim,none,No group differences were noted in psychological and physical symptoms or QOL;,compression bandaging alone could account for the demonstrated volume reduction.
23803270,3,8,Premise,Claim,none,No group differences were noted in psychological and physical symptoms or QOL;,APNs can effectively treat lymphedema.
23803270,3,9,Premise,Claim,none,No group differences were noted in psychological and physical symptoms or QOL;,"Lasers may provide effective, less burdensome treatment for lymphedema."
23803270,3,10,Premise,Claim,none,No group differences were noted in psychological and physical symptoms or QOL;,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.
23803270,3,11,Premise,Claim,none,No group differences were noted in psychological and physical symptoms or QOL;,bioelectrical impedance and tape measurements can be used to assess lymphedema.
23803270,4,1,Premise,Premise,none,"however, treatment-related improvements were noted in symptom burden within all groups.",No statistically significant between-group differences were found in volume reduction;
23803270,4,2,Premise,Premise,none,"however, treatment-related improvements were noted in symptom burden within all groups.","however, all groups had clinically and statistically significant reduction in volume."
23803270,4,3,Premise,Premise,none,"however, treatment-related improvements were noted in symptom burden within all groups.",No group differences were noted in psychological and physical symptoms or QOL;
23803270,4,5,Premise,Premise,none,"however, treatment-related improvements were noted in symptom burden within all groups.",Skin improvement was noted in each group that received LLLT.
23803270,4,6,Premise,Claim,none,"however, treatment-related improvements were noted in symptom burden within all groups.",LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.
23803270,4,7,Premise,Claim,none,"however, treatment-related improvements were noted in symptom burden within all groups.",compression bandaging alone could account for the demonstrated volume reduction.
23803270,4,8,Premise,Claim,none,"however, treatment-related improvements were noted in symptom burden within all groups.",APNs can effectively treat lymphedema.
23803270,4,9,Premise,Claim,none,"however, treatment-related improvements were noted in symptom burden within all groups.","Lasers may provide effective, less burdensome treatment for lymphedema."
23803270,4,10,Premise,Claim,none,"however, treatment-related improvements were noted in symptom burden within all groups.",APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.
23803270,4,11,Premise,Claim,none,"however, treatment-related improvements were noted in symptom burden within all groups.",bioelectrical impedance and tape measurements can be used to assess lymphedema.
23803270,5,1,Premise,Premise,none,Skin improvement was noted in each group that received LLLT.,No statistically significant between-group differences were found in volume reduction;
23803270,5,2,Premise,Premise,none,Skin improvement was noted in each group that received LLLT.,"however, all groups had clinically and statistically significant reduction in volume."
23803270,5,3,Premise,Premise,none,Skin improvement was noted in each group that received LLLT.,No group differences were noted in psychological and physical symptoms or QOL;
23803270,5,4,Premise,Premise,none,Skin improvement was noted in each group that received LLLT.,"however, treatment-related improvements were noted in symptom burden within all groups."
23803270,5,6,Premise,Claim,none,Skin improvement was noted in each group that received LLLT.,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.
23803270,5,7,Premise,Claim,none,Skin improvement was noted in each group that received LLLT.,compression bandaging alone could account for the demonstrated volume reduction.
23803270,5,8,Premise,Claim,none,Skin improvement was noted in each group that received LLLT.,APNs can effectively treat lymphedema.
23803270,5,9,Premise,Claim,none,Skin improvement was noted in each group that received LLLT.,"Lasers may provide effective, less burdensome treatment for lymphedema."
23803270,5,10,Premise,Claim,none,Skin improvement was noted in each group that received LLLT.,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.
23803270,5,11,Premise,Claim,none,Skin improvement was noted in each group that received LLLT.,bioelectrical impedance and tape measurements can be used to assess lymphedema.
23803270,6,1,Claim,Premise,none,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.,No statistically significant between-group differences were found in volume reduction;
23803270,6,2,Claim,Premise,none,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.,"however, all groups had clinically and statistically significant reduction in volume."
23803270,6,3,Claim,Premise,none,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.,No group differences were noted in psychological and physical symptoms or QOL;
23803270,6,4,Claim,Premise,none,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.,"however, treatment-related improvements were noted in symptom burden within all groups."
23803270,6,5,Claim,Premise,none,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.,Skin improvement was noted in each group that received LLLT.
23803270,6,7,Claim,Claim,none,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.,compression bandaging alone could account for the demonstrated volume reduction.
23803270,6,8,Claim,Claim,none,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.,APNs can effectively treat lymphedema.
23803270,6,9,Claim,Claim,none,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.,"Lasers may provide effective, less burdensome treatment for lymphedema."
23803270,6,10,Claim,Claim,none,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.
23803270,6,11,Claim,Claim,none,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.,bioelectrical impedance and tape measurements can be used to assess lymphedema.
23803270,7,1,Claim,Premise,none,compression bandaging alone could account for the demonstrated volume reduction.,No statistically significant between-group differences were found in volume reduction;
23803270,7,2,Claim,Premise,none,compression bandaging alone could account for the demonstrated volume reduction.,"however, all groups had clinically and statistically significant reduction in volume."
23803270,7,3,Claim,Premise,none,compression bandaging alone could account for the demonstrated volume reduction.,No group differences were noted in psychological and physical symptoms or QOL;
23803270,7,4,Claim,Premise,none,compression bandaging alone could account for the demonstrated volume reduction.,"however, treatment-related improvements were noted in symptom burden within all groups."
23803270,7,5,Claim,Premise,none,compression bandaging alone could account for the demonstrated volume reduction.,Skin improvement was noted in each group that received LLLT.
23803270,7,6,Claim,Claim,none,compression bandaging alone could account for the demonstrated volume reduction.,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.
23803270,7,8,Claim,Claim,none,compression bandaging alone could account for the demonstrated volume reduction.,APNs can effectively treat lymphedema.
23803270,7,9,Claim,Claim,none,compression bandaging alone could account for the demonstrated volume reduction.,"Lasers may provide effective, less burdensome treatment for lymphedema."
23803270,7,10,Claim,Claim,none,compression bandaging alone could account for the demonstrated volume reduction.,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.
23803270,7,11,Claim,Claim,none,compression bandaging alone could account for the demonstrated volume reduction.,bioelectrical impedance and tape measurements can be used to assess lymphedema.
23803270,8,1,Claim,Premise,none,APNs can effectively treat lymphedema.,No statistically significant between-group differences were found in volume reduction;
23803270,8,2,Claim,Premise,none,APNs can effectively treat lymphedema.,"however, all groups had clinically and statistically significant reduction in volume."
23803270,8,3,Claim,Premise,none,APNs can effectively treat lymphedema.,No group differences were noted in psychological and physical symptoms or QOL;
23803270,8,4,Claim,Premise,none,APNs can effectively treat lymphedema.,"however, treatment-related improvements were noted in symptom burden within all groups."
23803270,8,5,Claim,Premise,none,APNs can effectively treat lymphedema.,Skin improvement was noted in each group that received LLLT.
23803270,8,6,Claim,Claim,none,APNs can effectively treat lymphedema.,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.
23803270,8,7,Claim,Claim,none,APNs can effectively treat lymphedema.,compression bandaging alone could account for the demonstrated volume reduction.
23803270,8,9,Claim,Claim,none,APNs can effectively treat lymphedema.,"Lasers may provide effective, less burdensome treatment for lymphedema."
23803270,8,10,Claim,Claim,none,APNs can effectively treat lymphedema.,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.
23803270,8,11,Claim,Claim,none,APNs can effectively treat lymphedema.,bioelectrical impedance and tape measurements can be used to assess lymphedema.
23803270,9,1,Claim,Premise,none,"Lasers may provide effective, less burdensome treatment for lymphedema.",No statistically significant between-group differences were found in volume reduction;
23803270,9,2,Claim,Premise,none,"Lasers may provide effective, less burdensome treatment for lymphedema.","however, all groups had clinically and statistically significant reduction in volume."
23803270,9,3,Claim,Premise,none,"Lasers may provide effective, less burdensome treatment for lymphedema.",No group differences were noted in psychological and physical symptoms or QOL;
23803270,9,4,Claim,Premise,none,"Lasers may provide effective, less burdensome treatment for lymphedema.","however, treatment-related improvements were noted in symptom burden within all groups."
23803270,9,5,Claim,Premise,none,"Lasers may provide effective, less burdensome treatment for lymphedema.",Skin improvement was noted in each group that received LLLT.
23803270,9,6,Claim,Claim,none,"Lasers may provide effective, less burdensome treatment for lymphedema.",LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.
23803270,9,7,Claim,Claim,none,"Lasers may provide effective, less burdensome treatment for lymphedema.",compression bandaging alone could account for the demonstrated volume reduction.
23803270,9,8,Claim,Claim,none,"Lasers may provide effective, less burdensome treatment for lymphedema.",APNs can effectively treat lymphedema.
23803270,9,10,Claim,Claim,none,"Lasers may provide effective, less burdensome treatment for lymphedema.",APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.
23803270,9,11,Claim,Claim,none,"Lasers may provide effective, less burdensome treatment for lymphedema.",bioelectrical impedance and tape measurements can be used to assess lymphedema.
23803270,10,1,Claim,Premise,none,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.,No statistically significant between-group differences were found in volume reduction;
23803270,10,2,Claim,Premise,none,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.,"however, all groups had clinically and statistically significant reduction in volume."
23803270,10,3,Claim,Premise,none,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.,No group differences were noted in psychological and physical symptoms or QOL;
23803270,10,4,Claim,Premise,none,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.,"however, treatment-related improvements were noted in symptom burden within all groups."
23803270,10,5,Claim,Premise,none,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.,Skin improvement was noted in each group that received LLLT.
23803270,10,6,Claim,Claim,none,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.
23803270,10,7,Claim,Claim,none,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.,compression bandaging alone could account for the demonstrated volume reduction.
23803270,10,8,Claim,Claim,none,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.,APNs can effectively treat lymphedema.
23803270,10,9,Claim,Claim,none,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.,"Lasers may provide effective, less burdensome treatment for lymphedema."
23803270,10,11,Claim,Claim,none,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.,bioelectrical impedance and tape measurements can be used to assess lymphedema.
23803270,11,1,Claim,Premise,none,bioelectrical impedance and tape measurements can be used to assess lymphedema.,No statistically significant between-group differences were found in volume reduction;
23803270,11,2,Claim,Premise,none,bioelectrical impedance and tape measurements can be used to assess lymphedema.,"however, all groups had clinically and statistically significant reduction in volume."
23803270,11,3,Claim,Premise,none,bioelectrical impedance and tape measurements can be used to assess lymphedema.,No group differences were noted in psychological and physical symptoms or QOL;
23803270,11,4,Claim,Premise,none,bioelectrical impedance and tape measurements can be used to assess lymphedema.,"however, treatment-related improvements were noted in symptom burden within all groups."
23803270,11,5,Claim,Premise,none,bioelectrical impedance and tape measurements can be used to assess lymphedema.,Skin improvement was noted in each group that received LLLT.
23803270,11,6,Claim,Claim,none,bioelectrical impedance and tape measurements can be used to assess lymphedema.,LLLT with bandaging may offer a time-saving therapeutic option to conventional MLD.
23803270,11,7,Claim,Claim,none,bioelectrical impedance and tape measurements can be used to assess lymphedema.,compression bandaging alone could account for the demonstrated volume reduction.
23803270,11,8,Claim,Claim,none,bioelectrical impedance and tape measurements can be used to assess lymphedema.,APNs can effectively treat lymphedema.
23803270,11,9,Claim,Claim,none,bioelectrical impedance and tape measurements can be used to assess lymphedema.,"Lasers may provide effective, less burdensome treatment for lymphedema."
23803270,11,10,Claim,Claim,none,bioelectrical impedance and tape measurements can be used to assess lymphedema.,APNs with lymphedema certification can effectively treat this patient population with the use of LLLT.
15157043,1,2,Claim,Premise,none,"Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life.","In all four patients, Hgb levels were normal at the time of the event."
15157043,1,3,Claim,Premise,none,"Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life.",No patient in G1 developed a thrombotic event.
15157043,1,4,Claim,Premise,none,"Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life.",There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.
15157043,1,5,Claim,Premise,none,"Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life.",The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.
15157043,1,6,Claim,Claim,none,"Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life.","This may relate to the administration of r-HuEPO in this high-risk population,"
15157043,1,7,Claim,Claim,none,"Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life.",but the small sample size and possible predisposing risk factors preclude definitive conclusions.
15157043,2,1,Premise,Claim,none,"In all four patients, Hgb levels were normal at the time of the event.","Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life."
15157043,2,3,Premise,Premise,none,"In all four patients, Hgb levels were normal at the time of the event.",No patient in G1 developed a thrombotic event.
15157043,2,4,Premise,Premise,none,"In all four patients, Hgb levels were normal at the time of the event.",There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.
15157043,2,5,Premise,Premise,none,"In all four patients, Hgb levels were normal at the time of the event.",The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.
15157043,2,6,Premise,Claim,none,"In all four patients, Hgb levels were normal at the time of the event.","This may relate to the administration of r-HuEPO in this high-risk population,"
15157043,2,7,Premise,Claim,none,"In all four patients, Hgb levels were normal at the time of the event.",but the small sample size and possible predisposing risk factors preclude definitive conclusions.
15157043,3,1,Premise,Claim,none,No patient in G1 developed a thrombotic event.,"Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life."
15157043,3,2,Premise,Premise,none,No patient in G1 developed a thrombotic event.,"In all four patients, Hgb levels were normal at the time of the event."
15157043,3,4,Premise,Premise,none,No patient in G1 developed a thrombotic event.,There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.
15157043,3,5,Premise,Premise,none,No patient in G1 developed a thrombotic event.,The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.
15157043,3,6,Premise,Claim,none,No patient in G1 developed a thrombotic event.,"This may relate to the administration of r-HuEPO in this high-risk population,"
15157043,3,7,Premise,Claim,none,No patient in G1 developed a thrombotic event.,but the small sample size and possible predisposing risk factors preclude definitive conclusions.
15157043,4,1,Premise,Claim,none,There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.,"Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life."
15157043,4,2,Premise,Premise,none,There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.,"In all four patients, Hgb levels were normal at the time of the event."
15157043,4,3,Premise,Premise,none,There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.,No patient in G1 developed a thrombotic event.
15157043,4,5,Premise,Premise,none,There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.,The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.
15157043,4,6,Premise,Claim,none,There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.,"This may relate to the administration of r-HuEPO in this high-risk population,"
15157043,4,7,Premise,Claim,none,There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.,but the small sample size and possible predisposing risk factors preclude definitive conclusions.
15157043,5,1,Premise,Claim,none,The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.,"Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life."
15157043,5,2,Premise,Premise,none,The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.,"In all four patients, Hgb levels were normal at the time of the event."
15157043,5,3,Premise,Premise,none,The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.,No patient in G1 developed a thrombotic event.
15157043,5,4,Premise,Premise,none,The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.,There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.
15157043,5,6,Premise,Claim,none,The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.,"This may relate to the administration of r-HuEPO in this high-risk population,"
15157043,5,7,Premise,Claim,none,The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.,but the small sample size and possible predisposing risk factors preclude definitive conclusions.
15157043,6,1,Claim,Claim,none,"This may relate to the administration of r-HuEPO in this high-risk population,","Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life."
15157043,6,2,Claim,Premise,none,"This may relate to the administration of r-HuEPO in this high-risk population,","In all four patients, Hgb levels were normal at the time of the event."
15157043,6,3,Claim,Premise,none,"This may relate to the administration of r-HuEPO in this high-risk population,",No patient in G1 developed a thrombotic event.
15157043,6,4,Claim,Premise,none,"This may relate to the administration of r-HuEPO in this high-risk population,",There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.
15157043,6,5,Claim,Premise,none,"This may relate to the administration of r-HuEPO in this high-risk population,",The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.
15157043,6,7,Claim,Claim,none,"This may relate to the administration of r-HuEPO in this high-risk population,",but the small sample size and possible predisposing risk factors preclude definitive conclusions.
15157043,7,1,Claim,Claim,none,but the small sample size and possible predisposing risk factors preclude definitive conclusions.,"Recombinant human erythropoietin (r-HuEPO) corrects cancer-related anemia and, thereby, improves quality of life."
15157043,7,2,Claim,Premise,none,but the small sample size and possible predisposing risk factors preclude definitive conclusions.,"In all four patients, Hgb levels were normal at the time of the event."
15157043,7,3,Claim,Premise,none,but the small sample size and possible predisposing risk factors preclude definitive conclusions.,No patient in G1 developed a thrombotic event.
15157043,7,4,Claim,Premise,none,but the small sample size and possible predisposing risk factors preclude definitive conclusions.,There were no significant differences in demographic characteristics or current chemotherapy regimen in G1 vs. G2.
15157043,7,5,Claim,Premise,none,but the small sample size and possible predisposing risk factors preclude definitive conclusions.,The increased incidence of thrombotic events in the r-HuEPO (G2) arm of this study exceeds that in prior studies in this population and prior r-HuEPO trials.
15157043,7,6,Claim,Claim,attack,but the small sample size and possible predisposing risk factors preclude definitive conclusions.,"This may relate to the administration of r-HuEPO in this high-risk population,"
11970761,1,2,Claim,Premise,none,"Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.","Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint."
11970761,1,3,Claim,Premise,none,"Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.","Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline."
11970761,1,4,Claim,Premise,none,"Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.","Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients."
11970761,1,5,Claim,Claim,none,"Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.",Denileukin diftitox was not associated with any clinically significant myelosuppression.
11970761,1,6,Claim,Claim,none,"Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions.","Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity."
11970761,2,1,Premise,Claim,none,"Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.","Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions."
11970761,2,3,Premise,Premise,none,"Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.","Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline."
11970761,2,4,Premise,Premise,none,"Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.","Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients."
11970761,2,5,Premise,Claim,none,"Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.",Denileukin diftitox was not associated with any clinically significant myelosuppression.
11970761,2,6,Premise,Claim,support,"Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint.","Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity."
11970761,3,1,Premise,Claim,none,"Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.","Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions."
11970761,3,2,Premise,Premise,none,"Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.","Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint."
11970761,3,4,Premise,Premise,none,"Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.","Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients."
11970761,3,5,Premise,Claim,none,"Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.",Denileukin diftitox was not associated with any clinically significant myelosuppression.
11970761,3,6,Premise,Claim,support,"Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline.","Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity."
11970761,4,1,Premise,Claim,none,"Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.","Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions."
11970761,4,2,Premise,Premise,none,"Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.","Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint."
11970761,4,3,Premise,Premise,none,"Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.","Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline."
11970761,4,5,Premise,Claim,none,"Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.",Denileukin diftitox was not associated with any clinically significant myelosuppression.
11970761,4,6,Premise,Claim,none,"Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients.","Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity."
11970761,5,1,Claim,Claim,none,Denileukin diftitox was not associated with any clinically significant myelosuppression.,"Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions."
11970761,5,2,Claim,Premise,none,Denileukin diftitox was not associated with any clinically significant myelosuppression.,"Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint."
11970761,5,3,Claim,Premise,none,Denileukin diftitox was not associated with any clinically significant myelosuppression.,"Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline."
11970761,5,4,Claim,Premise,none,Denileukin diftitox was not associated with any clinically significant myelosuppression.,"Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients."
11970761,5,6,Claim,Claim,none,Denileukin diftitox was not associated with any clinically significant myelosuppression.,"Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity."
11970761,6,1,Claim,Claim,none,"Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.","Cutaneous T-cell lymphoma (CTCL) can be associated with painful, pruritic, disfiguring lesions."
11970761,6,2,Claim,Premise,none,"Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.","Composite FACT-G and most individual subscale scores (physical, social/family, emotional, and functional well being) in documented responders (n = 21) gradually increased during the study period, generally reaching statistical significance (P < 0.05) by cycle 3, and were significantly (P < or = 0.041) higher than the scores of nonresponders at endpoint."
11970761,6,3,Claim,Premise,none,"Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.","Additionally for responders, assessments of skin severity and pruritus severity showed significant (P < or = 0.05) improvements at study endpoint compared with baseline."
11970761,6,4,Claim,Premise,none,"Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.","Adverse transfusion-related events (eg, hypersensitivity reactions, flu-like syndrome) were common during cycles 1 and 2, and vascular-leak syndrome occurred in 25% of patients."
11970761,6,5,Claim,Claim,none,"Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity.",Denileukin diftitox was not associated with any clinically significant myelosuppression.
18591555,1,2,Premise,Premise,none,"Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344).",Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).
18591555,1,3,Premise,Premise,none,"Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344).",Patients under combined treatment were at higher risk of severe thrombocytopenia.
18591555,1,4,Premise,Claim,support,"Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344).",Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.
18591555,2,1,Premise,Premise,none,Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).,"Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344)."
18591555,2,3,Premise,Premise,none,Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).,Patients under combined treatment were at higher risk of severe thrombocytopenia.
18591555,2,4,Premise,Claim,none,Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).,Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.
18591555,3,1,Premise,Premise,none,Patients under combined treatment were at higher risk of severe thrombocytopenia.,"Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344)."
18591555,3,2,Premise,Premise,none,Patients under combined treatment were at higher risk of severe thrombocytopenia.,Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).
18591555,3,4,Premise,Claim,none,Patients under combined treatment were at higher risk of severe thrombocytopenia.,Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.
18591555,4,1,Claim,Premise,none,Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.,"Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344)."
18591555,4,2,Claim,Premise,none,Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.,Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).
18591555,4,3,Claim,Premise,none,Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.,Patients under combined treatment were at higher risk of severe thrombocytopenia.
12783373,1,2,Claim,Premise,none,"Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).",Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.
12783373,1,3,Claim,Premise,none,"Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).","There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT)."
12783373,1,4,Claim,Premise,none,"Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).","Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT)."
12783373,1,5,Claim,Premise,none,"Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).","After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores."
12783373,1,6,Claim,Claim,none,"Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).",Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.
12783373,1,7,Claim,Claim,none,"Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL).",patients who crossed over to imatinib reported higher QoL than those who remained on IFN.
12783373,2,1,Premise,Claim,none,Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.,"Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."
12783373,2,3,Premise,Premise,none,Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.,"There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT)."
12783373,2,4,Premise,Premise,none,Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.,"Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT)."
12783373,2,5,Premise,Premise,none,Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.,"After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores."
12783373,2,6,Premise,Claim,none,Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.,Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.
12783373,2,7,Premise,Claim,none,Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.,patients who crossed over to imatinib reported higher QoL than those who remained on IFN.
12783373,3,1,Premise,Claim,none,"There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).","Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."
12783373,3,2,Premise,Premise,none,"There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).",Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.
12783373,3,4,Premise,Premise,none,"There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).","Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT)."
12783373,3,5,Premise,Premise,none,"There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).","After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores."
12783373,3,6,Premise,Claim,support,"There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).",Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.
12783373,3,7,Premise,Claim,none,"There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT).",patients who crossed over to imatinib reported higher QoL than those who remained on IFN.
12783373,4,1,Premise,Claim,none,"Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).","Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."
12783373,4,2,Premise,Premise,none,"Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).",Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.
12783373,4,3,Premise,Premise,none,"Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).","There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT)."
12783373,4,5,Premise,Premise,none,"Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).","After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores."
12783373,4,6,Premise,Claim,support,"Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).",Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.
12783373,4,7,Premise,Claim,none,"Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT).",patients who crossed over to imatinib reported higher QoL than those who remained on IFN.
12783373,5,1,Premise,Claim,none,"After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.","Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."
12783373,5,2,Premise,Premise,none,"After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.",Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.
12783373,5,3,Premise,Premise,none,"After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.","There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT)."
12783373,5,4,Premise,Premise,none,"After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.","Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT)."
12783373,5,6,Premise,Claim,none,"After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.",Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.
12783373,5,7,Premise,Claim,support,"After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores.",patients who crossed over to imatinib reported higher QoL than those who remained on IFN.
12783373,6,1,Claim,Claim,none,Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.,"Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."
12783373,6,2,Claim,Premise,none,Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.,Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.
12783373,6,3,Claim,Premise,none,Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.,"There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT)."
12783373,6,4,Claim,Premise,none,Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.,"Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT)."
12783373,6,5,Claim,Premise,none,Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.,"After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores."
12783373,6,7,Claim,Claim,none,Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.,patients who crossed over to imatinib reported higher QoL than those who remained on IFN.
12783373,7,1,Claim,Claim,none,patients who crossed over to imatinib reported higher QoL than those who remained on IFN.,"Imatinib (Gleevec), a highly effective specific tyrosine kinase inhibitor, demonstrates a better side effect profile than interferon-alpha (IFN), which impairs patients' quality of life (QoL)."
12783373,7,2,Claim,Premise,none,patients who crossed over to imatinib reported higher QoL than those who remained on IFN.,Two hundred sixty-one patients (50%) crossed over from IFN to imatinib and 11 (2%) crossed over from imatinib to IFN.
12783373,7,3,Claim,Premise,none,patients who crossed over to imatinib reported higher QoL than those who remained on IFN.,"There was a significant decline in TOI scores for the IFN treatment arm compared with preservation of baseline TOI scores in the imatinib arm (P <.001, ITT)."
12783373,7,4,Claim,Premise,none,patients who crossed over to imatinib reported higher QoL than those who remained on IFN.,"Mean social/family and EWB scores were 22.8 and 19.5, respectively, for imatinib and 21.6 and 17.6, respectively, for IFN (P <.001, ITT)."
12783373,7,5,Claim,Premise,none,patients who crossed over to imatinib reported higher QoL than those who remained on IFN.,"After crossing over from IFN to imatinib, patients experienced a significant (P <.001) increase in TOI scores."
12783373,7,6,Claim,Claim,none,patients who crossed over to imatinib reported higher QoL than those who remained on IFN.,Imatinib offers clear QoL advantages over IFN as first-line treatment of chronic-phase CML.
23820680,1,2,Premise,Premise,none,The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).,"At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem."
23820680,1,3,Premise,Premise,none,The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).,"At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;"
23820680,1,4,Premise,Premise,none,The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).,"the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function."
23820680,1,5,Premise,Premise,none,The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).,"Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,"
23820680,1,6,Premise,Claim,none,The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).,patients in whole stomach group suffered more severe nausea and vomiting.
23820680,1,7,Premise,Claim,support,The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).,Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery.
23820680,2,1,Premise,Premise,none,"At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem.",The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).
23820680,2,3,Premise,Premise,none,"At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem.","At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;"
23820680,2,4,Premise,Premise,none,"At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem.","the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function."
23820680,2,5,Premise,Premise,none,"At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem.","Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,"
23820680,2,6,Premise,Claim,support,"At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem.",patients in whole stomach group suffered more severe nausea and vomiting.
23820680,2,7,Premise,Claim,none,"At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem.",Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery.
23820680,3,1,Premise,Premise,none,"At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;",The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).
23820680,3,2,Premise,Premise,none,"At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;","At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem."
23820680,3,4,Premise,Premise,none,"At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;","the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function."
23820680,3,5,Premise,Premise,none,"At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;","Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,"
23820680,3,6,Premise,Claim,none,"At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;",patients in whole stomach group suffered more severe nausea and vomiting.
23820680,3,7,Premise,Claim,support,"At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;",Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery.
23820680,4,1,Premise,Premise,none,"the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function.",The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).
23820680,4,2,Premise,Premise,none,"the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function.","At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem."
23820680,4,3,Premise,Premise,none,"the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function.","At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;"
23820680,4,5,Premise,Premise,none,"the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function.","Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,"
23820680,4,6,Premise,Claim,none,"the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function.",patients in whole stomach group suffered more severe nausea and vomiting.
23820680,4,7,Premise,Claim,support,"the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function.",Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery.
23820680,5,1,Premise,Premise,none,"Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,",The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).
23820680,5,2,Premise,Premise,none,"Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,","At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem."
23820680,5,3,Premise,Premise,none,"Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,","At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;"
23820680,5,4,Premise,Premise,none,"Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,","the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function."
23820680,5,6,Premise,Claim,support,"Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,",patients in whole stomach group suffered more severe nausea and vomiting.
23820680,5,7,Premise,Claim,none,"Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,",Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery.
23820680,6,1,Claim,Premise,none,patients in whole stomach group suffered more severe nausea and vomiting.,The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).
23820680,6,2,Claim,Premise,none,patients in whole stomach group suffered more severe nausea and vomiting.,"At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem."
23820680,6,3,Claim,Premise,none,patients in whole stomach group suffered more severe nausea and vomiting.,"At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;"
23820680,6,4,Claim,Premise,none,patients in whole stomach group suffered more severe nausea and vomiting.,"the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function."
23820680,6,5,Claim,Premise,none,patients in whole stomach group suffered more severe nausea and vomiting.,"Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,"
23820680,6,7,Claim,Claim,none,patients in whole stomach group suffered more severe nausea and vomiting.,Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery.
23820680,7,1,Claim,Premise,none,Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery.,The perioperative complication rate was 26.9% in narrow gastric tube group and 48.1% in whole stomach group (P = 0.31).
23820680,7,2,Claim,Premise,none,Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery.,"At the time of 3 weeks after surgery, the reflux and dyspnea scores were higher in whole stomach group than in narrow gastric tube group, which meant that the patients in whole stomach group suffered more severe problem."
23820680,7,3,Claim,Premise,none,Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery.,"At the time of 6 months and 1 year after surgery, the reflux scores were lower in narrow gastric tube group than in whole stomach group, which revealed that there were less problems of reflux in the patients of narrow gastric tube group;"
23820680,7,4,Claim,Premise,none,Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery.,"the score of physical function scale in narrow gastric tube group was higher conversely, which suggested that the patients gain a better status in physical function."
23820680,7,5,Claim,Premise,none,Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery.,"Nausea and vomiting is the only notable symptom that was worse in whole stomach group at the time of 2 years after surgery,"
23820680,7,6,Claim,Claim,none,Narrow gastric tube reconstruction may be a good alternative choice for patients undergoing oncologic esophagectomy in view of better health-related quality of life after the surgery.,patients in whole stomach group suffered more severe nausea and vomiting.
12837811,1,2,Premise,Premise,none,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).",The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
12837811,1,3,Premise,Premise,none,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).",Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
12837811,1,4,Premise,Premise,none,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).","Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC."
12837811,1,5,Premise,Premise,none,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).","Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens."
12837811,1,6,Premise,Premise,none,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).","Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb."
12837811,1,7,Premise,Premise,none,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).","Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL."
12837811,1,8,Premise,Claim,support,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).",DC resulted in a more favorable overall response and survival rate than VC.
12837811,1,9,Premise,Claim,none,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).",Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
12837811,1,10,Premise,Claim,none,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416]).",These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
12837811,2,1,Premise,Premise,none,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416])."
12837811,2,3,Premise,Premise,none,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
12837811,2,4,Premise,Premise,none,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC."
12837811,2,5,Premise,Premise,none,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens."
12837811,2,6,Premise,Premise,none,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb."
12837811,2,7,Premise,Premise,none,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL."
12837811,2,8,Premise,Claim,support,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.,DC resulted in a more favorable overall response and survival rate than VC.
12837811,2,9,Premise,Claim,none,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
12837811,2,10,Premise,Claim,none,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
12837811,3,1,Premise,Premise,none,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416])."
12837811,3,2,Premise,Premise,none,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
12837811,3,4,Premise,Premise,none,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC."
12837811,3,5,Premise,Premise,none,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens."
12837811,3,6,Premise,Premise,none,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb."
12837811,3,7,Premise,Premise,none,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL."
12837811,3,8,Premise,Claim,support,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).,DC resulted in a more favorable overall response and survival rate than VC.
12837811,3,9,Premise,Claim,none,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
12837811,3,10,Premise,Claim,none,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
12837811,4,1,Premise,Premise,none,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.","Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416])."
12837811,4,2,Premise,Premise,none,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.",The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
12837811,4,3,Premise,Premise,none,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.",Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
12837811,4,5,Premise,Premise,none,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.","Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens."
12837811,4,6,Premise,Premise,none,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.","Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb."
12837811,4,7,Premise,Premise,none,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.","Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL."
12837811,4,8,Premise,Claim,support,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.",DC resulted in a more favorable overall response and survival rate than VC.
12837811,4,9,Premise,Claim,none,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.",Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
12837811,4,10,Premise,Claim,none,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC.",These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
12837811,5,1,Premise,Premise,none,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.","Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416])."
12837811,5,2,Premise,Premise,none,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.",The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
12837811,5,3,Premise,Premise,none,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.",Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
12837811,5,4,Premise,Premise,none,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.","Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC."
12837811,5,6,Premise,Premise,none,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.","Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb."
12837811,5,7,Premise,Premise,none,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.","Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL."
12837811,5,8,Premise,Claim,none,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.",DC resulted in a more favorable overall response and survival rate than VC.
12837811,5,9,Premise,Claim,support,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.",Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
12837811,5,10,Premise,Claim,none,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens.",These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
12837811,6,1,Premise,Premise,none,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.","Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416])."
12837811,6,2,Premise,Premise,none,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.",The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
12837811,6,3,Premise,Premise,none,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.",Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
12837811,6,4,Premise,Premise,none,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.","Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC."
12837811,6,5,Premise,Premise,none,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.","Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens."
12837811,6,7,Premise,Premise,none,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.","Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL."
12837811,6,8,Premise,Claim,none,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.",DC resulted in a more favorable overall response and survival rate than VC.
12837811,6,9,Premise,Claim,support,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.",Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
12837811,6,10,Premise,Claim,none,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb.",These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
12837811,7,1,Premise,Premise,none,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.","Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416])."
12837811,7,2,Premise,Premise,none,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.",The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
12837811,7,3,Premise,Premise,none,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.",Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
12837811,7,4,Premise,Premise,none,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.","Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC."
12837811,7,5,Premise,Premise,none,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.","Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens."
12837811,7,6,Premise,Premise,none,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.","Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb."
12837811,7,8,Premise,Claim,none,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.",DC resulted in a more favorable overall response and survival rate than VC.
12837811,7,9,Premise,Claim,support,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.",Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
12837811,7,10,Premise,Claim,none,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL.",These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
12837811,8,1,Claim,Premise,none,DC resulted in a more favorable overall response and survival rate than VC.,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416])."
12837811,8,2,Claim,Premise,none,DC resulted in a more favorable overall response and survival rate than VC.,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
12837811,8,3,Claim,Premise,none,DC resulted in a more favorable overall response and survival rate than VC.,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
12837811,8,4,Claim,Premise,none,DC resulted in a more favorable overall response and survival rate than VC.,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC."
12837811,8,5,Claim,Premise,none,DC resulted in a more favorable overall response and survival rate than VC.,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens."
12837811,8,6,Claim,Premise,none,DC resulted in a more favorable overall response and survival rate than VC.,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb."
12837811,8,7,Claim,Premise,none,DC resulted in a more favorable overall response and survival rate than VC.,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL."
12837811,8,9,Claim,Claim,none,DC resulted in a more favorable overall response and survival rate than VC.,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
12837811,8,10,Claim,Claim,support,DC resulted in a more favorable overall response and survival rate than VC.,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
12837811,9,1,Claim,Premise,none,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416])."
12837811,9,2,Claim,Premise,none,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
12837811,9,3,Claim,Premise,none,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
12837811,9,4,Claim,Premise,none,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC."
12837811,9,5,Claim,Premise,none,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens."
12837811,9,6,Claim,Premise,none,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb."
12837811,9,7,Claim,Premise,none,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL."
12837811,9,8,Claim,Claim,none,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.,DC resulted in a more favorable overall response and survival rate than VC.
12837811,9,10,Claim,Claim,support,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.
12837811,10,1,Claim,Premise,none,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.,"Patients treated with DC had a median survival of 11.3 v 10.1 months for VC-treated patients (P =.044; hazard ratio, 1.183 [97.2% confidence interval, 0.989 to 1.416])."
12837811,10,2,Claim,Premise,none,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.,The 2-year survival rate was 21% for DC-treated patients and 14% for VC-treated patients.
12837811,10,3,Claim,Premise,none,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.,Overall response rate was 31.6% for DC-treated patients v 24.5% for VC-treated patients (P =.029).
12837811,10,4,Claim,Premise,none,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.,"Median survival (9.4 v 9.9 months [for VC]; P =.657; hazard ratio, 1.048 [97.2 confidence interval, 0.877 to 1.253]) and response (23.9%) with DCb were similar to those results for VC."
12837811,10,5,Claim,Premise,none,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.,"Neutropenia, thrombocytopenia, infection, and febrile neutropenia were similar with all three regimens."
12837811,10,6,Claim,Premise,none,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.,"Grade 3 to 4 anemia, nausea, and vomiting were more common (P <.01) with VC than with DC or DCb."
12837811,10,7,Claim,Premise,none,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.,"Patients treated with either docetaxel regimen had consistently improved QoL compared with VC-treated patients, who experienced deterioration in QoL."
12837811,10,8,Claim,Claim,none,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.,DC resulted in a more favorable overall response and survival rate than VC.
12837811,10,9,Claim,Claim,none,These findings demonstrate that a docetaxel plus platinum combination is an effective treatment option with a favorable therapeutic index for first-line treatment of advanced or metastatic NSCLC.,Both DC and DCb were better tolerated and provided patients with consistently improved QoL compared with VC.
15284262,1,2,Premise,Premise,none,Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).,"The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001)."
15284262,1,3,Premise,Premise,none,Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).,There was no difference in median survival (8.8 months v 9.7 months).
15284262,1,4,Premise,Premise,none,Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).,Grade 3 to 4 anemia and neutropenia were more common in the combination arm.
15284262,1,5,Premise,Premise,none,Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).,"There was no significant difference in QOL scores,"
15284262,1,6,Premise,Premise,none,Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).,"although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death."
15284262,1,7,Premise,Claim,support,Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).,C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.
15284262,2,1,Premise,Premise,none,"The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001).",Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).
15284262,2,3,Premise,Premise,none,"The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001).",There was no difference in median survival (8.8 months v 9.7 months).
15284262,2,4,Premise,Premise,none,"The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001).",Grade 3 to 4 anemia and neutropenia were more common in the combination arm.
15284262,2,5,Premise,Premise,none,"The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001).","There was no significant difference in QOL scores,"
15284262,2,6,Premise,Premise,none,"The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001).","although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death."
15284262,2,7,Premise,Claim,support,"The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001).",C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.
15284262,3,1,Premise,Premise,none,There was no difference in median survival (8.8 months v 9.7 months).,Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).
15284262,3,2,Premise,Premise,none,There was no difference in median survival (8.8 months v 9.7 months).,"The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001)."
15284262,3,4,Premise,Premise,none,There was no difference in median survival (8.8 months v 9.7 months).,Grade 3 to 4 anemia and neutropenia were more common in the combination arm.
15284262,3,5,Premise,Premise,none,There was no difference in median survival (8.8 months v 9.7 months).,"There was no significant difference in QOL scores,"
15284262,3,6,Premise,Premise,none,There was no difference in median survival (8.8 months v 9.7 months).,"although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death."
15284262,3,7,Premise,Claim,none,There was no difference in median survival (8.8 months v 9.7 months).,C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.
15284262,4,1,Premise,Premise,none,Grade 3 to 4 anemia and neutropenia were more common in the combination arm.,Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).
15284262,4,2,Premise,Premise,none,Grade 3 to 4 anemia and neutropenia were more common in the combination arm.,"The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001)."
15284262,4,3,Premise,Premise,none,Grade 3 to 4 anemia and neutropenia were more common in the combination arm.,There was no difference in median survival (8.8 months v 9.7 months).
15284262,4,5,Premise,Premise,none,Grade 3 to 4 anemia and neutropenia were more common in the combination arm.,"There was no significant difference in QOL scores,"
15284262,4,6,Premise,Premise,none,Grade 3 to 4 anemia and neutropenia were more common in the combination arm.,"although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death."
15284262,4,7,Premise,Claim,none,Grade 3 to 4 anemia and neutropenia were more common in the combination arm.,C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.
15284262,5,1,Premise,Premise,none,"There was no significant difference in QOL scores,",Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).
15284262,5,2,Premise,Premise,none,"There was no significant difference in QOL scores,","The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001)."
15284262,5,3,Premise,Premise,none,"There was no significant difference in QOL scores,",There was no difference in median survival (8.8 months v 9.7 months).
15284262,5,4,Premise,Premise,none,"There was no significant difference in QOL scores,",Grade 3 to 4 anemia and neutropenia were more common in the combination arm.
15284262,5,6,Premise,Premise,none,"There was no significant difference in QOL scores,","although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death."
15284262,5,7,Premise,Claim,support,"There was no significant difference in QOL scores,",C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.
15284262,6,1,Premise,Premise,none,"although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death.",Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).
15284262,6,2,Premise,Premise,none,"although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death.","The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001)."
15284262,6,3,Premise,Premise,none,"although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death.",There was no difference in median survival (8.8 months v 9.7 months).
15284262,6,4,Premise,Premise,none,"although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death.",Grade 3 to 4 anemia and neutropenia were more common in the combination arm.
15284262,6,5,Premise,Premise,attack,"although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death.","There was no significant difference in QOL scores,"
15284262,6,7,Premise,Claim,none,"although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death.",C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.
15284262,7,1,Claim,Premise,none,C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.,Objective responses occurred in 19% (6% complete plus 13% partial) of patients receiving cisplatin versus 36% (15% complete plus 21% partial) receiving C+P (P = .002).
15284262,7,2,Claim,Premise,none,C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.,"The median PFS was 2.8 and 4.8 months, respectively, for cisplatin versus C+P (P < .001)."
15284262,7,3,Claim,Premise,none,C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.,There was no difference in median survival (8.8 months v 9.7 months).
15284262,7,4,Claim,Premise,none,C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.,Grade 3 to 4 anemia and neutropenia were more common in the combination arm.
15284262,7,5,Claim,Premise,none,C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.,"There was no significant difference in QOL scores,"
15284262,7,6,Claim,Premise,none,C+P is superior to cisplatin alone with respect to response rate and PFS with sustained QOL.,"although a disproportionate number of patients (cisplatin, n = 50; C+P, n = 33) dropped out of the QOL component, presumably because of increasing disease, deteriorating health status, or early death."
24019545,1,2,MajorClaim,Premise,none,"Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3.","PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042)."
24019545,1,3,MajorClaim,Premise,none,"Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3.","The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105)."
24019545,1,4,MajorClaim,Premise,none,"Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3.",Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).
24019545,1,5,MajorClaim,Premise,none,"Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3.",AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).
24019545,1,6,MajorClaim,Claim,none,"Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3.","Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC."
24019545,2,1,Premise,MajorClaim,none,"PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042).","Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3."
24019545,2,3,Premise,Premise,none,"PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042).","The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105)."
24019545,2,4,Premise,Premise,none,"PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042).",Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).
24019545,2,5,Premise,Premise,none,"PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042).",AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).
24019545,2,6,Premise,Claim,support,"PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042).","Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC."
24019545,3,1,Premise,MajorClaim,none,"The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105).","Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3."
24019545,3,2,Premise,Premise,none,"The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105).","PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042)."
24019545,3,4,Premise,Premise,none,"The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105).",Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).
24019545,3,5,Premise,Premise,none,"The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105).",AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).
24019545,3,6,Premise,Claim,support,"The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105).","Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC."
24019545,4,1,Premise,MajorClaim,none,Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).,"Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3."
24019545,4,2,Premise,Premise,none,Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).,"PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042)."
24019545,4,3,Premise,Premise,none,Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).,"The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105)."
24019545,4,5,Premise,Premise,none,Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).,AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).
24019545,4,6,Premise,Claim,support,Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).,"Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC."
24019545,5,1,Premise,MajorClaim,none,AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).,"Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3."
24019545,5,2,Premise,Premise,none,AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).,"PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042)."
24019545,5,3,Premise,Premise,none,AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).,"The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105)."
24019545,5,4,Premise,Premise,none,AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).,Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).
24019545,5,6,Premise,Claim,support,AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).,"Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC."
24019545,6,1,Claim,MajorClaim,none,"Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC.","Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3."
24019545,6,2,Claim,Premise,none,"Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC.","PFS was longer with tivozanib than with sorafenib in the overall population (median, 11.9 v 9.1 months; hazard ratio [HR], 0.797; 95% CI, 0.639 to 0.993; P = .042)."
24019545,6,3,Claim,Premise,none,"Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC.","The final overall survival (OS) analysis showed a trend toward longer survival on the sorafenib arm than on the tivozanib arm (median, 29.3 v 28.8 months; HR, 1.245; 95% CI, 0.954 to 1.624; P = .105)."
24019545,6,4,Claim,Premise,none,"Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC.",Adverse events (AEs) more common with tivozanib than with sorafenib were hypertension (44% v 34%) and dysphonia (21% v 5%).
24019545,6,5,Claim,Premise,none,"Tivozanib demonstrated improved PFS, but not OS, and a differentiated safety profile, compared with sorafenib, as initial targeted therapy for metastatic RCC.",AEs more common with sorafenib than with tivozanib were hand-foot skin reaction (54% v 14%) and diarrhea (33% v 23%).
17690882,1,2,Premise,Premise,none,"Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema.",KPS was improved from baseline to post-chemotherapy in both arms.
17690882,1,3,Premise,Premise,none,"Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema.","QOL data showed improvement in some symptom scores,"
17690882,1,4,Premise,Premise,none,"Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema.",but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.
17690882,1,5,Premise,Premise,none,"Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema.","Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%)."
17690882,1,6,Premise,Premise,none,"Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema.","Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months)."
17690882,1,7,Premise,Claim,support,"Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema.",Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.
17690882,1,8,Premise,Claim,none,"Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema.","The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation"
17690882,2,1,Premise,Premise,none,KPS was improved from baseline to post-chemotherapy in both arms.,"Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema."
17690882,2,3,Premise,Premise,none,KPS was improved from baseline to post-chemotherapy in both arms.,"QOL data showed improvement in some symptom scores,"
17690882,2,4,Premise,Premise,none,KPS was improved from baseline to post-chemotherapy in both arms.,but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.
17690882,2,5,Premise,Premise,none,KPS was improved from baseline to post-chemotherapy in both arms.,"Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%)."
17690882,2,6,Premise,Premise,none,KPS was improved from baseline to post-chemotherapy in both arms.,"Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months)."
17690882,2,7,Premise,Claim,support,KPS was improved from baseline to post-chemotherapy in both arms.,Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.
17690882,2,8,Premise,Claim,none,KPS was improved from baseline to post-chemotherapy in both arms.,"The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation"
17690882,3,1,Premise,Premise,none,"QOL data showed improvement in some symptom scores,","Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema."
17690882,3,2,Premise,Premise,none,"QOL data showed improvement in some symptom scores,",KPS was improved from baseline to post-chemotherapy in both arms.
17690882,3,4,Premise,Premise,none,"QOL data showed improvement in some symptom scores,",but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.
17690882,3,5,Premise,Premise,none,"QOL data showed improvement in some symptom scores,","Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%)."
17690882,3,6,Premise,Premise,none,"QOL data showed improvement in some symptom scores,","Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months)."
17690882,3,7,Premise,Claim,support,"QOL data showed improvement in some symptom scores,",Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.
17690882,3,8,Premise,Claim,none,"QOL data showed improvement in some symptom scores,","The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation"
17690882,4,1,Premise,Premise,none,but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.,"Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema."
17690882,4,2,Premise,Premise,none,but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.,KPS was improved from baseline to post-chemotherapy in both arms.
17690882,4,3,Premise,Premise,attack,but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.,"QOL data showed improvement in some symptom scores,"
17690882,4,5,Premise,Premise,none,but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.,"Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%)."
17690882,4,6,Premise,Premise,none,but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.,"Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months)."
17690882,4,7,Premise,Claim,none,but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.,Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.
17690882,4,8,Premise,Claim,none,but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.,"The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation"
17690882,5,1,Premise,Premise,none,"Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%).","Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema."
17690882,5,2,Premise,Premise,none,"Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%).",KPS was improved from baseline to post-chemotherapy in both arms.
17690882,5,3,Premise,Premise,none,"Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%).","QOL data showed improvement in some symptom scores,"
17690882,5,4,Premise,Premise,none,"Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%).",but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.
17690882,5,6,Premise,Premise,none,"Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%).","Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months)."
17690882,5,7,Premise,Claim,none,"Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%).",Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.
17690882,5,8,Premise,Claim,support,"Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%).","The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation"
17690882,6,1,Premise,Premise,none,"Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months).","Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema."
17690882,6,2,Premise,Premise,none,"Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months).",KPS was improved from baseline to post-chemotherapy in both arms.
17690882,6,3,Premise,Premise,none,"Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months).","QOL data showed improvement in some symptom scores,"
17690882,6,4,Premise,Premise,none,"Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months).",but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.
17690882,6,5,Premise,Premise,none,"Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months).","Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%)."
17690882,6,7,Premise,Claim,none,"Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months).",Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.
17690882,6,8,Premise,Claim,support,"Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months).","The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation"
17690882,7,1,Claim,Premise,none,Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.,"Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema."
17690882,7,2,Claim,Premise,none,Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.,KPS was improved from baseline to post-chemotherapy in both arms.
17690882,7,3,Claim,Premise,none,Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.,"QOL data showed improvement in some symptom scores,"
17690882,7,4,Claim,Premise,none,Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.,but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.
17690882,7,5,Claim,Premise,none,Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.,"Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%)."
17690882,7,6,Claim,Premise,none,Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.,"Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months)."
17690882,7,8,Claim,Claim,none,Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.,"The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation"
17690882,8,1,Claim,Premise,none,"The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation","Eighteen patients experienced brief and reversible adverse events during transfusion, including two patients with acute pulmonary edema."
17690882,8,2,Claim,Premise,none,"The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation",KPS was improved from baseline to post-chemotherapy in both arms.
17690882,8,3,Claim,Premise,none,"The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation","QOL data showed improvement in some symptom scores,"
17690882,8,4,Claim,Premise,none,"The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation",but there was no difference in the QOL scores between the two arms at baseline and all four cycles of treatment.
17690882,8,5,Claim,Premise,none,"The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation","Similar response rates were observed in both arms (arm 1, 30%; arm 2, 35%)."
17690882,8,6,Claim,Premise,none,"The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation","Both arms showed similar chemotherapy duration (3.8 and 4.1 months, respectively), progression-free survival (4.0 and 4.1 months) and overall survival (9.9 and 9.3 months)."
17690882,8,7,Claim,Claim,none,"The observation of equivalent outcomes at the two target Hb levels supports the feasibility of anemia correction to Hb 10 g/dl, which merits further evaluation",Red blood cell transfusion achieving Hb level above 10 g/dl might contribute to the improvement of the KPS and QOL seen in patients with AGC.
9626213,1,2,Premise,Premise,none,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays.","There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B."
9626213,1,3,Premise,Premise,none,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays.","In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B."
9626213,1,4,Premise,Claim,attack,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays.",The frequency and severity of other toxicities were comparable between the two arms.
9626213,1,5,Premise,Premise,none,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays.",Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).
9626213,1,6,Premise,Premise,none,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays.","There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B."
9626213,1,7,Premise,Premise,none,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays.","Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively."
9626213,1,8,Premise,Premise,none,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays.","Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks."
9626213,1,9,Premise,Claim,none,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays.","In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL."
9626213,1,10,Premise,Claim,none,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays.","Although survival was not improved,"
9626213,1,11,Premise,Claim,none,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays.",arm B offers a better palliation for advanced NSCLC patients than arm A.
9626213,2,1,Premise,Premise,none,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.","Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays."
9626213,2,3,Premise,Premise,none,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.","In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B."
9626213,2,4,Premise,Claim,support,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.",The frequency and severity of other toxicities were comparable between the two arms.
9626213,2,5,Premise,Premise,none,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.",Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).
9626213,2,6,Premise,Premise,none,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.","There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B."
9626213,2,7,Premise,Premise,none,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.","Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively."
9626213,2,8,Premise,Premise,none,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.","Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks."
9626213,2,9,Premise,Claim,none,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.","In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL."
9626213,2,10,Premise,Claim,none,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.","Although survival was not improved,"
9626213,2,11,Premise,Claim,none,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B.",arm B offers a better palliation for advanced NSCLC patients than arm A.
9626213,3,1,Premise,Premise,none,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B.","Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays."
9626213,3,2,Premise,Premise,none,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B.","There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B."
9626213,3,4,Premise,Claim,attack,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B.",The frequency and severity of other toxicities were comparable between the two arms.
9626213,3,5,Premise,Premise,none,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B.",Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).
9626213,3,6,Premise,Premise,none,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B.","There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B."
9626213,3,7,Premise,Premise,none,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B.","Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively."
9626213,3,8,Premise,Premise,none,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B.","Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks."
9626213,3,9,Premise,Claim,none,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B.","In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL."
9626213,3,10,Premise,Claim,none,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B.","Although survival was not improved,"
9626213,3,11,Premise,Claim,none,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B.",arm B offers a better palliation for advanced NSCLC patients than arm A.
9626213,4,1,Claim,Premise,none,The frequency and severity of other toxicities were comparable between the two arms.,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays."
9626213,4,2,Claim,Premise,none,The frequency and severity of other toxicities were comparable between the two arms.,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B."
9626213,4,3,Claim,Premise,none,The frequency and severity of other toxicities were comparable between the two arms.,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B."
9626213,4,5,Claim,Premise,none,The frequency and severity of other toxicities were comparable between the two arms.,Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).
9626213,4,6,Claim,Premise,none,The frequency and severity of other toxicities were comparable between the two arms.,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B."
9626213,4,7,Claim,Premise,none,The frequency and severity of other toxicities were comparable between the two arms.,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively."
9626213,4,8,Claim,Premise,none,The frequency and severity of other toxicities were comparable between the two arms.,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks."
9626213,4,9,Claim,Claim,none,The frequency and severity of other toxicities were comparable between the two arms.,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL."
9626213,4,10,Claim,Claim,none,The frequency and severity of other toxicities were comparable between the two arms.,"Although survival was not improved,"
9626213,4,11,Claim,Claim,none,The frequency and severity of other toxicities were comparable between the two arms.,arm B offers a better palliation for advanced NSCLC patients than arm A.
9626213,5,1,Premise,Premise,none,Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays."
9626213,5,2,Premise,Premise,none,Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B."
9626213,5,3,Premise,Premise,none,Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B."
9626213,5,4,Premise,Claim,none,Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).,The frequency and severity of other toxicities were comparable between the two arms.
9626213,5,6,Premise,Premise,none,Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B."
9626213,5,7,Premise,Premise,none,Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively."
9626213,5,8,Premise,Premise,none,Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks."
9626213,5,9,Premise,Claim,support,Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL."
9626213,5,10,Premise,Claim,none,Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).,"Although survival was not improved,"
9626213,5,11,Premise,Claim,none,Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).,arm B offers a better palliation for advanced NSCLC patients than arm A.
9626213,6,1,Premise,Premise,none,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B.","Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays."
9626213,6,2,Premise,Premise,none,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B.","There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B."
9626213,6,3,Premise,Premise,none,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B.","In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B."
9626213,6,4,Premise,Claim,none,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B.",The frequency and severity of other toxicities were comparable between the two arms.
9626213,6,5,Premise,Premise,none,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B.",Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).
9626213,6,7,Premise,Premise,none,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B.","Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively."
9626213,6,8,Premise,Premise,none,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B.","Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks."
9626213,6,9,Premise,Claim,none,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B.","In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL."
9626213,6,10,Premise,Claim,support,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B.","Although survival was not improved,"
9626213,6,11,Premise,Claim,none,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B.",arm B offers a better palliation for advanced NSCLC patients than arm A.
9626213,7,1,Premise,Premise,none,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively.","Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays."
9626213,7,2,Premise,Premise,none,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively.","There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B."
9626213,7,3,Premise,Premise,none,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively.","In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B."
9626213,7,4,Premise,Claim,none,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively.",The frequency and severity of other toxicities were comparable between the two arms.
9626213,7,5,Premise,Premise,none,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively.",Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).
9626213,7,6,Premise,Premise,none,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively.","There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B."
9626213,7,8,Premise,Premise,none,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively.","Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks."
9626213,7,9,Premise,Claim,none,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively.","In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL."
9626213,7,10,Premise,Claim,support,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively.","Although survival was not improved,"
9626213,7,11,Premise,Claim,none,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively.",arm B offers a better palliation for advanced NSCLC patients than arm A.
9626213,8,1,Premise,Premise,none,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks.","Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays."
9626213,8,2,Premise,Premise,none,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks.","There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B."
9626213,8,3,Premise,Premise,none,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks.","In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B."
9626213,8,4,Premise,Claim,none,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks.",The frequency and severity of other toxicities were comparable between the two arms.
9626213,8,5,Premise,Premise,none,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks.",Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).
9626213,8,6,Premise,Premise,none,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks.","There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B."
9626213,8,7,Premise,Premise,none,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks.","Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively."
9626213,8,9,Premise,Claim,support,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks.","In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL."
9626213,8,10,Premise,Claim,none,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks.","Although survival was not improved,"
9626213,8,11,Premise,Claim,none,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks.",arm B offers a better palliation for advanced NSCLC patients than arm A.
9626213,9,1,Claim,Premise,none,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL.","Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays."
9626213,9,2,Claim,Premise,none,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL.","There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B."
9626213,9,3,Claim,Premise,none,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL.","In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B."
9626213,9,4,Claim,Claim,none,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL.",The frequency and severity of other toxicities were comparable between the two arms.
9626213,9,5,Claim,Premise,none,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL.",Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).
9626213,9,6,Claim,Premise,none,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL.","There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B."
9626213,9,7,Claim,Premise,none,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL.","Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively."
9626213,9,8,Claim,Premise,none,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL.","Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks."
9626213,9,10,Claim,Claim,none,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL.","Although survival was not improved,"
9626213,9,11,Claim,Claim,none,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL.",arm B offers a better palliation for advanced NSCLC patients than arm A.
9626213,10,1,Claim,Premise,none,"Although survival was not improved,","Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays."
9626213,10,2,Claim,Premise,none,"Although survival was not improved,","There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B."
9626213,10,3,Claim,Premise,none,"Although survival was not improved,","In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B."
9626213,10,4,Claim,Claim,none,"Although survival was not improved,",The frequency and severity of other toxicities were comparable between the two arms.
9626213,10,5,Claim,Premise,none,"Although survival was not improved,",Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).
9626213,10,6,Claim,Premise,none,"Although survival was not improved,","There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B."
9626213,10,7,Claim,Premise,none,"Although survival was not improved,","Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively."
9626213,10,8,Claim,Premise,none,"Although survival was not improved,","Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks."
9626213,10,9,Claim,Claim,none,"Although survival was not improved,","In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL."
9626213,10,11,Claim,Claim,attack,"Although survival was not improved,",arm B offers a better palliation for advanced NSCLC patients than arm A.
9626213,11,1,Claim,Premise,none,arm B offers a better palliation for advanced NSCLC patients than arm A.,"Hematologic toxicity was significantly more severe in arm A (leukopenia, neutropenia, and thrombocytopenia grade 3 or 4: 66% v 19%, 83% v 55%, 36% v 2% in arms A and B, respectively), which resulted in more febrile neutropenia (27% v 3% in arms A and B, respectively), dose reductions, and treatment delays."
9626213,11,2,Claim,Premise,none,arm B offers a better palliation for advanced NSCLC patients than arm A.,"There were a total of nine toxic deaths, six due to neutropenic sepsis: five in arm A and one in arm B."
9626213,11,3,Claim,Premise,none,arm B offers a better palliation for advanced NSCLC patients than arm A.,"In contrast, arthralgia/myalgia (grade 2 or 3, 4% v 17%), peripheral neurotoxicity (grade 2 or 3, 6% v 29%), and hypersensitivity reactions (1% v 7%, all grades) were significantly more frequent in arm B."
9626213,11,4,Claim,Claim,none,arm B offers a better palliation for advanced NSCLC patients than arm A.,The frequency and severity of other toxicities were comparable between the two arms.
9626213,11,5,Claim,Premise,none,arm B offers a better palliation for advanced NSCLC patients than arm A.,Responses were one complete and 44 partial on arm A (28%) and two complete and 61 partial (41%) on arm B (P = .018).
9626213,11,6,Claim,Premise,none,arm B offers a better palliation for advanced NSCLC patients than arm A.,"There was no significant difference in survival, with median and 1-year survivals 9.9 versus 9.7 months and 41% versus 43%, respectively in arm A and B."
9626213,11,7,Claim,Premise,none,arm B offers a better palliation for advanced NSCLC patients than arm A.,"Progression-free survival was 4.9 and 5.4 months in arm A and B, respectively."
9626213,11,8,Claim,Premise,none,arm B offers a better palliation for advanced NSCLC patients than arm A.,"Arm B achieved a better score at week 6 for emotional, cognitive and social functioning, global health status, fatigue, and appetite loss, which was lost at 12 weeks."
9626213,11,9,Claim,Claim,none,arm B offers a better palliation for advanced NSCLC patients than arm A.,"In conclusion, arm B appears superior to arm A with regard to response rate, side effects, and QoL."
9626213,11,10,Claim,Claim,none,arm B offers a better palliation for advanced NSCLC patients than arm A.,"Although survival was not improved,"
12657097,1,2,Premise,Premise,none,"At radical prostatectomy, pathological variables were not significantly different in the two groups.","Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),"
12657097,1,3,Premise,Premise,none,"At radical prostatectomy, pathological variables were not significantly different in the two groups.","complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group."
12657097,1,4,Premise,Premise,none,"At radical prostatectomy, pathological variables were not significantly different in the two groups.","After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group."
12657097,1,5,Premise,Premise,none,"At radical prostatectomy, pathological variables were not significantly different in the two groups.","At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group."
12657097,1,6,Premise,Claim,none,"At radical prostatectomy, pathological variables were not significantly different in the two groups.",This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
12657097,2,1,Premise,Premise,none,"Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),","At radical prostatectomy, pathological variables were not significantly different in the two groups."
12657097,2,3,Premise,Premise,none,"Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),","complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group."
12657097,2,4,Premise,Premise,none,"Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),","After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group."
12657097,2,5,Premise,Premise,none,"Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),","At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group."
12657097,2,6,Premise,Claim,support,"Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),",This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
12657097,3,1,Premise,Premise,none,"complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.","At radical prostatectomy, pathological variables were not significantly different in the two groups."
12657097,3,2,Premise,Premise,none,"complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.","Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),"
12657097,3,4,Premise,Premise,none,"complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.","After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group."
12657097,3,5,Premise,Premise,none,"complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.","At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group."
12657097,3,6,Premise,Claim,support,"complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.",This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
12657097,4,1,Premise,Premise,none,"After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.","At radical prostatectomy, pathological variables were not significantly different in the two groups."
12657097,4,2,Premise,Premise,none,"After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.","Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),"
12657097,4,3,Premise,Premise,none,"After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.","complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group."
12657097,4,5,Premise,Premise,none,"After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.","At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group."
12657097,4,6,Premise,Claim,support,"After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.",This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
12657097,5,1,Premise,Premise,none,"At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.","At radical prostatectomy, pathological variables were not significantly different in the two groups."
12657097,5,2,Premise,Premise,none,"At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.","Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),"
12657097,5,3,Premise,Premise,none,"At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.","complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group."
12657097,5,4,Premise,Premise,none,"At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.","After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group."
12657097,5,6,Premise,Claim,support,"At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.",This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
12657097,6,1,Claim,Premise,none,This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.,"At radical prostatectomy, pathological variables were not significantly different in the two groups."
12657097,6,2,Claim,Premise,none,This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.,"Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),"
12657097,6,3,Claim,Premise,none,This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.,"complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group."
12657097,6,4,Claim,Premise,none,This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.,"After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group."
12657097,6,5,Claim,Premise,none,This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.,"At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group."
9643663,1,2,Premise,Premise,none,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.","In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%)."
9643663,1,3,Premise,Premise,none,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.",Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
9643663,1,4,Premise,Premise,none,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.",'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
9643663,1,5,Premise,Claim,none,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.","in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died."
9643663,1,6,Premise,Claim,none,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.",An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
9643663,1,7,Premise,Claim,support,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.",'Casodex' 150 mg is less effective than castration in patients with M1 disease.
9643663,1,8,Premise,Claim,none,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.",'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
9643663,1,9,Premise,MajorClaim,none,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.",Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
9643663,2,1,Premise,Premise,none,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).","At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks."
9643663,2,3,Premise,Premise,none,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).",Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
9643663,2,4,Premise,Premise,none,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).",'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
9643663,2,5,Premise,Claim,none,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).","in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died."
9643663,2,6,Premise,Claim,none,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).",An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
9643663,2,7,Premise,Claim,attack,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).",'Casodex' 150 mg is less effective than castration in patients with M1 disease.
9643663,2,8,Premise,Claim,support,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).",'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
9643663,2,9,Premise,MajorClaim,none,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).",Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
9643663,3,1,Premise,Premise,none,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks."
9643663,3,2,Premise,Premise,none,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%)."
9643663,3,4,Premise,Premise,none,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
9643663,3,5,Premise,Claim,none,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died."
9643663,3,6,Premise,Claim,none,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
9643663,3,7,Premise,Claim,none,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.,'Casodex' 150 mg is less effective than castration in patients with M1 disease.
9643663,3,8,Premise,Claim,support,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
9643663,3,9,Premise,MajorClaim,none,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
9643663,4,1,Premise,Premise,none,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks."
9643663,4,2,Premise,Premise,none,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%)."
9643663,4,3,Premise,Premise,none,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
9643663,4,5,Premise,Claim,none,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died."
9643663,4,6,Premise,Claim,none,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
9643663,4,7,Premise,Claim,none,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.,'Casodex' 150 mg is less effective than castration in patients with M1 disease.
9643663,4,8,Premise,Claim,support,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
9643663,4,9,Premise,MajorClaim,none,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
9643663,5,1,Claim,Premise,none,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.","At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks."
9643663,5,2,Claim,Premise,none,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.","In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%)."
9643663,5,3,Claim,Premise,none,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.",Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
9643663,5,4,Claim,Premise,none,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.",'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
9643663,5,6,Claim,Claim,none,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.",An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
9643663,5,7,Claim,Claim,none,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.",'Casodex' 150 mg is less effective than castration in patients with M1 disease.
9643663,5,8,Claim,Claim,none,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.",'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
9643663,5,9,Claim,MajorClaim,none,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.",Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
9643663,6,1,Claim,Premise,none,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks."
9643663,6,2,Claim,Premise,none,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%)."
9643663,6,3,Claim,Premise,none,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
9643663,6,4,Claim,Premise,none,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
9643663,6,5,Claim,Claim,none,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died."
9643663,6,7,Claim,Claim,none,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.,'Casodex' 150 mg is less effective than castration in patients with M1 disease.
9643663,6,8,Claim,Claim,none,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
9643663,6,9,Claim,MajorClaim,none,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
9643663,7,1,Claim,Premise,none,'Casodex' 150 mg is less effective than castration in patients with M1 disease.,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks."
9643663,7,2,Claim,Premise,none,'Casodex' 150 mg is less effective than castration in patients with M1 disease.,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%)."
9643663,7,3,Claim,Premise,none,'Casodex' 150 mg is less effective than castration in patients with M1 disease.,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
9643663,7,4,Claim,Premise,none,'Casodex' 150 mg is less effective than castration in patients with M1 disease.,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
9643663,7,5,Claim,Claim,none,'Casodex' 150 mg is less effective than castration in patients with M1 disease.,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died."
9643663,7,6,Claim,Claim,none,'Casodex' 150 mg is less effective than castration in patients with M1 disease.,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
9643663,7,8,Claim,Claim,none,'Casodex' 150 mg is less effective than castration in patients with M1 disease.,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
9643663,7,9,Claim,MajorClaim,none,'Casodex' 150 mg is less effective than castration in patients with M1 disease.,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
9643663,8,1,Claim,Premise,none,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks."
9643663,8,2,Claim,Premise,none,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%)."
9643663,8,3,Claim,Premise,none,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
9643663,8,4,Claim,Premise,none,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
9643663,8,5,Claim,Claim,none,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died."
9643663,8,6,Claim,Claim,none,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
9643663,8,7,Claim,Claim,none,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.,'Casodex' 150 mg is less effective than castration in patients with M1 disease.
9643663,8,9,Claim,MajorClaim,support,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
9643663,9,1,MajorClaim,Premise,none,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.,"At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks."
9643663,9,2,MajorClaim,Premise,none,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.,"In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%)."
9643663,9,3,MajorClaim,Premise,none,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.,Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
9643663,9,4,MajorClaim,Premise,none,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.,'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
9643663,9,5,MajorClaim,Claim,none,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.,"in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died."
9643663,9,6,MajorClaim,Claim,none,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.,An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
9643663,9,7,MajorClaim,Claim,none,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.,'Casodex' 150 mg is less effective than castration in patients with M1 disease.
9643663,9,8,MajorClaim,Claim,none,Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.,'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
15288288,1,2,Premise,Premise,none,"Dysphagia improved more rapidly after stent placement than after brachytherapy,",but long-term relief of dysphagia was better after brachytherapy.
15288288,1,3,Premise,Premise,none,"Dysphagia improved more rapidly after stent placement than after brachytherapy,","For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05)."
15288288,1,4,Premise,Premise,none,"Dysphagia improved more rapidly after stent placement than after brachytherapy,","Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up)."
15288288,1,5,Premise,Premise,none,"Dysphagia improved more rapidly after stent placement than after brachytherapy,",This decline was more pronounced in the stent group.
15288288,1,6,Premise,Premise,none,"Dysphagia improved more rapidly after stent placement than after brachytherapy,","Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up."
15288288,1,7,Premise,Premise,none,"Dysphagia improved more rapidly after stent placement than after brachytherapy,","Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,"
15288288,1,8,Premise,Premise,none,"Dysphagia improved more rapidly after stent placement than after brachytherapy,",general pain levels increased to a minor extent.
15288288,1,9,Premise,Claim,support,"Dysphagia improved more rapidly after stent placement than after brachytherapy,",The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.
15288288,1,10,Premise,Claim,none,"Dysphagia improved more rapidly after stent placement than after brachytherapy,","Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,"
15288288,1,11,Premise,Premise,none,"Dysphagia improved more rapidly after stent placement than after brachytherapy,",since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.
15288288,2,1,Premise,Premise,attack,but long-term relief of dysphagia was better after brachytherapy.,"Dysphagia improved more rapidly after stent placement than after brachytherapy,"
15288288,2,3,Premise,Premise,none,but long-term relief of dysphagia was better after brachytherapy.,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05)."
15288288,2,4,Premise,Premise,none,but long-term relief of dysphagia was better after brachytherapy.,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up)."
15288288,2,5,Premise,Premise,none,but long-term relief of dysphagia was better after brachytherapy.,This decline was more pronounced in the stent group.
15288288,2,6,Premise,Premise,none,but long-term relief of dysphagia was better after brachytherapy.,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up."
15288288,2,7,Premise,Premise,none,but long-term relief of dysphagia was better after brachytherapy.,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,"
15288288,2,8,Premise,Premise,none,but long-term relief of dysphagia was better after brachytherapy.,general pain levels increased to a minor extent.
15288288,2,9,Premise,Claim,none,but long-term relief of dysphagia was better after brachytherapy.,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.
15288288,2,10,Premise,Claim,none,but long-term relief of dysphagia was better after brachytherapy.,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,"
15288288,2,11,Premise,Premise,none,but long-term relief of dysphagia was better after brachytherapy.,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.
15288288,3,1,Premise,Premise,none,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05).","Dysphagia improved more rapidly after stent placement than after brachytherapy,"
15288288,3,2,Premise,Premise,none,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05).",but long-term relief of dysphagia was better after brachytherapy.
15288288,3,4,Premise,Premise,none,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05).","Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up)."
15288288,3,5,Premise,Premise,none,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05).",This decline was more pronounced in the stent group.
15288288,3,6,Premise,Premise,none,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05).","Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up."
15288288,3,7,Premise,Premise,none,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05).","Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,"
15288288,3,8,Premise,Premise,none,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05).",general pain levels increased to a minor extent.
15288288,3,9,Premise,Claim,support,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05).",The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.
15288288,3,10,Premise,Claim,none,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05).","Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,"
15288288,3,11,Premise,Premise,none,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05).",since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.
15288288,4,1,Premise,Premise,none,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up).","Dysphagia improved more rapidly after stent placement than after brachytherapy,"
15288288,4,2,Premise,Premise,none,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up).",but long-term relief of dysphagia was better after brachytherapy.
15288288,4,3,Premise,Premise,none,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up).","For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05)."
15288288,4,5,Premise,Premise,none,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up).",This decline was more pronounced in the stent group.
15288288,4,6,Premise,Premise,none,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up).","Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up."
15288288,4,7,Premise,Premise,none,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up).","Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,"
15288288,4,8,Premise,Premise,none,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up).",general pain levels increased to a minor extent.
15288288,4,9,Premise,Claim,support,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up).",The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.
15288288,4,10,Premise,Claim,none,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up).","Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,"
15288288,4,11,Premise,Premise,none,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up).",since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.
15288288,5,1,Premise,Premise,none,This decline was more pronounced in the stent group.,"Dysphagia improved more rapidly after stent placement than after brachytherapy,"
15288288,5,2,Premise,Premise,none,This decline was more pronounced in the stent group.,but long-term relief of dysphagia was better after brachytherapy.
15288288,5,3,Premise,Premise,none,This decline was more pronounced in the stent group.,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05)."
15288288,5,4,Premise,Premise,none,This decline was more pronounced in the stent group.,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up)."
15288288,5,6,Premise,Premise,none,This decline was more pronounced in the stent group.,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up."
15288288,5,7,Premise,Premise,none,This decline was more pronounced in the stent group.,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,"
15288288,5,8,Premise,Premise,none,This decline was more pronounced in the stent group.,general pain levels increased to a minor extent.
15288288,5,9,Premise,Claim,support,This decline was more pronounced in the stent group.,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.
15288288,5,10,Premise,Claim,none,This decline was more pronounced in the stent group.,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,"
15288288,5,11,Premise,Premise,none,This decline was more pronounced in the stent group.,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.
15288288,6,1,Premise,Premise,none,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up.","Dysphagia improved more rapidly after stent placement than after brachytherapy,"
15288288,6,2,Premise,Premise,none,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up.",but long-term relief of dysphagia was better after brachytherapy.
15288288,6,3,Premise,Premise,none,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up.","For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05)."
15288288,6,4,Premise,Premise,none,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up.","Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up)."
15288288,6,5,Premise,Premise,none,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up.",This decline was more pronounced in the stent group.
15288288,6,7,Premise,Premise,none,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up.","Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,"
15288288,6,8,Premise,Premise,none,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up.",general pain levels increased to a minor extent.
15288288,6,9,Premise,Claim,support,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up.",The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.
15288288,6,10,Premise,Claim,none,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up.","Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,"
15288288,6,11,Premise,Premise,none,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up.",since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.
15288288,7,1,Premise,Premise,none,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,","Dysphagia improved more rapidly after stent placement than after brachytherapy,"
15288288,7,2,Premise,Premise,none,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,",but long-term relief of dysphagia was better after brachytherapy.
15288288,7,3,Premise,Premise,none,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,","For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05)."
15288288,7,4,Premise,Premise,none,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,","Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up)."
15288288,7,5,Premise,Premise,none,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,",This decline was more pronounced in the stent group.
15288288,7,6,Premise,Premise,none,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,","Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up."
15288288,7,8,Premise,Premise,none,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,",general pain levels increased to a minor extent.
15288288,7,9,Premise,Claim,support,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,",The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.
15288288,7,10,Premise,Claim,none,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,","Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,"
15288288,7,11,Premise,Premise,none,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,",since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.
15288288,8,1,Premise,Premise,none,general pain levels increased to a minor extent.,"Dysphagia improved more rapidly after stent placement than after brachytherapy,"
15288288,8,2,Premise,Premise,none,general pain levels increased to a minor extent.,but long-term relief of dysphagia was better after brachytherapy.
15288288,8,3,Premise,Premise,none,general pain levels increased to a minor extent.,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05)."
15288288,8,4,Premise,Premise,none,general pain levels increased to a minor extent.,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up)."
15288288,8,5,Premise,Premise,none,general pain levels increased to a minor extent.,This decline was more pronounced in the stent group.
15288288,8,6,Premise,Premise,none,general pain levels increased to a minor extent.,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up."
15288288,8,7,Premise,Premise,none,general pain levels increased to a minor extent.,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,"
15288288,8,9,Premise,Claim,support,general pain levels increased to a minor extent.,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.
15288288,8,10,Premise,Claim,none,general pain levels increased to a minor extent.,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,"
15288288,8,11,Premise,Premise,none,general pain levels increased to a minor extent.,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.
15288288,9,1,Claim,Premise,none,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.,"Dysphagia improved more rapidly after stent placement than after brachytherapy,"
15288288,9,2,Claim,Premise,none,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.,but long-term relief of dysphagia was better after brachytherapy.
15288288,9,3,Claim,Premise,none,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05)."
15288288,9,4,Claim,Premise,none,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up)."
15288288,9,5,Claim,Premise,none,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.,This decline was more pronounced in the stent group.
15288288,9,6,Claim,Premise,none,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up."
15288288,9,7,Claim,Premise,none,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,"
15288288,9,8,Claim,Premise,none,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.,general pain levels increased to a minor extent.
15288288,9,10,Claim,Claim,none,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,"
15288288,9,11,Claim,Premise,none,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.
15288288,10,1,Claim,Premise,none,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,","Dysphagia improved more rapidly after stent placement than after brachytherapy,"
15288288,10,2,Claim,Premise,none,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,",but long-term relief of dysphagia was better after brachytherapy.
15288288,10,3,Claim,Premise,none,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,","For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05)."
15288288,10,4,Claim,Premise,none,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,","Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up)."
15288288,10,5,Claim,Premise,none,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,",This decline was more pronounced in the stent group.
15288288,10,6,Claim,Premise,none,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,","Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up."
15288288,10,7,Claim,Premise,none,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,","Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,"
15288288,10,8,Claim,Premise,none,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,",general pain levels increased to a minor extent.
15288288,10,9,Claim,Claim,attack,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,",The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.
15288288,10,11,Claim,Premise,none,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,",since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.
15288288,11,1,Premise,Premise,none,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.,"Dysphagia improved more rapidly after stent placement than after brachytherapy,"
15288288,11,2,Premise,Premise,none,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.,but long-term relief of dysphagia was better after brachytherapy.
15288288,11,3,Premise,Premise,none,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.,"For generic HRQoL, there was an overall significant difference in favour of brachytherapy on four out of five functional scales of the EORTC QLQ-C30 (role, emotional, cognitive and social) (P < 0.05)."
15288288,11,4,Premise,Premise,none,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.,"Generic HRQoL deteriorated over time on all functional scales of the EORTC QLQ C-30 and EQ-5D, in particular physical and role functioning (on average -23 and -24 on a 100 points scale during 0.5 years of follow-up)."
15288288,11,5,Premise,Premise,none,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.,This decline was more pronounced in the stent group.
15288288,11,6,Premise,Premise,none,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.,"Major improvements were seen on the dysphagia and eating scales of the EORTC OES-23, in contrast to other scales of this disease-specific measure, which remained almost stable during follow-up."
15288288,11,7,Premise,Premise,none,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.,"Reported levels of chest or abdominal pain remained stable during follow-up in both treatment groups,"
15288288,11,8,Premise,Premise,none,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.,general pain levels increased to a minor extent.
15288288,11,9,Premise,Claim,none,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.,The effects of single dose brachytherapy on HRQoL compared favourably to those of stent placement for the palliation of oesophageal cancer.
15288288,11,10,Premise,Claim,support,since these were more responsive in measuring patients' functioning and well-being during follow-up than disease-specific HRQoL scales.,"Future studies on palliative care for oesophageal cancer should at least include generic HRQoL scales,"
15274068,1,2,Claim,Premise,none,Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.,Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.
15274068,1,3,Claim,Premise,none,Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.,There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).
15274068,1,4,Claim,Premise,none,Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203)."
15274068,1,5,Claim,Premise,none,Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003)."
15274068,1,6,Claim,Premise,none,Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.,Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.
15274068,1,7,Claim,Claim,none,Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue."
15274068,1,8,Claim,Claim,none,Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.,Improved physical functioning may be necessary to combat radiation fatigue.
15274068,2,1,Premise,Claim,none,Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.,Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.
15274068,2,3,Premise,Premise,none,Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.,There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).
15274068,2,4,Premise,Premise,none,Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203)."
15274068,2,5,Premise,Premise,none,Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003)."
15274068,2,6,Premise,Premise,none,Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.,Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.
15274068,2,7,Premise,Claim,none,Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue."
15274068,2,8,Premise,Claim,none,Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.,Improved physical functioning may be necessary to combat radiation fatigue.
15274068,3,1,Premise,Claim,none,There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).,Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.
15274068,3,2,Premise,Premise,none,There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).,Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.
15274068,3,4,Premise,Premise,none,There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203)."
15274068,3,5,Premise,Premise,none,There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003)."
15274068,3,6,Premise,Premise,none,There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).,Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.
15274068,3,7,Premise,Claim,none,There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue."
15274068,3,8,Premise,Claim,none,There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).,Improved physical functioning may be necessary to combat radiation fatigue.
15274068,4,1,Premise,Claim,none,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203).",Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.
15274068,4,2,Premise,Premise,none,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203).",Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.
15274068,4,3,Premise,Premise,none,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203).",There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).
15274068,4,5,Premise,Premise,none,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203).","A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003)."
15274068,4,6,Premise,Premise,none,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203).",Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.
15274068,4,7,Premise,Claim,support,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203).","Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue."
15274068,4,8,Premise,Claim,none,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203).",Improved physical functioning may be necessary to combat radiation fatigue.
15274068,5,1,Premise,Claim,none,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003).",Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.
15274068,5,2,Premise,Premise,none,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003).",Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.
15274068,5,3,Premise,Premise,none,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003).",There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).
15274068,5,4,Premise,Premise,none,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003).","Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203)."
15274068,5,6,Premise,Premise,none,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003).",Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.
15274068,5,7,Premise,Claim,support,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003).","Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue."
15274068,5,8,Premise,Claim,none,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003).",Improved physical functioning may be necessary to combat radiation fatigue.
15274068,6,1,Premise,Claim,none,Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.,Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.
15274068,6,2,Premise,Premise,none,Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.,Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.
15274068,6,3,Premise,Premise,none,Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.,There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).
15274068,6,4,Premise,Premise,none,Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203)."
15274068,6,5,Premise,Premise,none,Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003)."
15274068,6,7,Premise,Claim,none,Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue."
15274068,6,8,Premise,Claim,support,Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.,Improved physical functioning may be necessary to combat radiation fatigue.
15274068,7,1,Claim,Claim,none,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue.",Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.
15274068,7,2,Claim,Premise,none,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue.",Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.
15274068,7,3,Claim,Premise,none,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue.",There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).
15274068,7,4,Claim,Premise,none,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue.","Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203)."
15274068,7,5,Claim,Premise,none,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue.","A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003)."
15274068,7,6,Claim,Premise,none,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue.",Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.
15274068,7,8,Claim,Claim,support,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue.",Improved physical functioning may be necessary to combat radiation fatigue.
15274068,8,1,Claim,Claim,none,Improved physical functioning may be necessary to combat radiation fatigue.,Advice to rest and take things easy if patients become fatigued during radiotherapy may be detrimental.
15274068,8,2,Claim,Premise,none,Improved physical functioning may be necessary to combat radiation fatigue.,Aerobic walking improves physical functioning and has been an intervention for chemotherapy-related fatigue.
15274068,8,3,Claim,Premise,none,Improved physical functioning may be necessary to combat radiation fatigue.,There were no significant between group differences noted with regard to fatigue scores at baseline (P = 0.55) or after 4 weeks of radiotherapy (P = 0.18).
15274068,8,4,Claim,Premise,none,Improved physical functioning may be necessary to combat radiation fatigue.,"Men in the control group had significant increases in fatigue scores from baseline to the end of radiotherapy (P = 0.013), with no significant increases observed in the exercise group (P = 0.203)."
15274068,8,5,Claim,Premise,none,Improved physical functioning may be necessary to combat radiation fatigue.,"A nonsignificant reduction (2.4%) in shuttle test distance at the end of radiotherapy was observed in the control group; however, in the exercise group, there was a significant increase (13.2%) in distance walked (P = 0.0003)."
15274068,8,6,Claim,Premise,none,Improved physical functioning may be necessary to combat radiation fatigue.,Men who followed advice to rest and take things easy if they became fatigued demonstrated a slight deterioration in physical functioning and a significant increase in fatigue at the end of radiotherapy.
15274068,8,7,Claim,Claim,none,Improved physical functioning may be necessary to combat radiation fatigue.,"Home-based, moderate-intensity walking produced a significant improvement in physical functioning with no significant increase in fatigue."
12721239,1,2,Premise,Premise,none,"Peak oxygen consumption increased by 0.24 L/min in the exercise group,","whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001)."
12721239,1,3,Premise,Premise,none,"Peak oxygen consumption increased by 0.24 L/min in the exercise group,","Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001)."
12721239,1,4,Premise,Premise,none,"Peak oxygen consumption increased by 0.24 L/min in the exercise group,",Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).
12721239,1,5,Premise,Claim,support,"Peak oxygen consumption increased by 0.24 L/min in the exercise group,",Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.
12721239,2,1,Premise,Premise,none,"whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).","Peak oxygen consumption increased by 0.24 L/min in the exercise group,"
12721239,2,3,Premise,Premise,none,"whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).","Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001)."
12721239,2,4,Premise,Premise,none,"whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).",Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).
12721239,2,5,Premise,Claim,support,"whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001).",Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.
12721239,3,1,Premise,Premise,none,"Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).","Peak oxygen consumption increased by 0.24 L/min in the exercise group,"
12721239,3,2,Premise,Premise,none,"Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).","whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001)."
12721239,3,4,Premise,Premise,none,"Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).",Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).
12721239,3,5,Premise,Claim,support,"Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001).",Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.
12721239,4,1,Premise,Premise,none,Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).,"Peak oxygen consumption increased by 0.24 L/min in the exercise group,"
12721239,4,2,Premise,Premise,none,Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).,"whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001)."
12721239,4,3,Premise,Premise,none,Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).,"Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001)."
12721239,4,5,Premise,Claim,support,Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).,Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.
12721239,5,1,Claim,Premise,none,Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.,"Peak oxygen consumption increased by 0.24 L/min in the exercise group,"
12721239,5,2,Claim,Premise,none,Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.,"whereas it decreased by 0.05 L/min in the control group (mean difference, 0.29 L/min; 95% confidence interval [CI], 0.18 to 0.40; P <.001)."
12721239,5,3,Claim,Premise,none,Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.,"Overall QOL increased by 9.1 points in the exercise group compared with 0.3 points in the control group (mean difference, 8.8 points; 95% CI, 3.6 to 14.0; P =.001)."
12721239,5,4,Claim,Premise,none,Exercise training had beneficial effects on cardiopulmonary function and QOL in postmenopausal breast cancer survivors.,Pearson correlations indicated that change in peak oxygen consumption correlated with change in overall QOL (r = 0.45; P <.01).
11387359,1,2,Premise,Premise,none,"Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).","Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients."
11387359,1,3,Premise,Premise,none,"Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).","Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),"
11387359,1,4,Premise,Premise,none,"Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).",Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.
11387359,1,5,Premise,Premise,none,"Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).",Adverse events were comparable between groups.
11387359,1,6,Premise,Claim,support,"Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).",Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.
11387359,1,7,Premise,Claim,none,"Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001).",Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
11387359,2,1,Premise,Premise,none,"Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.","Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001)."
11387359,2,3,Premise,Premise,none,"Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.","Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),"
11387359,2,4,Premise,Premise,none,"Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.",Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.
11387359,2,5,Premise,Premise,none,"Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.",Adverse events were comparable between groups.
11387359,2,6,Premise,Claim,support,"Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.",Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.
11387359,2,7,Premise,Claim,none,"Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients.",Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
11387359,3,1,Premise,Premise,none,"Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),","Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001)."
11387359,3,2,Premise,Premise,none,"Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),","Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients."
11387359,3,4,Premise,Premise,none,"Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),",Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.
11387359,3,5,Premise,Premise,none,"Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),",Adverse events were comparable between groups.
11387359,3,6,Premise,Claim,none,"Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),",Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.
11387359,3,7,Premise,Claim,support,"Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),",Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
11387359,4,1,Premise,Premise,none,Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.,"Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001)."
11387359,4,2,Premise,Premise,none,Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.,"Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients."
11387359,4,3,Premise,Premise,none,Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.,"Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),"
11387359,4,5,Premise,Premise,none,Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.,Adverse events were comparable between groups.
11387359,4,6,Premise,Claim,support,Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.,Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.
11387359,4,7,Premise,Claim,none,Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.,Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
11387359,5,1,Premise,Premise,none,Adverse events were comparable between groups.,"Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001)."
11387359,5,2,Premise,Premise,none,Adverse events were comparable between groups.,"Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients."
11387359,5,3,Premise,Premise,none,Adverse events were comparable between groups.,"Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),"
11387359,5,4,Premise,Premise,none,Adverse events were comparable between groups.,Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.
11387359,5,6,Premise,Claim,support,Adverse events were comparable between groups.,Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.
11387359,5,7,Premise,Claim,none,Adverse events were comparable between groups.,Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
11387359,6,1,Claim,Premise,none,Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.,"Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001)."
11387359,6,2,Claim,Premise,none,Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.,"Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients."
11387359,6,3,Claim,Premise,none,Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.,"Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),"
11387359,6,4,Claim,Premise,none,Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.,Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.
11387359,6,5,Claim,Premise,none,Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.,Adverse events were comparable between groups.
11387359,6,7,Claim,Claim,none,Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.,Encouraging results regarding increased survival warrant another trial designed to confirm these findings.
11387359,7,1,Claim,Premise,none,Encouraging results regarding increased survival warrant another trial designed to confirm these findings.,"Epoetin alfa, compared with placebo, significantly decreased transfusion requirements (P =.0057) and increased hemoglobin (P <.001)."
11387359,7,2,Claim,Premise,none,Encouraging results regarding increased survival warrant another trial designed to confirm these findings.,"Improvement of all primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue, was significantly (P <.01) greater for epoetin alfa versus placebo patients."
11387359,7,3,Claim,Premise,none,Encouraging results regarding increased survival warrant another trial designed to confirm these findings.,"Kaplan-Meier estimates showed a trend in overall survival favoring epoetin alfa (P =.13, log-rank test),"
11387359,7,4,Claim,Premise,none,Encouraging results regarding increased survival warrant another trial designed to confirm these findings.,Cox regression analysis showed an estimated hazards ratio of 1.309 (P =.052) favoring epoetin alfa.
11387359,7,5,Claim,Premise,none,Encouraging results regarding increased survival warrant another trial designed to confirm these findings.,Adverse events were comparable between groups.
11387359,7,6,Claim,Claim,none,Encouraging results regarding increased survival warrant another trial designed to confirm these findings.,Epoetin alfa safely and effectively ameliorates anemia and significantly improves QOL in cancer patients receiving nonplatinum chemotherapy.
15251160,1,2,Claim,Premise,none,Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.,Ibandronate was generally well tolerated.
15251160,1,3,Claim,Premise,none,Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.,"Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,"
15251160,1,4,Claim,Premise,none,Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.,"but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001)."
15251160,1,5,Claim,Premise,none,Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.,A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.
15251160,1,6,Claim,Premise,none,Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.,"Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05)."
15251160,1,7,Claim,Premise,none,Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.,Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.
15251160,1,8,Claim,Claim,none,Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.,"I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer."
15251160,2,1,Premise,Claim,none,Ibandronate was generally well tolerated.,Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.
15251160,2,3,Premise,Premise,none,Ibandronate was generally well tolerated.,"Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,"
15251160,2,4,Premise,Premise,none,Ibandronate was generally well tolerated.,"but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001)."
15251160,2,5,Premise,Premise,none,Ibandronate was generally well tolerated.,A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.
15251160,2,6,Premise,Premise,none,Ibandronate was generally well tolerated.,"Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05)."
15251160,2,7,Premise,Premise,none,Ibandronate was generally well tolerated.,Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.
15251160,2,8,Premise,Claim,support,Ibandronate was generally well tolerated.,"I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer."
15251160,3,1,Premise,Claim,none,"Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,",Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.
15251160,3,2,Premise,Premise,none,"Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,",Ibandronate was generally well tolerated.
15251160,3,4,Premise,Premise,none,"Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,","but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001)."
15251160,3,5,Premise,Premise,none,"Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,",A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.
15251160,3,6,Premise,Premise,none,"Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,","Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05)."
15251160,3,7,Premise,Premise,none,"Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,",Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.
15251160,3,8,Premise,Claim,support,"Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,","I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer."
15251160,4,1,Premise,Claim,none,"but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001).",Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.
15251160,4,2,Premise,Premise,none,"but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001).",Ibandronate was generally well tolerated.
15251160,4,3,Premise,Premise,attack,"but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001).","Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,"
15251160,4,5,Premise,Premise,none,"but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001).",A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.
15251160,4,6,Premise,Premise,none,"but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001).","Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05)."
15251160,4,7,Premise,Premise,none,"but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001).",Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.
15251160,4,8,Premise,Claim,none,"but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001).","I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer."
15251160,5,1,Premise,Claim,none,A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.,Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.
15251160,5,2,Premise,Premise,none,A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.,Ibandronate was generally well tolerated.
15251160,5,3,Premise,Premise,none,A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.,"Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,"
15251160,5,4,Premise,Premise,none,A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.,"but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001)."
15251160,5,6,Premise,Premise,none,A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.,"Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05)."
15251160,5,7,Premise,Premise,none,A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.,Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.
15251160,5,8,Premise,Claim,support,A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.,"I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer."
15251160,6,1,Premise,Claim,none,"Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05).",Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.
15251160,6,2,Premise,Premise,none,"Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05).",Ibandronate was generally well tolerated.
15251160,6,3,Premise,Premise,none,"Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05).","Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,"
15251160,6,4,Premise,Premise,none,"Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05).","but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001)."
15251160,6,5,Premise,Premise,none,"Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05).",A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.
15251160,6,7,Premise,Premise,none,"Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05).",Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.
15251160,6,8,Premise,Claim,support,"Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05).","I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer."
15251160,7,1,Premise,Claim,none,Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.,Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.
15251160,7,2,Premise,Premise,none,Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.,Ibandronate was generally well tolerated.
15251160,7,3,Premise,Premise,none,Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.,"Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,"
15251160,7,4,Premise,Premise,none,Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.,"but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001)."
15251160,7,5,Premise,Premise,none,Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.,A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.
15251160,7,6,Premise,Premise,none,Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.,"Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05)."
15251160,7,8,Premise,Claim,support,Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.,"I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer."
15251160,8,1,Claim,Claim,none,"I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer.",Bone metastases occur in most women with advanced breast cancer and can lead to considerable morbidity and a rapid deterioration in the patient's quality of life.
15251160,8,2,Claim,Premise,none,"I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer.",Ibandronate was generally well tolerated.
15251160,8,3,Claim,Premise,none,"I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer.","Compared with baseline measurements, the bone pain score was increased at the last assessment in both the placebo and 2 mg ibandronate groups,"
15251160,8,4,Claim,Premise,none,"I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer.","but was significantly reduced in the patients receiving 6 mg ibandronate (-0.28+/-1.11, P < 0.001)."
15251160,8,5,Claim,Premise,none,"I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer.",A significant improvement in quality of life was demonstrated for patients treated with ibandronate (P < 0.05) for all global health status.
15251160,8,6,Claim,Premise,none,"I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer.","Overall, at the last assessment, the 6 mg ibandronate group showed significantly better functioning compared with placebo (P = 0.004), and had significantly better scores on the domains of physical, emotional, and social functioning, and in global health status (P < 0.05)."
15251160,8,7,Claim,Premise,none,"I.v. ibandronate treatment leads to significant improvements in quality of life, and is an effective and well-tolerated palliative treatment in patients with bone metastases due to breast cancer.",Significant improvements in the symptoms of fatigue and pain were also observed in the 6 mg ibandronate group.
12118027,1,2,Premise,Premise,none,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
12118027,1,3,Premise,Premise,none,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
12118027,1,4,Premise,Premise,none,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).,Toxicities in both arms were mild.
12118027,1,5,Premise,Premise,none,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen."
12118027,1,6,Premise,Premise,none,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).,No patients developed hemolytic uremic syndrome.
12118027,1,7,Premise,Claim,none,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,"
12118027,1,8,Premise,Premise,none,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).,although there was no statistically significant difference in QOL between arms.
12118027,1,9,Premise,Claim,support,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,"
12118027,1,10,Premise,Claim,none,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).,but this did not translate into a survival advantage.
12118027,1,11,Premise,Claim,none,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
12118027,2,1,Premise,Premise,none,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
12118027,2,3,Premise,Premise,none,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
12118027,2,4,Premise,Premise,none,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).,Toxicities in both arms were mild.
12118027,2,5,Premise,Premise,none,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen."
12118027,2,6,Premise,Premise,none,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).,No patients developed hemolytic uremic syndrome.
12118027,2,7,Premise,Claim,none,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,"
12118027,2,8,Premise,Premise,none,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).,although there was no statistically significant difference in QOL between arms.
12118027,2,9,Premise,Claim,none,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,"
12118027,2,10,Premise,Claim,support,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).,but this did not translate into a survival advantage.
12118027,2,11,Premise,Claim,none,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
12118027,3,1,Premise,Premise,none,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
12118027,3,2,Premise,Premise,none,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
12118027,3,4,Premise,Premise,none,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).,Toxicities in both arms were mild.
12118027,3,5,Premise,Premise,none,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen."
12118027,3,6,Premise,Premise,none,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).,No patients developed hemolytic uremic syndrome.
12118027,3,7,Premise,Claim,none,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,"
12118027,3,8,Premise,Premise,none,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).,although there was no statistically significant difference in QOL between arms.
12118027,3,9,Premise,Claim,none,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,"
12118027,3,10,Premise,Claim,support,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).,but this did not translate into a survival advantage.
12118027,3,11,Premise,Claim,none,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
12118027,4,1,Premise,Premise,none,Toxicities in both arms were mild.,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
12118027,4,2,Premise,Premise,none,Toxicities in both arms were mild.,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
12118027,4,3,Premise,Premise,none,Toxicities in both arms were mild.,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
12118027,4,5,Premise,Premise,none,Toxicities in both arms were mild.,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen."
12118027,4,6,Premise,Premise,none,Toxicities in both arms were mild.,No patients developed hemolytic uremic syndrome.
12118027,4,7,Premise,Claim,none,Toxicities in both arms were mild.,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,"
12118027,4,8,Premise,Premise,none,Toxicities in both arms were mild.,although there was no statistically significant difference in QOL between arms.
12118027,4,9,Premise,Claim,none,Toxicities in both arms were mild.,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,"
12118027,4,10,Premise,Claim,none,Toxicities in both arms were mild.,but this did not translate into a survival advantage.
12118027,4,11,Premise,Claim,none,Toxicities in both arms were mild.,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
12118027,5,1,Premise,Premise,none,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.",The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
12118027,5,2,Premise,Premise,none,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.",Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
12118027,5,3,Premise,Premise,none,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.",Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
12118027,5,4,Premise,Premise,none,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.",Toxicities in both arms were mild.
12118027,5,6,Premise,Premise,none,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.",No patients developed hemolytic uremic syndrome.
12118027,5,7,Premise,Claim,none,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.","Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,"
12118027,5,8,Premise,Premise,none,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.",although there was no statistically significant difference in QOL between arms.
12118027,5,9,Premise,Claim,none,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.","PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,"
12118027,5,10,Premise,Claim,none,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.",but this did not translate into a survival advantage.
12118027,5,11,Premise,Claim,none,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen.",These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
12118027,6,1,Premise,Premise,none,No patients developed hemolytic uremic syndrome.,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
12118027,6,2,Premise,Premise,none,No patients developed hemolytic uremic syndrome.,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
12118027,6,3,Premise,Premise,none,No patients developed hemolytic uremic syndrome.,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
12118027,6,4,Premise,Premise,none,No patients developed hemolytic uremic syndrome.,Toxicities in both arms were mild.
12118027,6,5,Premise,Premise,none,No patients developed hemolytic uremic syndrome.,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen."
12118027,6,7,Premise,Claim,none,No patients developed hemolytic uremic syndrome.,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,"
12118027,6,8,Premise,Premise,none,No patients developed hemolytic uremic syndrome.,although there was no statistically significant difference in QOL between arms.
12118027,6,9,Premise,Claim,none,No patients developed hemolytic uremic syndrome.,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,"
12118027,6,10,Premise,Claim,none,No patients developed hemolytic uremic syndrome.,but this did not translate into a survival advantage.
12118027,6,11,Premise,Claim,none,No patients developed hemolytic uremic syndrome.,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
12118027,7,1,Claim,Premise,none,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,",The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
12118027,7,2,Claim,Premise,none,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,",Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
12118027,7,3,Claim,Premise,none,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,",Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
12118027,7,4,Claim,Premise,none,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,",Toxicities in both arms were mild.
12118027,7,5,Claim,Premise,none,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,","There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen."
12118027,7,6,Claim,Premise,none,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,",No patients developed hemolytic uremic syndrome.
12118027,7,8,Claim,Premise,none,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,",although there was no statistically significant difference in QOL between arms.
12118027,7,9,Claim,Claim,none,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,","PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,"
12118027,7,10,Claim,Claim,none,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,",but this did not translate into a survival advantage.
12118027,7,11,Claim,Claim,support,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,",These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
12118027,8,1,Premise,Premise,none,although there was no statistically significant difference in QOL between arms.,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
12118027,8,2,Premise,Premise,none,although there was no statistically significant difference in QOL between arms.,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
12118027,8,3,Premise,Premise,none,although there was no statistically significant difference in QOL between arms.,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
12118027,8,4,Premise,Premise,none,although there was no statistically significant difference in QOL between arms.,Toxicities in both arms were mild.
12118027,8,5,Premise,Premise,none,although there was no statistically significant difference in QOL between arms.,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen."
12118027,8,6,Premise,Premise,none,although there was no statistically significant difference in QOL between arms.,No patients developed hemolytic uremic syndrome.
12118027,8,7,Premise,Claim,attack,although there was no statistically significant difference in QOL between arms.,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,"
12118027,8,9,Premise,Claim,none,although there was no statistically significant difference in QOL between arms.,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,"
12118027,8,10,Premise,Claim,none,although there was no statistically significant difference in QOL between arms.,but this did not translate into a survival advantage.
12118027,8,11,Premise,Claim,none,although there was no statistically significant difference in QOL between arms.,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
12118027,9,1,Claim,Premise,none,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,",The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
12118027,9,2,Claim,Premise,none,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,",Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
12118027,9,3,Claim,Premise,none,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,",Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
12118027,9,4,Claim,Premise,none,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,",Toxicities in both arms were mild.
12118027,9,5,Claim,Premise,none,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,","There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen."
12118027,9,6,Claim,Premise,none,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,",No patients developed hemolytic uremic syndrome.
12118027,9,7,Claim,Claim,none,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,","Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,"
12118027,9,8,Claim,Premise,none,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,",although there was no statistically significant difference in QOL between arms.
12118027,9,10,Claim,Claim,none,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,",but this did not translate into a survival advantage.
12118027,9,11,Claim,Claim,support,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,",These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
12118027,10,1,Claim,Premise,none,but this did not translate into a survival advantage.,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
12118027,10,2,Claim,Premise,none,but this did not translate into a survival advantage.,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
12118027,10,3,Claim,Premise,none,but this did not translate into a survival advantage.,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
12118027,10,4,Claim,Premise,none,but this did not translate into a survival advantage.,Toxicities in both arms were mild.
12118027,10,5,Claim,Premise,none,but this did not translate into a survival advantage.,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen."
12118027,10,6,Claim,Premise,none,but this did not translate into a survival advantage.,No patients developed hemolytic uremic syndrome.
12118027,10,7,Claim,Claim,none,but this did not translate into a survival advantage.,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,"
12118027,10,8,Claim,Premise,none,but this did not translate into a survival advantage.,although there was no statistically significant difference in QOL between arms.
12118027,10,9,Claim,Claim,attack,but this did not translate into a survival advantage.,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,"
12118027,10,11,Claim,Claim,none,but this did not translate into a survival advantage.,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.
12118027,11,1,Claim,Premise,none,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.,The overall response rate was 8.4% (95% confidence interval [CI]) 3.2% to 13.7% for patients treated with PVI 5-FU alone compared with 17.6%; 95% CI 10.3% to 25.1% for PVI 5-FU plus MMC (P =.04).
12118027,11,2,Claim,Premise,none,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.,Median failure-free survival was 2.8 months for PVI 5-FU and 3.8 months for PVI 5-FU plus MMC (P =.14).
12118027,11,3,Claim,Premise,none,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.,Median survival was 5.1 months for PVI 5-FU and 6.5 months for PVI 5-FU plus MMC (P =.34).
12118027,11,4,Claim,Premise,none,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.,Toxicities in both arms were mild.
12118027,11,5,Claim,Premise,none,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.,"There was an increased incidence of neutropenia in the 5-FU plus MMC arm (P <.01), although no differences in infection were seen."
12118027,11,6,Claim,Premise,none,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.,No patients developed hemolytic uremic syndrome.
12118027,11,7,Claim,Claim,none,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.,"Global QOL improved significantly after 24 weeks of treatment compared with baseline for patients receiving 5-FU plus MMC,"
12118027,11,8,Claim,Premise,none,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.,although there was no statistically significant difference in QOL between arms.
12118027,11,9,Claim,Claim,none,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.,"PVI 5-FU plus MMC resulted in a superior response rate in comparison with PVI 5-FU alone in advanced pancreatic cancer,"
12118027,11,10,Claim,Claim,none,These results emphasize the importance of chemotherapy in this setting and the continuing value of the fluoropyrimidines in pancreatic cancer.,but this did not translate into a survival advantage.
15139072,1,2,MajorClaim,Premise,none,Research suggests that stress-reduction programs tailored to the cancer setting help patients cope with the effects of treatment and improve their quality of life.,Patients in the TY group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; P < 0.004).
15139072,1,3,MajorClaim,Premise,none,Research suggests that stress-reduction programs tailored to the cancer setting help patients cope with the effects of treatment and improve their quality of life.,"This included better subjective sleep quality (P < 0.02), faster sleep latency (P < 0.01), longer sleep duration (P < 0.03), and less use of sleep medications (P < 0.02)."
15139072,1,4,MajorClaim,Premise,none,Research suggests that stress-reduction programs tailored to the cancer setting help patients cope with the effects of treatment and improve their quality of life.,"There were no significant differences between groups in terms of intrusion or avoidance, state anxiety, depression, or fatigue."
15139072,1,5,MajorClaim,Claim,none,Research suggests that stress-reduction programs tailored to the cancer setting help patients cope with the effects of treatment and improve their quality of life.,The participation rates suggested that a TY program is feasible for patients with cancer and that such a program significantly improves sleep-related outcomes.
15139072,1,6,MajorClaim,Premise,none,Research suggests that stress-reduction programs tailored to the cancer setting help patients cope with the effects of treatment and improve their quality of life.,"However, there were no significant differences between groups for the other outcomes."
15139072,2,1,Premise,MajorClaim,none,Patients in the TY group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; P < 0.004).,Research suggests that stress-reduction programs tailored to the cancer setting help patients cope with the effects of treatment and improve their quality of life.
15139072,2,3,Premise,Premise,none,Patients in the TY group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; P < 0.004).,"This included better subjective sleep quality (P < 0.02), faster sleep latency (P < 0.01), longer sleep duration (P < 0.03), and less use of sleep medications (P < 0.02)."
15139072,2,4,Premise,Premise,none,Patients in the TY group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; P < 0.004).,"There were no significant differences between groups in terms of intrusion or avoidance, state anxiety, depression, or fatigue."
15139072,2,5,Premise,Claim,support,Patients in the TY group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; P < 0.004).,The participation rates suggested that a TY program is feasible for patients with cancer and that such a program significantly improves sleep-related outcomes.
15139072,2,6,Premise,Premise,none,Patients in the TY group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; P < 0.004).,"However, there were no significant differences between groups for the other outcomes."
15139072,3,1,Premise,MajorClaim,none,"This included better subjective sleep quality (P < 0.02), faster sleep latency (P < 0.01), longer sleep duration (P < 0.03), and less use of sleep medications (P < 0.02).",Research suggests that stress-reduction programs tailored to the cancer setting help patients cope with the effects of treatment and improve their quality of life.
15139072,3,2,Premise,Premise,none,"This included better subjective sleep quality (P < 0.02), faster sleep latency (P < 0.01), longer sleep duration (P < 0.03), and less use of sleep medications (P < 0.02).",Patients in the TY group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; P < 0.004).
15139072,3,4,Premise,Premise,none,"This included better subjective sleep quality (P < 0.02), faster sleep latency (P < 0.01), longer sleep duration (P < 0.03), and less use of sleep medications (P < 0.02).","There were no significant differences between groups in terms of intrusion or avoidance, state anxiety, depression, or fatigue."
15139072,3,5,Premise,Claim,support,"This included better subjective sleep quality (P < 0.02), faster sleep latency (P < 0.01), longer sleep duration (P < 0.03), and less use of sleep medications (P < 0.02).",The participation rates suggested that a TY program is feasible for patients with cancer and that such a program significantly improves sleep-related outcomes.
15139072,3,6,Premise,Premise,none,"This included better subjective sleep quality (P < 0.02), faster sleep latency (P < 0.01), longer sleep duration (P < 0.03), and less use of sleep medications (P < 0.02).","However, there were no significant differences between groups for the other outcomes."
15139072,4,1,Premise,MajorClaim,none,"There were no significant differences between groups in terms of intrusion or avoidance, state anxiety, depression, or fatigue.",Research suggests that stress-reduction programs tailored to the cancer setting help patients cope with the effects of treatment and improve their quality of life.
15139072,4,2,Premise,Premise,none,"There were no significant differences between groups in terms of intrusion or avoidance, state anxiety, depression, or fatigue.",Patients in the TY group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; P < 0.004).
15139072,4,3,Premise,Premise,none,"There were no significant differences between groups in terms of intrusion or avoidance, state anxiety, depression, or fatigue.","This included better subjective sleep quality (P < 0.02), faster sleep latency (P < 0.01), longer sleep duration (P < 0.03), and less use of sleep medications (P < 0.02)."
15139072,4,5,Premise,Claim,none,"There were no significant differences between groups in terms of intrusion or avoidance, state anxiety, depression, or fatigue.",The participation rates suggested that a TY program is feasible for patients with cancer and that such a program significantly improves sleep-related outcomes.
15139072,4,6,Premise,Premise,support,"There were no significant differences between groups in terms of intrusion or avoidance, state anxiety, depression, or fatigue.","However, there were no significant differences between groups for the other outcomes."
15139072,5,1,Claim,MajorClaim,none,The participation rates suggested that a TY program is feasible for patients with cancer and that such a program significantly improves sleep-related outcomes.,Research suggests that stress-reduction programs tailored to the cancer setting help patients cope with the effects of treatment and improve their quality of life.
15139072,5,2,Claim,Premise,none,The participation rates suggested that a TY program is feasible for patients with cancer and that such a program significantly improves sleep-related outcomes.,Patients in the TY group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; P < 0.004).
15139072,5,3,Claim,Premise,none,The participation rates suggested that a TY program is feasible for patients with cancer and that such a program significantly improves sleep-related outcomes.,"This included better subjective sleep quality (P < 0.02), faster sleep latency (P < 0.01), longer sleep duration (P < 0.03), and less use of sleep medications (P < 0.02)."
15139072,5,4,Claim,Premise,none,The participation rates suggested that a TY program is feasible for patients with cancer and that such a program significantly improves sleep-related outcomes.,"There were no significant differences between groups in terms of intrusion or avoidance, state anxiety, depression, or fatigue."
15139072,5,6,Claim,Premise,none,The participation rates suggested that a TY program is feasible for patients with cancer and that such a program significantly improves sleep-related outcomes.,"However, there were no significant differences between groups for the other outcomes."
15139072,6,1,Premise,MajorClaim,none,"However, there were no significant differences between groups for the other outcomes.",Research suggests that stress-reduction programs tailored to the cancer setting help patients cope with the effects of treatment and improve their quality of life.
15139072,6,2,Premise,Premise,none,"However, there were no significant differences between groups for the other outcomes.",Patients in the TY group reported significantly lower sleep disturbance scores during follow-up compared with patients in the wait-list control group (5.8 vs. 8.1; P < 0.004).
15139072,6,3,Premise,Premise,none,"However, there were no significant differences between groups for the other outcomes.","This included better subjective sleep quality (P < 0.02), faster sleep latency (P < 0.01), longer sleep duration (P < 0.03), and less use of sleep medications (P < 0.02)."
15139072,6,4,Premise,Premise,none,"However, there were no significant differences between groups for the other outcomes.","There were no significant differences between groups in terms of intrusion or avoidance, state anxiety, depression, or fatigue."
15139072,6,5,Premise,Claim,none,"However, there were no significant differences between groups for the other outcomes.",The participation rates suggested that a TY program is feasible for patients with cancer and that such a program significantly improves sleep-related outcomes.
12721238,1,2,Claim,Claim,none,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.",These physical changes can negatively affect health-related quality of life.
12721238,1,3,Claim,Claim,none,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.","Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat."
12721238,1,4,Claim,Premise,none,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.",Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
12721238,1,5,Claim,Premise,none,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.",Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
12721238,1,6,Claim,Premise,none,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.","The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds."
12721238,1,7,Claim,Claim,none,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.",Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
12721238,1,8,Claim,MajorClaim,none,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue.",This form of exercise can be an important component of supportive care for these patients.
12721238,2,1,Claim,Claim,none,These physical changes can negatively affect health-related quality of life.,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue."
12721238,2,3,Claim,Claim,none,These physical changes can negatively affect health-related quality of life.,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat."
12721238,2,4,Claim,Premise,none,These physical changes can negatively affect health-related quality of life.,Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
12721238,2,5,Claim,Premise,none,These physical changes can negatively affect health-related quality of life.,Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
12721238,2,6,Claim,Premise,none,These physical changes can negatively affect health-related quality of life.,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds."
12721238,2,7,Claim,Claim,none,These physical changes can negatively affect health-related quality of life.,Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
12721238,2,8,Claim,MajorClaim,none,These physical changes can negatively affect health-related quality of life.,This form of exercise can be an important component of supportive care for these patients.
12721238,3,1,Claim,Claim,none,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.","Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue."
12721238,3,2,Claim,Claim,none,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.",These physical changes can negatively affect health-related quality of life.
12721238,3,4,Claim,Premise,none,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.",Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
12721238,3,5,Claim,Premise,none,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.",Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
12721238,3,6,Claim,Premise,none,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.","The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds."
12721238,3,7,Claim,Claim,none,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.",Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
12721238,3,8,Claim,MajorClaim,none,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat.",This form of exercise can be an important component of supportive care for these patients.
12721238,4,1,Premise,Claim,none,Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue."
12721238,4,2,Premise,Claim,none,Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.,These physical changes can negatively affect health-related quality of life.
12721238,4,3,Premise,Claim,none,Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat."
12721238,4,5,Premise,Premise,none,Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.,Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
12721238,4,6,Premise,Premise,none,Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds."
12721238,4,7,Premise,Claim,support,Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.,Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
12721238,4,8,Premise,MajorClaim,none,Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.,This form of exercise can be an important component of supportive care for these patients.
12721238,5,1,Premise,Claim,none,Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue."
12721238,5,2,Premise,Claim,none,Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.,These physical changes can negatively affect health-related quality of life.
12721238,5,3,Premise,Claim,none,Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat."
12721238,5,4,Premise,Premise,none,Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.,Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
12721238,5,6,Premise,Premise,none,Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds."
12721238,5,7,Premise,Claim,none,Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.,Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
12721238,5,8,Premise,MajorClaim,none,Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.,This form of exercise can be an important component of supportive care for these patients.
12721238,6,1,Premise,Claim,none,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.","Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue."
12721238,6,2,Premise,Claim,none,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.",These physical changes can negatively affect health-related quality of life.
12721238,6,3,Premise,Claim,none,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.","Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat."
12721238,6,4,Premise,Premise,none,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.",Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
12721238,6,5,Premise,Premise,none,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.",Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
12721238,6,7,Premise,Claim,none,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.",Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
12721238,6,8,Premise,MajorClaim,none,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds.",This form of exercise can be an important component of supportive care for these patients.
12721238,7,1,Claim,Claim,none,Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue."
12721238,7,2,Claim,Claim,none,Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.,These physical changes can negatively affect health-related quality of life.
12721238,7,3,Claim,Claim,none,Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat."
12721238,7,4,Claim,Premise,none,Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.,Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
12721238,7,5,Claim,Premise,none,Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.,Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
12721238,7,6,Claim,Premise,none,Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds."
12721238,7,8,Claim,MajorClaim,support,Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.,This form of exercise can be an important component of supportive care for these patients.
12721238,8,1,MajorClaim,Claim,none,This form of exercise can be an important component of supportive care for these patients.,"Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean body tissue."
12721238,8,2,MajorClaim,Claim,none,This form of exercise can be an important component of supportive care for these patients.,These physical changes can negatively affect health-related quality of life.
12721238,8,3,MajorClaim,Claim,none,This form of exercise can be an important component of supportive care for these patients.,"Resistance exercise may help to counter some of these side effects by reducing fatigue, elevating mood, building muscle mass, and reducing body fat."
12721238,8,4,MajorClaim,Premise,none,This form of exercise can be an important component of supportive care for these patients.,Men assigned to resistance exercise had less interference from fatigue on activities of daily living (P =.002) and higher quality of life (P =.001) than men in the control group.
12721238,8,5,MajorClaim,Premise,none,This form of exercise can be an important component of supportive care for these patients.,Men in the intervention group demonstrated higher levels of upper body (P =.009) and lower body (P <.001) muscular fitness than men in the control group.
12721238,8,6,MajorClaim,Premise,none,This form of exercise can be an important component of supportive care for these patients.,"The 12-week resistance exercise intervention did not improve body composition as measured by changes in body weight, body mass index, waist circumference, or subcutaneous skinfolds."
12721238,8,7,MajorClaim,Claim,none,This form of exercise can be an important component of supportive care for these patients.,Resistance exercise reduces fatigue and improves quality of life and muscular fitness in men with prostate cancer receiving androgen deprivation therapy.
16524633,1,2,MajorClaim,Claim,none,Morbidity is an important issue in cancer research.,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,"
16524633,1,3,MajorClaim,Claim,none,Morbidity is an important issue in cancer research.,but like other toxicity scoring systems it has not been formally validated.
16524633,1,4,MajorClaim,Premise,none,Morbidity is an important issue in cancer research.,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
16524633,1,5,MajorClaim,Premise,none,Morbidity is an important issue in cancer research.,The conceptually similar endpoints of the two methods correlated significantly.
16524633,1,6,MajorClaim,Premise,none,Morbidity is an important issue in cancer research.,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
16524633,1,7,MajorClaim,Premise,none,Morbidity is an important issue in cancer research.,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
16524633,1,8,MajorClaim,Premise,none,Morbidity is an important issue in cancer research.,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
16524633,1,9,MajorClaim,Claim,none,Morbidity is an important issue in cancer research.,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
16524633,1,10,MajorClaim,Claim,none,Morbidity is an important issue in cancer research.,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0."
16524633,2,1,Claim,MajorClaim,none,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,",Morbidity is an important issue in cancer research.
16524633,2,3,Claim,Claim,none,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,",but like other toxicity scoring systems it has not been formally validated.
16524633,2,4,Claim,Premise,none,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,",The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
16524633,2,5,Claim,Premise,none,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,",The conceptually similar endpoints of the two methods correlated significantly.
16524633,2,6,Claim,Premise,none,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,",The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
16524633,2,7,Claim,Premise,none,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,",The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
16524633,2,8,Claim,Premise,none,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,",A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
16524633,2,9,Claim,Claim,none,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,",The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
16524633,2,10,Claim,Claim,none,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,","This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0."
16524633,3,1,Claim,MajorClaim,none,but like other toxicity scoring systems it has not been formally validated.,Morbidity is an important issue in cancer research.
16524633,3,2,Claim,Claim,attack,but like other toxicity scoring systems it has not been formally validated.,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,"
16524633,3,4,Claim,Premise,none,but like other toxicity scoring systems it has not been formally validated.,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
16524633,3,5,Claim,Premise,none,but like other toxicity scoring systems it has not been formally validated.,The conceptually similar endpoints of the two methods correlated significantly.
16524633,3,6,Claim,Premise,none,but like other toxicity scoring systems it has not been formally validated.,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
16524633,3,7,Claim,Premise,none,but like other toxicity scoring systems it has not been formally validated.,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
16524633,3,8,Claim,Premise,none,but like other toxicity scoring systems it has not been formally validated.,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
16524633,3,9,Claim,Claim,none,but like other toxicity scoring systems it has not been formally validated.,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
16524633,3,10,Claim,Claim,none,but like other toxicity scoring systems it has not been formally validated.,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0."
16524633,4,1,Premise,MajorClaim,none,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.,Morbidity is an important issue in cancer research.
16524633,4,2,Premise,Claim,none,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,"
16524633,4,3,Premise,Claim,none,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.,but like other toxicity scoring systems it has not been formally validated.
16524633,4,5,Premise,Premise,none,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.,The conceptually similar endpoints of the two methods correlated significantly.
16524633,4,6,Premise,Premise,none,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
16524633,4,7,Premise,Premise,none,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
16524633,4,8,Premise,Premise,none,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
16524633,4,9,Premise,Claim,support,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
16524633,4,10,Premise,Claim,none,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0."
16524633,5,1,Premise,MajorClaim,none,The conceptually similar endpoints of the two methods correlated significantly.,Morbidity is an important issue in cancer research.
16524633,5,2,Premise,Claim,none,The conceptually similar endpoints of the two methods correlated significantly.,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,"
16524633,5,3,Premise,Claim,none,The conceptually similar endpoints of the two methods correlated significantly.,but like other toxicity scoring systems it has not been formally validated.
16524633,5,4,Premise,Premise,support,The conceptually similar endpoints of the two methods correlated significantly.,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
16524633,5,6,Premise,Premise,none,The conceptually similar endpoints of the two methods correlated significantly.,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
16524633,5,7,Premise,Premise,none,The conceptually similar endpoints of the two methods correlated significantly.,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
16524633,5,8,Premise,Premise,none,The conceptually similar endpoints of the two methods correlated significantly.,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
16524633,5,9,Premise,Claim,none,The conceptually similar endpoints of the two methods correlated significantly.,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
16524633,5,10,Premise,Claim,none,The conceptually similar endpoints of the two methods correlated significantly.,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0."
16524633,6,1,Premise,MajorClaim,none,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.,Morbidity is an important issue in cancer research.
16524633,6,2,Premise,Claim,none,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,"
16524633,6,3,Premise,Claim,none,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.,but like other toxicity scoring systems it has not been formally validated.
16524633,6,4,Premise,Premise,none,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
16524633,6,5,Premise,Premise,none,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.,The conceptually similar endpoints of the two methods correlated significantly.
16524633,6,7,Premise,Premise,none,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
16524633,6,8,Premise,Premise,none,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
16524633,6,9,Premise,Claim,support,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
16524633,6,10,Premise,Claim,none,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0."
16524633,7,1,Premise,MajorClaim,none,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.,Morbidity is an important issue in cancer research.
16524633,7,2,Premise,Claim,none,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,"
16524633,7,3,Premise,Claim,none,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.,but like other toxicity scoring systems it has not been formally validated.
16524633,7,4,Premise,Premise,none,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
16524633,7,5,Premise,Premise,none,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.,The conceptually similar endpoints of the two methods correlated significantly.
16524633,7,6,Premise,Premise,none,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
16524633,7,8,Premise,Premise,none,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
16524633,7,9,Premise,Claim,support,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
16524633,7,10,Premise,Claim,none,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0."
16524633,8,1,Premise,MajorClaim,none,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.,Morbidity is an important issue in cancer research.
16524633,8,2,Premise,Claim,none,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,"
16524633,8,3,Premise,Claim,none,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.,but like other toxicity scoring systems it has not been formally validated.
16524633,8,4,Premise,Premise,none,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
16524633,8,5,Premise,Premise,none,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.,The conceptually similar endpoints of the two methods correlated significantly.
16524633,8,6,Premise,Premise,none,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
16524633,8,7,Premise,Premise,none,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
16524633,8,9,Premise,Claim,support,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
16524633,8,10,Premise,Claim,none,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0."
16524633,9,1,Claim,MajorClaim,none,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.,Morbidity is an important issue in cancer research.
16524633,9,2,Claim,Claim,none,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.,"The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,"
16524633,9,3,Claim,Claim,none,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.,but like other toxicity scoring systems it has not been formally validated.
16524633,9,4,Claim,Premise,none,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.,The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
16524633,9,5,Claim,Premise,none,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.,The conceptually similar endpoints of the two methods correlated significantly.
16524633,9,6,Claim,Premise,none,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.,The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
16524633,9,7,Claim,Premise,none,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.,The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
16524633,9,8,Claim,Premise,none,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.,A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
16524633,9,10,Claim,Claim,none,The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0."
16524633,10,1,Claim,MajorClaim,none,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.",Morbidity is an important issue in cancer research.
16524633,10,2,Claim,Claim,none,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.","The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,"
16524633,10,3,Claim,Claim,none,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.",but like other toxicity scoring systems it has not been formally validated.
16524633,10,4,Claim,Premise,none,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.",The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
16524633,10,5,Claim,Premise,none,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.",The conceptually similar endpoints of the two methods correlated significantly.
16524633,10,6,Claim,Premise,none,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.",The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
16524633,10,7,Claim,Premise,none,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.",The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
16524633,10,8,Claim,Premise,none,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.",A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
16524633,10,9,Claim,Claim,attack,"This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.",The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
23771714,1,2,Premise,Premise,none,PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95 % CI 0.785-1.304); median 10.4 months XP vs. 9.2 months EP].,"Overall survival was also similar [HR 1.027 (95 % CI 0.740-1.424); median 22.0 vs. 26.1 months], and response rate was 47 % versus 42 %."
23771714,1,3,Premise,Premise,none,PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95 % CI 0.785-1.304); median 10.4 months XP vs. 9.2 months EP].,Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.
23771714,1,4,Premise,Premise,none,PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95 % CI 0.785-1.304); median 10.4 months XP vs. 9.2 months EP].,There were no major differences in QoL.
23771714,1,5,Premise,Claim,none,PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95 % CI 0.785-1.304); median 10.4 months XP vs. 9.2 months EP].,"Although, noninferiority of XP to EP was formally not proven,"
23771714,1,6,Premise,Claim,support,PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95 % CI 0.785-1.304); median 10.4 months XP vs. 9.2 months EP].,first-line XP was active and feasible.
23771714,1,7,Premise,Claim,none,PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95 % CI 0.785-1.304); median 10.4 months XP vs. 9.2 months EP].,"XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines."
23771714,2,1,Premise,Premise,none,"Overall survival was also similar [HR 1.027 (95 % CI 0.740-1.424); median 22.0 vs. 26.1 months], and response rate was 47 % versus 42 %.",PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95 % CI 0.785-1.304); median 10.4 months XP vs. 9.2 months EP].
23771714,2,3,Premise,Premise,none,"Overall survival was also similar [HR 1.027 (95 % CI 0.740-1.424); median 22.0 vs. 26.1 months], and response rate was 47 % versus 42 %.",Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.
23771714,2,4,Premise,Premise,none,"Overall survival was also similar [HR 1.027 (95 % CI 0.740-1.424); median 22.0 vs. 26.1 months], and response rate was 47 % versus 42 %.",There were no major differences in QoL.
23771714,2,5,Premise,Claim,none,"Overall survival was also similar [HR 1.027 (95 % CI 0.740-1.424); median 22.0 vs. 26.1 months], and response rate was 47 % versus 42 %.","Although, noninferiority of XP to EP was formally not proven,"
23771714,2,6,Premise,Claim,support,"Overall survival was also similar [HR 1.027 (95 % CI 0.740-1.424); median 22.0 vs. 26.1 months], and response rate was 47 % versus 42 %.",first-line XP was active and feasible.
23771714,2,7,Premise,Claim,none,"Overall survival was also similar [HR 1.027 (95 % CI 0.740-1.424); median 22.0 vs. 26.1 months], and response rate was 47 % versus 42 %.","XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines."
23771714,3,1,Premise,Premise,none,Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.,PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95 % CI 0.785-1.304); median 10.4 months XP vs. 9.2 months EP].
23771714,3,2,Premise,Premise,none,Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.,"Overall survival was also similar [HR 1.027 (95 % CI 0.740-1.424); median 22.0 vs. 26.1 months], and response rate was 47 % versus 42 %."
23771714,3,4,Premise,Premise,none,Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.,There were no major differences in QoL.
23771714,3,5,Premise,Claim,none,Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.,"Although, noninferiority of XP to EP was formally not proven,"
23771714,3,6,Premise,Claim,none,Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.,first-line XP was active and feasible.
23771714,3,7,Premise,Claim,support,Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.,"XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines."
23771714,4,1,Premise,Premise,none,There were no major differences in QoL.,PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95 % CI 0.785-1.304); median 10.4 months XP vs. 9.2 months EP].
23771714,4,2,Premise,Premise,none,There were no major differences in QoL.,"Overall survival was also similar [HR 1.027 (95 % CI 0.740-1.424); median 22.0 vs. 26.1 months], and response rate was 47 % versus 42 %."
23771714,4,3,Premise,Premise,none,There were no major differences in QoL.,Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.
23771714,4,5,Premise,Claim,none,There were no major differences in QoL.,"Although, noninferiority of XP to EP was formally not proven,"
23771714,4,6,Premise,Claim,none,There were no major differences in QoL.,first-line XP was active and feasible.
23771714,4,7,Premise,Claim,support,There were no major differences in QoL.,"XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines."
23771714,5,1,Claim,Premise,none,"Although, noninferiority of XP to EP was formally not proven,",PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95 % CI 0.785-1.304); median 10.4 months XP vs. 9.2 months EP].
23771714,5,2,Claim,Premise,none,"Although, noninferiority of XP to EP was formally not proven,","Overall survival was also similar [HR 1.027 (95 % CI 0.740-1.424); median 22.0 vs. 26.1 months], and response rate was 47 % versus 42 %."
23771714,5,3,Claim,Premise,none,"Although, noninferiority of XP to EP was formally not proven,",Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.
23771714,5,4,Claim,Premise,none,"Although, noninferiority of XP to EP was formally not proven,",There were no major differences in QoL.
23771714,5,6,Claim,Claim,attack,"Although, noninferiority of XP to EP was formally not proven,",first-line XP was active and feasible.
23771714,5,7,Claim,Claim,none,"Although, noninferiority of XP to EP was formally not proven,","XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines."
23771714,6,1,Claim,Premise,none,first-line XP was active and feasible.,PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95 % CI 0.785-1.304); median 10.4 months XP vs. 9.2 months EP].
23771714,6,2,Claim,Premise,none,first-line XP was active and feasible.,"Overall survival was also similar [HR 1.027 (95 % CI 0.740-1.424); median 22.0 vs. 26.1 months], and response rate was 47 % versus 42 %."
23771714,6,3,Claim,Premise,none,first-line XP was active and feasible.,Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.
23771714,6,4,Claim,Premise,none,first-line XP was active and feasible.,There were no major differences in QoL.
23771714,6,5,Claim,Claim,none,first-line XP was active and feasible.,"Although, noninferiority of XP to EP was formally not proven,"
23771714,6,7,Claim,Claim,support,first-line XP was active and feasible.,"XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines."
23771714,7,1,Claim,Premise,none,"XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines.",PFS was similar in the two arms [HR: XP vs. EP: 1.012 (95 % CI 0.785-1.304); median 10.4 months XP vs. 9.2 months EP].
23771714,7,2,Claim,Premise,none,"XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines.","Overall survival was also similar [HR 1.027 (95 % CI 0.740-1.424); median 22.0 vs. 26.1 months], and response rate was 47 % versus 42 %."
23771714,7,3,Claim,Premise,none,"XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines.",Both regimens were tolerable: there were more grade 3/4 diarrhea and grade 3 hand-foot syndromes with XP and more grade 3/4 hematologic toxicities with EP.
23771714,7,4,Claim,Premise,none,"XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines.",There were no major differences in QoL.
23771714,7,5,Claim,Claim,none,"XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines.","Although, noninferiority of XP to EP was formally not proven,"
23771714,7,6,Claim,Claim,none,"XP is a valid first-line alternative to anthracycline/taxane regimens, especially in patients previously treated with adjuvant anthracyclines.",first-line XP was active and feasible.
12118024,1,2,Premise,Premise,none,"After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.",Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
12118024,1,3,Premise,Premise,none,"After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.","Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,"
12118024,1,4,Premise,Premise,none,"After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.",but the differences were not statistically significant.
12118024,1,5,Premise,Premise,none,"After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.",There were no differences in the proportions of patients in the two groups that reported worsening.
12118024,1,6,Premise,Claim,support,"After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.",Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
12118024,2,1,Premise,Premise,none,Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.,"After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores."
12118024,2,3,Premise,Premise,none,Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.,"Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,"
12118024,2,4,Premise,Premise,none,Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.,but the differences were not statistically significant.
12118024,2,5,Premise,Premise,none,Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.,There were no differences in the proportions of patients in the two groups that reported worsening.
12118024,2,6,Premise,Claim,support,Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.,Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
12118024,3,1,Premise,Premise,none,"Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,","After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores."
12118024,3,2,Premise,Premise,none,"Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,",Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
12118024,3,4,Premise,Premise,none,"Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,",but the differences were not statistically significant.
12118024,3,5,Premise,Premise,none,"Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,",There were no differences in the proportions of patients in the two groups that reported worsening.
12118024,3,6,Premise,Claim,none,"Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,",Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
12118024,4,1,Premise,Premise,none,but the differences were not statistically significant.,"After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores."
12118024,4,2,Premise,Premise,none,but the differences were not statistically significant.,Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
12118024,4,3,Premise,Premise,attack,but the differences were not statistically significant.,"Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,"
12118024,4,5,Premise,Premise,none,but the differences were not statistically significant.,There were no differences in the proportions of patients in the two groups that reported worsening.
12118024,4,6,Premise,Claim,none,but the differences were not statistically significant.,Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
12118024,5,1,Premise,Premise,none,There were no differences in the proportions of patients in the two groups that reported worsening.,"After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores."
12118024,5,2,Premise,Premise,none,There were no differences in the proportions of patients in the two groups that reported worsening.,Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
12118024,5,3,Premise,Premise,none,There were no differences in the proportions of patients in the two groups that reported worsening.,"Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,"
12118024,5,4,Premise,Premise,none,There were no differences in the proportions of patients in the two groups that reported worsening.,but the differences were not statistically significant.
12118024,5,6,Premise,Claim,none,There were no differences in the proportions of patients in the two groups that reported worsening.,Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
12118024,6,1,Claim,Premise,none,Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.,"After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores."
12118024,6,2,Claim,Premise,none,Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.,Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
12118024,6,3,Claim,Premise,none,Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.,"Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,"
12118024,6,4,Claim,Premise,none,Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.,but the differences were not statistically significant.
12118024,6,5,Claim,Premise,none,Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.,There were no differences in the proportions of patients in the two groups that reported worsening.
12915593,1,2,Premise,Premise,none,"In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.","The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63)."
12915593,1,3,Premise,Premise,none,"In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.","The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months."
12915593,1,4,Premise,Premise,none,"In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.","Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles)."
12915593,1,5,Premise,Premise,none,"In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.","Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone."
12915593,1,6,Premise,Premise,none,"In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.",The number of hospital admissions and the number of days in hospital were not different.
12915593,1,7,Premise,Claim,support,"In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.","In elderly patients, G-CSF improved the RDI of CHOP,"
12915593,1,8,Premise,Premise,none,"In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.",but this did not lead to a higher complete response rate or better overall survival.
12915593,1,9,Premise,Claim,none,"In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF.",G-CSF did not prevent serious infections.
12915593,2,1,Premise,Premise,none,"The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).","In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF."
12915593,2,3,Premise,Premise,none,"The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).","The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months."
12915593,2,4,Premise,Premise,none,"The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).","Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles)."
12915593,2,5,Premise,Premise,none,"The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).","Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone."
12915593,2,6,Premise,Premise,none,"The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).",The number of hospital admissions and the number of days in hospital were not different.
12915593,2,7,Premise,Claim,none,"The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).","In elderly patients, G-CSF improved the RDI of CHOP,"
12915593,2,8,Premise,Premise,none,"The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).",but this did not lead to a higher complete response rate or better overall survival.
12915593,2,9,Premise,Claim,none,"The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63).",G-CSF did not prevent serious infections.
12915593,3,1,Premise,Premise,none,"The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.","In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF."
12915593,3,2,Premise,Premise,none,"The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.","The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63)."
12915593,3,4,Premise,Premise,none,"The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.","Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles)."
12915593,3,5,Premise,Premise,none,"The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.","Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone."
12915593,3,6,Premise,Premise,none,"The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.",The number of hospital admissions and the number of days in hospital were not different.
12915593,3,7,Premise,Claim,none,"The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.","In elderly patients, G-CSF improved the RDI of CHOP,"
12915593,3,8,Premise,Premise,none,"The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.",but this did not lead to a higher complete response rate or better overall survival.
12915593,3,9,Premise,Claim,none,"The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months.",G-CSF did not prevent serious infections.
12915593,4,1,Premise,Premise,none,"Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).","In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF."
12915593,4,2,Premise,Premise,none,"Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).","The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63)."
12915593,4,3,Premise,Premise,none,"Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).","The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months."
12915593,4,5,Premise,Premise,none,"Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).","Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone."
12915593,4,6,Premise,Premise,none,"Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).",The number of hospital admissions and the number of days in hospital were not different.
12915593,4,7,Premise,Claim,none,"Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).","In elderly patients, G-CSF improved the RDI of CHOP,"
12915593,4,8,Premise,Premise,none,"Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).",but this did not lead to a higher complete response rate or better overall survival.
12915593,4,9,Premise,Claim,none,"Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles).",G-CSF did not prevent serious infections.
12915593,5,1,Premise,Premise,none,"Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.","In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF."
12915593,5,2,Premise,Premise,none,"Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.","The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63)."
12915593,5,3,Premise,Premise,none,"Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.","The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months."
12915593,5,4,Premise,Premise,none,"Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.","Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles)."
12915593,5,6,Premise,Premise,none,"Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.",The number of hospital admissions and the number of days in hospital were not different.
12915593,5,7,Premise,Claim,none,"Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.","In elderly patients, G-CSF improved the RDI of CHOP,"
12915593,5,8,Premise,Premise,none,"Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.",but this did not lead to a higher complete response rate or better overall survival.
12915593,5,9,Premise,Claim,none,"Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone.",G-CSF did not prevent serious infections.
12915593,6,1,Premise,Premise,none,The number of hospital admissions and the number of days in hospital were not different.,"In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF."
12915593,6,2,Premise,Premise,none,The number of hospital admissions and the number of days in hospital were not different.,"The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63)."
12915593,6,3,Premise,Premise,none,The number of hospital admissions and the number of days in hospital were not different.,"The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months."
12915593,6,4,Premise,Premise,none,The number of hospital admissions and the number of days in hospital were not different.,"Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles)."
12915593,6,5,Premise,Premise,none,The number of hospital admissions and the number of days in hospital were not different.,"Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone."
12915593,6,7,Premise,Claim,none,The number of hospital admissions and the number of days in hospital were not different.,"In elderly patients, G-CSF improved the RDI of CHOP,"
12915593,6,8,Premise,Premise,none,The number of hospital admissions and the number of days in hospital were not different.,but this did not lead to a higher complete response rate or better overall survival.
12915593,6,9,Premise,Claim,none,The number of hospital admissions and the number of days in hospital were not different.,G-CSF did not prevent serious infections.
12915593,7,1,Claim,Premise,none,"In elderly patients, G-CSF improved the RDI of CHOP,","In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF."
12915593,7,2,Claim,Premise,none,"In elderly patients, G-CSF improved the RDI of CHOP,","The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63)."
12915593,7,3,Claim,Premise,none,"In elderly patients, G-CSF improved the RDI of CHOP,","The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months."
12915593,7,4,Claim,Premise,none,"In elderly patients, G-CSF improved the RDI of CHOP,","Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles)."
12915593,7,5,Claim,Premise,none,"In elderly patients, G-CSF improved the RDI of CHOP,","Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone."
12915593,7,6,Claim,Premise,none,"In elderly patients, G-CSF improved the RDI of CHOP,",The number of hospital admissions and the number of days in hospital were not different.
12915593,7,8,Claim,Premise,none,"In elderly patients, G-CSF improved the RDI of CHOP,",but this did not lead to a higher complete response rate or better overall survival.
12915593,7,9,Claim,Claim,none,"In elderly patients, G-CSF improved the RDI of CHOP,",G-CSF did not prevent serious infections.
12915593,8,1,Premise,Premise,none,but this did not lead to a higher complete response rate or better overall survival.,"In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF."
12915593,8,2,Premise,Premise,none,but this did not lead to a higher complete response rate or better overall survival.,"The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63)."
12915593,8,3,Premise,Premise,none,but this did not lead to a higher complete response rate or better overall survival.,"The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months."
12915593,8,4,Premise,Premise,none,but this did not lead to a higher complete response rate or better overall survival.,"Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles)."
12915593,8,5,Premise,Premise,none,but this did not lead to a higher complete response rate or better overall survival.,"Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone."
12915593,8,6,Premise,Premise,none,but this did not lead to a higher complete response rate or better overall survival.,The number of hospital admissions and the number of days in hospital were not different.
12915593,8,7,Premise,Claim,attack,but this did not lead to a higher complete response rate or better overall survival.,"In elderly patients, G-CSF improved the RDI of CHOP,"
12915593,8,9,Premise,Claim,none,but this did not lead to a higher complete response rate or better overall survival.,G-CSF did not prevent serious infections.
12915593,9,1,Claim,Premise,none,G-CSF did not prevent serious infections.,"In 389 eligible patients, the relative dose intensities (RDIs) of cyclophosphamide (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) were higher in patients treated with CHOP plus G-CSF."
12915593,9,2,Claim,Premise,none,G-CSF did not prevent serious infections.,"The complete response rates were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63)."
12915593,9,3,Claim,Premise,none,G-CSF did not prevent serious infections.,"The actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months."
12915593,9,4,Claim,Premise,none,G-CSF did not prevent serious infections.,"Patients treated with CHOP plus G-CSF had an identical incidence of infections, with World Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles)."
12915593,9,5,Claim,Premise,none,G-CSF did not prevent serious infections.,"Only the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 6 days; P =.006) than with CHOP alone."
12915593,9,6,Claim,Premise,none,G-CSF did not prevent serious infections.,The number of hospital admissions and the number of days in hospital were not different.
12915593,9,7,Claim,Claim,none,G-CSF did not prevent serious infections.,"In elderly patients, G-CSF improved the RDI of CHOP,"
12915593,9,8,Claim,Premise,none,G-CSF did not prevent serious infections.,but this did not lead to a higher complete response rate or better overall survival.
16505413,1,2,Claim,Premise,none,"for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome.","Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034)."
16505413,1,3,Claim,Premise,none,"for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome.",Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.
16505413,1,4,Claim,Premise,none,"for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome.",Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.
16505413,1,5,Claim,Premise,none,"for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome.","Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively."
16505413,1,6,Claim,Premise,none,"for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome.","A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05)."
16505413,1,7,Claim,Premise,none,"for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome.","For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17)."
16505413,1,8,Claim,Claim,none,"for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome.","HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy."
16505413,1,9,Claim,Claim,none,"for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome.",Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.
16505413,2,1,Premise,Claim,none,"Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034).","for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome."
16505413,2,3,Premise,Premise,none,"Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034).",Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.
16505413,2,4,Premise,Premise,none,"Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034).",Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.
16505413,2,5,Premise,Premise,none,"Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034).","Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively."
16505413,2,6,Premise,Premise,none,"Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034).","A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05)."
16505413,2,7,Premise,Premise,none,"Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034).","For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17)."
16505413,2,8,Premise,Claim,support,"Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034).","HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy."
16505413,2,9,Premise,Claim,none,"Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034).",Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.
16505413,3,1,Premise,Claim,none,Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.,"for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome."
16505413,3,2,Premise,Premise,none,Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.,"Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034)."
16505413,3,4,Premise,Premise,none,Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.,Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.
16505413,3,5,Premise,Premise,none,Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.,"Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively."
16505413,3,6,Premise,Premise,none,Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.,"A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05)."
16505413,3,7,Premise,Premise,none,Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.,"For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17)."
16505413,3,8,Premise,Claim,support,Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.,"HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy."
16505413,3,9,Premise,Claim,none,Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.,Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.
16505413,4,1,Premise,Claim,none,Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.,"for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome."
16505413,4,2,Premise,Premise,none,Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.,"Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034)."
16505413,4,3,Premise,Premise,none,Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.,Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.
16505413,4,5,Premise,Premise,none,Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.,"Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively."
16505413,4,6,Premise,Premise,none,Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.,"A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05)."
16505413,4,7,Premise,Premise,none,Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.,"For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17)."
16505413,4,8,Premise,Claim,support,Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.,"HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy."
16505413,4,9,Premise,Claim,none,Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.,Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.
16505413,5,1,Premise,Claim,none,"Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively.","for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome."
16505413,5,2,Premise,Premise,none,"Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively.","Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034)."
16505413,5,3,Premise,Premise,none,"Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively.",Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.
16505413,5,4,Premise,Premise,none,"Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively.",Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.
16505413,5,6,Premise,Premise,none,"Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively.","A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05)."
16505413,5,7,Premise,Premise,none,"Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively.","For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17)."
16505413,5,8,Premise,Claim,support,"Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively.","HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy."
16505413,5,9,Premise,Claim,none,"Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively.",Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.
16505413,6,1,Premise,Claim,none,"A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05).","for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome."
16505413,6,2,Premise,Premise,none,"A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05).","Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034)."
16505413,6,3,Premise,Premise,none,"A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05).",Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.
16505413,6,4,Premise,Premise,none,"A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05).",Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.
16505413,6,5,Premise,Premise,none,"A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05).","Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively."
16505413,6,7,Premise,Premise,none,"A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05).","For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17)."
16505413,6,8,Premise,Claim,support,"A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05).","HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy."
16505413,6,9,Premise,Claim,none,"A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05).",Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.
16505413,7,1,Premise,Claim,none,"For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17).","for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome."
16505413,7,2,Premise,Premise,none,"For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17).","Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034)."
16505413,7,3,Premise,Premise,none,"For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17).",Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.
16505413,7,4,Premise,Premise,none,"For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17).",Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.
16505413,7,5,Premise,Premise,none,"For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17).","Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively."
16505413,7,6,Premise,Premise,none,"For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17).","A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05)."
16505413,7,8,Premise,Claim,support,"For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17).","HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy."
16505413,7,9,Premise,Claim,none,"For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17).",Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.
16505413,8,1,Claim,Claim,none,"HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy.","for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome."
16505413,8,2,Claim,Premise,none,"HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy.","Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034)."
16505413,8,3,Claim,Premise,none,"HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy.",Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.
16505413,8,4,Claim,Premise,none,"HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy.",Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.
16505413,8,5,Claim,Premise,none,"HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy.","Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively."
16505413,8,6,Claim,Premise,none,"HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy.","A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05)."
16505413,8,7,Claim,Premise,none,"HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy.","For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17)."
16505413,8,9,Claim,Claim,none,"HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy.",Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.
16505413,9,1,Claim,Claim,none,Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.,"for patients with hepatic metastases from colorectal cancer, hepatic arterial infusion (HAI) of chemotherapy may improve outcome."
16505413,9,2,Claim,Premise,none,Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.,"Overall survival was significantly longer for HAI versus systemic treatment (median, 24.4 v 20 months; P = .0034), as were response rates (47% and 24%; P = .012) and time to hepatic progression (THP; 9.8 v 7.3 months; P = .034)."
16505413,9,3,Claim,Premise,none,Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.,Time to extrahepatic progression (7.7 v 14.8 months; P = .029) was significantly shorter in the HAI group.
16505413,9,4,Claim,Premise,none,Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.,Quality-of-life measurements showed improved physical functioning in the HAI group at the 3- and 6-month follow-up assessments.
16505413,9,5,Claim,Premise,none,Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.,"Toxicity included grade > or = 3 neutropenia (2% and 45%; P < .01), stomatitis (0% and 24%; P < .01), and bilirubin elevation (18.6% and 0; P < .01) in the HAI and systemic treatment groups, respectively."
16505413,9,6,Claim,Premise,none,Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.,"A greater proportion of men versus women receiving HAI experienced biliary toxicity (37% and 15%, respectively; P = .05)."
16505413,9,7,Claim,Premise,none,Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.,"For HAI patients with thymidylate synthase levels in tumor less than or > or = 4, the median survival was 24 and 14 months, respectively (P = .17)."
16505413,9,8,Claim,Claim,none,Additional studies need to address the overall benefit and cost of new chemotherapy agents versus HAI alone or the combination of HAI with new agents.,"HAI therapy increased overall survival, response rate, THP, and was associated with better physical functioning compared with systemic therapy."
17674351,1,2,Claim,Premise,none,Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.,"Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight."
17674351,1,3,Claim,Premise,none,Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.,Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
17674351,1,4,Claim,Premise,none,Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.,"The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82)."
17674351,1,5,Claim,Premise,none,Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.,preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
17674351,1,6,Claim,Premise,none,Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.,Infection rates were negligible in both groups.
17674351,1,7,Claim,Premise,none,Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.,"Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival."
17674351,1,8,Claim,Claim,none,Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.,"Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease."
17674351,2,1,Premise,Claim,none,"Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.",Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
17674351,2,3,Premise,Premise,none,"Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.",Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
17674351,2,4,Premise,Premise,none,"Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.","The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82)."
17674351,2,5,Premise,Premise,none,"Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.",preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
17674351,2,6,Premise,Premise,none,"Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.",Infection rates were negligible in both groups.
17674351,2,7,Premise,Premise,none,"Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.","Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival."
17674351,2,8,Premise,Claim,support,"Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.","Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease."
17674351,3,1,Premise,Claim,none,Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.,Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
17674351,3,2,Premise,Premise,none,Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.,"Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight."
17674351,3,4,Premise,Premise,none,Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.,"The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82)."
17674351,3,5,Premise,Premise,none,Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.,preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
17674351,3,6,Premise,Premise,none,Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.,Infection rates were negligible in both groups.
17674351,3,7,Premise,Premise,none,Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.,"Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival."
17674351,3,8,Premise,Claim,support,Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.,"Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease."
17674351,4,1,Premise,Claim,none,"The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).",Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
17674351,4,2,Premise,Premise,none,"The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).","Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight."
17674351,4,3,Premise,Premise,none,"The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).",Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
17674351,4,5,Premise,Premise,none,"The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).",preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
17674351,4,6,Premise,Premise,none,"The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).",Infection rates were negligible in both groups.
17674351,4,7,Premise,Premise,none,"The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).","Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival."
17674351,4,8,Premise,Claim,none,"The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).","Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease."
17674351,5,1,Premise,Claim,none,preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).,Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
17674351,5,2,Premise,Premise,none,preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).,"Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight."
17674351,5,3,Premise,Premise,none,preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).,Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
17674351,5,4,Premise,Premise,none,preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).,"The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82)."
17674351,5,6,Premise,Premise,none,preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).,Infection rates were negligible in both groups.
17674351,5,7,Premise,Premise,none,preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).,"Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival."
17674351,5,8,Premise,Claim,none,preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).,"Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease."
17674351,6,1,Premise,Claim,none,Infection rates were negligible in both groups.,Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
17674351,6,2,Premise,Premise,none,Infection rates were negligible in both groups.,"Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight."
17674351,6,3,Premise,Premise,none,Infection rates were negligible in both groups.,Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
17674351,6,4,Premise,Premise,none,Infection rates were negligible in both groups.,"The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82)."
17674351,6,5,Premise,Premise,none,Infection rates were negligible in both groups.,preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
17674351,6,7,Premise,Premise,none,Infection rates were negligible in both groups.,"Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival."
17674351,6,8,Premise,Claim,none,Infection rates were negligible in both groups.,"Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease."
17674351,7,1,Premise,Claim,none,"Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.",Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
17674351,7,2,Premise,Premise,none,"Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.","Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight."
17674351,7,3,Premise,Premise,none,"Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.",Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
17674351,7,4,Premise,Premise,none,"Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.","The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82)."
17674351,7,5,Premise,Premise,none,"Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.",preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
17674351,7,6,Premise,Premise,none,"Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.",Infection rates were negligible in both groups.
17674351,7,8,Premise,Claim,none,"Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.","Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease."
17674351,8,1,Claim,Claim,none,"Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.",Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
17674351,8,2,Claim,Premise,none,"Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.","Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight."
17674351,8,3,Claim,Premise,none,"Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.",Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
17674351,8,4,Claim,Premise,none,"Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.","The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82)."
17674351,8,5,Claim,Premise,none,"Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.",preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
17674351,8,6,Claim,Premise,none,"Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.",Infection rates were negligible in both groups.
17674351,8,7,Claim,Premise,none,"Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.","Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival."
23749688,1,2,Premise,Premise,none,"Meaningful differences in aerobic fitness between the exercise and usual care groups at both the 8-week [mean 3.0 mL kg(-1) min(-1) (95 % CI -1.1-7.0)] and 3-month follow-up [2.1 mL kg(-1) min(-1) (-2.3-6.6)] were found,",although these differences did not achieve statistical significance (p values >0.14).
23749688,1,3,Premise,Premise,none,"Meaningful differences in aerobic fitness between the exercise and usual care groups at both the 8-week [mean 3.0 mL kg(-1) min(-1) (95 % CI -1.1-7.0)] and 3-month follow-up [2.1 mL kg(-1) min(-1) (-2.3-6.6)] were found,",Self-reported physical activity increased in the exercise group (EG) compared to the usual care group at both 8-week (p = 0.01) and 3-month follow-up (p = 0.03) and significant differences in favour of the EG were found for physical well-being at both the 8-week (p = 0.03) and 3-month follow-up (p = 0.04).
23749688,1,4,Premise,Premise,none,"Meaningful differences in aerobic fitness between the exercise and usual care groups at both the 8-week [mean 3.0 mL kg(-1) min(-1) (95 % CI -1.1-7.0)] and 3-month follow-up [2.1 mL kg(-1) min(-1) (-2.3-6.6)] were found,","Improvements in fatigue (p = 0.01), total quality of life plus fatigue (p = 0.04), and a composite physical functioning score (p = 0.01) at the 3-month follow-up were also found."
23749688,1,5,Premise,Claim,support,"Meaningful differences in aerobic fitness between the exercise and usual care groups at both the 8-week [mean 3.0 mL kg(-1) min(-1) (95 % CI -1.1-7.0)] and 3-month follow-up [2.1 mL kg(-1) min(-1) (-2.3-6.6)] were found,","The PEACH trial suggests that 8 weeks of supervised aerobic exercise training was feasible and may improve aerobic fitness, fatigue and quality of life in de-conditioned cancer survivors during the early survivorship phase."
23749688,1,6,Premise,Claim,none,"Meaningful differences in aerobic fitness between the exercise and usual care groups at both the 8-week [mean 3.0 mL kg(-1) min(-1) (95 % CI -1.1-7.0)] and 3-month follow-up [2.1 mL kg(-1) min(-1) (-2.3-6.6)] were found,","Exercise interventions commenced in the early survivorship phase appear safe, feasible and may lead to improvements in QOL and fatigue."
23749688,2,1,Premise,Premise,attack,although these differences did not achieve statistical significance (p values >0.14).,"Meaningful differences in aerobic fitness between the exercise and usual care groups at both the 8-week [mean 3.0 mL kg(-1) min(-1) (95 % CI -1.1-7.0)] and 3-month follow-up [2.1 mL kg(-1) min(-1) (-2.3-6.6)] were found,"
23749688,2,3,Premise,Premise,none,although these differences did not achieve statistical significance (p values >0.14).,Self-reported physical activity increased in the exercise group (EG) compared to the usual care group at both 8-week (p = 0.01) and 3-month follow-up (p = 0.03) and significant differences in favour of the EG were found for physical well-being at both the 8-week (p = 0.03) and 3-month follow-up (p = 0.04).
23749688,2,4,Premise,Premise,none,although these differences did not achieve statistical significance (p values >0.14).,"Improvements in fatigue (p = 0.01), total quality of life plus fatigue (p = 0.04), and a composite physical functioning score (p = 0.01) at the 3-month follow-up were also found."
23749688,2,5,Premise,Claim,none,although these differences did not achieve statistical significance (p values >0.14).,"The PEACH trial suggests that 8 weeks of supervised aerobic exercise training was feasible and may improve aerobic fitness, fatigue and quality of life in de-conditioned cancer survivors during the early survivorship phase."
23749688,2,6,Premise,Claim,none,although these differences did not achieve statistical significance (p values >0.14).,"Exercise interventions commenced in the early survivorship phase appear safe, feasible and may lead to improvements in QOL and fatigue."
23749688,3,1,Premise,Premise,none,Self-reported physical activity increased in the exercise group (EG) compared to the usual care group at both 8-week (p = 0.01) and 3-month follow-up (p = 0.03) and significant differences in favour of the EG were found for physical well-being at both the 8-week (p = 0.03) and 3-month follow-up (p = 0.04).,"Meaningful differences in aerobic fitness between the exercise and usual care groups at both the 8-week [mean 3.0 mL kg(-1) min(-1) (95 % CI -1.1-7.0)] and 3-month follow-up [2.1 mL kg(-1) min(-1) (-2.3-6.6)] were found,"
23749688,3,2,Premise,Premise,none,Self-reported physical activity increased in the exercise group (EG) compared to the usual care group at both 8-week (p = 0.01) and 3-month follow-up (p = 0.03) and significant differences in favour of the EG were found for physical well-being at both the 8-week (p = 0.03) and 3-month follow-up (p = 0.04).,although these differences did not achieve statistical significance (p values >0.14).
23749688,3,4,Premise,Premise,none,Self-reported physical activity increased in the exercise group (EG) compared to the usual care group at both 8-week (p = 0.01) and 3-month follow-up (p = 0.03) and significant differences in favour of the EG were found for physical well-being at both the 8-week (p = 0.03) and 3-month follow-up (p = 0.04).,"Improvements in fatigue (p = 0.01), total quality of life plus fatigue (p = 0.04), and a composite physical functioning score (p = 0.01) at the 3-month follow-up were also found."
23749688,3,5,Premise,Claim,support,Self-reported physical activity increased in the exercise group (EG) compared to the usual care group at both 8-week (p = 0.01) and 3-month follow-up (p = 0.03) and significant differences in favour of the EG were found for physical well-being at both the 8-week (p = 0.03) and 3-month follow-up (p = 0.04).,"The PEACH trial suggests that 8 weeks of supervised aerobic exercise training was feasible and may improve aerobic fitness, fatigue and quality of life in de-conditioned cancer survivors during the early survivorship phase."
23749688,3,6,Premise,Claim,none,Self-reported physical activity increased in the exercise group (EG) compared to the usual care group at both 8-week (p = 0.01) and 3-month follow-up (p = 0.03) and significant differences in favour of the EG were found for physical well-being at both the 8-week (p = 0.03) and 3-month follow-up (p = 0.04).,"Exercise interventions commenced in the early survivorship phase appear safe, feasible and may lead to improvements in QOL and fatigue."
23749688,4,1,Premise,Premise,none,"Improvements in fatigue (p = 0.01), total quality of life plus fatigue (p = 0.04), and a composite physical functioning score (p = 0.01) at the 3-month follow-up were also found.","Meaningful differences in aerobic fitness between the exercise and usual care groups at both the 8-week [mean 3.0 mL kg(-1) min(-1) (95 % CI -1.1-7.0)] and 3-month follow-up [2.1 mL kg(-1) min(-1) (-2.3-6.6)] were found,"
23749688,4,2,Premise,Premise,none,"Improvements in fatigue (p = 0.01), total quality of life plus fatigue (p = 0.04), and a composite physical functioning score (p = 0.01) at the 3-month follow-up were also found.",although these differences did not achieve statistical significance (p values >0.14).
23749688,4,3,Premise,Premise,none,"Improvements in fatigue (p = 0.01), total quality of life plus fatigue (p = 0.04), and a composite physical functioning score (p = 0.01) at the 3-month follow-up were also found.",Self-reported physical activity increased in the exercise group (EG) compared to the usual care group at both 8-week (p = 0.01) and 3-month follow-up (p = 0.03) and significant differences in favour of the EG were found for physical well-being at both the 8-week (p = 0.03) and 3-month follow-up (p = 0.04).
23749688,4,5,Premise,Claim,support,"Improvements in fatigue (p = 0.01), total quality of life plus fatigue (p = 0.04), and a composite physical functioning score (p = 0.01) at the 3-month follow-up were also found.","The PEACH trial suggests that 8 weeks of supervised aerobic exercise training was feasible and may improve aerobic fitness, fatigue and quality of life in de-conditioned cancer survivors during the early survivorship phase."
23749688,4,6,Premise,Claim,none,"Improvements in fatigue (p = 0.01), total quality of life plus fatigue (p = 0.04), and a composite physical functioning score (p = 0.01) at the 3-month follow-up were also found.","Exercise interventions commenced in the early survivorship phase appear safe, feasible and may lead to improvements in QOL and fatigue."
23749688,5,1,Claim,Premise,none,"The PEACH trial suggests that 8 weeks of supervised aerobic exercise training was feasible and may improve aerobic fitness, fatigue and quality of life in de-conditioned cancer survivors during the early survivorship phase.","Meaningful differences in aerobic fitness between the exercise and usual care groups at both the 8-week [mean 3.0 mL kg(-1) min(-1) (95 % CI -1.1-7.0)] and 3-month follow-up [2.1 mL kg(-1) min(-1) (-2.3-6.6)] were found,"
23749688,5,2,Claim,Premise,none,"The PEACH trial suggests that 8 weeks of supervised aerobic exercise training was feasible and may improve aerobic fitness, fatigue and quality of life in de-conditioned cancer survivors during the early survivorship phase.",although these differences did not achieve statistical significance (p values >0.14).
23749688,5,3,Claim,Premise,none,"The PEACH trial suggests that 8 weeks of supervised aerobic exercise training was feasible and may improve aerobic fitness, fatigue and quality of life in de-conditioned cancer survivors during the early survivorship phase.",Self-reported physical activity increased in the exercise group (EG) compared to the usual care group at both 8-week (p = 0.01) and 3-month follow-up (p = 0.03) and significant differences in favour of the EG were found for physical well-being at both the 8-week (p = 0.03) and 3-month follow-up (p = 0.04).
23749688,5,4,Claim,Premise,none,"The PEACH trial suggests that 8 weeks of supervised aerobic exercise training was feasible and may improve aerobic fitness, fatigue and quality of life in de-conditioned cancer survivors during the early survivorship phase.","Improvements in fatigue (p = 0.01), total quality of life plus fatigue (p = 0.04), and a composite physical functioning score (p = 0.01) at the 3-month follow-up were also found."
23749688,5,6,Claim,Claim,support,"The PEACH trial suggests that 8 weeks of supervised aerobic exercise training was feasible and may improve aerobic fitness, fatigue and quality of life in de-conditioned cancer survivors during the early survivorship phase.","Exercise interventions commenced in the early survivorship phase appear safe, feasible and may lead to improvements in QOL and fatigue."
23749688,6,1,Claim,Premise,none,"Exercise interventions commenced in the early survivorship phase appear safe, feasible and may lead to improvements in QOL and fatigue.","Meaningful differences in aerobic fitness between the exercise and usual care groups at both the 8-week [mean 3.0 mL kg(-1) min(-1) (95 % CI -1.1-7.0)] and 3-month follow-up [2.1 mL kg(-1) min(-1) (-2.3-6.6)] were found,"
23749688,6,2,Claim,Premise,none,"Exercise interventions commenced in the early survivorship phase appear safe, feasible and may lead to improvements in QOL and fatigue.",although these differences did not achieve statistical significance (p values >0.14).
23749688,6,3,Claim,Premise,none,"Exercise interventions commenced in the early survivorship phase appear safe, feasible and may lead to improvements in QOL and fatigue.",Self-reported physical activity increased in the exercise group (EG) compared to the usual care group at both 8-week (p = 0.01) and 3-month follow-up (p = 0.03) and significant differences in favour of the EG were found for physical well-being at both the 8-week (p = 0.03) and 3-month follow-up (p = 0.04).
23749688,6,4,Claim,Premise,none,"Exercise interventions commenced in the early survivorship phase appear safe, feasible and may lead to improvements in QOL and fatigue.","Improvements in fatigue (p = 0.01), total quality of life plus fatigue (p = 0.04), and a composite physical functioning score (p = 0.01) at the 3-month follow-up were also found."
23749688,6,5,Claim,Claim,none,"Exercise interventions commenced in the early survivorship phase appear safe, feasible and may lead to improvements in QOL and fatigue.","The PEACH trial suggests that 8 weeks of supervised aerobic exercise training was feasible and may improve aerobic fitness, fatigue and quality of life in de-conditioned cancer survivors during the early survivorship phase."
16462503,1,2,Claim,Claim,none,Fatigue has a significant impact on the quality of life (QOL) of cancer patients.,Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
16462503,1,3,Claim,Premise,none,Fatigue has a significant impact on the quality of life (QOL) of cancer patients.,"Most of scores indicated less fatigue (higher score) in the standard treatment group,"
16462503,1,4,Claim,Premise,none,Fatigue has a significant impact on the quality of life (QOL) of cancer patients.,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm."
16462503,1,5,Claim,Premise,none,Fatigue has a significant impact on the quality of life (QOL) of cancer patients.,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27."
16462503,1,6,Claim,Premise,none,Fatigue has a significant impact on the quality of life (QOL) of cancer patients.,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels."
16462503,1,7,Claim,Premise,none,Fatigue has a significant impact on the quality of life (QOL) of cancer patients.,Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
16462503,1,8,Claim,Claim,none,Fatigue has a significant impact on the quality of life (QOL) of cancer patients.,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,"
16462503,1,9,Claim,Claim,none,Fatigue has a significant impact on the quality of life (QOL) of cancer patients.,there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
16462503,2,1,Claim,Claim,none,Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.,Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
16462503,2,3,Claim,Premise,none,Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.,"Most of scores indicated less fatigue (higher score) in the standard treatment group,"
16462503,2,4,Claim,Premise,none,Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm."
16462503,2,5,Claim,Premise,none,Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27."
16462503,2,6,Claim,Premise,none,Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels."
16462503,2,7,Claim,Premise,none,Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.,Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
16462503,2,8,Claim,Claim,none,Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,"
16462503,2,9,Claim,Claim,none,Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.,there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
16462503,3,1,Premise,Claim,none,"Most of scores indicated less fatigue (higher score) in the standard treatment group,",Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
16462503,3,2,Premise,Claim,none,"Most of scores indicated less fatigue (higher score) in the standard treatment group,",Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
16462503,3,4,Premise,Premise,none,"Most of scores indicated less fatigue (higher score) in the standard treatment group,","but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm."
16462503,3,5,Premise,Premise,none,"Most of scores indicated less fatigue (higher score) in the standard treatment group,","For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27."
16462503,3,6,Premise,Premise,none,"Most of scores indicated less fatigue (higher score) in the standard treatment group,","Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels."
16462503,3,7,Premise,Premise,none,"Most of scores indicated less fatigue (higher score) in the standard treatment group,",Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
16462503,3,8,Premise,Claim,attack,"Most of scores indicated less fatigue (higher score) in the standard treatment group,","Clinically, this structured multidisciplinary intervention had no impact on fatigue,"
16462503,3,9,Premise,Claim,none,"Most of scores indicated less fatigue (higher score) in the standard treatment group,",there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
16462503,4,1,Premise,Claim,none,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.",Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
16462503,4,2,Premise,Claim,none,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.",Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
16462503,4,3,Premise,Premise,attack,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.","Most of scores indicated less fatigue (higher score) in the standard treatment group,"
16462503,4,5,Premise,Premise,none,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.","For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27."
16462503,4,6,Premise,Premise,none,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.","Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels."
16462503,4,7,Premise,Premise,none,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.",Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
16462503,4,8,Premise,Claim,none,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.","Clinically, this structured multidisciplinary intervention had no impact on fatigue,"
16462503,4,9,Premise,Claim,none,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.",there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
16462503,5,1,Premise,Claim,none,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.",Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
16462503,5,2,Premise,Claim,none,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.",Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
16462503,5,3,Premise,Premise,none,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.","Most of scores indicated less fatigue (higher score) in the standard treatment group,"
16462503,5,4,Premise,Premise,none,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.","but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm."
16462503,5,6,Premise,Premise,none,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.","Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels."
16462503,5,7,Premise,Premise,none,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.",Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
16462503,5,8,Premise,Claim,support,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.","Clinically, this structured multidisciplinary intervention had no impact on fatigue,"
16462503,5,9,Premise,Claim,none,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.",there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
16462503,6,1,Premise,Claim,none,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.",Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
16462503,6,2,Premise,Claim,none,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.",Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
16462503,6,3,Premise,Premise,none,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.","Most of scores indicated less fatigue (higher score) in the standard treatment group,"
16462503,6,4,Premise,Premise,none,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.","but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm."
16462503,6,5,Premise,Premise,none,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.","For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27."
16462503,6,7,Premise,Premise,none,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.",Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
16462503,6,8,Premise,Claim,support,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.","Clinically, this structured multidisciplinary intervention had no impact on fatigue,"
16462503,6,9,Premise,Claim,none,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.",there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
16462503,7,1,Premise,Claim,none,Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline,Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
16462503,7,2,Premise,Claim,none,Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline,Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
16462503,7,3,Premise,Premise,none,Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline,"Most of scores indicated less fatigue (higher score) in the standard treatment group,"
16462503,7,4,Premise,Premise,none,Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm."
16462503,7,5,Premise,Premise,none,Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27."
16462503,7,6,Premise,Premise,none,Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels."
16462503,7,8,Premise,Claim,none,Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,"
16462503,7,9,Premise,Claim,support,Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline,there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
16462503,8,1,Claim,Claim,none,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,",Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
16462503,8,2,Claim,Claim,none,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,",Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
16462503,8,3,Claim,Premise,none,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,","Most of scores indicated less fatigue (higher score) in the standard treatment group,"
16462503,8,4,Claim,Premise,none,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,","but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm."
16462503,8,5,Claim,Premise,none,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,","For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27."
16462503,8,6,Claim,Premise,none,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,","Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels."
16462503,8,7,Claim,Premise,none,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,",Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
16462503,8,9,Claim,Claim,none,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,",there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
16462503,9,1,Claim,Claim,none,there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.,Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
16462503,9,2,Claim,Claim,none,there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.,Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
16462503,9,3,Claim,Premise,none,there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.,"Most of scores indicated less fatigue (higher score) in the standard treatment group,"
16462503,9,4,Claim,Premise,none,there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.,"but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm."
16462503,9,5,Claim,Premise,none,there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.,"For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27."
16462503,9,6,Claim,Premise,none,there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.,"Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels."
16462503,9,7,Claim,Premise,none,there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.,Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
16462503,9,8,Claim,Claim,none,there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.,"Clinically, this structured multidisciplinary intervention had no impact on fatigue,"
23860204,1,2,Premise,Premise,none,Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs -2.20g/dL change for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red blood cell transfusion (12.8% vs 28.1%; P < .0001).,The incidence of thrombotic events was 7% in the epoetin alfa arm vs 3% in the control arm.
23860204,1,3,Premise,Premise,none,Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs -2.20g/dL change for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red blood cell transfusion (12.8% vs 28.1%; P < .0001).,"After a median follow-up of 62 months, epoetin alfa treatment did not affect overall survival, relapse-free survival, or intramammary relapse."
23860204,1,4,Premise,Claim,support,Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs -2.20g/dL change for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red blood cell transfusion (12.8% vs 28.1%; P < .0001).,Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival.
23860204,1,5,Premise,Claim,none,Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs -2.20g/dL change for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red blood cell transfusion (12.8% vs 28.1%; P < .0001).,"However, epoetin alfa had an adverse effect, resulting in increased thrombosis."
23860204,2,1,Premise,Premise,none,The incidence of thrombotic events was 7% in the epoetin alfa arm vs 3% in the control arm.,Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs -2.20g/dL change for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red blood cell transfusion (12.8% vs 28.1%; P < .0001).
23860204,2,3,Premise,Premise,none,The incidence of thrombotic events was 7% in the epoetin alfa arm vs 3% in the control arm.,"After a median follow-up of 62 months, epoetin alfa treatment did not affect overall survival, relapse-free survival, or intramammary relapse."
23860204,2,4,Premise,Claim,none,The incidence of thrombotic events was 7% in the epoetin alfa arm vs 3% in the control arm.,Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival.
23860204,2,5,Premise,Claim,support,The incidence of thrombotic events was 7% in the epoetin alfa arm vs 3% in the control arm.,"However, epoetin alfa had an adverse effect, resulting in increased thrombosis."
23860204,3,1,Premise,Premise,none,"After a median follow-up of 62 months, epoetin alfa treatment did not affect overall survival, relapse-free survival, or intramammary relapse.",Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs -2.20g/dL change for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red blood cell transfusion (12.8% vs 28.1%; P < .0001).
23860204,3,2,Premise,Premise,none,"After a median follow-up of 62 months, epoetin alfa treatment did not affect overall survival, relapse-free survival, or intramammary relapse.",The incidence of thrombotic events was 7% in the epoetin alfa arm vs 3% in the control arm.
23860204,3,4,Premise,Claim,support,"After a median follow-up of 62 months, epoetin alfa treatment did not affect overall survival, relapse-free survival, or intramammary relapse.",Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival.
23860204,3,5,Premise,Claim,none,"After a median follow-up of 62 months, epoetin alfa treatment did not affect overall survival, relapse-free survival, or intramammary relapse.","However, epoetin alfa had an adverse effect, resulting in increased thrombosis."
23860204,4,1,Claim,Premise,none,Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival.,Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs -2.20g/dL change for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red blood cell transfusion (12.8% vs 28.1%; P < .0001).
23860204,4,2,Claim,Premise,none,Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival.,The incidence of thrombotic events was 7% in the epoetin alfa arm vs 3% in the control arm.
23860204,4,3,Claim,Premise,none,Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival.,"After a median follow-up of 62 months, epoetin alfa treatment did not affect overall survival, relapse-free survival, or intramammary relapse."
23860204,4,5,Claim,Claim,none,Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival.,"However, epoetin alfa had an adverse effect, resulting in increased thrombosis."
23860204,5,1,Claim,Premise,none,"However, epoetin alfa had an adverse effect, resulting in increased thrombosis.",Epoetin alfa avoided the decrease in hemoglobin level (no decrease in the epoetin alfa group vs -2.20g/dL change for the control group; P < .001) and statistically significantly reduced the percentage of subjects requiring red blood cell transfusion (12.8% vs 28.1%; P < .0001).
23860204,5,2,Claim,Premise,none,"However, epoetin alfa had an adverse effect, resulting in increased thrombosis.",The incidence of thrombotic events was 7% in the epoetin alfa arm vs 3% in the control arm.
23860204,5,3,Claim,Premise,none,"However, epoetin alfa had an adverse effect, resulting in increased thrombosis.","After a median follow-up of 62 months, epoetin alfa treatment did not affect overall survival, relapse-free survival, or intramammary relapse."
23860204,5,4,Claim,Claim,none,"However, epoetin alfa had an adverse effect, resulting in increased thrombosis.",Epoetin alfa resulted in improved hemoglobin levels and decreased transfusions without an impact on relapse-free or overall survival.
23615094,1,2,Premise,Premise,none,"Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test).",There was a significant reduction in tumor volume over time in the GKRS group.
23615094,1,3,Premise,Premise,none,"Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test).","The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001)."
23615094,1,4,Premise,Premise,none,"Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test).",Symptom and QoL development did not differ significantly between the groups.
23615094,1,5,Premise,Claim,none,"Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test).","In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold."
23615094,1,6,Premise,Claim,support,"Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test).",Hearing is lost at similar rates in both groups.
23615094,1,7,Premise,Claim,none,"Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test).",Symptoms and QoL seem not to be significantly affected by GKRS.
23615094,2,1,Premise,Premise,none,There was a significant reduction in tumor volume over time in the GKRS group.,"Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test)."
23615094,2,3,Premise,Premise,none,There was a significant reduction in tumor volume over time in the GKRS group.,"The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001)."
23615094,2,4,Premise,Premise,none,There was a significant reduction in tumor volume over time in the GKRS group.,Symptom and QoL development did not differ significantly between the groups.
23615094,2,5,Premise,Claim,support,There was a significant reduction in tumor volume over time in the GKRS group.,"In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold."
23615094,2,6,Premise,Claim,none,There was a significant reduction in tumor volume over time in the GKRS group.,Hearing is lost at similar rates in both groups.
23615094,2,7,Premise,Claim,none,There was a significant reduction in tumor volume over time in the GKRS group.,Symptoms and QoL seem not to be significantly affected by GKRS.
23615094,3,1,Premise,Premise,none,"The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001).","Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test)."
23615094,3,2,Premise,Premise,none,"The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001).",There was a significant reduction in tumor volume over time in the GKRS group.
23615094,3,4,Premise,Premise,none,"The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001).",Symptom and QoL development did not differ significantly between the groups.
23615094,3,5,Premise,Claim,none,"The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001).","In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold."
23615094,3,6,Premise,Claim,none,"The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001).",Hearing is lost at similar rates in both groups.
23615094,3,7,Premise,Claim,none,"The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001).",Symptoms and QoL seem not to be significantly affected by GKRS.
23615094,4,1,Premise,Premise,none,Symptom and QoL development did not differ significantly between the groups.,"Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test)."
23615094,4,2,Premise,Premise,none,Symptom and QoL development did not differ significantly between the groups.,There was a significant reduction in tumor volume over time in the GKRS group.
23615094,4,3,Premise,Premise,none,Symptom and QoL development did not differ significantly between the groups.,"The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001)."
23615094,4,5,Premise,Claim,none,Symptom and QoL development did not differ significantly between the groups.,"In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold."
23615094,4,6,Premise,Claim,none,Symptom and QoL development did not differ significantly between the groups.,Hearing is lost at similar rates in both groups.
23615094,4,7,Premise,Claim,support,Symptom and QoL development did not differ significantly between the groups.,Symptoms and QoL seem not to be significantly affected by GKRS.
23615094,5,1,Claim,Premise,none,"In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold.","Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test)."
23615094,5,2,Claim,Premise,none,"In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold.",There was a significant reduction in tumor volume over time in the GKRS group.
23615094,5,3,Claim,Premise,none,"In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold.","The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001)."
23615094,5,4,Claim,Premise,none,"In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold.",Symptom and QoL development did not differ significantly between the groups.
23615094,5,6,Claim,Claim,none,"In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold.",Hearing is lost at similar rates in both groups.
23615094,5,7,Claim,Claim,none,"In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold.",Symptoms and QoL seem not to be significantly affected by GKRS.
23615094,6,1,Claim,Premise,none,Hearing is lost at similar rates in both groups.,"Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test)."
23615094,6,2,Claim,Premise,none,Hearing is lost at similar rates in both groups.,There was a significant reduction in tumor volume over time in the GKRS group.
23615094,6,3,Claim,Premise,none,Hearing is lost at similar rates in both groups.,"The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001)."
23615094,6,4,Claim,Premise,none,Hearing is lost at similar rates in both groups.,Symptom and QoL development did not differ significantly between the groups.
23615094,6,5,Claim,Claim,none,Hearing is lost at similar rates in both groups.,"In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold."
23615094,6,7,Claim,Claim,none,Hearing is lost at similar rates in both groups.,Symptoms and QoL seem not to be significantly affected by GKRS.
23615094,7,1,Claim,Premise,none,Symptoms and QoL seem not to be significantly affected by GKRS.,"Serviceable hearing was lost in 54 of 71 (76%) (CM) and 34 of 53 (64%) (GKRS) patients during the study period (not significant, log-rank test)."
23615094,7,2,Claim,Premise,none,Symptoms and QoL seem not to be significantly affected by GKRS.,There was a significant reduction in tumor volume over time in the GKRS group.
23615094,7,3,Claim,Premise,none,Symptoms and QoL seem not to be significantly affected by GKRS.,"The need for treatment following initial GKRS or CM differed at highly significant levels (log-rank test, P < .001)."
23615094,7,4,Claim,Premise,none,Symptoms and QoL seem not to be significantly affected by GKRS.,Symptom and QoL development did not differ significantly between the groups.
23615094,7,5,Claim,Claim,none,Symptoms and QoL seem not to be significantly affected by GKRS.,"In VS patients, GKRS reduces the tumor growth rate and thereby the incidence rate of new treatment about tenfold."
23615094,7,6,Claim,Claim,none,Symptoms and QoL seem not to be significantly affected by GKRS.,Hearing is lost at similar rates in both groups.
21911723,1,2,Claim,Premise,none,octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.,"Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86)."
21911723,1,3,Claim,Premise,none,octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.,"Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001)."
21911723,1,4,Claim,Premise,none,octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.,"At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels."
21911723,1,5,Claim,Premise,none,octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.,"Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis."
21911723,1,6,Claim,Claim,none,octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.,Octreotide did not add significant clinical benefit.
21911723,1,7,Claim,Claim,none,octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.,High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome.
21911723,2,1,Premise,Claim,none,"Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86).",octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.
21911723,2,3,Premise,Premise,none,"Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86).","Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001)."
21911723,2,4,Premise,Premise,none,"Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86).","At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels."
21911723,2,5,Premise,Premise,none,"Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86).","Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis."
21911723,2,6,Premise,Claim,support,"Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86).",Octreotide did not add significant clinical benefit.
21911723,2,7,Premise,Claim,none,"Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86).",High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome.
21911723,3,1,Premise,Claim,none,"Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001).",octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.
21911723,3,2,Premise,Premise,none,"Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001).","Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86)."
21911723,3,4,Premise,Premise,none,"Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001).","At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels."
21911723,3,5,Premise,Premise,none,"Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001).","Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis."
21911723,3,6,Premise,Claim,support,"Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001).",Octreotide did not add significant clinical benefit.
21911723,3,7,Premise,Claim,none,"Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001).",High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome.
21911723,4,1,Premise,Claim,support,"At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels.",octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.
21911723,4,2,Premise,Premise,none,"At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels.","Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86)."
21911723,4,3,Premise,Premise,none,"At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels.","Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001)."
21911723,4,5,Premise,Premise,none,"At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels.","Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis."
21911723,4,6,Premise,Claim,none,"At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels.",Octreotide did not add significant clinical benefit.
21911723,4,7,Premise,Claim,none,"At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels.",High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome.
21911723,5,1,Premise,Claim,none,"Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis.",octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.
21911723,5,2,Premise,Premise,none,"Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis.","Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86)."
21911723,5,3,Premise,Premise,none,"Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis.","Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001)."
21911723,5,4,Premise,Premise,none,"Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis.","At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels."
21911723,5,6,Premise,Claim,none,"Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis.",Octreotide did not add significant clinical benefit.
21911723,5,7,Premise,Claim,support,"Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis.",High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome.
21911723,6,1,Claim,Claim,none,Octreotide did not add significant clinical benefit.,octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.
21911723,6,2,Claim,Premise,none,Octreotide did not add significant clinical benefit.,"Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86)."
21911723,6,3,Claim,Premise,none,Octreotide did not add significant clinical benefit.,"Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001)."
21911723,6,4,Claim,Premise,none,Octreotide did not add significant clinical benefit.,"At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels."
21911723,6,5,Claim,Premise,none,Octreotide did not add significant clinical benefit.,"Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis."
21911723,6,7,Claim,Claim,none,Octreotide did not add significant clinical benefit.,High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome.
21911723,7,1,Claim,Claim,none,High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome.,octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence.
21911723,7,2,Claim,Premise,none,High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome.,"Adjusted hazard ratios (HRs; TAM-OCT to TAM) were 0.93 for EFS (95% CI, 0.71 to 1.22; P = .62), 0.84 for RFS (95% CI, 0.59 to 1.18; P = .31), and 0.97 for OS (95% CI, 0.69 to 1.37; P = .86)."
21911723,7,3,Claim,Premise,none,High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome.,"Among patients with normal baseline gallbladder imaging, cholecystectomy was required in 23.0% of those receiving TAM-OCT but in only 1.4% of those receiving TAM (P < .001)."
21911723,7,4,Claim,Premise,none,High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome.,"At 4 months, TAM-OCT had significantly (P < .001) lowered IGF-1, IGF binding protein 3, and C-peptide levels."
21911723,7,5,Claim,Premise,none,High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome.,"Older age (P = .02), tumor size (P = .001), nodal status (P = .01), high C-peptide levels (P < .001), and higher body mass index (BMI) in models excluding C-peptide (P < .001) were associated with poorer EFS in multivariate analysis."
21911723,7,6,Claim,Claim,none,High C-peptide levels (surrogate for insulin secretion rate) and high BMI were associated with poor outcome.,Octreotide did not add significant clinical benefit.
20734132,1,2,Premise,Premise,none,"Participants in the intervention group demonstrated greater improvement in health-related quality of life between baseline and the 3-month assessment [mean (sd) EQ-5D VAS (0-100) baseline: 72.6 (15.6), 3 month: 80.6 (11.6)] when compared to control group participants [baseline: 77.5 (13.5), 3 month: 74.1 (20.6), P = 0.006] and also improved more in terms of physical function [mean (sd) EORTC C30 physical function scale intervention (0-100) baseline: 84.9 (14.8), 3 month: 86.9 (10.7), control baseline: 91.3 (9.6), 3 month: 86.7 (14.9), P = 0.02].",Upper limb volumes were also lower amongst intervention group participants.
20734132,1,3,Premise,Premise,none,"Participants in the intervention group demonstrated greater improvement in health-related quality of life between baseline and the 3-month assessment [mean (sd) EQ-5D VAS (0-100) baseline: 72.6 (15.6), 3 month: 80.6 (11.6)] when compared to control group participants [baseline: 77.5 (13.5), 3 month: 74.1 (20.6), P = 0.006] and also improved more in terms of physical function [mean (sd) EORTC C30 physical function scale intervention (0-100) baseline: 84.9 (14.8), 3 month: 86.9 (10.7), control baseline: 91.3 (9.6), 3 month: 86.7 (14.9), P = 0.02].",there was low probability that the intervention would be both less costly and more effective than the control condition (range probability = 0.05-50.02% depending on approach).
20734132,1,4,Premise,Claim,support,"Participants in the intervention group demonstrated greater improvement in health-related quality of life between baseline and the 3-month assessment [mean (sd) EQ-5D VAS (0-100) baseline: 72.6 (15.6), 3 month: 80.6 (11.6)] when compared to control group participants [baseline: 77.5 (13.5), 3 month: 74.1 (20.6), P = 0.006] and also improved more in terms of physical function [mean (sd) EORTC C30 physical function scale intervention (0-100) baseline: 84.9 (14.8), 3 month: 86.9 (10.7), control baseline: 91.3 (9.6), 3 month: 86.7 (14.9), P = 0.02].",Provision of multimodal exercise programs will improve the short-term health of women undergoing adjuvant therapy for breast cancer but are of questionable economic efficiency.
20734132,2,1,Premise,Premise,none,Upper limb volumes were also lower amongst intervention group participants.,"Participants in the intervention group demonstrated greater improvement in health-related quality of life between baseline and the 3-month assessment [mean (sd) EQ-5D VAS (0-100) baseline: 72.6 (15.6), 3 month: 80.6 (11.6)] when compared to control group participants [baseline: 77.5 (13.5), 3 month: 74.1 (20.6), P = 0.006] and also improved more in terms of physical function [mean (sd) EORTC C30 physical function scale intervention (0-100) baseline: 84.9 (14.8), 3 month: 86.9 (10.7), control baseline: 91.3 (9.6), 3 month: 86.7 (14.9), P = 0.02]."
20734132,2,3,Premise,Premise,none,Upper limb volumes were also lower amongst intervention group participants.,there was low probability that the intervention would be both less costly and more effective than the control condition (range probability = 0.05-50.02% depending on approach).
20734132,2,4,Premise,Claim,support,Upper limb volumes were also lower amongst intervention group participants.,Provision of multimodal exercise programs will improve the short-term health of women undergoing adjuvant therapy for breast cancer but are of questionable economic efficiency.
20734132,3,1,Premise,Premise,none,there was low probability that the intervention would be both less costly and more effective than the control condition (range probability = 0.05-50.02% depending on approach).,"Participants in the intervention group demonstrated greater improvement in health-related quality of life between baseline and the 3-month assessment [mean (sd) EQ-5D VAS (0-100) baseline: 72.6 (15.6), 3 month: 80.6 (11.6)] when compared to control group participants [baseline: 77.5 (13.5), 3 month: 74.1 (20.6), P = 0.006] and also improved more in terms of physical function [mean (sd) EORTC C30 physical function scale intervention (0-100) baseline: 84.9 (14.8), 3 month: 86.9 (10.7), control baseline: 91.3 (9.6), 3 month: 86.7 (14.9), P = 0.02]."
20734132,3,2,Premise,Premise,none,there was low probability that the intervention would be both less costly and more effective than the control condition (range probability = 0.05-50.02% depending on approach).,Upper limb volumes were also lower amongst intervention group participants.
20734132,3,4,Premise,Claim,support,there was low probability that the intervention would be both less costly and more effective than the control condition (range probability = 0.05-50.02% depending on approach).,Provision of multimodal exercise programs will improve the short-term health of women undergoing adjuvant therapy for breast cancer but are of questionable economic efficiency.
20734132,4,1,Claim,Premise,none,Provision of multimodal exercise programs will improve the short-term health of women undergoing adjuvant therapy for breast cancer but are of questionable economic efficiency.,"Participants in the intervention group demonstrated greater improvement in health-related quality of life between baseline and the 3-month assessment [mean (sd) EQ-5D VAS (0-100) baseline: 72.6 (15.6), 3 month: 80.6 (11.6)] when compared to control group participants [baseline: 77.5 (13.5), 3 month: 74.1 (20.6), P = 0.006] and also improved more in terms of physical function [mean (sd) EORTC C30 physical function scale intervention (0-100) baseline: 84.9 (14.8), 3 month: 86.9 (10.7), control baseline: 91.3 (9.6), 3 month: 86.7 (14.9), P = 0.02]."
20734132,4,2,Claim,Premise,none,Provision of multimodal exercise programs will improve the short-term health of women undergoing adjuvant therapy for breast cancer but are of questionable economic efficiency.,Upper limb volumes were also lower amongst intervention group participants.
20734132,4,3,Claim,Premise,none,Provision of multimodal exercise programs will improve the short-term health of women undergoing adjuvant therapy for breast cancer but are of questionable economic efficiency.,there was low probability that the intervention would be both less costly and more effective than the control condition (range probability = 0.05-50.02% depending on approach).
23793805,1,2,Premise,Premise,none,"The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073).",Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).
23793805,1,3,Premise,Premise,none,"The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073).","The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups."
23793805,1,4,Premise,Premise,none,"The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073).",No clinically meaningful differences were detected between the two groups in long-term QOL.
23793805,1,5,Premise,Claim,support,"The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073).",LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.
23793805,1,6,Premise,Claim,none,"The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073).",Marginal benefits in mild complications were observed with LADG.
23793805,1,7,Premise,Claim,none,"The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073).",LADG did not show advantages over ODG regarding other complications and long-term QOL.
23793805,2,1,Premise,Premise,none,Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).,"The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073)."
23793805,2,3,Premise,Premise,none,Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).,"The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups."
23793805,2,4,Premise,Premise,none,Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).,No clinically meaningful differences were detected between the two groups in long-term QOL.
23793805,2,5,Premise,Claim,none,Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).,LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.
23793805,2,6,Premise,Claim,support,Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).,Marginal benefits in mild complications were observed with LADG.
23793805,2,7,Premise,Claim,none,Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).,LADG did not show advantages over ODG regarding other complications and long-term QOL.
23793805,3,1,Premise,Premise,none,"The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups.","The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073)."
23793805,3,2,Premise,Premise,none,"The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups.",Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).
23793805,3,4,Premise,Premise,none,"The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups.",No clinically meaningful differences were detected between the two groups in long-term QOL.
23793805,3,5,Premise,Claim,none,"The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups.",LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.
23793805,3,6,Premise,Claim,none,"The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups.",Marginal benefits in mild complications were observed with LADG.
23793805,3,7,Premise,Claim,support,"The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups.",LADG did not show advantages over ODG regarding other complications and long-term QOL.
23793805,4,1,Premise,Premise,none,No clinically meaningful differences were detected between the two groups in long-term QOL.,"The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073)."
23793805,4,2,Premise,Premise,none,No clinically meaningful differences were detected between the two groups in long-term QOL.,Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).
23793805,4,3,Premise,Premise,none,No clinically meaningful differences were detected between the two groups in long-term QOL.,"The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups."
23793805,4,5,Premise,Claim,none,No clinically meaningful differences were detected between the two groups in long-term QOL.,LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.
23793805,4,6,Premise,Claim,none,No clinically meaningful differences were detected between the two groups in long-term QOL.,Marginal benefits in mild complications were observed with LADG.
23793805,4,7,Premise,Claim,support,No clinically meaningful differences were detected between the two groups in long-term QOL.,LADG did not show advantages over ODG regarding other complications and long-term QOL.
23793805,5,1,Claim,Premise,none,LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.,"The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073)."
23793805,5,2,Claim,Premise,none,LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.,Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).
23793805,5,3,Claim,Premise,none,LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.,"The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups."
23793805,5,4,Claim,Premise,none,LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.,No clinically meaningful differences were detected between the two groups in long-term QOL.
23793805,5,6,Claim,Claim,none,LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.,Marginal benefits in mild complications were observed with LADG.
23793805,5,7,Claim,Claim,none,LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.,LADG did not show advantages over ODG regarding other complications and long-term QOL.
23793805,6,1,Claim,Premise,none,Marginal benefits in mild complications were observed with LADG.,"The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073)."
23793805,6,2,Claim,Premise,none,Marginal benefits in mild complications were observed with LADG.,Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).
23793805,6,3,Claim,Premise,none,Marginal benefits in mild complications were observed with LADG.,"The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups."
23793805,6,4,Claim,Premise,none,Marginal benefits in mild complications were observed with LADG.,No clinically meaningful differences were detected between the two groups in long-term QOL.
23793805,6,5,Claim,Claim,none,Marginal benefits in mild complications were observed with LADG.,LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.
23793805,6,7,Claim,Claim,none,Marginal benefits in mild complications were observed with LADG.,LADG did not show advantages over ODG regarding other complications and long-term QOL.
23793805,7,1,Claim,Premise,none,LADG did not show advantages over ODG regarding other complications and long-term QOL.,"The LADG and ODG groups showed similar survival [5-year DFS rate: 98.8 % vs. 97.6 %, respectively (P = 0.514), 5-year overall survival (OS) rate: 97.6 vs. 96.3 %, respectively (P = 0.721)] or overall complication rate (29.3 vs. 42.7 %, respectively; P = 0.073)."
23793805,7,2,Claim,Premise,none,LADG did not show advantages over ODG regarding other complications and long-term QOL.,Mild complications were significantly less frequent in the LADG group than in the ODG group (23.2 vs. 41.5 %; P = 0.012).
23793805,7,3,Claim,Premise,none,LADG did not show advantages over ODG regarding other complications and long-term QOL.,"The rates of moderate, severe, and long-term complications (i.e., 31 days to 5 years after surgery) did not differ significantly between groups."
23793805,7,4,Claim,Premise,none,LADG did not show advantages over ODG regarding other complications and long-term QOL.,No clinically meaningful differences were detected between the two groups in long-term QOL.
23793805,7,5,Claim,Claim,none,LADG did not show advantages over ODG regarding other complications and long-term QOL.,LADG showed similar DFS and OS compared to ODG in treating early gastric cancer.
23793805,7,6,Claim,Claim,none,LADG did not show advantages over ODG regarding other complications and long-term QOL.,Marginal benefits in mild complications were observed with LADG.
23816967,1,2,Premise,Premise,none,"Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19).",More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).
23816967,1,3,Premise,Premise,none,"Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19).",Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).
23816967,1,4,Premise,Premise,none,"Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19).","Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy."
23816967,1,5,Premise,Premise,none,"Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19).","Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01)."
23816967,1,6,Premise,Claim,support,"Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19).","In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse."
23816967,1,7,Premise,Claim,none,"Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19).",Global health status/QoL was also improved over time with afatinib compared with chemotherapy.
23816967,2,1,Premise,Premise,none,More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).,"Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19)."
23816967,2,3,Premise,Premise,none,More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).,Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).
23816967,2,4,Premise,Premise,none,More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).,"Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy."
23816967,2,5,Premise,Premise,none,More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).,"Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01)."
23816967,2,6,Premise,Claim,support,More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).,"In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse."
23816967,2,7,Premise,Claim,none,More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).,Global health status/QoL was also improved over time with afatinib compared with chemotherapy.
23816967,3,1,Premise,Premise,none,Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).,"Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19)."
23816967,3,2,Premise,Premise,none,Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).,More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).
23816967,3,4,Premise,Premise,none,Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).,"Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy."
23816967,3,5,Premise,Premise,none,Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).,"Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01)."
23816967,3,6,Premise,Claim,support,Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).,"In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse."
23816967,3,7,Premise,Claim,none,Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).,Global health status/QoL was also improved over time with afatinib compared with chemotherapy.
23816967,4,1,Premise,Premise,none,"Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy.","Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19)."
23816967,4,2,Premise,Premise,none,"Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy.",More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).
23816967,4,3,Premise,Premise,none,"Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy.",Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).
23816967,4,5,Premise,Premise,none,"Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy.","Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01)."
23816967,4,6,Premise,Claim,none,"Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy.","In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse."
23816967,4,7,Premise,Claim,support,"Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy.",Global health status/QoL was also improved over time with afatinib compared with chemotherapy.
23816967,5,1,Premise,Premise,none,"Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01).","Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19)."
23816967,5,2,Premise,Premise,none,"Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01).",More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).
23816967,5,3,Premise,Premise,none,"Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01).",Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).
23816967,5,4,Premise,Premise,none,"Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01).","Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy."
23816967,5,6,Premise,Claim,support,"Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01).","In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse."
23816967,5,7,Premise,Claim,none,"Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01).",Global health status/QoL was also improved over time with afatinib compared with chemotherapy.
23816967,6,1,Claim,Premise,none,"In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse.","Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19)."
23816967,6,2,Claim,Premise,none,"In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse.",More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).
23816967,6,3,Claim,Premise,none,"In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse.",Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).
23816967,6,4,Claim,Premise,none,"In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse.","Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy."
23816967,6,5,Claim,Premise,none,"In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse.","Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01)."
23816967,6,7,Claim,Claim,none,"In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse.",Global health status/QoL was also improved over time with afatinib compared with chemotherapy.
23816967,7,1,Claim,Premise,none,Global health status/QoL was also improved over time with afatinib compared with chemotherapy.,"Compared with chemotherapy, afatinib significantly delayed the time to deterioration for cough (hazard ratio [HR], 0.60; 95% CI, 0.41 to 0.87; P = .007) and dyspnea (HR, 0.68; 95% CI, 0.50 to 0.93; P = .015), but not pain (HR, 0.83; 95% CI, 0.62 to 1.10; P = .19)."
23816967,7,2,Claim,Premise,none,Global health status/QoL was also improved over time with afatinib compared with chemotherapy.,More patients on afatinib (64%) versus chemotherapy (50%) experienced improvements in dyspnea scores (P = .010).
23816967,7,3,Claim,Premise,none,Global health status/QoL was also improved over time with afatinib compared with chemotherapy.,Differences in mean scores over time significantly favored afatinib over chemotherapy for cough (P < .001) and dyspnea (P < .001).
23816967,7,4,Claim,Premise,none,Global health status/QoL was also improved over time with afatinib compared with chemotherapy.,"Afatinib showed significantly better mean scores over time in global health status/QoL (P = .015) and physical (P < .001), role (P = .004), and cognitive (P = .007) functioning compared with chemotherapy."
23816967,7,5,Claim,Premise,none,Global health status/QoL was also improved over time with afatinib compared with chemotherapy.,"Fatigue and nausea were worse with chemotherapy, whereas diarrhea, dysphagia, and sore mouth were worse with afatinib (all P < .01)."
23816967,7,6,Claim,Claim,none,Global health status/QoL was also improved over time with afatinib compared with chemotherapy.,"In patients with lung adenocarcinoma with EGFR mutations, first-line afatinib was associated with better control of cough and dyspnea compared with chemotherapy, although diarrhea, dysphagia, and sore mouth were worse."
20680680,1,2,Premise,Premise,none,There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization.,"Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia."
20680680,1,3,Premise,Premise,none,There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization.,"At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning."
20680680,1,4,Premise,Premise,none,There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization.,"Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group."
20680680,1,5,Premise,Claim,support,There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization.,"At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET."
20680680,1,6,Premise,Claim,none,There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization.,"after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life."
20680680,2,1,Premise,Premise,none,"Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia.",There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization.
20680680,2,3,Premise,Premise,none,"Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia.","At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning."
20680680,2,4,Premise,Premise,none,"Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia.","Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group."
20680680,2,5,Premise,Claim,support,"Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia.","At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET."
20680680,2,6,Premise,Claim,none,"Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia.","after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life."
20680680,3,1,Premise,Premise,none,"At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning.",There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization.
20680680,3,2,Premise,Premise,none,"At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning.","Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia."
20680680,3,4,Premise,Premise,none,"At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning.","Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group."
20680680,3,5,Premise,Claim,none,"At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning.","At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET."
20680680,3,6,Premise,Claim,support,"At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning.","after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life."
20680680,4,1,Premise,Premise,none,"Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group.",There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization.
20680680,4,2,Premise,Premise,none,"Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group.","Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia."
20680680,4,3,Premise,Premise,none,"Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group.","At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning."
20680680,4,5,Premise,Claim,none,"Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group.","At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET."
20680680,4,6,Premise,Claim,support,"Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group.","after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life."
20680680,5,1,Claim,Premise,none,"At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET.",There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization.
20680680,5,2,Claim,Premise,none,"At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET.","Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia."
20680680,5,3,Claim,Premise,none,"At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET.","At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning."
20680680,5,4,Claim,Premise,none,"At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET.","Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group."
20680680,5,6,Claim,Claim,none,"At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET.","after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life."
20680680,6,1,Claim,Premise,none,"after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life.",There were no statistically significant differences between the TEX group and the ET group on any of the subscales 2 months after randomization.
20680680,6,2,Claim,Premise,none,"after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life.","Small clinical differences (5-10 points) in favor of the ET group were found for global quality of life, role functioning, social functioning, and insomnia."
20680680,6,3,Claim,Premise,none,"after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life.","At the 9-months assessment, the TEX group scored statistically significantly higher on global quality of life and physical functioning."
20680680,6,4,Claim,Premise,none,"after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life.","Small clinically significant differences were found for global quality of life, physical functioning, role functioning, emotional functioning, dyspnoea, and insomnia, all in favour of the TEX group."
20680680,6,5,Claim,Claim,none,"after 9 months, when the patients had adapted to treatment, the TEX group seemed to have a slightly better quality of life.","At the 2-months assessment, when side-effects of chemotherapy were present, patients in the TEX group appeared to fare a bit worse than those receiving ET."
20821047,1,2,Premise,Premise,none,Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001).,There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.
20821047,1,3,Premise,Premise,none,Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001).,Nearly 80% of patients reported one or more side effects with either agent.
20821047,1,4,Premise,Premise,none,Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001).,"No differences in frequency, grade, or range of side effects were seen between drugs."
20821047,1,5,Premise,Claim,support,Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001).,both AIs are equally well tolerated.
20821047,1,6,Premise,Claim,support,Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001).,There were no significant differences in QOL scores between the two drugs.
20821047,2,1,Premise,Premise,none,There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.,Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001).
20821047,2,3,Premise,Premise,none,There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.,Nearly 80% of patients reported one or more side effects with either agent.
20821047,2,4,Premise,Premise,none,There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.,"No differences in frequency, grade, or range of side effects were seen between drugs."
20821047,2,5,Premise,Claim,support,There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.,both AIs are equally well tolerated.
20821047,2,6,Premise,Claim,support,There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.,There were no significant differences in QOL scores between the two drugs.
20821047,3,1,Premise,Premise,none,Nearly 80% of patients reported one or more side effects with either agent.,Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001).
20821047,3,2,Premise,Premise,none,Nearly 80% of patients reported one or more side effects with either agent.,There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.
20821047,3,4,Premise,Premise,none,Nearly 80% of patients reported one or more side effects with either agent.,"No differences in frequency, grade, or range of side effects were seen between drugs."
20821047,3,5,Premise,Claim,attack,Nearly 80% of patients reported one or more side effects with either agent.,both AIs are equally well tolerated.
20821047,3,6,Premise,Claim,none,Nearly 80% of patients reported one or more side effects with either agent.,There were no significant differences in QOL scores between the two drugs.
20821047,4,1,Premise,Premise,none,"No differences in frequency, grade, or range of side effects were seen between drugs.",Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001).
20821047,4,2,Premise,Premise,none,"No differences in frequency, grade, or range of side effects were seen between drugs.",There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.
20821047,4,3,Premise,Premise,none,"No differences in frequency, grade, or range of side effects were seen between drugs.",Nearly 80% of patients reported one or more side effects with either agent.
20821047,4,5,Premise,Claim,support,"No differences in frequency, grade, or range of side effects were seen between drugs.",both AIs are equally well tolerated.
20821047,4,6,Premise,Claim,none,"No differences in frequency, grade, or range of side effects were seen between drugs.",There were no significant differences in QOL scores between the two drugs.
20821047,5,1,Claim,Premise,none,both AIs are equally well tolerated.,Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001).
20821047,5,2,Claim,Premise,none,both AIs are equally well tolerated.,There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.
20821047,5,3,Claim,Premise,none,both AIs are equally well tolerated.,Nearly 80% of patients reported one or more side effects with either agent.
20821047,5,4,Claim,Premise,none,both AIs are equally well tolerated.,"No differences in frequency, grade, or range of side effects were seen between drugs."
20821047,5,6,Claim,Claim,none,both AIs are equally well tolerated.,There were no significant differences in QOL scores between the two drugs.
20821047,6,1,Claim,Premise,none,There were no significant differences in QOL scores between the two drugs.,Tamoxifen-naïve patients had a higher mean ES (endocrine symptoms subscale) score at entry versus those having extended therapy (66.0 vs. 61.9; P = 0.001).
20821047,6,2,Claim,Premise,none,There were no significant differences in QOL scores between the two drugs.,There was no significant change in FACT-B-ES (overall) scores or ES scores while patients were taking anastrozole or letrozole and no significant differences between drugs.
20821047,6,3,Claim,Premise,none,There were no significant differences in QOL scores between the two drugs.,Nearly 80% of patients reported one or more side effects with either agent.
20821047,6,4,Claim,Premise,none,There were no significant differences in QOL scores between the two drugs.,"No differences in frequency, grade, or range of side effects were seen between drugs."
20821047,6,5,Claim,Claim,none,There were no significant differences in QOL scores between the two drugs.,both AIs are equally well tolerated.
